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Abstract 
The Myelodysplastic syndromes (MDSs) are comprised of a heterogeneous group of clonal 
disorders characterised by ineffective haematopoiesis. Although 30 to 35% of MDS cases 
progress to Acute Myeloid Leukaemia (AML), the majority of patients die from blood related 
ailments caused by progressive bone marrow failure. Large-scale genomic rearrangements 
are a key feature of MDS, with different aberrations conferring specific risks of progression.  
Telomere erosion, dysfunction and fusion, creating cycles of anaphase bridging breakage 
and fusion is a mechanism that has the potential to drive genomic instability in many 
tumour types including MDS. The key aim of this project was to examine the role that 
telomere dysfunction may play in the generation of genomic rearrangements observed in 
MDS/AML.  
High resolution Single Telomere Length Analysis (STELA) revealed telomere shortening when 
compared to age-matched individuals in two cohorts of MDS and AML patients; this 
included large-scale telomeric deletion events observed within the MDS cohort. A PCR 
based telomere fusion assay detected telomere-telomere fusion events at a frequency that 
was consistent with sporadic fusion arising as a consequence of large-scale deletion. 
Telomerase activity was up-regulated in AML which may contribute to the reduction of 
deletion and fusion events in these cells. 
Sequence analysis revealed that telomere fusion was associated with microhomology and 
sub-telomeric deletion; this profile was consistent with error-prone Ku-independent 
alternative end joining processes.  
Telomere length at diagnosis irrespective of conventional markers appeared to influence the 
overall survival of MDS patients, but this was not apparent in AML. More importantly, 
telomere length was able to refine favourable prognostic markers, specifically good risk 
cytogenetics, uni-lineage cytopenia and low-risk IPSS (International Prognostic Scoring 
System) scores of which MDS patients bearing shorter telomeres for their respective age 
displayed reduced overall survival. This may be a particularly important finding given the 
heterogeneous clinical outcomes observed within low-risk MDS patients. 
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Chapter 1: Introduction 
Part 1: Myelodysplastic Syndromes (MDSs) and Acute Myeloid Leukaemia 
(AML) 
1.1 Haematopoietic System 
The haematopoietic system is currently displayed as a multi-step hierarchy governed by a 
primitive haematopoietic stem cell (HSC) (Figure 1.1). HSCs have the unique ability to both 
self-renew and differentiate in order to maintain haematopoietic homeostasis.1,2 They are a 
heterogeneous pool of cells consisting of at least two functionally distinct HSC populations, 
long-term self-renewing (LT-HSCs) and short-term self-renewing (ST-HSCs). Whereas, LT-
HSCs have life-long self-renewing potential, ST-HSCs are more restricted in self-renewal 
capacity.3,4 A low frequency of HSCs exist with 2 to 5 HSCs per 105 total adult bone marrow 
cells5 and such cells are thought to be enriched within the Lin-CD34+CD38-CD90+CD45RA- 
population of human marrow.6 Following loss of self-renewal potential, HSCs give rise to 
Multipotent Progenitors (MPPs) which commit to either myeloid or lymphoid lineages.7  
MPPs differentiate into common myeloid progenitors (CMPs) or common lymphoid 
progenitors (CLPs) that undergo further differentiation along their lineage to generate 
mature, functional peripheral blood cells. CLPs and CMPs show very limited or no self-
renewal activity8,9 and it has been proposed that the CLP and CMP populations represent 
the earliest branch points between lymphoid and myeloid lineages.9 T and B lymphocytes 
and natural killer cells are released from the CLP pathway8 whereas, platelets, erythrocytes, 
granulocytes and monocytes are derived from the CMP lineage.9  
It has been previously demonstrated in young mice that the percentage of LT-HSCs that 
enter S/G2/M of the cell cycle is approximately 5% per unit time.
10 However, this fraction of 
cells increases significantly with age in vivo.11 Quantitative and qualitative abnormalities of 
haematopoietic cells can arise under conditions of haematological stress. It has been 
proposed that such abnormalities might arise as part of the normal aging process where 
increased replication of haematopoietic cells may act in an attempt to compensate for the 
haematopoietic deficits that develop with age. Alternatively, an accumulation of genetic 
lesions with age might induce increased proliferation of HSCs and disrupt the regulation of 
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differentiation. Such processes have the potential to induce neoplastic transformation of 
HSCs. The increase in proliferation observed in older mice may share some relation to the 
higher incidence of leukaemia found in aging individuals.11 
 
 
 
 
 
 
 
 
 
 
 
Notably, haematological disorders including Chronic Lymphocytic Leukaemia (CLL), Chronic 
Myeloid Leukaemia, Acute Lymphoblastic Leukaemia (ALL), Myelodysplastic Syndromes 
(MDSs) and Acute Myeloid Leukaemia (AML) are common in the elderly population12-16 and 
have been proposed to arise under such circumstances.12,17 
1.2 MDS Pathology 
The Myelodysplastic Syndromes (MDSs) are comprised of a heterogeneous group of clonal 
disorders with ineffective haematopoiesis.18 It is considered to exist as a premalignant 
condition that has a 30 to 35% chance of transformation to Acute Myeloid Leukaemia 
(AML).19    
Figure 1.1: The haematopoietic system is currently displayed as a multi-step hierarchy 
governed by a primitive haematopoietic stem cell (HSC). Cells differentiate along their 
respective lineages in order to generate mature, functional blood cells.  
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According to the World Health Organisation (WHO) classification system for haematological 
cancers MDS is one of the five major categories of myeloid neoplasms20 with an estimated 
incidence of 2 to 12 new cases per 100,000 people each year which has been noted to 
increase among persons aged 70 or older.15  
The diagnosis of MDS is suspected from an abnormal complete blood count (CBC) but is 
confirmed following a bone marrow (BM) aspiration and biopsy. The BM aspirate allows for 
a detailed evaluation on cellular morphology and can evaluate the percentage of blast cells 
present in the marrow.21   
The marrow cellularity is normal or hypercellular in 90% of MDS patients22 but is 
hypocellular in 5 to 10% of cases.23 Haematopoietic failure disrupts homeostasis resulting in 
cytopenias, i.e. peripheral blood cell counts lower than the expected range for the healthy 
population. Accordingly, differentiated cells and their precursors are either dysfunctional or 
are eradicated by apoptosis.15 Consequently, dyserythropoiesis, dysgranulopoiesis and 
dysmegakaryocytopoiesis result in an insufficient production in erythrocytes, granulocytes 
and platelets along their respective lineage.24 Patients often suffer with anaemia that is 
refractory to therapy, i.e. transfusion dependent and can become immune compromised 
increasing their chance of a recurrent infection. Patients may also haemorrhage more 
readily as a consequence of reduced platelet counts. MDS has an unpredictable course but a 
tendency to worsen overtime and can range from an indolent disease spanning years to a 
type that rapidly evolves to overt leukaemia.25 Despite being a disease of the elderly, the 
majority of patients die as a consequence of blood cytopenias and not from age-related co-
morbidity or AML progression.26 Accordingly, it has been previously implicated that the 
majority of patients with low-risk disease (85%) die of MDS-related causes.26 Infection, 
either caused by pneumonia or sepsis accounted for the majority of deaths (38%), whereas 
AML transformation arose in only 15% of patients.26 Patients that endure co-lineage 
cytopenias show an increase in morbidity and reduced overall survival. Such individuals also 
have a reduced latency period prior to AML transformation.27  
A subset of patients with MDS present with a hypocellular bone marrow.23 Clinically it 
shares similar manifestations with normo/hypercellular MDS including cytopenias and bone 
marrow dyspoiesis.28 However, it has been described as an independent parameter of 
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survival among low-risk MDS patients. Whereas, hypocellularity did not influence the overall 
survival within high-risk MDS patients, low-risk MDS patients presenting with hypocellularity 
showed longer overall survival when compared to patients presenting with 
normo/hypercellular MDS.28 
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Classification and Prognostic Scoring Systems for MDS/AML 
Classification systems including those devised by the French-American-British (FAB) and 
World Health Organisation (WHO) are generally used as diagnostic tools which can be used 
to define specific disease entities of clinical significance. In contrast, patient prognosis is 
determined by disease-specific characteristics such as chromosomal abnormalities and 
haematopoietic insufficiency that are combined into a risk scoring system so as to predict 
patient outcome and facilitate in therapeutic decisions. Such risk scores include the 
International Prognostic Scoring System (IPSS) and the Revised-IPSS (IPSS-R) for MDS 
patients and the Hill’s Scoring system for patients with AML.  
1.3 French-American-British (FAB) Classification  
The FAB criterion for the classification of the Myelodysplastic Syndromes (MDS) and Acute 
Myeloid Leukaemia (AML) was proposed around 30 years ago. MDS was divided into five 
subgroups (Table 1.1) based largely on the percentage of blasts in the bone marrow (BM) 
and peripheral blood (PB) and the presence or absence of ringed sideroblasts or increased 
circulatory monocytes.24 In the FAB classification, AML was defined as a BM composed of 
>30% blasts. 
 
FAB Classification PB Findings BM Findings 
Refractory Anaemia (RA) <1% blasts <5% blasts 
RA with Ringed Sideroblasts 
(RARS) 
<1% blasts 
<5% blasts 
15% ringed sideroblasts 
RA with Excess Blasts (RAEB) 0 to 4% blasts 5% to 20% blasts 
RAEB in Transformation (RAEB-T) 5% blasts 21% to 30% blasts 
Chronic Myelomonocytic 
Leukaemia (CMML) 
<5% blasts 
>109/l monocytes 
1% to 20% 
 
 
AML was divided into the subgroups M0 to M729-31 (Table 1.2) characterised by the 
maturation of the major cell lineage(s) involved:  
Table 1.1: FAB classification of MDS  
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Show various degrees of granulocytic 
differentiation  
 
M0: AML with Minimal Myeloid Differentiation 
M1: Myeloblastic Leukaemia without Maturation 
M2: Myeloblastic Leukaemia with Maturation              
M3: Hypergranular Promyelocytic Leukaemia 
M4: Myelomonocytic Leukaemia -[Granulocytic and monocytic differentiation] 
M5: Monocytic Leukaemia -[Monocyte differentiation] 
M6: Erythroleukaemia -[Erythrocyte differentiation] 
M7: Megakaryoblastic Leukaemia -[Megakaryocyte differentiation] 
 
1.4 The World Health Organisation (WHO) Classification  
The WHO Classification relies on a combination of clinical, morphologic, immunophenotypic, 
genetic and other biologic features to define specific disease entities. The WHO criteria 
apply to initial diagnostic peripheral blood (PB) and bone marrow (BM) obtained prior to 
any definitive therapy for a suspected haematological neoplasm. 
1.4.1 WHO Classification for the Myelodysplastic Syndromes (MDS) 
At least 10% of cells derived from one myeloid bone marrow lineage i.e. erythroid, 
granulocytic or megakaryocytic must show dysplasia for the lineage to be considered as 
dysplastic.32 However, causes of secondary dysplasia such as nutritional deficiencies, 
medications or infection should be excluded before a diagnosis of MDS can be confirmed. 
In the WHO classification (Table 1.3), the blast threshold for the diagnosis of AML was 
reduced from 30% to 20% in the PB or BM which therefore eliminated the FAB category 
RAEB-T.33 The FAB category of RAEB was also refined into RAEB-1 and RAEB-2 depending on 
the blast percentage in the blood and marrow and the presence or absence of Auer rods.33 
RAEB-1 has also been redefined to include patients who present with a 2 to 4% blast 
percentage in the blood even if there is less than 5% blasts in the marrow.32 In contrast, 
patients with 5 to 19% blasts in the blood or 10 to 19% blasts in the bone marrow are 
categorised as RAEB-2, the highest grade of MDS.    
Table 1.2: FAB classification of AML  
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Additionally, Chronic Myelomonocytic Leukaemia (CMML) was incorporated into a separate 
category termed ‘the Myelodysplastic/Myeloproliferative Neoplasms’ since it demonstrates 
clinical, laboratory and morphologic features associated with both a Myelodysplastic 
Syndrome (MDS) and a Myeloproliferative Neoplasm (MPN).33 CMML has also been 
separated into two entities: CMML-1 and CMML-2 that can be distinguished by the 
percentage of blast cells in the marrow and peripheral blood. Promonocytes and <10% and 
<5% blasts in the BM and PB, respectively define CMML-1 whereas promonocytes and 10% 
blasts in the BM and 5% blasts in the PB describe CMML-2.  
 
MDS Subtype PB Findings BM Findings 
Refractory Cytopenia with 
Uni-lineage Dysplasia 
(RCUD) 
- Refractory Anaemia 
(RA) 
- Refractory 
Neutropenia (RN) 
- Refractory 
Thrombocytopenia 
(RT) 
- <1% blasts 
- Uni-/bi-cytopenia 
- Unilineage dysplasia: 10 
of cells in one myeloid 
lineage 
- <5% blasts 
- Ring sideroblasts account 
for less than 15% of 
erythroid precursors 
 
Refractory Anaemia with 
Ring Sideroblasts (RARS) 
- Anaemia 
- No blasts 
- 15% of erythroid 
precursors are ring 
sideroblasts 
- Dyserythropoiesis only 
- <5% blasts 
Refractory Cytopenia with 
Multi-lineage Dysplasia 
(RCMD) 
 
- Cytopenia(s) 
- No or rare blasts 
- No Auer rods 
- <1x 109/l 
monocytes 
- Dysplasia in 10% of cells 
in 2 or more lineages 
- <5% blasts 
- No Auer rods 
 
Table 1.3: WHO classification of MDS  
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Refractory Anaemia with 
Excess Blasts-1 (RAEB-1) 
- Cytopenia(s) 
- <5% blasts 
- No Auer rods 
- <1x 109/l 
monocytes 
- Uni-lineage or multi-
lineage dysplasia 
- 5 to 9% blasts 
- No Auer rods 
Refractory Anaemia with 
Excess Blasts-2 (RAEB-2) 
 
- Cytopenia(s) 
- 5 to 19% blasts 
- Auer rods 
- <1x 109/l 
monocytes 
- Uni-lineage or multi-
lineage dysplasia 
- 10 to 19% blasts 
- Auer rods 
Myelodysplastic Syndrome 
associated with isolated 
del(5q): “the 5q- 
Syndrome” 
- Favourable outcome 
- Low incidence of 
AML 
- Anaemia 
- Normal/ elevated 
platelets 
- No or rare blasts 
- Normal to increased 
megakaryocytes with 
hypolobated nuclei 
- <5% blasts 
- del(5q) is the sole 
cytogenetic abnormality 
- No Auer rods 
Myelodysplastic 
Syndrome, Unclassifiable 
(MDS-U) 
- Cytopenia 
- <1% blasts 
- Unequivocal dysplasia in 
<10% of cells in one or 
more myeloid lineages 
when accompanied by a 
cytogenetic abnormality 
considered as 
presumptive evidence for 
a diagnosis of MDS (Table 
1.2).  
- <5% blasts 
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Clonal cytogenetic abnormalities occur in about 50% of MDS cases.34,35 If a patient presents 
with persistent cytopenia in the absence of conclusive morphologic features, a presumptive 
diagnosis of MDS can be made if a specific clonal chromosomal abnormality is present32 
(Table 1.4).  
 
Unbalanced Abnormalities Balanced Abnormalities 
-7 or del(7q) t(11;16)(q23;p13.3) 
-5 or del(5q) t(1;3)(p36.3;q21.2) 
-13 or del(13q) t(3;21)(q26.2;q22.1) 
i(17q) or t(17p) t(2;11)(p21;q23) 
del(11q) t(6;9)(p23;q34)   
idic(X)(q13)   inv(3)(q21;q26.2) 
del(9q)  
del(12p) or t(12p)  
 
Diagnosis can be problematic for patients who present MDS with hypocellularity (h-MDS) 
which arises in 10% of adult MDS.36 When the marrow is normal or hypercellular and 
dysplasia is detected, myelodysplasia can be distinguished from Aplastic Anaemia (AA).37 
However, in cases where the bone marrow cellularity is low (<20%),36,38 an accurate 
morphological analysis may be difficult to perform because of inadequate material from 
hypoplastic specimens.36,39 The majority of h-MDS cases are classed as Refractory Anaemia 
(RA) and such characteristics including an absence of increased blast count and mild 
dyserythropoiesis can overlap with what is seen in AA.36 Clonal cytogenetic abnormalities 
are usually considered diagnostic of MDS but 50% of cases present with a normal 
karyotype.37,39 Additionally, cytogenetic testing may be less reliable because of a low 
number of cells37,39 making it more difficult to differentiate between these disorders. 
 
 
 
Table 1.4: A presumptive diagnosis of MDS can be made if a specific clonal chromosomal abnormality is 
present. 
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Table 1.5: WHO classification of AML 
1.4.2 WHO Classification for Acute Myeloid Leukaemia (AML) 
In the WHO scheme, a myeloid neoplasm with 20% or more blasts in the PB or BM is 
considered to be AML whether it arises de novo, in the setting of a previously diagnosed 
Myelodysplastic Syndrome (MDS), Myelodysplastic/Myeloproliferative neoplasm 
(MDS/MPN), or blast transformation in a previously diagnosed Myeloproliferative neoplasm 
(MPN), such as Primary Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia. It 
may also occur following therapy to a non-haematological malignancy.32,33 However, a 
diagnosis of AML can be made regardless of the blast percentage in such cases associated 
with specific genetic abnormalities, i.e. t(8;21)(q22;q22); RUNX1-RUNX1T1, 
inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); CBF-MYH11 and t(15;17)(q22;q21); PML-
RAR.33 Table 1.5 represents the WHO classification of Acute Myeloid Leukaemia (AML).  
 
Acute Myeloid Leukaemia (AML) 
with Recurrent Genetic 
Abnormalities 
 
(Variant MLL translocations should 
be specified at diagnosis since over 
80 partner genes can participate in 
the translocation with MLL 
therefore resulting in variable 
biological characteristics)  
 
 
- AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
- AML with inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22); CBF-MYH11 
- Acute Promyelocytic Leukaemia (APL) with 
t(15;17)(q22;q21); PML-RAR 
- AML with t(9;11)(p22;q23); MLLT3-MLL 
- AML with t(6;9)(p23;q34); DEK-NUP214 
- AML with inv(3)(q21;q26.2) or 
t(3;3)(q21;q26.2); RPN1-EVI1 
- AML (megakaryoblastic) with 
t(1;22)(p13;q13); RBM15-MKL1 
- AML with mutated NPM1 (Provisional entity) 
- AML with mutated CEBPA (Provisional entity) 
Acute Myeloid Leukaemia (AML) 
with Myelodysplasia-related 
changes (AML-MRC) 
- 20% blasts with,  
- Morphologic dysplasia in 50% of at least 2 
myeloid lineages or,  
- A history of MDS or MDS/MPN or  
- with MDS related cytogenetic abn (Table 1.6)  
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Therapy-related Myeloid 
Neoplasms (t-AML/t-MDS) and (t-
AML/t-MDS/MPN) 
Occurring as a late complication of cytotoxic 
chemotherapy and/or radiotherapy 
Acute Myeloid Leukaemia, Not 
Otherwise Specified (NOS) 
 
Cases that do not fulfil the WHO 
criteria of the other AML 
categories. Account for 25% to 30% 
of all cases. However, this group 
will continue to reduce with the 
recognition of more genetic 
subgroups.  
 
- AML with Minimal Differentiation  
- AML without Maturation  
- AML with Maturation  
- Acute Myelomonocytic Leukaemia  
- Acute Monoblastic/Monocytic Leukaemia  
- Acute Erythroid Leukaemia  
         - Pure Erythroid Leukaemia 
         - Erythroleukaemia, Erythroid/Myeloid 
- Acute Megakaryoblastic Leukaemia  
- Acute Basophilic Leukaemia 
- Acute Panmyelosis with Myelofibrosis 
- Myeloid Sarcoma 
Acute Leukaemia of Ambiguous 
Lineage 
 
Show no clear evidence of 
differentiation along a single 
lineage. 
 
- Undifferentiated Acute Leukaemia (AUL) 
- Cases with no lineage specific markers  
- Mixed Phenotype Acute Leukaemia (MPAL)  
- Blasts co-express certain antigens of 
more than one lineage on the same 
cell or that have separate populations 
of blasts that are of different lineages 
 
It has been argued that 90% of patients with therapy-related disease share cytogenetic 
abnormalities with those observed in ‘AML with Myelodysplasia-related changes’ or in ‘AML 
with recurrent cytogenetic abnormalities’ and therefore could be more appropriately 
classified into those categories,32 however patients with therapy-related myeloid neoplasms 
have significantly worse outcomes than their de novo counterparts with the same genetic 
abnormality suggesting that that there are biological differences.40-42 
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Unbalanced Abnormalities Balanced Abnormalities 
-7 or del(7q) t(11;16)(q23;p13.3) 
-5 or del(5q) t(3;5)(q25;q34) 
del(11q) t(5;7)(q33;q11.2) 
-13 or del(13q) t(2;11)(p21;q23) 
i(17q) or t(17p) t(5;12)(q33;p12) 
del(12p) or t(12p) t(1;3)(p36.3;q21.1) 
del(9q) t(5;17)(q33;p13)   
idic(X)(q13) t(5;10)(q33;q21)  
 t(3;21)(q26.2;22.1) 
 
1.5 International Prognostic Scoring System (IPSS) for MDS 
Patient outlook can be predicted using the IPSS43 or the more recent IPSS-R44 scoring system 
and facilitate in making therapeutic decisions.  
The prognostic outlook of MDS patients can be determined using the IPSS scoring system 
devised in 1997.43 It relies on three major variables including bone marrow blast percentage 
(BM blast %), the number of cytopenias and karyotypic complexity with which can be 
divided into Good, Intermediate or Poor (Table 1.7). Cytopenias are defined as a 
haemoglobin level of under 10g/dl, an absolute neutrophil count (ANC) of less than 1800/l 
and a platelet count of less than 100,000/l. 
 
Good Normal, del(5q) only, del(20q) only, -Y only 
Intermediate Other abnormalities 
Poor Complex Abnormalities ( 3 anomalies), 
chromosome 7 abnormalities 
 
By combining the risk scores listed in Table 1.8, patient outlook can be stratified into four 
prognostic subgroups: Low, Intermediate-1, Intermediate-2 or High (Table 1.9). Overall 
survival decreases in advanced subgroups with low-risk patients showing prolonged survival. 
Moreover, Low and Int-1 subgroups could be further refined based on patient age. Notably, 
Table 1.6: The cytogenetic abnormalities sufficient for a diagnosis of AML with myelodysplasia-related changes 
when 20% or more BM and PB blasts are present.  
Table 1.7: Chromosomal abnormalities associated with a good, intermediate or poor risk in the IPSS.  
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individuals 60 years or less showed improved overall survival in contrast to older patients.  
High-risk patients show increased mortality as a consequence of Acute Myeloid Leukaemia 
(AML) development whereas low-risk patients more likely die of complications associated 
with bone marrow failure. In contrast to high-risk patients, leukaemic evolution was 
prolonged in patients that did develop AML in lower risk groups.  
 
Prognostic variable Score  
 0 0.5 1.0 1.5 2.0 
BM blast % <5 5-10 - 11-20 21-30 
Karyotype Good Intermediate Poor - - 
Cytopenia 0/1 2/3 - - - 
 
Prognostic Risk Group Combined Risk Score 
Low 0 
Intermediate-1 (Int-1) 0.5-1.0 
Intermediate-2 (Int-2) 1.5-2.0 
High 2.5 
 
1.6 Revised-International Prognostic Scoring System (IPSS-R) for MDS 
As in IPSS, the cytogenetic subgroup, bone marrow blast percentage and cytopenia remain 
prognostically relevant within the revised IPSS score (IPSS-R),44 however patient outlook has 
been further refined by incorporating novel chromosomal abnormalities (Table 1.10) and by 
analysing the depth of blood cell cytopenia. Accordingly, instead of the number of 
cytopenias, i.e. 1 to 3; haemoglobin, platelet or absolute neutrophil counts were stratified 
using relative cut-off points as listed in Table 1.11.  
 
 
 
Table 1.9: The total value of the risk scores predicts patient outlook which varies from low, int-1, int-2 or high 
risk 
Table 1.8: The severity of each prognostic variable gives a score value which is later summed to predict 
patient outlook.  
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Very Good -Y, del(11q) 
Good 
Normal, del(5q), del(12p), del(20q), double anomalies 
including del(5q) 
Intermediate 
del(7q), +8, +19, i(17q), any other single or double 
independent clones 
Poor 
-7, inv(3)/t(3q)/del(3q), double anomalies including -7/del(7q), 
complex: 3 abnormalities 
Very Poor Complex: >3 abnormalities 
   
The IPSS-R further refined bone marrow blast percentage (Table 1.11). Patients presenting 
with 0% to 2% bone marrow blasts showed prolonged overall survival and time to AML 
evolution when compared to patients presenting with >2% to <5% blasts, thereby refining 
the IPSS blast category of <5% blasts. It was also observed that clinical outcomes in terms of 
overall survival and AML evolution were similar in individuals who presented with >10% to 
20% bone marrow blasts versus 21% to 30% blasts therefore the newly revised IPSS-R 
combined these two parameters into >10% to 30%. 
 
 
  
Prognostic 
Variable 
Score  
 0 0.5 1.0 1.5 2.0 3.0 4.0 
Cytogenetics 
Very 
Good 
- Good - Intermediate Poor 
Very 
Poor 
BM Blast % 2 - >2 to <5 - 5 to 10 >10 - 
Haemoglobin 
(g/dL) 
10 - 8 to <10 < 8 -  - - 
Platelets 
(109/L) 
100 
50 to 
<100 
<50 - - - - 
ANC (109/L) 0.8 <0.8 - - - - - 
 
Thus, using additional features the revised-IPSS scoring system could be differentiated into 5 
prognostic subgroups (Table 1.12) for overall survival and AML evolution: Very Low, Low, 
Intermediate, High and Very High. Moreover, the IPSS-R could be further adjusted for 
Table 1.10: Chromosomal abnormalities associated either very good to very poor risk scores in the revised-
IPSS. 
Table 1.11: The severity of each prognostic variable gives a score value which is later summed to predict 
patient outlook. Haemoglobin, platelet or absolute neutrophil counts have been stratified using relative cut-
off points and blast counts have been further refined in the IPSS-R. 
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patient age categorising patients based on the IPSS-RA scoring system, however this was 
only applicable for overall survival and not AML evolution. Accordingly, the median age of 
the patient cohort from which the prognostic risk score categories were calculated from was 
70 years, therefore risk scores could be age-adjusted using the following formula: (Years - 
70) x [0.05 - (IPSS-R Risk Score x 0.0005)], added onto the IPSS-R score. Notably, younger 
individuals showed prolonged overall survival in contrast to older patients in which overall 
survival reduced with aging.  
 
 
 
Prognostic Risk Group Combined Risk Score 
Very Low 1.5 
Low >1.5 to 3 
Intermediate >3 to 4.5 
High >4.5 to 6 
Very High >6 
 
1.7 Therapeutic Options in MDS 
The pathogenesis and prognostic outlook of MDS among the population is very diverse, thus 
hindering the choice of therapeutic options. A large fraction of MDS patients receive 
supportive care including transfusions or growth factors for cytopenias, such as 
erythropoietin or granulocyte stimulating factor rather than a disease-specific therapy. 
However, cytogenetic analysis has facilitated in predicting the patient’s risk of AML 
transformation and provides a basis for drug selection.21 Thus, patients initially diagnosed 
with a lower risk MDS may be identified as having a poorer outcome and might benefit from 
early therapeutic intervention. Furthermore, patients who are ineligible for transplantation, 
such that they may be of an unfavourable age, may benefit from an MDS-specific therapy. 
Accordingly, the FDA has approved three such treatments for use in the USA. These consist 
of two hypomethylating drugs decitabine45 and 5-azacitidine46 and the thalidomide 
derivative lenalidomide.47 Inactivation of tumour suppressor genes (TSG) by promoter 
hypermethylation can be reversed during DNA synthesis. Decitabine is a cytosine nucleoside 
analogue that can inhibit DNA methylation when incorporated into DNA, thus reactivating 
Table 1.12: The total value of the risk scores predicts patient outlook. Five subgroups were devised in the 
IPSS-R from very low to very high risk.  
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the TSG.45 Transfusion independence,45 a significant increase in progression-free survival 
and reduced AML transformation rate have been observed in a phase III randomised study 
comparing decitabine with supportive care only.45 Improvements in the quality of life have 
also been documented.48 When undergoing a phase III trial, the DNA methyl-transferase 
inhibitor, 5-azacitidine has demonstrated prolonged patient survival and a reduced risk of 
AML transformation in higher risk patients.46 Lenalidomide is the third drug that has been 
approved in the USA. This drug works favourably with patients that endure the 
chromosomal abnormality 5q31 deletion since it has shown a selective cytotoxicity towards 
the del(5q) clone.47 It has been observed that the drug is able to suppress the del(5q) clone 
restoring transfusion independence in this group of patients. Although accepted in the USA, 
Lenalidomide has not been approved in Europe due to the frequency of treatment-related 
AML transformation.21 Accordingly, a third of patients who are refractory to treatment have 
a high risk of AML progression. These patients often develop complex karyotypes as a result 
of genetic instability.49    
1.8 Prognostic Scoring in Acute Myeloid Leukaemia  
Patients who are eligible to receive standard induction chemotherapy for Acute Myeloid 
Leukaemia (AML) are treated under the “7 + 3” regimen that includes 7 days of cytosine 
arabinoside (Ara-C) and 3 days of anthracycline.50 However, this excludes patients 
diagnosed with Acute Promyelocytic Leukaemia (APL) who specifically receive a combination 
of anthracycline and all-trans Retinoic Acid (ATRA). The presence of PML/RARin APL cells 
denotes sensitivity to the differentiation inducing agent ATRA.51 This subset of patients has 
a favourable prognosis with sustained long term remission and excellent overall survival.52  
Following the first course of induction chemotherapy, therapeutic management depends on 
variable clinical parameters which assess the patient’s response to treatment and risk of 
relapse in CR (complete remission). Such parameters include age, leukaemia cytogenetics 
(Table 1.14), and response status after course 1, presenting white blood cell (WBC) count 
and AML type (de novo/ secondary AML). Secondary AML can either follow prior cytotoxic 
chemotherapy or radiotherapy for other cancers or arise subsequently to an antecedent 
haematological disorder.53 The response status after the first course of induction 
chemotherapy is categorised as: 
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- CR [complete remission; BM is regenerating normal haematopoietic cells and 
contains <5% blast cells. An absolute neutrophil count of >1x109/l and platelet count 
of 100x109/l]  
- PR [partial remission; BM is regenerating normal haematopoietic cells and blast 
count has reduced by at least half to a value between 5 and 25% leukaemic cells] 
- RD [resistant disease; BM shows persistent AML and patient survives at least 7 days 
beyond the end of course 1] 
Cox Regression analysis has been undertaken on patients derived from the Medical 
Research Council (MRC) AML trials 10 and 12 to provide a number of weighted factors which 
could be used to define patients as good, standard or high-risk. Table 1.13 shows how this 
index can be calculated:  
 
 
 
 
Defined cut-off points for dividing patients into good, standard or high-risk are arbitrary 
since outcome probabilities are produced as a continuum.53,54 Patients with low-risk AML 
may continue induction chemotherapy for a further 3 or 4 cycles as a curative treatment 
(consolidation chemotherapy).55 Conversely, high-risk patients may be eligible candidates 
for an allogeneic or autologous Stem Cell Transplant (SCT) provided that a suitable donor is 
available.50 If AML cases fail to respond to conventional chemotherapy (resistant AML), 
patients may be offered alternative or investigational treatment.53      
Elderly patients (>70 years) who do receive intensive chemotherapy show poor 5 year 
survival rates of less than 10% in contrast to over 50% of cases in children.54 Notably, older 
individuals are more likely to show a poorer tolerance to chemotherapeutic drugs. However, 
secondary AML arising from an antecedent haematological disorder is more prevalent in the 
elderly16 and patients commonly present with unbalanced and complex karyotypes16,56  
including abnormalities of chromosomes 5, 7 and 17.57 
Index = 0.01325*Age (in years) + 0.16994*Sex (1=Male, 0=Female) + 
0.22131*Diagnosis(1=De novo, 2=Secondary) + 0.65082*Cytogenetics (1=Favourable, 
2=Intermediate, 3=Adverse) + 0.19529*Status Post C1 (1=Complete Response, 2=Partial 
Response, 3=No Response) + 0.00169* WBC Count (x109/l) 
Table 1.13: Patient outlook can be calculated using a number of weighted factors that calculate a risk score  
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Cytogenetic and Molecular Genetic Characteristics in AML 
The key determinant in influencing patient outcome is the diagnostic karyotype, of which 
60% of patients present with an abnormal karyotype.58 Specific biological entities of AML 
that include APL with t(15;17)(q22;q21), AML with t(8;21)(q22;q22) and AML with 
inv(16)(p13.1;q22)/t(16;16)(p13.1;q22) can be treated using tailored therapy with a 
relatively favourable prognosis.52,55 These individuals show low relapse rates in complete 
remission (CR) are therefore unlikely candidates for bone marrow transplantation. 
Conversely, AML patients that present with an adverse karyotype have a very poor 
prognosis with conventional chemotherapy58 and are therefore considered for a bone 
marrow transplant (Table.1.14).  
 
Favourable 
Irrespective of the presence of additional cytogenetics:  
 t(8;21)(q22;q22) 
 inv(16)(p13.1;q22)/ t(16;16)(p13.1;q22) 
 t(15;17)(q22;q21) 
Intermediate 
 Normal karyotype 
 Structural or numerical changes not encompassed 
by favourable/adverse risk groups 
Adverse 
 [abn(3q)] 
 del(5q)/-5 
  -7 
 Complex Karyotype:  5 unrelated abnormalities 
 
The mutation status of specific genes can also influence patient outcome such that their 
identification may further refine patient prognosis, particularly within patients that present 
with a normal karyotype detected amongst 40% of AML cases.58 Such molecular markers 
associated with AML include FLT3, NPM1, CEBPA and KIT.  
The FLT3 (FMS-like tyrosine kinase 3) receptor plays a role in the survival, proliferation and 
differentiation of haematopoietic cells.59,60 Mutations in the receptor, in the form of an 
Table 1.14: Chromosomal abnormalities which define favourable, intermediate or adverse cytogenetics 
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internal tandem duplication (ITD) of the juxtamembrane domain and point mutations within 
the tyrosine kinase domain (TKD) both result in its constitutive activation.61 Tandem 
duplications are thought to disrupt the interaction between the juxtamembrane domain and 
the activation loop destabilising the inactive configuration of the kinase. The conformational 
change causes cytokine independent proliferation of haematopoietic cells.62 Mutations in 
the TKD alter the configuration of the activation loop to enable increased access to ATP and 
substrates to the kinase.62 The ITD mutation has been detected in 25% of AML cases, 
whereas the TKD mutation has been detected in 5 to 10% of cases.62,63 FLT3/ITD has been 
frequently documented in AML cases with an inferior outcome64,65 whereas the prognostic 
impact of the FLT3/TKD mutation is less clear. 60,66-68  
NPM1 functions as a molecular chaperone that shuttles between the nucleus and 
cytoplasm.69 It is predominantly nucleolar, however 30% of AML patients bear a mutated 
NPM1 resulting in its aberrant localisation in the cytoplasm (NPMc+).70,71 The NPMc+ 
mutation is a marker of a favourable prognosis72 however, these patients regularly harbour 
the FLT3/ITD and thus the favourable outcome is diminished in these patients.73,74    
CEBP (CCAAT/enhancer binding protein alpha) is a transcription factor that is essential for 
granulocytic development.75 Loss of CEBP function in myeloid cells causes a block in 
granulocytic differentiation.75,76 Mutations in the CEBP occur in approximately 15% of 
cytogenetically normal AML cases and can present as either biallelic or monoallelic 
mutations. Biallelic mutations frequently involve a combination of an N-terminal frame-shift 
mutation on one allele and a C-terminal in-frame mutation on the other which result in 
protein truncation and an impairment of DNA binding activity, respectively. In contrast, a 
monoalleic mutation presents with either an N or C-terminal mutation. A more favourable 
prognosis has been indicated in cytogenetically normal AML patients that present with the 
biallelic mutation. Patients with monoallelic CEBP show a similar outlook to patients with 
wild-type CEBP. Although monoallelic CEBP is commonly associated with additional 
mutations, i.e. NPM1 and FLT3 ITD/TKD, biallelic CEBP continues to be associated with 
improved prognosis with no difference between monoallelic and wild-type CEBP following 
the exclusion of these concurrent abnormalities.77 However, the prognostic significance of 
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monoallelic CEBP is controversial since it has been recently reported to possibly confer a 
favourable prognosis in patients with both wild-type FLT3/ITD and wild-type NPM1.75  
Favourable risk groups may be further stratified into prognostic subgroups with a less 
favourable outcome. Accordingly, AML patients presenting with Core-Binding Factor (CBF) 
AMLs i.e. AML with inv(16) or AML with t(8;21) have an adverse prognosis in the presence of 
a KIT mutation. This subset of patients have a 6-fold increase in relapse in the first CR when 
compared to CBF AML without the KIT mutation.78  
1.9 Therapeutic Studies in AML 
It has been reported that the addition of a purine analogue, Cladribine to standard induction 
therapy can increase complete remission rates and improve overall survival when compared 
with induction chemotherapy alone. Haematological and non-haematological toxicity were 
comparable among treatment groups. Moreover, in contrast to induction therapy alone, the 
addition of Cladribine achieved complete remission and improved overall survival in patients 
presenting with adverse karyotypes, higher initial white blood cell counts and aged over 
50.79  
Phase II trials have demonstrated that Clofarabine, a second generation purine analogue is 
well tolerated in older adults with AML who are considered unfit for conventional 
chemotherapy. In contrast to patients treated with low dose Ara-C (LDAC), patients treated 
with Clofarabine as a single agent show improved complete remission. However, despite 
improved remission rates survival was inferior in patients with refractory AML treated with 
Clofarabine (107 days; LDAC vs. 60 days; Clofarabine) and in patients with relapsed disease 
(40 weeks; LDAC vs. 20 weeks; Clofarabine).80 Yet Clofarabine has been shown to achieve 
improved complete remission in individuals presenting with adverse cytogenetics (44%; 
Clofarabine vs. 0%; LDAC) and secondary AML (31%; Clofarabine vs. 4%; LDAC).81   
Pre-treatment with DNA-hypomethylating agents prior to the standard “7+3” induction has 
been demonstrated to increase the efficacy of induction chemotherapy in AML. It was 
proposed that the inactivation of TSGs by aberrant DNA methylation during carcinogenesis 
may contribute to the resistance of leukaemic cells to cytotoxic treatment. In a phase I trial, 
AML patients (median age 55 years) with a less than favourable risk were pre-treated with 
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the hypomethylating agent Decitabine.82 83% of patients achieved complete remission after 
two cycles of induction chemotherapy and 53% were still alive after a median 32 month 
follow-up. It has been proposed that Decitabine may act as a chemosensitiser and 
complement the cytotoxic effects of standard induction chemotherapy by reactivation of 
TSG expression.   
Allogeneic-Haematopoietic Stem Cell Transplantation (Allo-HSCT) is a widely used approach 
for a treatment of advanced AML and high-risk MDS however, only 20 to 30% of patients 
with high-risk AML become long-term survivors after a BMT with the most common causes 
of treatment failure including relapse, non-relapse mortality (NRT) and Graft vs. Host 
Disease (GVHD). Conventional preparative regimens for Allo-HSCT are often high-dose and 
thus older patients or those with attendant co-morbidities are ineligible candidates due to 
treatment associated complications. Patients presenting with >5% blasts in the marrow 
prior to Allo-HSCT conditioning show relapse rates greater than 50% when treated with a 
reduced intensity regimen composed of Total body irradiation (TBI) and Fludarabine.83 
Efforts to decrease relapse rates have been focused on therapy intensification, such as 
increasing TBI dosage. Although this has been successful in reducing relapse rates, non-
relapse mortality is escalated as a consequence of surpassing normal organ tolerability.84 A 
phase I trial of targeted haematopoietic irradiation with 131I-labelled anti-CD45 antibodies 
(131I-BC8 Ab) has been demonstrated to reduce relapse rates to 40% in elderly patients 
presenting with advanced AML or high-risk MDS in the marrow prior to Allo-HSCT 
conditioning.85 Of note, 86% of patients in this study presented with >5% blasts at the 
beginning of the conditioning regimen. The one year survival estimate of the entire cohort 
in this trial was 41%, among those 46% presented with AML in remission, 46% with relapsed 
AML, 38% with refractory AML and 33% with high-risk MDS prior to Allo-HSCT conditioning.   
1.10 MDS Cell of Origin 
Cytogenetic abnormalities associated with the neoplastic clone are often observed in 
multiple myeloid lineages including peripheral blood granulocytes, monocytes and 
erythrocytes. Accordingly, it has been assumed that the primary neoplastic event originates 
in a committed myeloid progenitor, particularly since MDS rarely transforms into Acute 
Lymphoblastic Leukaemia (ALL).19,86 However, the clonal involvement of non-myeloid cells 
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has been detected in a subset of patients raising the possibility that the initial 
transformation event can occur in a more primitive stem cell with multi-lineage potential.34 
The apparent myeloid lineage restriction could be a consequence of genetic (and epigenetic) 
abnormalities that have developed in a HSC causing suppression of lymphoid differentiation 
and providing a false observation.19,87 Alternatively, a sustainable lymphocytic population 
may arise from a long-lived lymphoid progenitor generated before the cytogenetic 
abnormality occurred.88 It has also been postulated that an efficient compensatory 
mechanism from a low fraction of normal stem cells might be supporting T- and B-cell 
production.19  
X-chromosome inactivation may provide information in determining cellular clonality in 
female patients on condition that constitutional skewing of X-inactivation is excluded.89 Cells 
derived from the same progenitor would retain the X chromosome inactivation pattern, 
thus this population of cells would have a monoclonal distribution. Conversely, a polyclonal 
pattern of clonality would be established if cells were derived from alternate 
progenitors.90,91 The digestion of the un-methylated X-chromosome at heterozygous loci, 
i.e. HUMARA (Human Androgen Receptor) or PGK (Phosphoglycerate Kinase) can provide 
information on the clonal nature of haematopoiesis by means of visualising the clonality of 
the inactive X chromosome by Restriction Fragment Length Polymorphism (RFLP) analysis. 
Monoclonal X-inactivation patterns of PGK have been detected in the bone marrow, 
granulocytic and T-lymphocytic fractions of the peripheral blood in MDS patients that show 
a polyclonal X-inactivation pattern in corresponding skin tissue.90 RFLP analysis of the 
HUMARA locus from sorted haematopoietic cells demonstrated a monoclonal distribution 
within CD34+CD38-, CD34+CD38+ and in mature myeloid cells. Although a polyclonal pattern 
of T and B-lymphocytes was detected in the majority of patients, a CMML and RAEB patient 
showed monoclonality of the B-lymphocyte and T-lymphocyte populations, respectively 
suggesting the clonal involvement of an MDS precursor common to both myeloid and 
lymphoid lineages. The identification of a polyclonality in T-lymphocytes derived from the 
CMML patient is suggestive of an MDS precursor that is common to both myeloid and B-
lymphocytic lineages.92 Accordingly, single lymphohaematopoietic progenitors have 
demonstrated their ability to yield progeny committed to either the myeloid or B-lymphoid 
lineages in vitro.93,94 
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FISH (Fluorescence in situ Hybridisation) analysis has demonstrated the clonal nature of 
common chromosome abnormalities within purified bone marrow cells. The 5q deletion has 
been previously detected in the vast majority of cells derived from the CD34+CD38- (94 to 
98%) and CD34+CD38+ (>88%) fractions. Although commonly detected within myeloid 
progenitors, the deletion was also detected in 25 to 90% of pro-B and 98% of pro-T-cell 
progenitors within three of five investigated patients and in one case respectively. This is 
consistent with the initial transformation event arising in a cell with multi-potent 
potential.19 Furthermore, patient-derived CD34+CD38- cells failed to reconstitute 
haematopoiesis in vitro and in vivo in contrast to normal controls.19   
A high percentage of pluripotent stem cells (CD34+Thy-1+), pro-B cell progenitors 
(CD34+CD19+) and T/natural killer progenitor cells (CD34+CD7+) have been observed to bear 
an isolated monosomy 7 whereas its detection was below the cut-off value in T-and B-
lymphocytes. However, 60% of natural killer cells retained the monosomy 7 suggesting that 
T-and B-lymphocyte progenitors positive for the aneuploidy may only undergo limited 
differentiation.95 This is consistent with previous observations that have identified the 5q 
deletion in pro-B and pro-T cell progenitors but not within mature T- and B-lymphocytes.19 
However, in vitro expansion may facilitate in the detection of a minor monoclonal 
lymphocyte pool. Accordingly, a monoclonal pattern of the X-linked Glucose-6-phosphate 
dehydrogenase (G6PD) has been detected in Esptein-Barr virus (EBV) transformed B-
lymphocytes. The B-lymphoblastoid cell lines carried the identical isoenzyme that was 
detected in myeloid cells.96 Furthermore, clonal chromosomal markers on B-lymphoblastoid 
cell lines have shown the presence of an identical 20q deletion to that observed in myeloid 
cells.97 Although this indicates the involvement of a cell with both myeloid and lymphoid 
potentiality, Phytohaemagglutinin (PHA)-stimulated cells did not show the 20q deletion. 
Although a deletion at 20q may prevent T-lymphocyte differentiation, it has also been 
postulated that a close relationship may exist between B-lymphocytes and myeloid cells.97  
1.11 AML Cell of Origin 
It has been proposed that two models may provide insight into the development of the AML 
clone. The first model implicates that the initial event originates within a committed 
progenitor in which the phenotype of the leukaemic blasts is dependent on the degree of 
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differentiation. Thus, the degree of commitment influences the AML FAB characteristic.98 
However, for a committed progenitor that has lost its ability to self-replicate; leukaemic 
transformation would need to acquire further genetic changes that are already intrinsic to 
the HSC.1,4 The alternative model proposes that leukaemic transformation arises within a 
primitive stem cell and the characteristic of that genetic event determines the pathway of 
differentiation.98 This concept may explain the absence or appearance of lymphoid 
differentiation in a subset of AML patients.  
The transplantation of AML cells derived from donor patients into NOD-SCID (Non-obese 
Diabetic/Severe Combined Immunodeficiency) mice has demonstrated that the AML cell 
population exists as a hierarchy which is comparable to that found within normal bone 
marrow. A small population of primitive CD34++CD38- (0.2% of the total leukaemic cell 
population) can successfully engraft AML cells in NOD-SCID mice and resemble the 
differentiation pathway specific to the patient donor FAB subtype.98 Furthermore, these 
cells had the capability to engraft human cells to the equivalent level following serial 
transplantation in secondary recipients.98 Persistent and transient leukaemic clones were 
established throughout serial transplantation. While it was established that persistent 
clones have a long-term repopulation capacity, which rarely commit along a lineage, 
transient clones were concluded to have a short-term repopulation capacity and commit 
more regularly eventually resulting in ‘clonal extinction’. Accordingly, it was assumed that 
AML cells form a highly organised hierarchy that is comparable to that of the stem cell pool 
retaining function and regulation in which the leukaemia-initiating event occurs in primitive 
cells and not in committed progenitors.98 However, it has been previously observed that 
AML-M1 can be engrafted into SCID mice with both CD34+ and CD34- fractions.99 Although it 
disfavours this model, it was proposed that multiple genetic events arose in the CD34 
fraction uncoupling function from lineage expression.99 Despite the apparent propensity of 
HSC transformation, AML-M3 may be an exception; the PML/RARfusion gene was 
observed only within the CD34+CD38+ population, thus transformation was probably 
acquired at the level of a committed progenitor.100 
Normal primitive HSCs defined as CD34+CD38-/lo Thy-1+ were found depleted in AML 
patients in remission carrying the AML1/ETO [t(8;21)(q22;q22)] translocation. Instead, the 
leukaemic bone marrow contained a small population of primitive leukaemic cells that had 
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the ability to self-renew with a CD34+CD38-/lo Thy-1- phenotype. In this study, this 
population of cells were not leukaemic and still retained the ability to differentiate into 
mature myeloid cells in vitro. Differentiated myeloid cells were positive for AML1/ETO and 
the translocation was also detected in B-lymphocytes101 strongly suggesting that the initial 
event occurred at the stem cell level however, the downregulation of Thy-1 may implicate 
that additional event(s) occurred in a normal Thy-1+ HSC causing the loss of the Thy-1 
phenotype.4 
1.12 Chromosomal Abnormalities  
The karyotype of abnormal cells is an independent predictor of therapy response, duration 
of remission and survival. Acquired cytogenetic aberrations are detected in 50 to 60% of 
newly diagnosed patients with MDS with a predominance of non-random chromosome copy 
number alterations.34,35 However, low sensitivity methods such as conventional cytogenetic 
G-banding analysis fails to detect karyotypic abnormalities in 50% of patients.102 Although 
the karyotype is termed ‘normal’,103 patient outcome is heterogeneous with some 
individuals’ rapidly deteriorating following diagnosis.104 
15 to 30% of patients with de novo MDS/AML have complex chromosome aberrations with 
no specific rearrangement involving three or more chromosomes.105 These patients have a 
significantly inferior prognosis and show a poor response to treatment including a 
considerable reduction in the success of a bone marrow transplant.106 
The 5q deletion is the most frequently reported chromosome deletion in MDS occurring in 
10 to 15% of patients.107 An interstitial deletion of 5q, the del(5)(q13q33) is regularly 
detected although other variants including del(5)(q31q35) and del(5)(q13q35) have been 
identified.108 Although, it is cytogenetically indistinguishable from deleted chromosome 5 of 
other myeloid disorders, the critical minimally deleted region (CDR) associated with the 
indolent 5q- syndrome is distinct from the CDR associated with more aggressive types of 
MDS or AML, thus specifying two separate genomic intervals on chromosome 5q.  
The 1.5Mb CDR mapped between 5q32 and 5q33109 has been documented to contain 
various genes including RPS14 and miRNAs including miR-145.110,111 The haploinsufficiency 
of these genes has been implicated in the pathogenesis of the 5q- syndrome with regard to 
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defective erythropoiesis and megakaryocytic dysplasia,110,111 respectively. Haploinsufficiency 
of RPS14 results in defects in ribosome biogenesis and translation. In response to ribosome 
dysfunction, HDM2 is prevented from inducing p53 ubiquitination.112 Consequently, p53 
accumulates and cell cycle arrest or apoptosis ensues. It has been previously demonstrated 
that CD34+ cells with a RPS14 knockdown show a reduction in the capacity to differentiate in 
vitro along the erythroid lineage. Notably, p53 was prevalent in early and late CD71+ 
erythroid progenitors consistent with an elevated percentage of the cells restricted to the 
G0/G1 phase of the cell cycle. Other myeloid inclined lineages including early myeloid 
progenitors (CD13+, CD33+, CD45+), leukocytes (CD11b+) and megakaryocytes (CD41+) did 
not show increased levels of p53. Defective erythropoiesis was also detected in the absence 
of ribosome dysfunction i.e. under conditions where HDM2 was chemically inhibited in vitro 
and in vivo.112 This implicates that erythroid cells show increased sensitivity to p53 than 
other myeloid derived lineages.112 Notably, DNA damage or telomere dysfunction could be 
readily detected in erythroid cells and therefore readily removed from the cell cycle. 
Consistent with this, Acute Erythroid Leukaemia occurs infrequently in patients manifesting 
the 5q- syndrome113 however, p53 inactivation may play a role in the leukaemic progression 
in these cases.   
Conversely, the 1-1.5Mb CDR commonly identified in AML and more advanced forms of 
MDS is mapped to 5q31114 which includes EGR1 and CTNNA1. 5q deletions observed in AML 
are usually associated with a complex karyotype and an inferior prognosis.115,116 Consistent 
with this, EGR1 (Early Growth Response 1) has shown to be a direct transcriptional regulator 
of many tumour suppressor genes (TSG) including p53 and p21.117 Moreover, it has been 
proposed that loss of function of EGR1 plays an initiating role in the development of 
MDS/AML as observed in EGR1+/- mice. Notably, the haploinsufficiency of EGR1 led to the 
development of lymphoid and myeloid malignancies in the murine model.118  
Monosomy 7 and a 7q deletion have been implicated in refractoriness to therapy and short 
survival. It was previously demonstrated that the loss at 7q31 is associated with the 
development of larger 7q- clones and short survival in patients with haematological disease 
including MDS and AML. Furthermore, a lower frequency of complex karyotypes was 
detected in patients who had retained 7q31119 suggesting that a candidate TSG is mapped to 
this locus. It has been recently documented that the loss of DOCK4 located at 7q31 may play 
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a role in myeloid disease. Accordingly, haematopoiesis colony assays demonstrated that 
reduced expression of DOCK4 in primary CD34+ cells resulted in a significant decrease in 
erythroid and myeloid colony formation as well as a significant increase in apoptosis of 
CD34+ cells.120 Furthermore, DOCK4 has been implicated to play a role in the formation of 
cellular adheren junctions in which its loss has been associated with enhanced tumour 
invasiveness in vivo.121  
Advanced MDS is characterised by high levels of genomic instability in comparison to early 
MDS. This is consistent with the downregulation Chk1 and Rad51 which has been noted to 
occur by at least 2-fold in advanced MDS.122 This implicates a dysfunction in cell cycle 
control and homologous recombination repair of DNA double strand breaks respectively. 
Cells show an increase in genomic instability and acquire a growth advantage leading to 
malignant transformation.122 
Aberrant DNA methylation in the promoter region of TSGs is an alternative to chromosome 
deletion for silencing TSGs. Concordantly, MDS patients show a significantly greater number 
of aberrantly methylated loci that include TSGs and genes involved in cell differentiation.123  
The p15INK4B cyclin-dependent kinase inhibitor is commonly hypermethylated in MDS with 
increased methylation status corresponding to disease progression.124,125 Accordingly, 
p15INK4B hypermethylation may provide a growth advantage by enabling cells to progress 
through the G1 phase of the cell cycle. Consistent with this, advanced MDS is associated with 
genomic alterations and loss of cell cycle control that can enable the clone to acquire 
additional genomic aberrations. Clonal variation and positive selection can then provide 
neoplastic advantage. 
Mutations of the Ten-Eleven Translocation-2 (Tet2) arise in 26% of MDS cases.126 It has been 
implicated to regulate the DNA methylation of genes important for myelopoiesis and 
leukaemogenesis.127 Tet2-/-mice show characteristics typical to CMML patients including 
neutrophilia and monocytosis with 33% developing pronounced splenomegaly and 
hepatomegaly caused by either erythroblast or myeloid cell infiltration, i.e. myeloblasts, 
monocytes, macrophages and neutrophils. This is suggestive that Tet2 functions as a tumour 
suppressor in myelopoiesis. Tet2 haploinsufficiency induced myeloid malignancy in 8% of 
mice; however, erythroblast infiltration was not detected. Furthermore, disease latency was 
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longer when compared to Tet2-/-mice.127 Thus, it has been implicated that Tet2 alters the 
disease phenotype in a dose-dependent manner. In keeping with this, loss of its function has 
been associated with an inferior prognosis e.g. a patient with a low IPSS risk score of 0 at 
diagnosis only survived for three months.128 
LOH (Loss of Heterozygosity) on 6q and 10p have been detected in a third of AML patients 
following MDS progression. Furthermore, allelic loss on 7p, 11q, 14q and 20q are also 
frequent events that have been observed in 23 to 27% of cases. It was proposed that 
recombination may be the mechanism responsible for LOH since no deletions were present 
on these arms.129 Consistent with this, Uniparental Disomy (UPD) has been recognised to 
occur in MDS.130  
UPD extending to the telomere has been identified in MDS on multiple chromosomes 
including 7p, 4q and 3q.130 The duplication of a pre-existing mutated TSG has the potential 
to completely inactivate its function, thus allowing clonal progression. Alternatively, 
activating mutations that are duplicated by UPD, i.e. FLT3 mutations can provide a growth 
advantage. Consistent with this, terminal UPD within the 13q12.11-qter comprised of the 
FLT3 locus has been described in AML cases with a normal karyotype.131 Furthermore, 
segmental UPD at FLT3/ITD has been observed in AML patients that have relapsed.132 It has 
been predicted that terminal LOH occurs in 10 to 20% of normal karyotype AML.131 
Furthermore, UPD has also been detected within the terminal region of 17p consistent with 
the loss of functional p53. Consistently, this patient presented with a complex karyotype.130 
The prevalence of p53 mutations has been studied extensively in MDS.133-136 Patients 
harbouring 17p monosomy have been found to have a higher propensity to develop a p53 
missense mutation on the remaining allele.133-135 It has been implicated that the complete 
abrogation of p53 results in a significantly shorter survival, leukaemic transformation and 
enhanced resistance to chemotherapy.135 p53 mutations have been found to accompany 
abnormal cytogenetics, particularly abnormalities involving chromosome 5 or 7.136  
1.13 Paradox  
MDS is a highly proliferative disorder with almost a third of marrow cells engaged in DNA 
synthesis.137 However, the bone marrow is simultaneously undergoing a high rate of cell 
death, which is particularly apparent in the early stages of the disease.138,139 In situ end 
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labelling (ISEL) of fragmented DNA in MDS bone marrow aspirates has shown that all three 
myeloid lineages, i.e. erythroid, megakaryocytic and granulocytic undergo apoptosis as well 
as stromal cells including fat cells, endothelial cells and fibroblasts.137 Accordingly, it was 
observed that over 75% of haematopoietic cells in the bone marrow were undergoing 
apoptosis in 50% of MDS cases.137 Notably, elevated apoptosis of differentiating cells may 
contribute to the existing paradox of hypercellularity in conjunction with peripheral blood 
cytopenias.22 Furthermore, it has been observed that cells which entered the S-phase of the 
cell cycle were also apoptotic implicating that an intact p53 pathway may be responsible for 
initiating apoptosis in replicating cells.137 Consistent with this, increased H2AX 
phosphorylation has been observed in the Lin-c-kit+Sca-1+ stem and progenitor cell 
population in an MDS mouse model in contrast to a wild-type.140 It has been proposed that 
the elevated level of apoptosis in MDS may function as a protective mechanism by reducing 
the number of premalignant cells that can acquire additional genetic mutations limiting the 
progress to AML.140  
Dual-labelled flow cytometry has been utilised to analyse the extent of apoptosis and 
proliferation of CD34+ cells following their transformation from MDS to Acute Myeloid 
Leukaemia.141 The level of CD34+ apoptosis exceeds the percentage of cells in the S-phase in 
RA/RARS patients. However, the evolution to RAEB-T/AML has been demonstrated to 
accompany a decrease in apoptosis.141 Accordingly, altered oncoprotein expression has 
been shown to accompany advanced disease supporting the accumulation of neoplastic 
CD34+ cells. C-myc has been observed to be a potent inducer of apoptosis under certain 
microenvironmental conditions, i.e. in the absence of stimulatory growth factors or in the 
presence of inhibitory cytokines,142 such as TNF. The expression of C-myc to Bcl-2 (blocks 
apoptosis) has been quantified in CD34+ cells derived from MDS patients of different stages 
as well as those from AML. It was observed that the degree of apoptosis occurring in CD34+ 
cells from MDS patients correlated with the relative C-myc:Bcl-2 oncoprotein ratio. 
Accordingly, apoptosis and the C-myc:Bcl-2 ratio was highest in RA/RARS but reduced 
sequentially with increased Bcl-2 expression, i.e. RA/RARS > Normal > RAEB/RAEB-T > 
AML.143 It has been documented that increased C-myc expression enhances cell cytotoxicity 
to TNF144Higher levels of TNF have been shown in MDS145 which may contribute to the 
apoptotic nature of this disease. However, the predisposition to apoptosis is reduced when 
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Bcl-2 expression is elevated.144 Whilst a near 4-fold reduction of bcl-2 expression has been 
observed in mouse models of early MDS when compared to wild-type mice140 an increase in 
bcl-2 expression has been associated with AML progression as well as a poor response to 
chemotherapy.146,147 
TNFhas been found at elevated levels in marrow plasma from MDS patients.145 It has the 
ability to regulate anti-apoptotic or pro-apoptotic effects on the cell by interacting with cell 
surface receptors TNFRI or TNFRII. Interaction with TNFRI can initiate anti- or pro-apoptotic 
responses by means of Nuclear Factor kappa B (NF-B) or induction of the caspase cascade 
respectively.148 TNFRII lacks a death domain and therefore it is only able to provide cellular 
protection. It has been previously observed that RA patients show a significant increase in 
TNFRI expression as compared to controls. In contrast, the expression level in late stage 
RAEB/ RAEB-T was similar or even lower to that found in controls.148 This is consistent with 
the higher apoptotic capacity in early stage disease. Furthermore, late stage MDS was 
associated with a significant increase in TNFRII expression consistent with blast cell 
accumulation and reduced apoptosis in advanced disease.148 Thus, a switch in favour of 
TNFRII from TNFRI plays a role in promoting MDS progression by reducing apoptosis of 
transformed cells.   
Activated cytotoxic CD8+ T-cells may contribute to the degree of myelosuppression by 
inducing apoptosis in by-standing normal haematopoietic cells149 and also prevent the 
propagation of the MDS clone. However, it has been proposed that in later stages MDS 
blasts have the advantage over T-cells and escape immune detection. Notably, B7-H1 
(CD274) molecules have been detected more often on MDS blasts in high-risk patients when 
compared to low-risk. B7-H1+ cells deliver an inhibitory signal to activated T-cells that 
express the Programmed cell Death-1 (PD-1) transmembrane protein. It has been observed 
that B7-H1+ blasts have greater proliferative capacity than B7-H1- blasts and have the ability 
to suppress T-cell proliferation and induce T-cell apoptosis.150 Thus, B7-H1 expression is 
associated with immune evasion and possibly with MDS progression.   
Normal CD34+ cells do not spontaneously express Fas but can be induced to do so with TNF 
in culture.151 Fas is a cell surface receptor that induces apoptosis when ligated by the Fas 
ligand (FasL), a cell surface molecule. Up-regulated Fas expression has been detected on 
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total BMMNC (bone marrow mononuclear cells) and on different BM subpopulations 
including CD34+, CD33+, glycophorin+ and CD14+ cells in MDS compared to normal controls. 
A strong negative correlation has been previously detected between Fas expression on 
CD34+ cells and the percentage of BM blast cells.152 Accordingly, patients with advanced 
disease had lower Fas expression. It has been suggested that low Fas expression in the BM 
of AML patients is associated with a low remission rate of induction chemotherapy. Thus, 
the ratio of Fas+ to Fas- cells was predictive of treatment outcome i.e. disease resistance to 
apoptosis.153   
Up-regulated TNFin MDS can induce Fas expression on normal cells increasing their 
susceptibility to apoptosis by FasL-expressing cells. Accordingly, the growth of clonogenic 
progenitors was inhibited by FasL-expression in MDS.154 FasL-expression is more 
pronounced on blasts cells in advanced MDS cases and has been observed to increase by at 
least three fold upon transformation to AML.154 Additionally, increased FasL-expression on 
malignant cells may facilitate in the escape from T-cell mediated immunological surveillance 
by inducing apoptosis in Fas+ T-cells.155 Nevertheless, MDS clonal cells expressing Fas on 
their surface are also susceptible to Fas-mediated cell death therefore, elevated anti-
apoptotic signals may provide a protective mechanism for these cells.  
Accordingly, an increase in Nuclear Factor kappa B (NF-B) activation has been found to 
correlate with disease stage156 with it being constitutively active in AML.157 NF-B is a 
transcription factor that regulates the expression of a variety of proteins that inhibit 
apoptosis and promote cell proliferation and survival.158 Notably, it has been implicated in 
the pharmacological resistance to many chemotherapeutic agents.159  
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Part 2: Telomeres 
1.14 History of Telomeres 
 
Early cytogenetic work demonstrated that X-ray induced chromosome breakage resulted in 
the production of chromosomal fusion between broken ends.160,161 The centromeres of the 
dicentric chromosome were pulled to opposite poles during anaphase generating a 
chromatin bridge which was subsequently broken following pole-ward migration of the 
centromeres.161 Thus, a loss or gain of genetic information was passed on to each daughter 
cell. It was proposed that these breakage-fusion-bridge (BFB) cycles continued indefinitely 
unless the broken end is ‘healed’.161 This was consistent with a previous observation that 
the natural chromosome ends did not take part in end-to-end fusions.160 Thus, it was 
proposed that the terminal end has a special function in sealing the end of the 
chromosome. The word ‘telomere’ was coined by Herman Muller in the late 1930s and 
derived from the Greek translation of ‘telos’ and ‘meros’ meaning, ‘end’ and ‘part’ 
respectively.  
The End Replication problem was later discovered following the elucidation of conventional 
DNA synthesis.162,163 Loss of chromosome terminal sequence with each round of replication 
was proposed to result from the inability of DNA polymerase to completely replicate the 
linear DNA molecule. Thus, it was proposed that telomere shortening acts as a cell-intrinsic 
clock that would eventually lead to replicative senescence.163 Consistent with this, a strong 
correlation between telomere length and cellular proliferative capacity has been 
documented.164 Sequencing the ends of chromosomes derived from Tetrahymena revealed 
that the terminal DNA sequence was composed of simple tracks of T and G residues.165 
These tandem copies of 6nt sequence TTGGGG were presumed to defend chromosomes 
against the end replication problem and other assaults on their integrity. It was later 
identified that the hexanucleotide TTAGGG is the telomere repeat sequence found in 
humans166 demonstrating the conservation of these repeats through evolution. 
1.15 The End Replication Problem 
The replication fork paves the way for DNA replication facilitating the synthesis of the 5’ to 
3’ leading strand and the 3’ to 5’ lagging strand. Assuming DNA synthesis initiates within the 
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molecule; the leading strand can be synthesised continuously in the direction of the 
replication fork completing synthesis to the 3’termini. An alternative process is required to 
synthesise the lagging strand since DNA polymerase is unable to initiate DNA replication in 
the 3’ to 5’ direction (Figure 1.2). Instead RNA primers are utilised and extended in the 5’ to 
3’ direction to generate a succession of Okazaki fragments. Prior to completion, the RNA 
primers are converted into DNA and the fragments are subsequently ligated. However, the 
most distal RNA primer is not converted to DNA due to the incapability of DNA polymerase 
to initiate replication de novo. Its subsequent degradation results in a 5’ gap in the newly 
synthesised strand. In principle if the most distal RNA primer is located at the terminus the 
minimum loss of sequence at the lagging strand would be the size of the RNA primer, i.e. 7 
to 10 nt167 however, it has been demonstrated in vitro that this loss may increase 
substantially (250nt) as a result of the priming initiation site.167,168 
 
In the absence of 3’ overhang resection, it has been proposed that telomeric double 
stranded DNA is lost at 0.25 the length of the single strand per population doubling.169 
Accordingly, a single stranded loss of 200nt per generation would account for a double 
strand loss of 50bp per cell doubling as described in human fibroblasts.169,170 The reason 
being it was assumed that only half of the cells amongst the distribution were losing single 
stranded DNA per generation, thus it was proposed that a single strand deletion would be 
Figure 1.2: Since DNA polymerase is unable to replicate DNA de novo, semi-conservative replication leaves a 
5’ gap in the newly synthesised strand.  
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attained upon the second generation and a double strand deletion every fourth generation. 
Moreover, this model also assumed that the variance in telomere length distributions would 
increase with each generation. Notably, an accumulation of variable single stranded and 
double stranded deletions in each daughter cell would result in an increase of the telomere 
length variance.169 This increase in the telomere length distribution has been previously 
demonstrated in fibroblast cells in culture.171     
A variation of telomere shortening can result in the division heterogeneity of cells derived 
from the same precursor however; prolonged telomere erosion ultimately leads to 
replicative senescence at which cells stop dividing in order to prevent further telomere loss. 
Accordingly, the telomere length distribution inevitably homogenises as the number of cells 
reaching cellular senescence accumulates with progressive replication.172 It has been 
observed that the heterogeneity of telomere length distributions is more pronounced within 
multiple clonal populations in contrast to single cell clones that show less variation in 
telomere length.173-175 Thus, telomere length distributions may be indicative of the relative 
clonality of the cell population.  
1.16 Telomerase 
The enzyme Telomerase was initially identified in Tetrahymena by its ability to add tandem 
TTGGGG repeats onto the 3’end of synthetic telomere primers.176 It has reverse  
transcriptase activity and synthesises telomeric DNA onto chromosome ends using an 
internal RNA template.177,178 Thus, telomerase is capable of compensating for the loss of 
terminal sequence that occurs as a result of the end replication problem. Telomerase 
activity has been detected in the germ line but is undetectable in normal somatic cells 
excluding proliferative cells of renewable tissues, i.e. haematopoietic stem cells, activated 
lymphocytes and intestinal crypt cells.179 Telomerase activity has been documented in 85% 
human malignancies, including colon cancer, neuroblastoma and in lung carcinoma. A large 
majority of cultured immortal cell lines also present detectable telomerase activity.180 Thus, 
the up-regulation of telomerase in malignant cells may contribute to their immortality by 
maintaining telomere length.   
Telomerase is composed of a catalytic core (hTERT) and an RNA template (hTR). hTR is 
present in cell lines and tissues that lack telomerase activity and has been detected in both 
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tumour and normal samples.181 Conversely, hTERT is detected in telomerase positive tissue, 
cancer cell lines and tumours but it is not detected in tissues that lack enzymatic 
activity.182,183 The level of hTR expression does not always correlate with telomerase 
activity, i.e. cellular immortalisation has been associated with a 100 to 2000 fold increase in 
telomerase activity but only a 2 fold increase in hTR expression.181 However, hTERT 
expression has been observed to reflect the presence of telomerase activity and has been 
implicated as the rate limiting determinant of the enzyme.182-186 Accordingly, ectopic 
expression of hTERT mRNA can induce telomerase activity in telomerase negative cells184 
and extend their cellular lifespan.185 hTERT expression has been detected in the earliest 
stages of cancer development including the breast,187 colon187 and lung squamous cell188 
carcinoma. Furthermore, it has been noted to gradually increase with progression into an 
invasive carcinoma showing prominent hTERT expression in later stages of cancer 
development. This suggests that telomerase activation is regulated during the progression 
of tumourigenesis but moreover, hTERT is a barrier that has to be overcome for telomerase 
activation required by cancer cells to gain telomerase dependent immortalisation.   
1.17 The Mechanism of Telomerase 
The template region is longer that the telomeric repeat they encode. The human template 
of telomerase RNA reads 3’-CAAUCCCAAUC- 5’ providing a coding region for the human 5’- 
TTAGGG- 3’.177 A portion of the template aligns through base pairing with the 3’overhang 
and DNA elongation ensues through copying of the template (Figure 1.3). However, the RNA 
templating region is restricted, such that the appropriate nucleotides are added to complete 
only one telomeric repeat unit.189 Upon completion, the newly extended DNA terminus 
dissociates from the RNA template and the enzyme complex translocates to enable another 
round of telomere repeat unit replication.189 The complementary DNA strand is then 
synthesised by means of lagging strand synthesis, thus completing telomere extension by 
telomerase. 
 36 
 
 
 
1.18 ‘Capping’ Linear Chromosomes 
It has been suggested that chromosome protection can be achieved by a telomere through 
a looping back mechanism. The 3’overhang loops back and invades the preceding telomeric 
tract which is thought to sequester DNA ends from DNA repair pathways. Electron 
microscope analysis has visualised this occurrence as large lariat structures or T-loops that 
exist at the ends of chromosomes.190 It was also observed that there is a close correlation 
between the length of the telomeric repeat array and the size of the T-loop implicating that 
the T-loop may encompass the whole telomere.190 It has been proposed that T-loops ‘seal’ 
the end of telomeres thus enabling cells to distinguish random DNA breaks from natural 
chromosome ends.190 The remodelling of telomere ends is enabled through a number of 
specialised telomere proteins that work in synchrony to generate a ‘cap’ at the ends of 
linear chromosomes.  
Figure 1.3: An illustration showing the process behind telomerase extension of telomeric ends (bases in red 
are copied from hTR (RNA template)). 
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1.19 The Shelterin Complex 
A multi-subunit protein complex that is referred to as Shelterin binds to telomere 
ends191,192 to facilitate the formation of the telomere ‘cap’.193 The complex is composed of 
six main proteins that mediate associations between the double and single stranded 
portions of the telomere (Figure 1.4).  
The TTAGGG Repeat Factors 1 and 2 (TRF1 and TRF2) proteins bind to the 5’YTAGGGTTR 3’ 
sequence in double stranded DNA and exist as either homodimers or oligomers.192 Although 
they do not interact directly;192 they are interconnected by the TRF1 and TRF2 Interacting 
Protein 2 (TIN2).194 TIN2 has a central position in the Shelterin complex as it facilitates in 
bridging the double stranded interacting proteins with those on the single stranded 
overhang. Its depletion results in destabilisation of the complex and consequential 
reductions of TRF1 and TRF2 at the telomere.195 TIN2 indirectly interacts with the Protection 
of Telomeres 1 (POT1) protein through the TIN2 and POT1 Interacting Protein 1 (TPP1).191 
This interaction is crucial since TPP1 tethers POT1 to TRF1 and TRF2 by the TPP1-TIN2 
bridge.196 POT1 binds directly to the 5’ TAGGGTTAG 3’ sequence on the single stranded 
overhang.192 It forms a heterodimer with TPP1 that functions to enhance its DNA binding 
affinity.192,194  
TRF1 and TRF2 are the core proteins in maintaining the structure of the T-loop. TRF1 has 
been shown to induce bending, looping and pairing of duplex DNA in vitro.197,198 However, 
the fundamental role of chromosome end ‘capping’ is dependent on TRF2.199 TRF2 has the 
ability to generate T-loops in vitro and it was proposed that it may stabilise190 and induce 
strand invasion of the 3’overhang into duplex telomeric DNA. Intra-telomeric synapsing of 
TTAGGG repeat arrays by TRF1 may also facilitate strand invasion by shaping of the T-
loop.190 As a result, natural chromosome ends would be inhibited from inducing cell cycle 
arrest or entering into deleterious inadvertent double strand break repair pathways.191 
Human cell lines expressing a dysfunctional TRF2 show telomere end-to-end fusion events 
including multiple fused, ring and dicentric chromosomes. It was demonstrated that the 
frequency of end-to-end fusions increased by 10 fold in these cells comparable to controls 
that rarely presented fusion events. Accordingly, these cells were TRF2 proficient and the 
protective function at telomeres was maintained.199 POT1 has also been implicated in 
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chromosome end protection. Its deficiency has been described to result in senescence and 
telomere fusions in mouse embryonic fibroblasts (MEFs) as well as enhancing 
tumourigenesis in vitro and in vivo in a p53 deficient background.200 However, the frequency 
of telomere fusions in POT1 deficient MEFs is considerably less than that in cells deleted for 
TRF2, i.e. 2% of chromosomes per cell201 vs. genome wide.202 This implicates that TRF2 has a 
dominant role in protecting telomeres against end joining by maintaining the T-loop 
structure preventing aberrant chromosome fusions. Notably, it has been proposed that 
although infrequent, the fusion events that arise with POT1 depletion may be associated 
with a transient open configuration of the T-loop during DNA replication. POT1 bound to the 
3’overhang may prevent end joining proteins from accessing telomere ends.201   
The Repressor/Activator Protein 1 (RAP1) is the final protein that associates with the 
Shelterin complex through interactions with TRF2. It has been proposed to interact with 
non-telomeric proteins that may provide maintenance of telomeric integrity. Furthermore, 
it has been suggested that RAP1 may act at telomeres in order to repress homologous 
recombination and unequal telomeric sister chromatid exchange (T-SCE). Accordingly, 
mouse embryonic fibroblast (MEFs) cells that express a mutant TRF2 incapable of 
interacting with RAP1 demonstrate an increased propensity of T-SCE at a similar frequency 
to TRF2-null cells.203 Unequal telomeric sister chromatid exchange (T-SCE) can threaten the 
integrity of individual telomeres by inducing abrupt telomere shortening. This can 
significantly reduce the proliferative capacity and viability of the daughter cell that acquires 
the shortened telomere.203  
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1.20 The Protein ‘Counting’ Model 
It has been proposed that the presence of POT1 on the 3’ single strand can negatively 
influence the telomerase activity by hindering base pairing between the RNA template and 
the 3’ terminus of the overhang.204 This has been suggested to be achieved through a 
protein ‘counting’ model198 that enables duplex telomeric DNA to relay information about 
the telomere length to the 3’overhang where telomerase activity is regulated.205    
The inhibition of TRF1 in telomerase expressing cell lines leads to telomere elongation and it 
has been assumed to act in cis by inhibiting telomerase activity at the telomere termini.206 
Conversely, overexpression of TRF1 leads to gradual telomere shortening in telomerase 
positive cell lines.207 Telomeres can exist in either an ‘open’ or ‘closed’ state. Telomerase 
accessibility is granted when telomeres are in the ‘open’ state whereas it is prohibited when 
telomeres are ‘closed’.198 The alteration in telomere access has been proposed to be 
governed by the amount of TRF1 bound to the telomere.  
It has been suggested that an accumulation of POT1 to the 3’overhang is dependent upon 
its interaction with TRF1. Longer telomeres will bind more TRF1 and therefore may facilitate 
Figure 1.4: Shelterin makes up the telomere ‘cap’. It is composed of 6 proteins: TRF1, TRF2, POT1, TIN2, 
TPP1 and RAP1. Associations between the double and single stranded portions of the telomere are 
mediated through protein interactions to facilitate in the shaping of the T-loop.  
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in the accumulation of POT1 to single stranded ends prohibiting telomerase accessibility. 
Accordingly, very short telomeres will be unable to bind sufficient amounts of TRF1 (and 
also POT1) enabling single stranded access to telomerase.191,198,205 This results in telomere 
length homeostasis that is regulated in cis by telomere associated proteins.   
1.21 Telomere Length Homeostasis 
Telomere length homeostasis is the result of the balance between telomere shortening and 
telomere lengthening. If telomeres were selected at random for telomerase extension then 
this may have catastrophic effects on the cell. Accordingly, if telomerase only acted on long 
but not short telomeres then cells would enter premature senescence or alternatively short 
telomeres could initiate oncogenesis. In contrast, if telomerase acted on short telomeres 
then cell viability and proliferation capacity would be maintained.  
It has been described that telomerase does not act on every telomere in the cell cycle.  
Accordingly, the frequency of telomere extension in Saccharomyces Cerevisiae increases 
steadily as a function of telomere length. Only 6 to 8% of telomeres were extended within 
long telomere distributions; whereas telomerase extended 42 to 46% of telomeres within 
short distributions, thus favouring the elongation of short telomeres.208 Telomerase has 
shown a preference for short telomeres in mice209 and human cells210 and it has been 
proposed that the mechanisms acting in cis favour telomerase association with short 
telomeres. However, this regulation is reduced if telomerase is in abundance. Telomere 
elongation at 0.25-0.8kb/PD far above physiological length has been observed in human 
primary and cancer cell lines overexpressing both hTERT and hTR.211 It was suggested that 
telomeres elongate in a length independent manner which further implicates that long 
telomeres have the potential to undergo telomerase extension if telomerase levels are high. 
Thus, to maintain telomere length homeostasis and preferable elongation of short 
telomeres then telomerase must be limited to enable regulation by telomeric proteins. 
Consistent with this, the elongation of short telomeres is favoured in mice with limiting 
telomerase activity.212 
It has been suggested that long telomeres switch back more rapidly into a non-extendible 
state (i.e. T-loop or 3’ overhang coverage by POT1) following DNA replication, thus 
increasing the probability of telomerase to extend short telomeres which are more likely to 
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be in an extendible state, i.e. open configuration.213 However, this regulation is reduced if 
telomerase is overexpressed enabling the elongation of long telomeres in a length 
independent manner. 
Thus, Shelterin not only provides protection against DSB (Double Strand Break) repair but 
also functions as a length sensing mechanism to provide control over telomere length 
homeostasis in telomerase positive cells.    
1.22 The G-quadruplex 
G-rich oligonucleotides that contain at least four short runs of G residues can fold into 
compact forms that are stabilised through the association of a K+ or Na+ cation. This 
structure is referred to as the G-quadruplex. The building blocks of the G-quadruplex are G-
quartets that arise from four guanines held in plane by Hoogsteen-hydrogen bonding in 
which each guanine serves as a hydrogen bond acceptor and donor.214,215 The planar G-
quartets stack on top of one another giving rise to four stranded helical structures. G-rich 
DNA oligonucleotides can form aggregates through G-G base pairing in vitro. Under non- 
denaturing conditions, electrophoresis has demonstrated that multiple intramolecular 
folded forms can originate from a DNA G-rich single strand.216 The structure of the G-
quadruplex is highly polymorphic since it can assemble in an intramolecular or 
intermolecular configuration with strands in a parallel or antiparallel orientation. 
Intermolecular structures can arise from the association of two dimers or four independent 
G-rich strands.215  
The guanine rich sequences within the 3’overhang have the propensity to form G-
quadruplexes. The dynamics of the folding and unfolding of the telomeric G-quadruplexes 
have been observed in vivo. The 16nt long G-overhang in the ciliate protozoan Stylonychia 
lemnae is bound by telomere end binding proteins TEBPand TEBP, which are both 
required for generating G-quadruplexes in vivo. TEBPcan bind directly to the 3’overhang 
however, TEBPrequires the interaction with TEBP to associate with the single strand to 
engage in G-quadruplex formation. The phosphorylation of the C-terminus of TEBP by 
Cyclin Dependent Kinase during the S-phase of the cell cycle causes TEBP to dissociate 
from TEBPand induces G-quadruplex unfolding for the end replication machinery.217 
Vertebrate homologues of TEBPand TEBP are POT1 and TPP1 respectively.218 However, 
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the C-terminus of TEBP is not conserved in TPP1 which may suggest an alternate role. 
Alternatively, longer vertebrate overhangs may have the capability of generating G-
quadruplexes without the aid of telomere proteins.219 However, it has recently been 
proposed that the POT1-TPP1 complex can fold and unfold the G-quadruplex by operating 
as a ‘sliding clamp’ that initiates near the more accessible 3’end of the overhang.220 The 
association with Shelterin via TIN2 enables POT1-TPP1 to slide along the single strand while 
tethered to the duplex DNA. This sliding mechanism may regulate the accessibility of the 
3’end and consequently telomerase elongation. 
G-quadruplexes can also resemble telomeric fragile sites that have the propensity in 
inducing replication fork stalling. TRF1 has been implicated in having a specific role in 
facilitating telomere replication. In its absence, multiple telomeric signals separated from 
chromatid ends were observed by means of Fluorescence in situ Hybridisation (FISH) 
analysis.221 It had been suggested that TRF1 may repress replication problems by recruiting 
helicases, e.g. BLM RecQ that can remove G4-DNA. Notably, BLM-deficient mouse cells 
show an increased frequency of spontaneous fragile telomeres.221 
Therefore it can be assumed that POT1 and G-quadruplex DNA play important roles in 
regulating telomere length homeostasis. Intermolecular formation of the G-quadruplex may 
also favour telomere-telomere interactions, i.e. recombination. However, G4-DNA has the 
propensity to generate extensively short telomeres as a result of telomere fragility and 
replication fork stalling. 
1.23 Telomerase and Cancer Therapeutics 
Telomerase activity is absent in most somatic cells therefore telomerase inhibition is 
unlikely to induce an adverse effect. Furthermore, telomerase competent cells, i.e. germ 
and stem cells have long telomeres as opposed to short telomeres in telomerase positive 
cancer cells. Moreover, elevated hTERT expression in cancer cells as opposed to low 
expression in normal cells has been demonstrated to provide a valuable target for 
immunological therapy. Thus, it has been proposed that cancer cells may be more sensitive 
to telomerase based therapies with the reduced probability of toxicity to normal tissue. 
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Telomerase immunotherapy is an alternative approach to destroying tumour cells. Antigen 
presenting cells i.e. autologous dendritic or B-cells are exposed to high levels of synthetic 
hTERT peptides or genetic components ex vivo which are subsequently transplanted into the 
patient. The antigen presenting cell then interacts with CD8+ cytotoxic T cells or CD4+ helper 
cells to elicit an immune response against TERT expressing cancer cells.222 One such 
immunotherapy is GRNVAC1. This is a preparation of autologous dendritic cells that are 
transfected with TERT mRNA. mRNA processing by dendritic cells encodes multiple 
variations of the TERT peptide inducing a polyclonal immune response.223 Therefore, 
GRNVAC1 treatment promotes an anti-tumour effect since it may target any variation of 
TERT expressed on tumour cells. GRNVAC1 has completed Phase II clinical trials in patients 
with AML and metastatic prostate cancer.224   
Compounds inhibiting telomerase directly can induce telomere shortening and subsequent 
genetic instability returning malignant cells to proliferative crisis. However, this therapeutic 
approach may be associated with a lag period that is dependent on telomere length. 
Furthermore, cancer cell may initiate ALT (Alternative Lengthening of Telomeres) and 
maintain telomere length through recombination. It has also been proposed that a 
functional DDR may be required to induce the apoptotic response in cells where telomerase 
inhibition has resulted in critically short telomeres.225 Thus, DDR (DNA Damage Response) 
components such as p53 may serve as an important genetic marker to help determine 
effective treatment options. 
GRN163L (Imetelstat) is one such inhibitor that acts as a ‘telomerase template antagonist.’  
It is a small molecule oligonucleotide that hybridises to the hTR template region preventing 
it from forming an active complex with hTERT. GRN163L has been shown to limit the growth 
of cancer in multiple tumour types including breast,226 bladder,227 lung228 and 
haematological cancers such as lymphoma and Multiple Myeloma.229 GRN163L has already 
completed several Phase I trials in patients with CLL (Chronic Lymphocytic Leukaemia) and 
solid tumors including breast cancer and non-small cell lung cancer.230 
Translocation and re-initiation is required to take place after each cycle of template copying. 
BIBR1532 is another telomerase inhibitor that reduces the number of added TTAGGG 
repeats but maintains the periodicity of six nucleotides. It has been implicated that 
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BIBR1532 affects the translocation of the enzyme DNA substrate complex or promotes the 
dissociation of the enzyme from the DNA following template copying.231 It has been shown 
to inhibit telomerase in several human cancer cell lines including breast, prostate and lung 
carcinoma.232 Additionally, in combination with chemotherapeutics it has been shown to 
induce enhanced sensitivity in human promyelocytic leukaemia resistant cell lines.233     
G-quadruplexes have also been discussed as a potential therapeutic approach. The RHPS4 
ligand can bind and stabilise G-quadruplexes hindering both telomerase and POT1 
association to the 3’overhang. Consistent with this, RHPS4 can induce telomere dysfunction 
by means of telomere shortening but can also induce short term effects by interfering with 
the Shelterin complex when provided at high concentrations. Accordingly, RHPS4 can lead 
to POT1 dissociation from the telomere and induce a DDR in melanoma cell lines.234   
1.24 Genetic Determination of Telomere Size  
 
There is considerable telomere length variation in the human population.235,236,237 This is 
underpinned by genetic variation. Previous studies have reported heritability estimates 
ranging from 36 to 90%.238 It has been proposed that common environmental factors may 
be responsible for the apparent discrepancy in reported heritability estimates, such as Body 
Mass Index (BMI) or smoking,239 however when compared to dizygotic and unrelated 
individuals of the same age the variation of telomere length between monozygotic twins 
was found to be the smallest.240  
1.25 Sub-telomere Structure 
The human genome is composed of dense concentrations of inter-chromosomal segmental 
sub-telomeric duplications that display considerable variation.241  
Human sub-telomeres are bounded proximally by chromosome specific sequences and 
distally by an array of least three telomere variant repeats (TVR) composed of TTGGGG, 
TGAGGG and TCAGGG that extend up to 3kb into the telomere repeat array. Distal to the 
TVR region lies a continuous block of TTAGGG repeats that extend to the chromosomal 
terminus.242-244  
Sub-telomeric regions are highly polymorphic with respect to copy number and 
chromosomal location.241 The presence or absence of these tracts can result in size 
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variations of homologous chromosomes by several 100kbs.245 Notably, allelic variations of 
up to 260kb have been observed to exist at the 16p telomere.246 Multiple chromosome ends 
show very high sequence similarity that may range between 90 and >99.5%.247 Moreover, 
these repeat regions may extend for up to 200kb in humans.247     
Human sub-telomeres contain members of 25 small gene families including those of 
odorant and cytokine receptors, tubulins, transcription factors and others of unknown 
function. Rearrangements within sub-telomeric regions may induce phenotypic variation 
and have the potential to contribute to human disorders. Mental retardation has previously 
been reported to originate from sub-telomere alterations that create sub-terminal 
microdeletions which are healed by the action of telomerase creating a new telomere.241 
1.26 Methods of Telomere Measurement 
 
1.26.1 Terminal Restriction Fragment (TRF) 
TRF analysis is the traditional method of measuring telomere length in samples of total 
human genomic DNA.248  
Genomic DNA is digested with frequently cutting restriction enzymes that digest the 
majority of the genome without cutting into the telomere repeat array. This leaves intact 
terminal restriction fragments (TRFs) which can be resolved by agarose gel electrophoresis 
and detected by Southern hybridisation with a telomere repeat containing probe.249 TRF 
requires microgram quantities of DNA per individual (105 cells) and therefore this may 
hinder the measurement of small tissue or cell samples.249  
 
TRF analysis is also biased towards longer telomere length.248 Accordingly, it is dependent 
on hybridisation and therefore may fail to detect short telomeres which are below the 
telomere length threshold. Moreover, it determines the genome wide telomere length of all 
ends simultaneously from a large number of cells. Although this reduces its resolution 
capacity, it also measures an overestimate of the average telomere length since TRF analysis 
includes heterogeneous quantities of sub-telomeric and TVR DNA.249 
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1.26.2 Quantitative-Fluorescence in situ Hybridisation (Q-FISH) 
Fluorescently labelled (CCCTAA)3 peptide nucleic acid (PNA) probes are hybridised to 
metaphase chromosome preparations.250 Under conditions of low ionic strength, the 
neutral PNA probe can anneal to complementary single stranded DNA sequences whereas 
single stranded DNA cannot therefore this allows the quantification of the fluorescent signal 
derived from telomeric sequences.251  
Although it is able to measure chromosome specific telomere length at single cell resolution, 
values are relative telomere measurements and not actual telomere length. Moreover, since 
this procedure relies on hybridisation a telomere length threshold exists such that ‘signal 
free ends’ may be misinterpreted as completely denuded telomeres which are actually 
those that contain telomere repeats below the detection threshold.249   
Q-FISH is unable to measure the telomere length in terminally senescent cells or cells with 
low mitotic indices.248  
1.26.3 Flow-Fluorescence in situ Hybridisation (Flow-FISH) 
Similarly to Q-FISH, flow FISH uses directly fluorescently labelled (CCCTAA)3 peptide nucleic 
acid (PNA) probes,251 however unlike Q-FISH the ‘genome wide’ telomere length is 
measured in individual cells in suspension including metaphase, interphase and senescent 
cells. Immuno-phenotyping can be utilised to measure the telomere length in distinct cell 
populations within a single sample.248 However, telomere length values are relative 
telomere measurements, not actual telomere length. 
1.26.4 Quantitative telomere-specific PCR (Q-PCR) 
Telomeres (T) are PCR-amplified using primers that anneal to both the C- and G-rich strands 
of the telomere; however mismatches are present along their length in order to reduce the 
formation of primer dimer derived products. The amplification is measured quantitatively 
and compared to that of a single copy gene (S) to generate a T/S ratio that is proportional to 
the average telomere length.252 Although this approach only requires nanogram quantities 
of DNA, it only provides the mean relative telomere length and not the actual length. 
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1.26.5 Single Telomere Length Analysis (STELA)  
STELA is a long-range single-molecule PCR approach that amplifies the double-stranded 
region of telomere repeats from specific chromosome ends.171 
The initial step in STELA consists of annealing a ‘telorette’ linker that is comprised of seven 
bases of TTAGGG repeat homology followed by a 20 nucleotide non-complementary tail to 
the G-rich 3’overhang of the telomere. Ligation to the 5’end of the duplex telomeric C-rich 
strand provides a telorette ‘tag’ to the end of the chromosome. PCR can then be performed 
on chromosome-specific telomeres utilising a ‘teltail’ primer that is complementary to the 
telorette tail and a chromosome-specific upstream primer located within the subtelomeric 
region. STELA products are identified as single bands on a gel following Southern 
hybridisation with a TTAGGG specific probe with each band representing a single telomeric 
molecule.171  
This approach has the ability to detect the full spectrum of telomere lengths at specific 
telomeres,171 particularly those that are very short which have the potential to initiate 
telomere fusion or replicative senescence.253-255   
Small quantities of input DNA (250pg/l) or as few as 42 cells can be analysed using STELA 
therefore enabling the measurement of telomere length in rare cell types. Whereas TRF 
analysis measures an overestimate of the average telomere length, STELA is able to measure 
the telomere length accurately since the exact distance of telomere adjacent DNA (sub-
telomeric and TVR) can be determined.171,249 
However, only a subset of chromosome ends can be measured using STELA due to the 
presence of extensive sub-telomeric homology.241,247 Notably, ends that encompass a 
unique telomere-adjacent sequence can only be analysed by STELA.  
 
1.27 Telomeres and Homologous Recombination   
Telomere length homeostasis involves cis acting regulators that negatively influence 
telomerase mediated extension256 to ensure limited heterogeneity of individual telomere 
lengths within a clone.235,257 Maintenance of homeostasis is apparent in immortalised cells 
and vital to ensure consistency of telomere length within the germ line.258 Telomerase has 
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the capability to add telomere repeats de novo, however, telomerase deficient 
Saccharomyces Cerevisiae257 and Kluyveromyces Lactis259 mutants are able to generate post- 
senescent survivors that maintain telomeric length through a RAD52 dependent 
homologous recombination pathway.  
The RAD52 epistasis group, composed of Rad51, Rad54 and Rad57 is required for the 
resistance against DSB instability in which a deletion renders Saccharomyces Cerevisiae 
highly sensitive to -radiation.260,261 Early studies have demonstrated RAD52 involvement in 
the homothallic mating type gene switching in Saccharomyces Cerevisiae262 which involves 
the exchange of genetic information initiated by a HO-endonuclease site specific DSB at the 
MAT locus. MAT is replaced by either the HML (Hidden MAT Left) or HMR (Hidden MAT 
Right) gene to confer sexual differentiation within a population of yeast cells.263 Incomplete 
HO-induced mating type switching can induce lethality in Rad52 yeast mutants.   
Post-senescent survivors with heterogeneous telomere and sub-telomere profiles259 can be 
generated by telomere/telomere or sub-telomere/sub-telomere recombination via the 
Rad50 and Rad51 subgroups respectively.264 It has been proposed that the Rad51 subgroup  
enables strand exchange in regions where the chromatin structure is repressed, such as sub-
telomeric regions.265,266 This heterogeneity of telomere lengths has also been observed in 
telomerase independent immortalised human tumour cell lines.267 It is thought that RAD52 
dependent telomere elongation is conferred through a Break Induced Replication (BIR) 
mechanism that enables homologous recombination between sequences on opposite 
arms.268 The resulting telomere capture provides the broken arm with a replica of sequence 
adjacent to the homology site up to the end of the telomere.269 This is referred to as ALT; an 
Alternative Lengthening of Telomeres. Although telomere length can be preserved though 
this mechanism; the high frequency of interstitial sub-telomeric homologs within the 
genome could be inadvertently used to generate non-reciprocal translocations269,270 and 
initiate a sequence of genomic rearrangements that may be detrimental to the cell. This is 
comparable to the high incidence of Alu repeats that have been proposed to account for 
0.3% of human diseases.271  
Additionally, recombination can occur intra-chromosomally269 and it has been postulated 
that the resolution of a recombination ‘T-loop like’ intermediate can generate extensive 
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telomere shortening (Telomere Rapid Deletion; TRD) within a single round of cell division. 
These telomeric events have been observed in yeast mutants that lack the ability to control 
telomerase accessibility through a deficiency in Rap1.272 TRDs maintained telomere 
homeostasis by restoring elongated telomeres back to their wild-type length.273 It has been 
proposed that yeast acquires a ‘yardstick’ mechanism that measures telomere lengths 
relative to each other. Furthermore, this approach of telomere truncation generates extra- 
chromosomal telomeric circles that can be exploited by short telomeres to elongate by 
telomere/telomere recombination via a ‘rolling loop’ mechanism.274 The mammalian 
ERCC1/XPF complex has been located at the telomere which is thought to prevent T-loop 
formation within interstitial telomere repeats that may result in TRDs and 
extrachromosomal circles (Telomere DNA containing Double Minutes; TDMs). Consistent 
with this, ERCC1 null MEFs (Mouse Embryonic Fibroblasts) undergo senescence 
prematurely.275  
The Mre11 complex is composed of the Mre11, Rad50 and Xrs2 (MRX) proteins in yeast or 
Mre11, Rad50 and Nbs1 (MRN) in humans.273 It has the ability to stabilise DNA strand 
interactions276 and thus playing a structural role in telomere/ telomere circle directed 
telomere elongation.274 Moreover, Saccharomyces Cerevisiae mutants in Rad50 show a 
reduction in TRDs suggesting it may also play a structural role in generating terminal 
deletions.273 Additionally, mutations within the BRCT (BRCA1 carboxyl terminal) domain on 
Rap1 result in a reduction of TRD events,256 possibly through a loss of interaction with the 
MRN complex. It has also been suggested that the nuclease activity of Mre11 generates the 
3’overhang on the newly replicated leading strand to provide protection against telomere 
end-to-end fusions by Non-Homologous End Joining (NHEJ). Mre11 mutant mouse 
fibroblasts deficient in TRF2 exhibit leading strand initiated sister chromatid fusions as a 
consequence of their transient blunt ends during synthesis.277 The MRN complex has also 
been proposed to facilitate in the generation of the telomerase substrate for telomere 
elongation.278,279 
1.28 Non-Homologous End Joining/Microhomology Mediated End Joining 
Non-Homologous End Joining (NHEJ) appears to be the most common pathway of DSB 
repair in mammalian cells.280 In the context of a TRF2 deficiency281 cells attempt to repair 
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damaged telomeres using NHEJ generating telomere-telomere fusions, dicentric or 
multicentric chromosomes. Classical NHEJ is dependent on the heterodimeric nuclear 
protein Ku282 that is comprised of subunits Ku70 and Ku80.282,283 In the event of a DSB, the 
Ku heterodimer binds to DNA ends and recruits several accessory factors that serve to 
process the broken ends.284 Ku mediates the recruitment of the catalytic subunit of an ATM-
related DNA protein kinase (DNA-PKcs)285 to DSBs that becomes activated on DNA 
binding.286 DNA-PKcs phosphorylates Artemis which functions as an endonuclease that 
cleaves at DNA structures containing 5’ or 3’ overhangs287 enabling subsequent ligation 
catalysed by the XRCC4/DNA Ligase IV complex.288,289 Intermediate gaps existing within the 
DNA break can be filled by the DNA Polymerases pol and pol 
Mice deficient in Ku or DNA-PKcs exhibit pronounced growth retardation and endure a scid 
phenotype that is characteristic of impaired lymphoid cell development due to a deficiency 
in the DNA NHEJ step of V(D)J recombination.261,285 Additionally, fibroblasts derived from Ku 
deficient mice demonstrated a reduced proliferation capacity and entered senescence 
prematurely.285 High levels of aneuploidy and chromosomal abnormalities have been 
detected in mice embryonic fibroblast cells deficient in Ku.290 In accordance with this the 
loss of Ku has been linked to telomere length reduction291,290 and a large increase in the 
frequency of TRD events.291 Furthermore, Ku deficiency in human somatic cells is lethal 
whereas a knockdown confers significant telomere shortening and increased apoptosis.292 
Fusion between short dysfunctional telomeres have been detected in human and mouse 
cells deficient in Ku80292and DNA-PKcs293,294 respectively. Telomere fusions were found to 
occur in DNA-PKcs deficient cells at a rate approximately 1 in 60 cells per round of cell 
division; whereas in DNA-PKcs proficient cells spontaneous fusions are nearly undetectable. 
This implies that Ku and DNA-PKcs make up a part of the telomere cap to protect against 
recombination or end degradation291,293,129 possibly facilitating in production of the 
3’overhang. 
The observation that telomere end-to-end fusions occur despite deficiencies in the NHEJ 
components suggests that an alternative ‘repair’ mechanism may operate at dysfunctional 
telomeres that is independent to NHEJ. Components of these alternative-NHEJ mechanisms 
have recently been characterised. Mutants of the DT40 chicken B cell defective in 
homologous repair and Ku-dependent NHEJ are able to repair DSBs.295 However, 
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deficiencies confer significant radiosensitivity and genomic instability. A ligase IV 
haploinsufficiency in mice mutants’ deficient in p16INK4a and p19ARF are prone to clonal 
chromosomal translocations involving deletions and amplifications which promote the 
development of soft tissue sarcomas.296  
The inactivation of HDF1 (Ku70 homolog) in rad52 mutant yeast strains increases the 
sensitivity to radiation.261 Rad52 yeast mutants unable to complete HO-induced mating 
type switching were found to escape lethality by deletion of their HO cut site and 
subsequent ligation.297 However, chromosome loss of up to 700bps has been observed 
flanking the break sites in rad52 yeast mutants with a significant number of events with 2 or 
more nucleotides of homology at a given junction.280 Hamster cell lines deficient in Ku80 or 
Xrcc4 exhibit sites of microhomology at DSB junctions implicating that their use for efficient 
alignment is compensated with the stability of microhomology base pairing in their 
absence.298 About 40%299 of large deletions in human disorders including cancers such as 
retinoblastoma300 and bladder cancer301 have been characterised by the presence of very 
short sequence homologies (2 to 6bp) at the breakpoints.302,303 This alternative pathway is 
independent of canonical NHEJ factors and is referred to as Microhomology Mediated End 
Joining (MMEJ). It favours the repair of DSBs through extensive deletion but may also result 
in insertions. Interestingly, regions of microhomology have been detected within telomere 
fusion junctions in telomerase null mice,209 in human cells undergoing crisis in culture255 and 
tumour cells.304 
It has been postulated that Ku-independent MMEJ requires a protein that is involved in the 
detection and alignment of DNA microhomology prior to the resection of the 3’overhangs. It 
has been suggested that the MRN complex may be associated with this process. Notably, 
Mre11 in conjunction with Rad50 may function to maintain a synapsis between the two 
ends. Telomere fusions in Mre11 deficient ATLD (Ataxia-Telangiectasia Like Disorder) cells 
carry short tracts of nucleotide insertions.305 It has been implicated that deficiencies in 
Mre11 may promote further genetic instability in a MMEJ dependent manner. Instead a 
translesion polymerase may extend an annealed sequence using templated error prone 
synthesis which may subsequently realign at another site of microhomology following 
dissociation and potentially result in genetic amplification.306 Templated nucleotides have 
also been detected in Drosophila mutants deficient in Rad51 and DNA ligase IV. These 
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repeats shared similarity with adjacent DNA and it was speculated that they are generated 
in an attempt to create microhomology that can be utilised for end joining.307   
Poly (ADP-ribose) Polymerase I [PARP-1] becomes activated by single strand DNA breaks and 
its activity has been proposed to promote the synapsis and ligation of double strand breaks 
in MMEJ. The DNA ligase III/XRCC1 complex previously implicated in Base Excision Repair/ 
Single-Strand Break Repair (BER/SSBR) has also been proposed to play a role in MMEJ.308 
Elevated levels of DNA ligase III has been detected in BCR/ABL+ CML (Chronic Myeloid 
Leukaemia) cells accompanying the down-regulation of the NHEJ factors, DNA ligase IV and 
Artemis. The majority of DSBs (80%) in these cells were repaired using microhomology at 
the break junctions; moreover a reduction of DNA ligase III resulted in a decrease in the 
frequency and size of microhomology.309 DNA ligase III has been postulated to form a 
complex with WRN, a 3’ to 5’ exonuclease of which its depletion has been found to cause 
the premature aging syndrome, Werner.310 Notably, a knockdown of WRN was observed to 
increase the size of deletions at repair junctions and thus it was proposed that WRN may 
play a role in limiting the extent of resection that takes place during DNA repair.309  
The efficiency of PARP-1 DSB synapse formation can be modulated by the stability of the 
microhomology overhang.308 An overhang composed of G:C bases is repaired much more 
efficiently.308,311 Furthermore, the dependence of canonical NHEJ in DSB repair is inversely 
correlated to the G:C content of the overhang suggesting that NHEJ is mostly required when 
the annealing of the overhangs is not energetically favourable.311 Accordingly, it has been 
proposed that NHEJ catalyses the synapsis of short overhangs through protein-protein 
interactions in which the energy provided by base pairing is limited.311      
Saccharomyces Cerevisiae utilises the Rad10-Rad1 endonuclease to remove the 3’overhang 
prior to ligation for single strand annealing (SSA) and MMEJ DNA repair.311 The mammalian 
ortholog ERCC1/XPF complex has been demonstrated in vivo to remove the 3’flap in 
mammalian cells in a pathway that is independent to the canonical NHEJ.312 Furthermore, 
the ERCC1/XPF complex facilitates DSB repair by removing the 3’overhang at the end of 
uncapped telomeres275 raising the possibility that telomere fusions may arise in an 
alternative pathway to NHEJ. Accordingly, the frequency of telomere fusion events has been 
shown to reduce significantly in cells deficient for both TRF2 and either ERCC1 or XPF.275 
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1.29 Telomeres and Cancer 
Telomeres within human somatic cells do not express telomerase and will continue to 
shorten at 50 to 100bp per cell division.294 Progressive telomere shortening will initiate 
replicative senescence in which cells stop dividing disenabling further telomere loss. It has 
been proposed that the onset of senescence is triggered by the shortest telomere within a 
distribution rather than the global average.209 Consistent with this, an accumulation of short 
telomeres has been observed in cells that are approaching senescence.313 A decline in the 
‘capping’ function of the telomere by loss of TRF2 and POT1 or when telomeres become 
critically short can compromise chromosome end protection and initiate an ATM (Ataxia-
Telangiectasia Mutated) or ATR (ATM and Rad3-related) kinase dependent DNA Damage 
Response (DDR) respectively.202 Activated ATM or ATR kinase phosphorylate regions of 
histones H2AX flanking into sub-telomeric regions to generate DNA damage foci at 
dysfunctional telomeres (Telomere dysfunction Induced Foci [TIFs]).314,315 Cells respond to 
TIFs by either entering into a p21 mediated permanent senescent state or become 
proapoptotic in response to p53.314 Consistent with this, hTERT immortalisation reduces the 
generation of TIFs in human fibroblasts in culture.316  
Efficient maintenance of cell cycle arrest in senescent cells depends on the continued 
activity of the DDR components since negatively interfering with their actions can restore 
cell cycle progression into the S phase of the cell cycle.317,314 Accordingly, carcinogen or 
virus-induced transformation can enable cells to acquire an extended lifespan and 
overcome cellular senescence.318 Post-senescent cellular replication will drive further 
telomere loss that may denude telomeres of all TTAGGG repeats. It has been implicated that 
telomere dysfunction may provide a stepwise accumulation of cytogenetic changes during 
cancer development through the formation of dicentric chromosomes by telomere-
telomere fusion. Dicentric chromosomes that are pulled apart during anaphase cause 
chromosome breakage and new recombinogenic free ends that can initiate and continue 
Breakage-Fusion-Bridge (BFB) cycles.319 Continuous BFB cycles can generate a wide 
spectrum of novel genetic alterations including non-reciprocal translocations (NRTs). This 
paradigm has been previously implicated in many human solid tumours including renal cell 
carcinoma,320 pancreatic carcinoma and osteosarcomas.321 Consequently, an accumulation 
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of non-reciprocal translocations (NRTs) may facilitate in carcinogenesis through positive 
selection.322 
Although, the vast majority of cells enduring genetic instability will cease to divide and die; a 
small proportion of cells may acquire a mechanism that enables telomere length stability.318 
Telomerase is expressed in >90% of human cancers.180 However, it is not expressed to 
excess in the majority of cases. Consequently, telomeres are either the same or shorter than 
those in adjacent normal tissue. Thus, it has been suggested that telomerase is required to 
maintain telomere function.323 Consistent with this, telomerase activity has shown to reduce 
the frequency of end-to-end chromosome fusions in the presence of critically short 
telomeres.212 It has been described that telomere dysfunction could promote carcinogenesis 
prior to telomerase activation. Accordingly, numerous end-to-end fusions and signal free 
ends have been observed in metaphase spreads derived from late generation mTR-/- p53-/- 
mutant mice.322 
Telomerase activation or elongation via homologous recombination can provide telomere 
length and genome stability to facilitate the outgrowth of a sub-clonal population with an 
altered phenotype. 
This model suggests that telomere dysfunction may initiate the neoplastic process to 
oncogenesis322 and the shortest telomere within the distribution may acquire this role 
through chromatid-chromatid  or inter-chromosomal fusion following replication.209 
Therefore, it can be assumed that replicative senescence functions as a protection 
mechanism against the initiation of BFB cycles following the generation of dicentric 
chromosomes.294  
Accordingly, deficiencies in ATM can cause disorders that fail to suppress DNA replication 
following DSBs consequently predisposing patients with a higher incidence of malignancies 
due to an elevated frequency of genetic instability and chromosomal translocations.138,324  
1.30 Telomeres and Haematological Disorders 
Despite being telomerase competent; CD34+ haematopoietic cells show a reduction in 
telomere length with age325 losing up to 33bp per year.326 Consistent with this, a transient 
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phase of rapid telomere shortening has been observed following an allogeneic bone marrow 
transplant prior to stabilisation and haematopoietic reconstitution. It was also observed that 
the extent of telomere shortening is inversely correlated with the number of mononuclear 
cells received by the recipient.327 This suggests that the proliferative pressure is less intense 
with a larger population of progenitor cells. Thus, increased telomere attrition may cause 
the diminished capacity of haematopoietic cell reserves through senescence or apoptosis. 
Furthermore, telomere dysfunction could lead to the acquisition of clonal translocations 
that could promote leukaemogenesis. Accordingly, late clonal disorders, such as MDS or 
acute leukaemia have noted to arise from a bone marrow transplant or high dose 
chemotherapy following the successful elimination of a former leukaemia, lymphoma or 
solid tumour.328 
Disease anticipation in families with Dyskeratosis Congenita (DC) is associated with telomere 
shortening.329 Mutated telomerase in DC fails to maintain telomere function causing 
accelerated exhaustion of stem cell reserves and consequential bone marrow failure. 
Marked similarities of clinical phenotypes observed in DC patients have been documented in 
mTR-/- mice where an age dependent compromise of haematopoietic reconstitution is 
observed following HSC ablation.330 Furthermore, a high incidence of teratocarinomas and 
lymphomas have been described in mTR-/- mice as well as reduced tumour latency following 
successive mTR-/- generations.330 Accordingly, it has been documented that a 196 fold 
increase in AML predisposition is present in patients with DC.331 It has been proposed that 
the limited level of telomerase activity within the haematopoietic system targets short 
telomeres in an act to maintain the stability of the genome of the highly proliferative bone 
marrow.212  
Terminal restriction fragment (TRF) length analysis has demonstrated that telomere 
shortening is a frequent observation in MDS and AML relative to aged matched controls332-
334 with the observation of significant telomere attrition in AML.335,336 Although this may 
indicate the mitotic history of the disease; telomere shortening has been associated with 
complex chromosomal rearrangements and poorer prognoses in a number of 
haematological disorders that include acquired Aplastic Anaemia (AA),337,338 Chronic 
Myeloid Leukaemia (CML),339,340 and Chronic Lymphocytic Leukaemia (CLL)341 and 
MDS/AML.333,334,342 However, telomere dysfunction is not coupled to the global average 
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length within the cell. Instead, it is the shortest telomere within the distribution that is vital 
for cell viability and chromosome stability. Therefore, the shortest telomere within the 
distribution can initiate chromosomal fusions209 that may play a role in the pathogenesis of 
MDS and its subsequent transition to AML.  
The activation of ATM/ATR regulated checkpoint pathways may collectively contribute to 
ineffective haematopoiesis in this disease and the ‘latency’ period prior to AML, in which a 
compromised DDR enables clonal expansion. Consistent with this, a DDR response that is 
commonly present at pre-invasive stages of major human cancers becomes abrogated with 
development. This concept has been applied to breast, colon, lung and bladder 
carcinomas.343 Furthermore, disease progression in MDS has been associated with 
inactivation of components required for a DDR. LOH at the ATM locus has been previously 
observed in AML344 and the loss of p53 has been implicated to result in significantly shorter 
survival, AML transformation and enhanced resistance to chemotherapy.135 Additionally, 
p53 mutations have been found to accompany abnormal cytogenetics.136 An ‘uncoupling’ 
effect has also been observed between functional ATM and its DDR response in AML. A 
positive correlation was observed between ATM activation and the number of blast cells 
present in the bone marrow; however downstream targets were uncoupled from inactive 
checkpoint kinases (chk-1 and chk-2) in AML enabling cells to evade cell cycle checkpoints 
and apoptosis.345 This is consistent with the presence of a DDR response during the pre-
malignant stage which becomes down-regulated with transformation.   
Short telomeres have also been associated with low haemoglobin concentrations and 
multiple cytopenias332 including a significant negative correlation between telomere length 
and the number of blasts in the bone marrow.336 Consistent with this, progressive telomere 
shortening has been associated with a consensual decrease in apoptosis of MDS CD34+ 
cells.346 It was proposed that in the absence of functional cell cycle checkpoints prolonged 
telomere reduction can initiate genetic instability which may promote blast cell proliferation 
and leukaemogenesis through positive selection.     
Most MDS patients have normal to low levels of telomerase332 that can increase by 18 fold 
in AML.335 Consistent with this; RAEB-T associated with high telomerase activity has shown 
progression into AML shortly after initial diagnosis.332 Furthermore, it has been 
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demonstrated that hTERT expression347 and telomerase activity342 are more pronounced in 
AML with complex rearrangements associated with the loss or gain of chromosome parts. 
Low levels of telomerase have been demonstrated to correlate with telomere shortening 
during the ex vivo expansion of MDS CD34+ cells. Despite telomerase activity, telomere 
maintenance is insufficient to completely prevent telomere loss in cells that are capable of 
increased cycling, i.e. 20 fold. However, increased telomerase activity in AML may be vital in 
preventing excessive telomere attrition in malignant cells that can proliferate up to 45 to 50 
fold of normal haematopoietic cells.335   
Despite an accumulation of telomerase competent blast cells in late MDS and AML; 
increased telomerase activity may also be a feature of the malignant phenotype that is vital 
to stabilise the genome acquired in AML cells. Thus, the reactivation of telomerase could 
occur as a late genetic event to promote colony formation, as reported in the blastic phase 
in CML.340     
Telomere shortening may not only represent a consequence but also be a predisposing 
factor for the development of MDS. The increased cell turnover in this disease may promote 
replicative senescence and genetic instability during the malignant transformation of 
haematopoietic cells.348  
1.31 Telomere Length Analysis in MDS/AML 
Telomere length has been analysed using various approaches in MDS and AML. Such 
techniques have included Terminal Restriction Fragment (TRF), Quantitative-Fluorescence in 
situ Hybridisation (Q-FISH), Flow-Fluorescence in situ Hybridisation (Flow-FISH) and 
Quantitative-Polymerase Chain Reaction (Q-PCR). Some of the studies and the results 
obtained regarding telomere length in MDS and AML have been discussed:  
 
Telomere length was measured using Flow-Fluorescence in situ Hybridisation (Flow-FISH) on 
fractionated peripheral blood (PB) granulocytes and CD34+ cellular populations derived from 
55 MDS patients (40 at diagnosis; 15 derived at 6 to 12 months following diagnosis).346 In 
contrast to what was observed in normal controls, telomere fluorescence did not decline 
with age in MDS derived PB granulocytes and CD34+ cells. Moreover, telomere fluorescence 
was shorter amongst MDS patients, particularly in patients presenting with 
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intermediate/unfavourable karyotypes and IPSS Intermediate-2/High-risk scores. The 
degree of apoptosis in the CD34+ population was directly correlated with telomere 
fluorescence and thus it was proposed that cell cycle checkpoints had been bypassed in 
these cases. Consistently, the extent of apoptosis was inversely correlated with the 
percentage of bone marrow blasts. This study observed that patients presenting with lower 
telomere fluorescence had significantly worse prognostic characteristics and suggested that 
telomere length might represent an independent prognostic factor that could be linked to 
an unfavourable outcome.  
Telomere dynamics has been analysed using Q-FISH analysis in a subset of 13 MDS patients 
at diagnosis.349 Telomere length was measured at the single cellular level and compared to 
telomere measurements derived from TRF analysis. The frequency of the telomere 
fluorescence intensity in each metaphase was summed to determine patterns of telomere 
length. In healthy aged-matched individuals, telomere length distributions were wide and 
skewed more towards longer telomeres. In contrast telomere length distributions derived 
from MDS metaphases were narrow and accumulated at shorter telomere lengths. 
Telomere length measurements analysed by TRF and Q-FISH analysis were comparable in 
normal controls. In contrast, telomere length measured by Q-FISH was shorter in MDS 
patients when compared to TRF analysis. Accordingly, MDS patients presented with 
telomere length in the range of 3.2kb to 17.5kb by TRF analysis; however peak telomere 
fluorescence values only ranged between 3.6kb to 4.8kb. MDS marrow cells contain at least 
two populations; one derived from the MDS clone and the other from normal background 
cells therefore, it was speculated that the superimposition of normal cells (with potentially 
longer telomeres) may be accountable for the longer telomeric length in TRF 
measurements. This study suggested that short telomeres in MDS may play a role in the 
pancytopenia that is feature of MDS patients and further proposed that some MDS cells 
may survive and divide with short telomere lengths, particularly since telomere signals 
accumulated at short length in MDS metaphases. Accordingly, it was speculated that 
telomerase activation may enable these cells to escape checkpoint mechanisms and enable 
clonal expansion.          
Telomere length, telomerase activity and mRNA expression of critical telomeric proteins was 
analysed in age-matched groups of AML (>90% blasts) with distinct chromosome 
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aberrations namely; AML with three or more gains and/or losses of chromosome parts, 
terminal deletions or non-reciprocal translocations (13 patients) and two control groups 
presenting with chromosomal abnormalities unlikely related to telomere dysfunction; AML 
with reciprocal translocations or inversions (17 patients) and AML without chromosome 
aberrations (8 patients).342 The aim of the study was to determine if telomere shortening 
(analysed using Q-FISH) played a role in generating extensive chromosomal instability. 
Telomere length was significantly shorter in AML with gains and/or losses in contrast to the 
control groups. Moreover, Q-FISH revealed extensive telomere shortening on individual 
chromosome arms in this subset of patients. It was speculated that critically short telomeres 
in these cells may have a role in generating chromosomal instability. Control groups 
presented with comparable telomerase activity to that within normal marrow however, 
AML patients with gains and/or losses showed elevated telomerase activity by 3 to 8 fold. It 
was speculated that telomere elongation by telomerase may be repressed by TRF1. Notably, 
high expression of TRF1 mRNA was observed in AML with gains and/or losses when 
compared with AML patients in control subgroups. This study suggested that critical 
telomere shortening and subsequent telomere dysfunction in AML patients may contribute 
to the development of chromosomal abnormalities that are detected in patients with gains 
and/or losses. It was further proposed that telomerase up-regulation in patients with gains 
and/or losses may indicate that these cells have already bypassed cellular crisis.  
Telomere length was analysed using Quantitative-Polymerase Chain Reaction (Q-PCR) in 167 
de novo paediatric AML patients presenting with at least 80% leukaemic cells at diagnosis in 
order to investigate if short telomeres were associated with AML characteristics and 
whether they contributed to an adverse outcome.350 Telomere length was not associated 
with age in AML patients. Moreover, extensive telomere shortening was observed among 
leukaemic cell populations in contrast to PB leukocytes derived from healthy controls. 
Telomere length was not significantly different among FAB subgroups and was not 
associated with the number of cytogenetic aberrations (numerical or structural), including 
complex karyotypes (3). Q-PCR fails to measure specific telomere length and therefore the 
authors considered that the chromosomal instability identified in these cases may be 
influenced by the shortest telomere within the cell. AML patients harbouring the FLT3/ITD 
mutation had shorter telomeres than patients without FLT3/ITD implicating that this might 
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reflect an extended mitotic history of leukaemic cells within this subgroup of patients. 
Telomere length did not influence the overall survival, event-free survival, the incidence of 
relapse or response to treatment. Accordingly, short telomeres did not appear to correlate 
with an unfavourable outcome.  
Telomere parameters were analysed in 137 patients diagnosed with de novo or secondary 
AML presenting with at least 80% blasts at diagnosis.347 Telomere length was measured 
using flow-FISH in peripheral blood (PB) granulocytes and compared with telomere 
measurements derived from PB granulocytes from a control group of healthy individuals. 
Telomere length was significantly shorter in AML patients when compared to aged-matched 
healthy controls and no correlation was identified between telomere length and disease 
status, i.e. de novo AML or secondary disease. Patients presenting with a high FLT3 ratio 
(mutant FLT3/ wild type ratio) had significantly shorter telomeres than those with a low 
FLT3 ratio and this was particularly pronounced in individuals exhibiting a normal karyotype. 
Patients with multiple cytogenetic abnormalities had the shortest telomeres when 
compared to those presenting with a normal karyotype. Moreover, the degree of 
chromosomal abnormalities correlated with hTERT expression. It was suggested that 
extensive telomere loss may contribute to the development of genetic instability in this 
subset of patients and that telomerase up-regulation permits the expansion of the AML 
clone by preventing cellular senescence. Telomere length did not have a significant 
influence on treatment response, overall survival or disease-free survival in AML patients. 
Telomere length was evaluated by TRF analysis in bone marrow and peripheral blood cells 
obtained from 50 patients presenting with de novo MDS and AML (arising from MDS) and 21 
untreated de novo AML.336 The aim of the study was to determine whether telomere 
shortening was associated with the progression of early to advanced MDS and subsequently 
towards acute leukaemia. Patients presenting with shorter TRFs than aged-matched 
controls increased with MDS progression such that 30% of early RA/RARS, 65% of advanced 
RAEB/RAEB-T and 80% of AML patients (secondary from MDS) had reductions in TRF length. 
Patients with de novo AML presented with the shortest TRF measurements. A significant 
negative correlation was detected between TRF measurement and the percentage of blasts. 
Moreover, a significant negative correlation was observed between TRF and IPSS score and 
thus it was suggested that telomere length may serve as a useful prognostic variable in the 
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assessment of risk and facilitate in making therapeutic decisions. Shorter TRFs were also 
detected amongst patients presenting with an abnormal karyotype when compared to 
patients with a normal karyotype. However, this difference was only significant in early MDS 
and diminished in advanced MDS and AML.    
Telomere length was measured using TRF analysis in 93 patients with MDS at the time of 
diagnosis332 and compared with TRF measurements derived from aged-matched controls. It 
was observed that 57% of patients presented with TRFs of aged-matched normal range 
whereas 38% and 5% had shortened TRFs and elongated TRFs, respectively. TRF 
measurements were not associated with FAB subgroups such that 34% of RA/RARS and 47% 
of RAEB-T patients showed shortened TRFs relative to age. 66% of patients with shortened 
TRFs presented with an abnormal karyotype in contrast to only 34% of patients with normal 
range TRFs. MDS patients with shortened TRFs had a significantly low haemoglobin 
concentration, a high marrow blast percentage, multiple cytopenia and poor cytogenetic 
changes. Additionally, the incidence of leukaemic transformation was significantly higher in 
MDS patients with shortened TRFs compared to those with normal range TRFs. Patients 
presenting with intermediate-2/ high IPSS scores had significantly shorter TRFs than those 
with low/ Intermediate-1 IPSS scores. It was also identified that patient outcome was 
significantly influenced by TRF length such that patients presenting with normal range TRFs 
had a favourable prognosis in contrast to those with abnormal TRFs (shortened/elongated 
TRFs). The majority of MDS patients analysed had normal-to-low levels of telomerase 
activity. Therefore, it was suggested that accelerated telomere erosion due to rapid cell 
division is not restored in patients presenting with shortened TRF measurements because 
telomerase activity is insufficient to maintain telomere length. 2 RAEB-T patients showed 
high telomerase activity and subsequently developed acute leukaemia shortly after 
diagnosis. Thus, it was proposed that accelerated telomere erosion may be an early event in 
MDS pathogenesis and that telomerase reactivation may be a late genetic event that 
enables AML transformation. This study suggested that TRF measurements at the time of 
diagnosis may refine individuals according to risk.   
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1.32 Aim of Research 
High resolution methodology will be utilised to analyse telomere length in a cohort of 80 
MDS and 144 AML patients. Single Telomere Length Analysis (STELA) is a long-range single 
molecule PCR approach that has the ability to amplify the double-stranded region of 
telomere repeats from specific chromosome ends.171 Telomere length analysis has 
previously been employed on MDS and AML however, STELA has the ability to detect the 
full spectrum of telomere lengths and is able to identify critically short telomeres which 
have the potential to induce replicative senescence or initiate cycles of telomere fusion and 
breakage.255,304,351   
STELA will be used to analyse whether telomere length at the XpYp and 17p telomere is 
associated with specific clinical parameters in MDS and AML. Such parameters in MDS will 
include age, marrow blast percentage, peripheral blood cytopenia, cytogenetics, 
International Prognostic Scoring System (IPSS) and overall survival. Whereas age, gender, 
marrow blast percentage, presenting white blood cell (WBC) count, AML type (de novo/ 
secondary), WHO performance status, FLT3 and NPM1 mutation status, response after first 
cycle of intensive chemotherapy and finally clinical outcome data including overall survival 
and disease-free survival will in analysed in AML.  
Additionally, specific features including atypical Telomere Rapid Deletions (TRDs), bimodal 
populations and Telomeric-Loss of Heterozygosity (Telomeric-LOH) will be checked for 
within STELA profiles. In the event of detecting bimodal populations at the XpYp telomere, 
allele-specific STELA will be employed by using previously characterised heterozygosities in 
the sub-telomeric region of XpYp.244 This will facilitate in determining whether this 
observation is a reflection of differing maternal and paternal contributions in the zygote. 
The non-functional Telomere Variant Repeat (TVR) region of the XpYp telomere will also be 
measured using TVR-PCR in order to calibrate the STELA data such that the length of the 
uninterrupted tandem repeats of TTAGGG can be established.   
Further studies will include TRAP (Telomere Repeat Amplification Protocol) to measure 
telomerase activity between a cohort of MDS and AML patients and the rate of telomere 
loss will be analysed in a small subset of MDS patients in which serial samples are available. 
Magnetic Dynabeads specific for the CD34+ antigen will be utilised to separate the CD34+ 
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and CD34- fractions derived from a set of 20 MDS patients and STELA will be subsequently 
performed to analyse the telomere length within each fraction so as to determine whether 
telomere erosion is more pronounced in the more primitive CD34+ population.    
In order to analyse the extent of telomere dysfunction in MDS and AML, a PCR-based 
telomere fusion assay will be used to detect and quantify single telomere-telomere fusion 
molecules between specific chromosome ends. Putative single fusion molecules will be re-
amplified with nested PCR primers to identify the participating telomeres and coexisting 
fusion junction. Finally, the nature of telomere fusions will be characterised using direct 
sequencing analysis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 64 
 
Chapter 2: 
Materials and Methods 
2.1 Patient samples 
Bone marrow mononuclear cells (BMMNC) derived from 80 MDS (median age 70 years; 
range 21 to 86 years) and 144 AML patients were collected at the time of diagnosis. All 
samples were acquired after written informed consent was obtained from each patient. 
Comprehensive clinical information available for the MDS and AML cohorts are listed in 
Table 2.1 and 2.2, respectively of which demographic information was only available for 110 
of these AML cases who had a median age of 60 years (range 17 to 82 years). MDS samples 
were kindly provided by Dr Paul Baines from a local tissue bank held in the Department of 
Haematology, Cardiff University, School of Medicine or were paid for via the Dundee tissue 
bank. AML samples were from the Cardiff AML Biobank, Cardiff University, School of 
Medicine and were derived from patients enrolled in the Medical Research Council (MRC) 
trials AML 14, 15, 16 and 17. 
Of the 144 AML samples analysed in this study, mean XpYp telomere length ±SD was 
provided for 87/144 patients by Bethan Britt-Compton. In addition, a comparator dataset 
derived from peripheral blood leukocytes from 68 healthy individuals (median age 31.5 
years; range 0 to 72.5 years) was provided by Duncan Baird.  
Serial samples were available from 4 MDS patients; these samples were analysed to quantify 
temporal telomere erosion. 
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Demographic information of MDS patients  
MDS patients: n = 80; Median age 70 years (range: 21 years to 86 years) 
Gender: n = 80 
Male: n = 50   Female: n = 30 
French-American-British (FAB) Score: n = 29  
RA/RARS: n = 17    
RAEB: n = 10 
RAEB-T: n = 2 
Cytopenia Number: n = 71 
1 Cytopenia: n = 26 
2 Cytopenia: n = 17 
3 Cytopenia: n = 28 
Cytogenetic Profile: n = 47  
Good: n = 23    
Intermediate: n = 10  
Poor: n = 14 
International Prognostic Scoring System (IPSS Score): n = 72 
Low: n = 20    
Intermediate-1: n = 14    
Intermediate-2: n = 6    
High: n = 32 
  
 
Table 2.1: Demographic information of MDS patients who were analysed within the current study. 
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Demographic information on AML patients 
Total AML patients: n = 144; Demographic information available for 110 of 144 patients. 
Median age 60 years (range: 17 years to 82 years) 
Gender: n = 110 
Male: n = 57   Female: n = 53 
AML type: n = 110 
De novo: n = 95   Secondary: n = 15 
Bone Marrow Blast %: n = 80 
1st Quartile 50.25%: n = 20 
2nd Quartile >50.25% to 78%: n = 20 
3rd Quartile >78% to 90.75%: n = 20  
4th Quartile >90.75%: n = 20 
Presenting White Blood Cell (WBC) count (x109/l): n = 110 
1st Quartile 11.45: n = 27 
2nd Quartile >11.45 to 30.50: n = 28 
3rd Quartile >30.50 to 76.53: n = 28 
4th Quartile >76.53: n = 27 
Cytogenetic Profile: n = 94 
Favourable: n = 7   Intermediate: n = 83   Adverse: n = 4 
World Health Organisation (WHO) Performance Status (PS): n = 110 
PS 0: n = 61   PS 1: n = 34   PS 2: n = 7   PS 3: n = 8 
Mutation Status 
FLT3/ITD+: n = 46   FLT3/ITD-: n = 53   FLT3/TKD+: n = 19   FLT3/TKD-: n = 65  
NPM1+: n = 52   NPM1-: n = 44  
Table 2.2: Demographic information of AML patients who were analysed within the current study. 
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2.2 DNA Extraction 
As described previously,171 DNA was extracted from bone marrow mononuclear cells using 
standard Proteinase K, RNase A and phenol/chloroform protocols. Accordingly, samples 
stored at -80°C were thawed quickly in a 37°C water bath and centrifuged at 6000g for 5 
minutes. The supernatant was removed and details belonging to each sample were noted. 
Cells were re-suspended in 1ml of 1xPBS (Phosphate Buffered Saline) and centrifuged for a 
second time at 6000g for 5 minutes. PBS was removed. This process was repeated until the 
medium was removed.  
20ml of Lysis buffer was made containing 100mM NaCl, 10mM Tris-HCl (pH 8.0), 5mM EDTA 
(pH 8.0), 0.50% SDS and filtered H2O. Lysis buffer was added to the cell pellet in accordance 
to the number of cells. Notably, 300l, 500l or 1ml of buffer was added to the sample if 
the cell population exceeded 1x105, 3x106 and 28x106, respectively. 3l, 5l or 10l of 
RNAse A (10mg/ml) and Proteinase K (20mg/ml) were subsequently added to each sample if 
the cellular population exceeded 1x105, 3x106 and 28x106, respectively. Samples were 
incubated at 45°C in a hot block overnight.  
Cells were centrifuged briefly and phenol/chloroform extraction commenced. 500l of ultra-
high purity phenol/chloroform was added and then each sample was placed on a tube 
rotator for 20 to 30 minutes. Samples were subsequently centrifuged at 13K for 4 to 6 
minutes.  
The top aqueous and interphase layers were transferred into a fresh tube containing 500l 
of phenol/chloroform. Samples were rotated for a second time for 20 to 30 minutes and 
centrifuged at 13K for 4 to 6 minutes. This process was repeated if the phenol/chloroform 
layer remained cloudy. Finally, the aqueous phase of each sample was transferred into a 
fresh tube. 
3M NaOAc (pH 5.2) was added to each sample. The 1:10 volume was required; salt to lysis 
buffer, i.e. used 50l of NaOAc if 500l lysis buffer was used. Ice cold 100% Ethanol was 
subsequently added and samples were left to stand on ice to enable DNA precipitation. 
The DNA was pelleted by centrifugation at 13K for 1 minute and the ethanol was removed. 
Residual salt was washed away by leaving the DNA pellet to stand in 70% ice cold ethanol 
 68 
 
over ice for 10 minutes. Samples were centrifuged at 13K for 1 minute and supernatant was 
removed. Finally, the DNA pellet was allowed to air dry and re-suspended in 50l, 25l or 
15l 10mM Tris-HCl (pH 8.0) depending on whether the pellet was large, medium or 
invisible respectively and placed in the fridge overnight.  
DNA was quantified in triplicate by Hoechst 33258 Fluorometry (BioRad). The instrument 
was warmed up for approximately 30 minutes prior to calibration. A 20ml working solution 
composed of 1xTNE and 0.001mg/ml Hoechst was prepared in filtered H2O and mixed.   
Standards (i.e. blank and calf thymus) and patient samples were prepared in 1ml working 
solution. Notably, 5l of calf thymus DNA (100ng/l) was utilised to achieve a standard of 
500ng. The fluorometer was calibrated and 1l of patient samples were measured in 
triplicate. Finally, samples were diluted in 10mM Tris-HCl (pH 8.0) to 10ng/l.  
2.3 Single Telomere Length Analysis (STELA) 
10ng/l genomic DNA diluted to 250pg/l in a 40l reaction containing 1l Telorette-2 
linker (10M) and 38l 10mM Tris-HCl (pH 8.0). Multiple PCRs (typically 6 reactions per 
sample) were carried out for each test DNA in 10l containing Taq Buffer (x1), 2mM of 
MgCl2, 1.2mM dNTPs, 0.5M Teltail, 0.5M XpYpE2 or 0.5M 17pseqrev1 (XpYp or 17p 
telomere adjacent primers) or 0.5M XpYp-427G/415C or 0.5M XpYp-427A/415T allele-
specific primers, 0.5 Units of a 10:1 mixture of Taq (Thermoscientific) and Pwo Polymerase 
(Roche) and 250pg diluted DNA. Reactions were cycled with an MJ PTC-225 thermocycler 
(MJ research) under the following conditions: 22 cycles of 94°C for 20secs, 65°C (XpYpE2) or 
66.5°C (XpYp-427G/415C and XpYp-427A/415T allele-specific primers) or 59°C (17pseqrev1) 
for 30secs, and 68°C 8 minutes. Allele specific haplotypes (AT or GC) were identified by 
genotyping of the XpYp telomere-adjacent DNA prior to STELA.  
Products were resolved by 0.5% Tris-acetate-ethylenediaminetetraacetic acid agarose gel 
electrophoresis. Prior to blotting, the DNA was depurinated in 0.25M HCl (Hydrochloric 
Acid) and denatured in 1.5M NaCl (Sodium Chloride) and 0.5M NaOH (Sodium Hydroxide). 
Products were identified by two separate Southern blot hybridisations using a random-
primed [α-33P]dCTP-labelled (GE Healthcare) telomere adjacent probe and TTAGGG repeat 
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probe. Probes that specifically target the 1kb (Stratagene) and 2.5kb (BioRad) molecular 
weight markers were also used in each hybridisation reaction.  
2.4 Hybridisation 
15ml of Church Buffer (1% BSA, 7% SDS, 1mM EDTA, 0.5M NaHPO4 [pH 7.2]) was transferred 
into a hybridisation bottle before being placed into a hybridisation oven set at 65°C. The 
DNA blot was washed in H2O and inserted into the bottle. To ensure sufficient buffer 
coverage of the membrane and block of non-specific binding sites the membrane was pre-
hybridised prior to adding the DNA probe.  
 
DNA was labelled using random oligomer labelling upon using the GE Healthcare DNA 
labelling beads (composed of buffer, dATP, dGTP, dTTP, random nonamers [d(N)9] and the 
Klenow fragment (E. coli DNA polymerase I). 25ng of probe was made up in a volume of 45l 
1xTE buffer (pH 8.0). The probe was denatured at 96°C on a heating block for 5 minutes and 
subsequently snap-cooled for 5 minutes over ice. In a radiation cabinet, 4l of [α-33P]dCTP 
(GE Healthcare) was added to the probe and the mixture was re-suspended. The probe 
mixture was placed into a 37°C water bath for at least 30 minutes before transferring 1l of 
a pre-made 1kb/2.5kb probe marker. 50l of H2O was added to the probe mixture and re-
suspended to ensure efficient mixing. Finally, the probe was denatured at 96°C on a heating 
block for 5 minutes and 25l was inserted into the centre of the pre-hybridised bottle. The 
bottle was placed back into the oven overnight.    
 
After hybridisation, excess probe was washed at high stringency from the nylon membrane 
in a buffer solution containing 0.1% SSC (saline-sodium citrate) and 0.1% SDS (sodium 
dodecyl sulphate). 
The hybridised fragments were detected by phorphorimaging with a Molecular Dynamics 
Storm 860 phosphorimager (GE Healthcare) and the molecular weights of DNA fragments 
were calculated using the Phoretix 1D quantifier (Nonlinear Dynamics).  
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2.5 Fusion Assay 
The telomere fusion assay was carried out as described previously.255 Multiple PCRs 
(typically 18 reactions per sample) were carried out for each test DNA in 10l containing Taq 
Buffer (x1), 2mM MgCl2 , 1.2mM dNTPs, 0.5M XpYpM, 0.5M 17p6, 0.5M 21q1, 0.5 Units 
Taq/Pwo (10:1) and 100ng gDNA. PCR reactions utilised the XpYpM and 17p6 primers in 
conjunction with the 21q1 primer. The 21q1 primer targets multiple chromosome ends 
which share homology with the 21q sub-telomere allowing the simultaneous detection of 13 
chromosome ends including 21q, 1q, 2q, 5q, 6q, 6p, 8p, 10q, 13q, 17p, 19p, 19q, 22q as well 
as the 2q13 interstitial telomeric locus.351  
Products were resolved by 0.5% Tris-acetate-ethylenediaminetetraacetic acid agarose gel 
electrophoresis and identified by Southern Hybridisation with random-primed [α-33P]dCTP 
labelled (GE Healthcare) XpYp and 17p telomere-adjacent probes; XpYpOG and 17p7, 
respectively. Probes were generated by PCR as described previously.255,351  
Probes that specifically target the 1kb (Stratagene) and 2.5kb (BioRad) molecular weight 
markers were also used in each hybridisation reaction. The hybridised fragments were 
detected by phorphorimaging with a Molecular Dynamics Storm 860 phosphorimager (GE 
Healthcare).  
 
Taking into account the DNA content of a single diploid cell at 6pg; the frequency of fusion 
could be calculated from the number of positive molecules compared with the number of 
input molecules. Further hybridisation was performed with the 21q1-adjacent probe;351 
however since this probe yields additional non-specific products the fusion frequency was 
not quantified.  
Fusion reactions were re-amplified using nested PCR primers (XpYpMb, 17p6b and 21q1C). 
Each re-amplification reaction (30l) contained Taq Buffer (x1), 2mM MgCl2 , 1.2mM dNTPs, 
0.5 Units Taq/Pwo (10:1) and a combination of  0.5M XpYpMb, 0.5M 17p6b or 0.5M 
21q1C. Fusion reactions were diluted by 1:20 in H2O and 3l of the product was added to 
the re-amplification reaction. 
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Products were resolved by 0.7% Tris-acetate-ethylenediaminetetraacetic acid agarose gel 
electrophoresis and were subsequently gel-purified (QIA quick Gel Extraction Kit; Qiagen) 
for direct sequencing analysis using BigDye 3.1 (Applied Biosystems) in conjunction with 
designed primers specific to the target sequence.  
2.6 TVR Mapping 
TVR-PCR was used to determine the distal extent of the XpYp TVR region. Three separate 
10l reactions per sample contained Taq Buffer (x1), 3mM MgCl2 , 1.2mM dNTPs, 1M of 
the XpYpE2 primer, 1M of the TVR primers: TTAGGG (TAG-TelW), TGAGGG (TAG-TelX) or 
TCAGGG (TAG-TelY), 100ng DNA and 0.5 Units Taq polymerase (no Pwo). Each PCR reaction 
was cycled 20 times at 96°C for 20secs, 67°C for 30secs and 70°C for 3 minutes. 
Products were resolved by 0.9% Tris-acetate-ethylenediaminetetraacetic acid agarose gel 
electrophoresis and detected by Southern blot hybridisation using a random-primed [α-
33P]dCTP-labelled (GE Healthcare) probe using the XpYpEB probe generated by PCR between 
primers XpYpE2 and XpYpB2. Probes that specifically target the 1kb (Stratagene) and 2.5kb 
(BioRad) molecular weight markers were also used in each hybridisation reaction.  
The hybridised fragments were detected by phorphorimaging with a Molecular Dynamics 
Storm 860 phosphorimager (GE Healthcare).  
2.7 CD34 Cell Purification using Magnetic Beads 
CD34 cells were purified from a subset of 20 MDS patients using the Dynal CD34 Progenitor 
Cell Selection System (Invitrogen). 100l of re-suspended CD34 Dynabeads were transferred 
into a 5ml FACS tube and washed in 900l of buffer (PBS with 0.1% Bovine Serum Albumin 
(BSA)). The tube was placed in a magnet (Magna bot 96 Promega Separation Device) for 1 
minute and the supernatant was discarded. After removing the tube from the magnet, the 
Dynabeads were re-suspended in 100l of buffer.  
Cryopreserved samples were rapidly thawed in a 37°C water bath and re-suspended. An 
aliquot equivalent to 1x106 cells was placed in a fresh tube marked ‘unsorted’ and taken 
aside. The remaining cells from the sample were transferred to the washed Dynabeads and 
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mixed briefly. Cells were then incubated at 2 to 8°C for 30 minutes on a shaker enabling 
gentle tilting and rotation.  
Following incubation, the tube was placed on the magnet for 2 minutes and the supernatant 
was transferred into a fresh tube marked ‘CD34 negative’. The bead-bound cells were re-
suspended in 1ml of cold buffer and returned to the magnet for 2 minutes. The supernatant 
was discarded. This process was repeated for a second time in order to wash the bead-
bound cells. Finally, the bead-bound cells were re-suspended in 400l of buffer and placed 
into a fresh tube marked ‘CD34 positive’.  
TRAP assay, DNA extraction and STELA at the XpYp and 17p telomere were subsequently 
performed.  
2.8 Telomerase Assay 
Telomerase activity was assessed according to the Telomeric Repeat Amplification Protocol 
(TRAP) TRAPeze RT Telomerase Detection Kit (Chemicon International). Cells (samples and 
telomerase positive control, i.e. 293 cell line) stored at -80°C were washed in 1xPBS prior to 
the TRAP assay. 105 to 106 MNCs were lysed in 200l of CHAPS Lysis Buffer and incubated on 
ice for 30 minutes. Samples were centrifuged at 12K for 20 minutes at 4°C and 160l of the 
supernatant was collected. The protein concentrations were measured and samples (as well 
as 293 cells) were diluted to 250ng/l in CHAPS lysis buffer. 10l of each sample (and 293 
cells) were heat treated at 85°C for 10 minutes in order to inactivate telomerase. Notably, 
these were used as telomerase negative controls for the TRAP assay.  
To generate a standard curve, stock TSR8 control template (20amoles/l) was serially 
diluted by 1:10 in CHAPS lysis buffer in order to prepare 2amoles/l, 0.2amoles/l and 
0.02amoles/l.  
Each 25l reaction consisted of 1xTRAPEZE RT Reaction Mix, 2 units of Taq Polymerase and 
2l of each sample (listed below) in nuclease free H2O.  
- TSR8 dilutions (20amoles/l, 2amoles/l, 0.2amoles/l and 0.02amoles/l) 
- 293 positive control  
- Minus Telomerase Control: CHAPS lysis buffer only 
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- No template control: Nuclease free H2O 
- Experimental samples: 2l of 250ng/l (i.e. 500ng/reaction) 
- Heat treated samples (and 293) telomerase negative controls  
Positive controls were also utilised for each sample to rule out false-negative results. The 
TSK control template was diluted in CHAPS lysis buffer down to 0.002amole/l for use as a 
positive control. Each 25l reaction consisted of 1xTRAPEZE RT Control Reaction Mix, 2 units 
of Taq Polymerase, 0.004 amoles of TSK control template and 2l of each sample (listed 
below) in nuclease free H2O.  
- Experimental samples: 2l of 250ng/l (i.e. 500ng/reaction) 
- 293 positive control  
Each PCR reaction was carried out in triplicate in a 96 clear-well plate format using the ABI 
PRISM 7900. Reactions were subjected to 30°C for 30 minutes for 1 cycle, 95°C for 5 minutes 
for 1 cycle and (94°C 15sec, 59°C 60sec, 45°C 20sec) X 45 cycles.   
2.9 Statistical Analysis 
The Kaplan-Meier method was used to calculate survival curves. Telomere data was 
expressed as the mean ±SD. Comparisons between groups were analysed using the 
Unpaired t-test. Values of p < 0.05 were considered significant. Statistical tests were 
performed utilising GraphPad Prism.   
 
2.10 Array-Comparative Genomic Hybridisation (Array-CGH)  
Array CGH was carried out as a service by Nimblegen (Roche NimbleGen, Madison, WI). 2g 
of tumour genomic DNA and reference DNA samples were independently labelled with 
either Cy3 or Cy5 dyes. Labelled DNA was co-hybridised to a NimbleGen comparative 
genomic hybridisation (CGH) array format 12 x 130000 (130000 probes). Reference samples 
were labelled with Cy 5 and test samples with Cy 3.  
2.11 Development of 6q STELA 
Sequence alignment of 5457 bases proximal to the published 6q terminus against a family of 
multiple chromosome ends was achieved using Clustal W. A 6q specific primer (6qspecific) 
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was designed to target a region 4070 bases proximal to the published end and a 
temperature gradient STELA reaction was subsequently performed under the following 
conditions: 22 cycles of 94°C for 20secs, (temperature gradient 55°C to 70°C) for 30secs, and 
68°C 8 minutes. STELA at 17p was utilised as a positive control. Southern blot hybridisations 
were performed using only the TTAGGG repeat probe. 
 
A sub-telomeric region sequenced to the adjacent telomeric TTAGGG tract was utilised to 
design primers that may be shared by the unidentified 6q terminus. STELA at 17p was used 
as a positive control. The favoured annealing temperature was identified by a gradient 
temperature STELA. Southern blot hybridisations were performed using only the TTAGGG 
repeat probe. 
A telomere-adjacent reverse primer used in conjunction with a 6q specific primer amplified 
a putative 6q specific product using conditions: 33 cycles of 94°C for 20secs, (temperature 
gradient 55°C to 70°C) for 30secs, and 68°C 8 minutes.  
The probe specific to this product was generated by re-amplification PCR (used gradient PCR 
since annealing temperature was unknown) between the forward primer ‘6qspecific’ and a 
downstream (1kb) reverse primer shared by the 6q family.  
The product was resolved by agarose gel electrophoresis, gel-purified (QIA quick Gel 
Extraction Kit; Qiagen) and quantified (ng/l) by comparing the intensity of the probe band 
against a range of 1kb ladder concentrations. 25ng/l was subsequently used for 
hybridisation.   
 
Direct sequencing of the region downstream to the 6q published terminus was performed 
with designed sub-telomeric primers present within the telomere adjacent region shared by 
members of the 6q family. 
2.12 Oligonucleotides  
STELA/ XpYp Genotyping 
XpYpE2: 5’ -TTGTCTCAGGGTCCTAGTG- 3’ 
XpYpB2: 5’ -TCTGAAAGTGGACC(A/T)ATCAG- 3’  
 75 
 
XpYp-427G/415C: 5’ -GGTTATCGACCAGGTGCTCC- 3’  
XpYp-427A/415T: 5’ -GGTTATCAACCAGGTGCTCT- 3’    
17pseqrev1: 5’ -GAATCCACGGATTGCTTTGTGTAC- 3’ 
Telorette2: 5’ -TGCTCCGTGCATCTGGCATCTAACCCT- 3’ 
Teltail: 5’ -TGCTCCGTGCATCTGGCATC- 3’ 
TVR-Mapping 
TAG-TELW: 5' -TCATGCGTCCATGGTCCGGACCCTTACCCTTACCCTNACCCTA- 3’ 
TAG-TELX: 5' -TCATGCGTCCATGGTCCGGACCCTTACCCTTACCCTNACCCTC- 3’ 
TAG-TELY: 5' -TCATGCGTCCATGGTCCGGACCCTTACCCTTACCCTNACCCTG- 3’ 
Fusion 
XpYpM: 5’ -ACCAGGTTTTCCAGTGTGTT- 3’ 
17p6: 5’ -GGCTGAACTATAGCCTCTGC- 3’ 
21q1: 5’ -CTTGGTGTCGAGAGAGGTAG- 3’ 
Re-amplification 
XpYpMb: 5’ -AGGTTTTCCAGTGTGTTATC- 3’ 
17p6b: 5’ -CTGAACTATAGCCTCTGCAATG- 3’ 
21q1C: 5’ -GTGTCGAGAGAGGTAGCTTTTAAATG- 3’ 
6q 
6qSpecific: 5’ -CTAGTTTCCTCTCTTATTAACATA- 3’  
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Chapter 3: 
Telomere Dynamics in MDS and AML 
3.1 Abstract 
Specific telomere length profiles were analysed using STELA at XpYp and 17p to determine 
the nature of telomere dynamics in a cohort of MDS and AML patients. STELA is a long-
range single-molecule PCR approach that amplifies the double-stranded region of telomere 
repeats from specific chromosome ends. Uniquely, STELA is capable of detecting short 
telomeres within the length ranges that have the potential to initiate telomere fusion. 
Patients with AML showed significantly shorter telomeres than those with MDS (p < 0.0001). 
Telomere length distributions appeared to homogenise in AML suggestive of blast 
accumulation and clonal expansion.  
Telomere loss is dictated by the end-replication problem but also by sporadic, atypical large- 
scale deletion events. A significantly higher percentage of truncated telomeres were 
observed at 17p in MDS which may have been associated with the abrogation of p53 and 
damage response mechanisms. An RAEB2 patient presented 9.1% of short telomeres at the 
17p telomere. A reduction of these events was apparent within the AML cohort; this may 
reflect the up-regulation of telomerase activity.  
TVR-PCR revealed extensive variation in measurements of TVR regions ranging from 0 to 3kb 
from individuals analysed. Extreme telomere shortening was apparent following correction 
for the TVR region with some patients demonstrating a lower 25th percentile of only 8 
TTAGGG repeats; these telomeres are within the length ranges at which telomere fusion is 
detected.  
Bimodal distributions were detected using STELA. These could be confirmed as a 
consequence of biallelic telomere length variation in a subset of patients.   
CD34+ cells failed to show increased telomere shortening, however provided the majority of 
these patients were low-risk, this may have been associated with the subsequent 
differentiation into CD34- cells. High-risk patients may have demonstrated a larger degree of 
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telomere shortening within the CD34+ fraction due to clonal expansion but associated with 
blocked differentiation.    
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3.2 Introduction 
Telomere shortening has been associated with advanced MDS and its progression into 
AML332-334 with the additional observation of a co-existing complex karyotype.333,334,342 
However, these studies have relied upon the global average of telomere length and have 
failed to show the prognostic implications that single, critically short telomeres may have 
with disease progression. Notably, it has been proposed that the shortest telomere within a 
cell has the propensity to initiate genomic instability.209  
STELA is a high resolution technique for telomere length analysis which has provided 
insights into the highly dynamic nature of single telomeric molecules. It is a long-range 
single-molecule PCR approach that amplifies the double-stranded region of telomere 
repeats from specific chromosome ends (Figure 3.1).171  
 
 
The initial step in STELA consists of annealing a ‘telorette’ linker that is comprised of seven 
bases of TTAGGG repeat homology followed by a 20 nucleotide non-complementary tail to 
the G-rich 3’overhang of the telomere. Ligation to the 5’end of the duplex telomeric C-rich 
strand provides a telorette ‘tag’ to the end of the chromosome. PCR can then be performed 
on chromosome-specific telomeres utilising a ‘teltail’ primer that is complementary to the 
telorette tail and a chromosome-specific upstream primer located within the sub-telomeric 
region. Such sub-telomeric primers that have been used in STELA reactions are XpYp and 
17p specific which are complementary to a region 433bp and 311bp from the start of the 
telomere, respectively. STELA products are identified as single bands on a gel following 
Southern hybridisation with a TTAGGG specific probe with each band representing a single 
Figure 3.1: A representation of STELA extracted from: Baird DM, Rowson J, Wynford-Thomas D, Kipling D. 
Extensive allelic variation and ultrashort telomeres in senescent human cells. Nat Genet. 2003;33:203-207. 
Single telomere amplification by means of utilising an upsteam chromosome or allele specific primer in 
conjunction with the teltail.    
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telomeric molecule (also containing a region of sub-telomeric DNA, i.e. 433bp at XpYp or 
311bp at 17p). This approach has the ability to detect the full spectrum of telomere lengths 
at specific telomeres,171 particularly those that are very short which have the potential to 
initiate telomere fusion.253-255   
Previous demonstrations using STELA have shown that telomeres have the propensity to 
undergo stochastic large-scale deletion events. Abrupt telomere deletion may be sufficient 
to generate a dysfunctional telomere which can reduce cell viability. More importantly, 
severely truncated telomeres have the potential to initiate a sequence of breakage-fusion- 
bridge (BFB) cycles by means of telomere fusion.254,255 It is possible that recombination or 
replication slippage may generate extensive telomere shortening.352  
By employing previously characterised heterozygosities (-427G/A and -415C/T) in DNA 
adjacent to the XpYp telomere,244 allele-specific STELA can determine whether bimodal 
distributions are composed of differing maternal and paternal contributions in the zygote. 
Differential telomere size distributions of up to 6.5kb have been observed at the XpYp 
telomere.171 Bimodal distributions may also be characteristic of the presence of non-tumour 
cells, particularly in bulk populations or alternatively by means of recombination creating a 
new sub-telomeric distribution of longer or shorter propensity.    
Blast accumulation in MDS and AML may present the tendency for reduced heterogeneity 
within telomere distributions. Increased homogenisation has been previously detected in 
CLL (Chronic Lymphocytic Leukaemia), particularly with disease progression and severity.253 
Telomeric loss of heterozygosity (LOH) can also be detected with STELA since it enables the 
quantification of single telomeric molecules. Loss at the 17p telomere was observed within 
CLL cells and further FISH analysis confirmed LOH at the p53 locus.253 
It has also been observed that the proximal end of the telomere contains an interspersion 
pattern of TTAGGG and telomere variant repeats (TVR) including TCAGGG and TGAGGG.244 
These TVR regions can vary in length from 0 to 3kb in the human population and their 
distribution can be determined by TVR repeat mapping by PCR (TVR-PCR).244 It has been 
proposed that the TVRs are a non-functional region of the telomere as TRF1, TRF2 and POT1 
show strong specificity for the TTAGGG tract and not to any repeat variants.192 Additionally, 
telomere fusions have been noted to include the TVR region which indicate that these 
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regions may not be capable of forming the protective telomeric cap.255 Therefore STELA 
profiles provide an overestimate of the telomere length distributions due to variable 
measurements of TVRs. Thus, by means of exploiting both STELA and TVR-PCR the 
functional telomeric tract composed of pure TTAGGG repeats can be analysed. Previous 
observations have implicated that a tract composed of only 13 TTAGGG repeats is sufficient 
to enter into breakage-fusion-bridge (BFB) cycles which can generate non-reciprocal 
translocations.255  
In this study, STELA was employed to determine the nature of telomere dynamics in MDS 
and AML. Telomere length was shorter within AML cells, consistent with previous 
observations.335,336 There was a tendency for telomere shortening at XpYp and telomeric 
LOH was confirmed at this chromosome in an AML patient. STELA profiles homogenised in 
AML demonstrating the clonal expansion of blast cells. Bimodal distributions had been 
characterised as allele-specific in a number of individuals but also events that were 
consistent with telomere elongation by additional mechanisms such as recombination were 
noted to occur. Severely truncated telomeres were present within some individuals, for 
example one RAEB2 patient presented with 9.1% of these events at 17p. Dysfunction at the 
17p telomere has the potential to initiate loss of genetic material on the 17p chromosome 
arm including the p53 gene. Telomerase activity was up-regulated in AML cells, consistent 
with cancer propagation.180 CD34+ cells failed to show elevated telomere shortening to its 
CD34- counterpart. TVR-PCR confirmed the presence of extensive TVRs (up to 3kb) such that 
the 25th percentile of specific telomere profiles displayed telomeres that were only 48bp or 
only 8 TTAGGG repeats.  
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Results 
3.3 Telomere Length in MDS and AML 
STELA analysis was undertaken on a panel of 80 MDS and 144 AML patients and the mean of 
each of the telomere length distributions was calculated. The mean of the whole MDS 
cohort was determined as 4.45kb (±1.49kb) [Mean (±SD)] and 4.47kb (±1.23kb) for the XpYp 
and 17p telomeres, respectively. Conversely, the mean telomere length distributions 
recorded within the AML cohort were 3.54kb (±1.35kb) at XpYp and 3.67kb (±0.89kb) at 17p 
(Figure 3.2). The telomere length within the AML cohort was significantly shorter than that 
recorded within the MDS cohort (p < 0.0001) illustrating that telomere shortening is a 
common feature in AML cells; this was apparent at both the XpYp and 17p telomeres.  
 
 
 
There was no significant difference between the XpYp and 17p telomere length within the 
MDS cohort (p = 0.8960), however, the telomere length at XpYp appeared shorter than the 
17p telomere in the AML cohort. Whilst this was not significant (p = 0.4848) it may have 
been skewed by the presence of a subset of samples (n = 6) with longer XpYp telomere 
lengths that have been specified as orange points in Figure 3.2. It was noted that these 
individual STELA profiles were more heterogeneous with a standard deviation of over 
2.50kb.  
Figure 3.2: Telomere length distibutions within MDS and AML derived cells. Telomere length was 
statistically shorter in AML (p < 0.0001). There appeared to be a tendency for telomere shortening at XpYp 
within the AML cohort. Orange points signify patients that may have induced telomere skewing within the 
distribution. It was noted that these patients had large standard deviation values (>2.50kb) implicating the 
presence of large intra-clonal heterogeneity.  
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Figure 3.3: Inter-individual telomere length heterogeneity at XpYp and 17p within MDS and AML. 
Telomere length appears to be more variable within the MDS cohort-this may have prognostic 
implications. Of particular interest, an MDS patient showed telomere distributions at XpYp and 
17p that were shorter than the lower 25
th 
percentile of the AML cohort (patient within highlighted 
red bars). Consistently, this patient progressed to AML.  
3.4 Inter-individual Telomere Length Variation 
Within the patient cohorts, the XpYp and 17p telomeres displayed heterogeneous length 
distributions amongst the individuals analysed, particularly within the MDS cohort. The 25th 
and 75th percentiles enabled cohort subdivision into three groups based on telomere length 
distributions at XpYp and 17p (Figure 3.3). 20 MDS patients had presented telomere length 
profiles below the 25th percentile of the cohort.  
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Figure 3.4: STELA profiles of 5 MDS patients. Patient #2 demonstrated the shortest telomere length 
distributions within the MDS cohort which was shorter than the 25
th
 percentile of the AML cohort.  
A subset of MDS patients displayed telomere length distributions below the lower 25th 
percentile of the AML cohort, in particular one individual that had presented a telomere 
length distribution of 1.77kb at the XpYp telomere and 2.28kb at 17p (Figure 3.3; red bars). 
This had represented the shortest telomere distributions recorded within the MDS cohort 
(Figure 3.4; Patient#2); this patient progressed to AML and survived for under a year post 
diagnosis.    
With this information at hand, it may be fair to speculate that telomere length has the 
potential to provide prognostic information, including the propensity of AML 
transformation.   
It appeared that telomere length homogenised between individuals within the AML cohort 
(Figures 3.2 and 3.3). This indicates the possibility that telomere length may display less 
prognostic potential in AML compared to MDS. Conversely, the heterogeneity of telomere 
length in MDS may have prognostic implications in itself. However, further insight into the 
clinical data associated with these samples may provide a more detailed analysis (Chapter 4 
and 5).  
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Figure 3.5: Regression analysis between the XpYp and 17p STELA distributions. There was a strong 
correlation between telomere length in both the MDS and AML cohort (r
2
 = 0.60, p < 0.0001).  
3.5 Telomere Length Correlation  
 
The mean XpYp and 17p telomere lengths from each sample were strongly correlated within 
the MDS (r2 = 0.5992; p < 0.0001) and AML (r2 = 0.6036; p < 0.0001) cohorts (Figure 3.5).  
The intersection of the axis revealed the 17p telomere to be 1.63kb and 1.37kb longer than 
that at XpYp in the MDS and AML cohorts, respectively. Whilst is it possible that the XpYp 
telomere may have a propensity for elevated rate of telomere shortening, this phenomenon 
hasn’t been observed in previous studies that indicated that telomeres at different ends 
erode at a constant rate.353 Instead, contrary to previous reports,354 it is possible that the 
17p telomere may have been set longer in the zygote. Alternatively, if the non-functional 
telomere variant repeat (TVRs) region is longer at the 17p telomere compared to XpYp then 
this will have the effect of making the length of the STELA distributions longer at 17p 
compared to XpYp.  
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3.6 Intra-clonal variation  
 
The heterogeneity of a telomere distribution can reflect the replicative history of the cell 
sample analysed, with cell populations derived from single cells exhibiting homogeneous 
distributions. In addition, the presence of non-tumour material with differing replicative 
histories, telomerase activity and telomere dynamics will render the telomere-length 
profiles more heterogeneous.  
The standard deviations (SD) of the XpYp telomere were significantly different between the 
MDS and AML cohorts (p = 0.0002) measuring 1.90kb (±0.78kb) and 1.54kb (±0.62kb), 
respectively. The difference in the standard deviation at the 17p telomere also reached 
significance with 1.84kb (±0.77kb) and 1.51kb (±0.53kb) (p = 0.0059) within the MDS and 
AML cohorts, respectively (Figure 3.6). Thus, it appears that telomere length distributions 
homogenise with progression to AML, consistent with malignant clonal evolution.  
Some individuals displayed extremely heterogeneous telomere length profiles with some 
displaying clear bimodal distributions; this may be explained by differential clonal 
distributions or by the presence of healthy and malignant cells. Alternatively, bimodal 
populations may also be the result of telomere length differences between maternal and 
paternal alleles. One further possibility is that a mutational event resulting in a large-scale 
change in telomere length could create a bimodal distribution. The mechanisms underlying 
Figure 3.6: Telomere length heterogeneity within each STELA profile. Telomere distributions homogenised 
within AML profiles, consistent with blast accumulation. Large SD values may be explained by allelic specific 
differences or recombination events.  
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this are not clear but they could include a recombination event that either elongates or 
shortens a telomeric molecule. Recombination can abruptly generate a sub-clone of cells 
with an altered proliferation potential.  
An example of a bimodal telomere-length distribution is shown in patient #1 in Figure 3.7. 
 
   
Here bimodality is observed at 17p but not at the XpYp telomere. The lack of an allele 
specific 17p polymorphism prevented the ability to rule out allele-specific length differences 
at 17p however, the unequal number of telomere molecules within each population (17 
within the longer and 47 molecules in the shorter) is inconsistent with allele-specific 
distributions, in which an equal number of molecules per distribution would be expected.  
This is also unlikely to represent a population of healthy cells exhibiting longer telomeres at 
17p and a shorter telomere at XpYp. Thus, the longer distribution may have arisen as a 
consequence of a mutation event that resulted in telomeric elongation specifically at 17p. 
This mechanism is not clear from this analysis; however one could speculate that this arose 
following a recombination event at the 17p telomere in a single cell of either normal or 
Figure 3.7: STELA profiles derived from 4 MDS patients. The bimodal distribution at 17p (represented 
with arrows) within the telomere profile of patient #1 illustrates a potential recombination event that 
has extended the average length of the telomere profile. In contrast, the telomere distribution at XpYp 
appears to be fairly homogeneous which is described by its much lower SD value. 
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Figure 3.8: A STELA profile illustrating a clear bimodal 
separation of allele specific telomeres. Analysing the 
telomere length of a specific allele revealed a short 
distribution of only 2.49kb at XpYp AT. 
malignant propensity, thus creating a sub-clone of cells that carry a 17p telomere longer 
than the overall distribution. 
 
A subset of bimodal distributions (n = 28) were a consequence of biallelic telomere length 
variation. Allele-specific STELA was performed on patients that were heterozygous for the 
AT and GC haplotypes adjacent to the XpYp telomere;244 an example of which is presented 
in Figure 3.8.  
 
 
 
The difference between the two distributions reached statistical significance (p < 0.0001). 
This patient was exhibiting a mean telomeric distribution of 3.21kb at the XpYp telomere; 
however, the shorter AT allele was only 2.49kb. Differentials between the telomere length 
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Figure 3.9: Differentials in length of allele specific telomere distributions. Significant differences (p < 
0.05) have been highlighted. More specifically yellow, orange and red bars signify those differences 
that are either mildly, intermediately or highly significant (p < 0.0001), respectively.  
distributions are illustrated in Figure 3.9; those that are highlighted exhibited significant 
differences (p < 0.05) between the sizes of the telomere distributions. Patient #18 in Figure 
3.9 presented with the clear bimodal distribution which is shown in Figure 3.8.  
The genotyping (Figure 3.10) of the XpYp telomere-adjacent DNA in the population was 
undertaken to identify individuals that were heterozygous and could be used for allele-
specific STELA.  This revealed that 36% of patients were AT/GC heterozygous. However, data 
on these haplotypes within the Caucasian population244 indicated that 45% (based on the 
Hardy-Weinberg principle) of individuals are heterozygous at this telomere. Using a Chi-
squared test it was apparent that the difference between that observed and what was 
expected reached statistical significance (p = 0.0363).  
 
 
 
 
 
 
 
 
Figure 3.10: Genotyping of the XpYp telomere-adjacent DNA. It was 
identified that only 36% of individuals were heterozygous at this telomere.  
(p = 0.0363).  
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LOH at a specific telomere can also be demonstrated by a reduction in the number of 
amplifiable molecules detected by STELA. Given an equal input amount of DNA, STELA will 
typically yield a similar number of amplifiable molecules. However, some individuals such as 
patient #3 illustrated in Figure 3.11 displayed fewer molecules at one telomere compared to 
the other. This patient’s telomere profile presented a population of 29 telomere molecules 
at 17p but only 2 at XpYp.  
To confirm this represented an LOH event and was not the result of a natural polymorphism 
at the XpYp telomere, an alternative XpYp primer (XpYpM) that binds a further 1.2kb 
(1666bp from the telomere) into the sub-telomeric region was utilised for the STELA 
reaction. Again loss of the XpYp telomere was also detected using this primer (Figure 3.12) 
providing further evidence in support of a telomeric LOH event.  
Figure 3.11: STELA telomere profiles derived from 5 AML patients. Patient #3 illustrates that telomeric LOH 
has occurred at the XpYp telomere.  
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Several individuals presented bimodal allelic telomere distributions (Figures 3.8 and Figure 
3.9); however it was revealed that the telomere length of the separated XpYp alleles was 
strongly correlated within the population (r2 = 0.5386; p < 0.0001; Figure 3.13). Accordingly, 
no apparent difference existed between the length of the two alleles (p = 0.1050; Figure 
3.13); this was in contrast to the differences observed between XpYp and the 17p telomeres 
(Figure 3.5). 
Figure 3.13: Similar telomere length was recorded at the different XpYp alleles with the AT allele 
showing a strong correlation with the GC allele (r
2
 = 0.5386; p < 0.0001). Telomere length was not 
significantly different between the alleles (p = 0.1050).  
Figure 3.12: The presence of LOH at the 
XpYp telomere was confirmed using an 
alternative XpYp primer (XpYpM). 
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3.7 Telomere Rapid Deletion (TRD) Events 
 
The telomere length distributions were superimposed by telomere rapid deletion (TRD) 
events (Figure 3.14; indicated by arrows). These telomeres had been identified as those that 
fall outside the normal range of telomere length by means of abrupt telomere deletion. The 
underlying mechanism that generates these rapid changes in telomere length have not been 
established but may include unequal-recombination/sister chromatid exchange, replication 
fork stalling or replication slippage.352 These events were quantified by quantifying the 
number of telomeric molecules 2.33SDs below the mean length of the distribution and 
recording them as a percentage of the total number of telomere molecules within each 
profile. 
 
The hypercellular nature of MDS may provoke the generation of TRDs by means of faulty 
DNA replication. Furthermore, the presence of telomerase in haematopoietic cells may not 
be sufficient to prevent the appearance of severely truncated telomeres which may be 
exacerbated by the hypercellularity in MDS. These telomeres can play a crucial role in 
Figure 3.14: Telomere rapid deletions were detected within STELA profiles. These occurred 2.33SDs below 
the mean of the telomere distributions (represented by small arrows). 
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determining cell viability and proliferative potential. It is the shortest telomere within a cell 
that has the potential to initiate senescence or an apoptotic response reducing the 
proliferative capacity of the cell.209  Furthermore, stochastically deleted telomeres have 
been shown to be directly involved in telomere fusion events.255 The mean frequency of TRD 
events observed at the XpYp telomere was recorded as 1.11% and 0.83% within the MDS 
and AML cohort, respectively, this difference was not significant (p = 0.2748). However at 
the 17p telomere a significant difference was observed, with 1.74% of TRD events within the 
MDS cohort and 0.94% within the AML cohort (p = 0.0404).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 93 
 
Figure 3.15: Telomerase activity was analysed using TRAP and the relative 
activity measured within MDS derived CD34
+
 cells and AML derived 
samples. It is expressed as relative activity to the positive control (293 cell 
line). A significant increase by 1.24 was detected in AML (p < 0.0001). 
3.8 Telomerase Up-regulation  
 
Telomerase activity was determined using the Telomeric Repeat Amplification Protocol 
(TRAP) assay. Despite an up-regulation of telomerase in over 90% of human malignancies,180 
cancer cells are commonly reported to possess shorter telomere length distributions when 
compared to adjacent normal tissue.323 
 
 
 
Telomerase activity was analysed in a subset (n = 12) of AML patients and compared to the 
telomerase activity detected in cell sorted CD34+ cells from a group of MDS patients (n = 
20). Consistent with previous observations,328,332,342,347 telomerase was significantly up-
regulated in AML (p < 0.0001; Figure 3.15).  
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Figure 3.16: There was a general propensity of telomere shortening with elevated telomerase activity. 
Red markers signify AML patients that show reduced telomere length and up-regulated telomerase. 
 
 
 
 
Telomerase activity was inversely correlated with telomere length at both chromosome 
ends (Figure 3.16). Furthermore, it was apparent that the AML patients exhibited both short 
telomeres and telomerase up-regulation; these patients are indicated as red points in Figure 
3.16. This is consistent with the current notion that although cancer cells are commonly 
associated with shorter telomeres than their pre-cancerous counterparts, telomerase 
activity is elevated to maintain telomere stability212,323 and prevent replicative senescence 
or apoptosis to enable unlimited proliferation during carcinogenesis.   
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3.9 Telomere Erosion 
 
Serial samples were provided from a small subset of MDS patients (n = 4). Although the 
sample size was small and the time between sampling was relatively short, it was of interest 
to see whether accelerated telomere erosion could be detected. Telomere length at XpYp 
and 17p were analysed at the time of diagnosis and also at a post diagnosis time period. 
Overall, no significant difference was detected between the telomere length recorded at 
XpYp (p = 0.3092) or 17p (p = 0.6373) at diagnosis and after a subsequent follow-up (Figure 
3.17). However, one patient exhibited significant telomere loss (p < 0.05) 3 years following 
diagnosis.  
 
 
 
Telomeres erode by 33bp/year in proliferating haematopoietic cells.326 The STELA 
presenting telomere distributions in patient #1 (Figure 3.18) illustrates a clear case of 
elevated telomere shortening. XpYp and 17p shortened at a roughly similar rate at 
Figure 3.17: No significant difference was detected between the telomere 
length of XpYp (p = 0.3092) and 17p (p = 0.6373) measured at diagnosis 
and after subsequent sampling.   
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Figure 3.18: STELA profile illustrating extensive telomere erosion in an 
MDS patient. The rate of attrition within this patient was 10 fold 
higher than within normal marrow. 
300bp/year. The bone marrow within this patient was losing telomere length 10 times faster 
than compared to healthy marrow.  
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3.10 TVR: Telomere Variant Repeat   
 
STELA provides an overestimate of the telomere length since it also measures a total of a 
sub-telomere region (i.e. 433bp into XpYp) and a Telomere Variant Repeat (TVR) region 
located within the first 1 to 3kb of the telomere repeat array. The length of this region 
varies considerably between individuals.244 Thus, the start of the pure TTAGGG repeat 
region of the telomere repeat array is not identified using STELA analysis alone.     
 
The TVR regions within each patient were analysed by using TVR-PCR (Figure 3.19) which 
characterises the full extent of the TVR distribution within the XpYp telomere. This 
Figure 3.19: The representation of TVR-PCR. Every 
three lanes represent the composition of the TVR 
region within each individual. The first of the three 
show the length of the TTAGGG repeat tract. The 
second and third measure the extent of TGAGGG and 
TCAGGG repeats, respectively and provide a 
measurement of their internal composition within the 
telomere.   
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information can be used to calibrate the STELA data so that the length of uninterrupted 
tandem repeats of TTAGGG can be established. 
The TVR repeats recorded ranged from 0 to 3kb into the telomere repeat array within the 
total population of individuals analysed. The mean size of the TVR region was 1.09kb 
(±0.72kb).  
 
 
The telomere length distribution at XpYp was shorter within the AML cohort following the 
exclusion of the TVR region (Figure 3.20). The mean telomere lengths were 3.36kb (±1.65kb) 
and 2.16kb (±1.16kb) within the MDS and AML cohort, respectively, this difference was 
significant (p < 0.0001; Figure 3.20).  
 
The shortest STELA profile that had been recorded within the MDS cohort was 1.77kb at the 
XpYp telomere (Figure 3.21; Patient #2); however, exclusion of the TVR region 
demonstrated that the pure TTAGGG tract was 1.25kb. This measurement exceeded that 
from an alternative MDS patient who showed the shortest pure XpYp TTAGGG tract at 
0.58kb. Prior to TVR mapping, STELA recorded this telomere profile as 2.92kb (Figure 3.21; 
Patient #1) and thus was excluded as one of the shortest. However, it was revealed that this 
Figure 3.20: The length of the pure TTAGGG tract is significantly 
shorter within the AML cohort (p < 0.0001).  
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Figure 3.21: Patient #2 was originally described as having 
the shortest telomere distribution within the MDS cohort; 
however, exclusion of the TVR region demonstrated that 
patient #1 had a shorter pure TTAGGG tract. Dotted lines 
illustrate the length of the TVR. 
patient only had 97 pure TTAGGG tracts on average at the XpYp telomere; this patient 
progressed to AML and was diagnosed with a poor cytogenetic risk score.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The shortest telomere length distribution that had been recorded following adjustment for 
TVR content was only 0.16kb (Figure 3.22; Patient #1). This was derived from an AML 
patient who had presented a STELA profile of 2.20kb prior to TVR exclusion. Thus, removal 
of the TVR region has the potential to reveal patients with critically short telomeres despite 
STELA profiles presenting a telomere length of a functional range. This patient only had 27 
TTAGGG repeats on average at the XpYp telomere.    
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Figure 3.22: The shortest functional TTAGGG tract that was 
recorded had been derived from an AML patient (patient 
#1). The pure telomere length was only 0.16kb. Dotted lines 
illustrate the length of the TVR.  
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3.11 Cell Fractionation 
 
MDS is considered to arise within cells capable of self-renewal,19,34 thus it has been 
proposed that the initial transformation event occurs within a primitive haematopoietic cell. 
Cells lose their CD34 expression with increased differentiation along their designated 
pathways, i.e. myeloid or lymphoid.4,8,9 Cells also progressively lose their self-renewal 
capacity as they differentiate into their more mature lineage specific counterparts.4,8,9  
 
Whole bone marrow aspirates were cell fractionated based on their CD34 cell surface 
expression from 20 MDS patients. CD34+ cells could be captured by using magnetic beads 
coated with an antibody specific for the CD34 antigen (Dynabeads) and subsequently 
isolated using a magnet. Telomere length was analysed in primitive CD34+ and more 
differentiated CD34- cells to determine if telomere shortening was more extensive in 
purified CD34+ cells. Analysis of the telomere distributions within each fractionation showed 
no difference in telomere length between the CD34+ and CD34- fractions (Figure 3.23). 
 
The paired analysis of CD34+ and CD34- sub-populations were not significantly different 
within the XpYp and 17p telomere distributions presenting p values of 0.6495 and 0.4321, 
respectively (Figures 3.23 and 3.24). However, the majority of this small group of patients 
Figure 3.23: Bulk cell populations from a panel of 20 MDS patients were purified into CD34
+
 and CD34
- 
sub-
populations. Telomere length distributions failed to show a significant difference at the XpYp (p = 0.6495) 
and 17p (p = 0.4321) telomere within the CD34
+
 and CD34
-
 fractions.  
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had been diagnosed with low-risk MDS and the CD34+ population of cells could be 
differentiating into their CD34- counterparts, thus an extensive loss of telomere repeats may 
not have been detected. Conversely, high-risk MDS has been associated with the inability of 
CD34+ cells to differentiate into their lineage specific cells. Thus, late stage MDS may show 
an elevated decline in telomere shortening within the CD34+ fraction. Alternatively, 
excessive apoptosis in early MDS138,139,141 may lead to the elimination of cells with shorter 
telomeres also preventing their detection.  
 
 
 
 
 
 
Figure 3.24: No significant difference was detected between 
paired values of telomere length within each cellular sub-
population (p = 0.6495 and p = 0.4321 at XpYp and 17p, 
respectively. Of note, significant differences (p < 0.05) in 
telomere length between sub-populations have been highlighted 
in red. 
 103 
 
3.12 Discussion 
STELA was employed to determine the nature of telomere dynamics in MDS and AML. STELA 
is a long-range single molecule PCR approach that amplifies the double-stranded region of 
telomere repeats from specific chromosome ends. Of particular importance, it is capable of 
observing the shortest telomere in the distribution that may play a role in disease 
pathogenesis by means of genetic instability.  
It was demonstrated that telomere length is significantly shorter within AML cells (p < 
0.0001); this was consistent with previous observations.335,336 The hyperproliferative nature 
of MDS may enhance the rate of telomere attrition which can eventually initiate genomic 
instability by means of telomere dysfunction. Notably, short telomeres in MDS have been 
associated with complex rearrangements and a poorer prognosis.333,334,342 MDS has been 
classed as a heterogeneous disease and patient prognosis has been dependent on particular 
clinical features such as blast count, cytopenia number and cytogenetics.21,24,43,355 The 
heterogeneity of telomere length profiles at diagnosis observed within the MDS cohort 
raises speculation that it may provide prognostic implications including patient susceptibility 
to AML. This was particularly apparent in one individual that had presented with a telomere 
length distribution at diagnosis which was shorter than the 25th percentile of the AML 
cohort; this patient progressed to AML. Further insight into the clinical data associated with 
patient samples may provide a more detailed analysis on telomere instability in MDS and 
AML prognosis. This will be referred to in Chapter 4 and 5, respectively.  
Homogenisation of telomere length distributions as a function of clinical staging has been 
observed in CLL cells.304 The heterogeneity of the telomere length profiles was significantly 
reduced in patients with AML compared to those in MDS. A reduction in telomere length 
heterogeneity in AML may be consistent with an accumulation of blast cells and clonal 
expansion. Additionally, it has been previously implicated that telomerase up-regulation is a 
feature of AML,328,332,342,347 thus the maintenance of telomere length homeostasis may 
result in the reduced telomere heterogeneity within this population of cells.  
 
 104 
 
Telomere length appeared to show a significant correlation between that at XpYp and 17p. 
Although it appeared that there was a general propensity of telomere shortening at XpYp, it 
should be noted that variable regions of telomere variant repeats (TVR) may extend the 
length of the pure telomeric tract. Alternatively, the length of the TTAGGG repeats may 
have been set longer at 17p. Furthermore, in addition to previous suggestions, cis-acting353 
mechanisms may skew the average length of the distribution. Such alterations may arise by 
means of telomere recombination which was apparent within a bimodal STELA profile at the 
17p telomere.  
 
Genotyping of the XpYp telomere-adjacent DNA revealed that 36% of all patients in this 
study were heterozygous for the GC and AT allele. This was a significant reduction to the 
expected 45% identified within the Caucasian population.244 Although this might reflect 
MDS/AML pathogenesis; loss of the Y chromosome is commonly observed in the bone 
marrow of elderly males who do not present with any haematological disease.356 Therefore, 
it is possible that this finding was a normal age-related phenomenon and not related to 
disease pathogenesis. However, the loss of a sex chromosome occurs in 50 to 60% of AML 
presenting with t(8;21).357 It has been proposed that haploinsufficiency within the 
pseudoautosomal region (PAR) may support the development of this subtype. The GM-CSF 
(granulocyte-monocyte colony stimulating factor) receptor, mapped 1180 to 1300kb from 
the XpYp telomere358 has been demonstrated to inhibit the immortalisation of t(8;21)+ 
murine and human leukaemic cell lines.359 Notably, it was proposed that it may play a role 
as a candidate tumour suppressor by enhancing the differentiation of preleukaemic myeloid 
cells.359  
In addition to end-replication losses, telomeres are also subjected to large scale deletion 
events that occur sporadically amongst the telomere distribution. Telomere rapid deletion 
(TRD) events have the propensity to induce the abrupt transition of a clone with a high 
proliferative capacity to a very low replication potential. The highly proliferative nature of 
this disease may induce replication slippage which has the potential to significantly reduce 
the proliferative capacity of a haematopoietic precursor. Thus, TRD events may contribute 
to the cytopenia severity in individual patients, particularly in the presence of a functional 
DNA damage response (DDR). 
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Furthermore, these telomeres can be quickly reduced to a critical length which may provoke 
genetic instability and AML transformation. Interestingly, a RAEB2 patient showed a high 
number of these deletion events (9.1%) at the 17p telomere. This may have been a 
mechanism in order to inactivate particular components of the DDR, in particular p53 which 
has been mapped to this chromosome. This raises speculation that the loss of the telomere 
at 17p in a pre-leukaemic state, i.e. MDS may allow for a more proliferative disease that has 
the potential to transform into leukaemia following the abrogation of p53. Consistently, the 
loss of p53 has been implicated to result in significantly shorter survival and AML 
transformation.135 
A reduction of TRD events was apparent in AML cells and may be associated with the up-
regulation of telomerase. Telomerase has shown a preference for short telomeres in mice209 
and human cells,210 thus its up-regulation may be of importance in the AML clone to reduce 
the level of genomic instability in the presence of critically short telomeres.  
Telomerase up-regulation was detected in AML cells (p < 0.0001), consistent with previous 
observations.328,332,342,347 Telomerase activity has been detected at low levels in MDS cells332 
and it has been proposed that the level of activity is unable to prevent extensive telomere 
attrition.335 However, increased telomerase activity in AML may be vital in preventing 
excessive telomere erosion in order to circumvent cellular senescence or apoptosis. Despite 
an accumulation of telomerase competent blast cells in late MDS and AML; increased 
telomerase may also be a feature of the malignant phenotype that is vital to stabilise the 
genome acquired in AML cells. Thus, promoting continued proliferation and clonal 
expansion of leukaemic cells.  
Telomeres erode by 33bp/year in proliferating haematopoietic cells;326 however, this would 
be expected to increase in cells that are actively proliferating. Accordingly, MDS has been 
associated with a hypercellular bone marrow; thus it may be expected that the rate of 
telomere shortening is elevated in haematopoietic cells. The proliferation rate of healthy 
cells may increase substantially in an attempt to maintain a peripheral blood homeostasis as 
a consequence of increased apoptosis. Notably, elevated telomere erosion was apparent 
within the STELA profiles derived from MDS patients. One such extreme case showed 
telomere erosion at 300bp/year. This is 10 fold higher than that described in healthy cells. 
Increased cellular proliferation can reduce the capacity of haematopoietic cell reserves by 
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means of telomere induced apoptosis or senescence increasing the extent of cytopenia 
severity. Furthermore, accelerated telomere erosion may reduce the latency period prior to 
AML transformation. Thus, serial samples may be able to determine the extent of cellular 
proliferation and rate of telomere attrition and provide prognostic information.  
The start of the functional TTAGGG tract varies considerably due to the presence of variable 
quantities of TVRs. The TVR region has been regarded as a non-functional region of the 
telomere since the Shelterin proteins TRF1, TRF2 and POT1 have a high specificity for the 
TTAGGG repeat tract.192 Furthermore, TVR regions have been observed within telomere 
fusions implicating that they provide no protective capping.255 The TVR region within each 
patient could be established by TVR-PCR. Variable measurements from 0 to 3kb had been 
observed. The shortest pure TTAGGG tract recorded was only 0.16kb and had been derived 
from an AML patient. Thus, on average the telomere distribution at XpYp was only 
composed of 27 repeats. More importantly, the STELA distribution derived from this 
individual revealed that the lower 25th percentile of telomeres was comprised of only 8 
TTAGGG repeats. Previous observation has implicated that a telomere of only 13 TTAGGG 
repeats is sufficient to induce telomere fusion.255 
 
It has been previously proposed that MDS initiates from cells capable of self-renewal,19,34 
thus it was speculated that CD34+ cells would show accelerated telomere erosion due to 
extensive cellular proliferation. However, paired analysis of telomere length between CD34+ 
and CD34- purified cells derived from the same patient failed to show a difference in 
telomere length. The majority of the patients analysed had been diagnosed with low-risk 
MDS and it was proposed that the apoptotic nature of early MDS138,139,141 may eliminate the 
clone that has the potential to show prolonged telomere attrition. MDS CD34+ cells may also 
still be capable of cellular differentiation into their CD34- counterparts and significant 
differences between the subcellular compartments could go undetected. It may be 
suggested that extensive telomere attrition of the CD34+ fraction would be more apparent 
in high-risk individuals where reduced apoptosis and a block in differentiation would ensue. 
Alternatively, an accumulation of genetic events may arise within the CD34 fraction 
uncoupling function from lineage expression. Thus, a CD34+ cell could lose its positive 
expression and clonal expansion and telomere attrition may be observed within the CD34- 
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fraction. It is also possible that the novel microenvironment generated by the disease has 
the propensity to promote cellular replication of stromal cells accelerating telomere 
attrition within the CD34- fraction. However, it also raises speculation that telomerase 
activity might have become up-regulated within a sub-population of cells providing 
telomere stability and rendering the inability to detect accelerated telomere erosion.  
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Chapter 4: 
Telomere Length and Prognosis in MDS 
4.1 Abstract 
The Myelodysplastic syndromes (MDSs) are comprised of a heterogeneous group of clonal 
disorders characterised by ineffective haematopoiesis. Although 30 to 35% of MDS cases 
progress to Acute Myeloid Leukaemia (AML); the majority of patients die from blood related 
ailments caused by progressive bone marrow failure. 
Telomere length conformed only weakly to the aging dogma in the MDS cohort suggesting 
that chronological age plays a minimal role in influencing the telomere length of 
haematological cells within MDS patients. 
There was a trend for decreasing telomere length with increasing blast count; however 
telomere length did not appear to influence the severity of cytopenia, cytogenetics or IPSS 
risk scores.  
When MDS patients were divided into subgroups based on diagnostic telomere length, 
patients bearing shorter telomeres for their respective age showed shorter overall survival 
rates. However, telomere length was only able to refine favourable prognostic markers that 
included good risk cytogenetics (p < 0.0001; HR = 27.26; 95%CI 5.538-134.2), uni-lineage 
cytopenia (p = 0.0144; HR = 7.457; 95%CI 1.492-37.26) and low-risk IPSS scores (p = 0.0489; 
HR = 3.026; 95%CI 1.006-9.109). Telomere length did not appear to influence the mortality 
rate within more unfavourable prognostic subgroups. Thus, telomere length may provide an 
independent prognostic indicator that could determine disease outlook in patients 
presenting with low-risk markers. This may be particularly informative provided that patient 
outcome is heterogeneous within low-risk cohorts. Moreover, the telomere length at 
diagnosis influenced the overall survival of MDS patients irrespective of conventional 
markers. 
In conclusion, this data suggests that the telomere length at diagnosis may provide a novel 
independent prognostic marker for delineating MDS patients into those with a favourable or 
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unfavourable outcome and quite possibly characterise low-risk individuals with the 
possibility of developing a more aggressive disease.   
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4.2 Introduction 
According to the World Health Organisation (WHO) classification system for haematological 
cancers the Myelodysplastic Syndromes (MDS) are one of the five major categories of 
myeloid neoplasms20 with an estimated incidence of 2 to 12 new cases per 100,000 people 
each year which has been noted to increase among persons aged 70 or older.15  
MDS is comprised of a heterogeneous group of clonal disorders associated with ineffective 
haematopoiesis.18 One third of patients with MDS will undergo leukaemic transformation 
into Acute Myeloid Leukaemia (AML), however a significant number die from complications 
of bone marrow failure without progressing into acute leukaemia.19  
MDS is suspected following an abnormal complete blood cell (CBC) count but is confirmed 
by means of a bone marrow (BM) biopsy that evaluates the cellular morphology and 
percentage of blast cells.21 Clinically, MDS results in an insufficient production of peripheral 
blood cells increasing the susceptibility of blood related disorders. Patients develop 
complications characterised by anaemia, haemorrhage and immune-compromise.15,24,26     
MDS marrow is normal or hypercellular in 90% of cases but differentiating cells are either 
dysfunctional or prematurely removed by apoptosis.22 This results in low peripheral blood 
counts (blood cytopenia(s)) commonly involving those of the myeloid lineage. Notably, 
dyserythropoiesis, dysgranulopoiesis and dysmegakaryocytopoiesis causes a reduction of 
erythrocytes, granulocytes and platelets respectively.24   
The FAB criterion for the classification of the Myelodysplastic Syndromes (MDS) was devised 
over 30 years ago. MDS was divided into five subgroups based on morphological features in 
the bone marrow (BM) and peripheral blood (PB).24 Marrow composed of fewer than 5% 
blast cells was regarded as either Refractory Anaemia (RA) or RA with Ringed Sideroblasts 
(RARS) with the latter composed of over 15% morphologically abnormal erythroid cells.43 
Refractory Anaemia with Excess Blasts (RAEB) was characterised by the appearance of 5 to 
20% blast cells with RAEB in transformation (RAEB-T) showing 21 to 30%.43 A blast cell count 
of over 30% was referred to as a leukaemic AML marrow by means of the FAB criterion.43 
The World Health Organisation (WHO) later proposed that RAEB be subdivided into RAEBI 
and RAEBII with regard to marrow blast cell percentage, i.e. 5 to 9% would be classed as 
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RAEBI whereas 10 to 19% as RAEBII.355 The WHO lowered the FAB standard for AML 
classification to 20% blasts provided that patients with 20 to 30% blasts (previously 
classified as RAEB-T) endured a similar prognosis to those with over 30% blasts.355 Although 
the presence of monocytosis could delineate CMML (Chronic Myelomonocytic Leukaemia) 
from other FAB subgroups,360 the WHO divided CMML into CMML-1 and CMML-2 due to its 
heterogeneous outcome.361 Less that 10% blasts represents that of CMML1 whereas 
CMML2 has been considered as bone marrow composed of 11 to 20% blasts.361  
The International Prognostic Scoring System (IPSS) was devised to predict patient outcome 
and facilitate in making therapeutic decisions, particularly since the prognosis of MDS is 
heterogeneous.103,104 This combines diagnostic clinical parameters including the percentage 
of blasts, number of cytopenia(s) and cytogenetics so as to calculate a risk score which can 
separate patients into distinctive subgroups comprised of low, intermediate-1 (Int-1), 
intermediate-2 (Int-2) and high-risk based on their mortality rate and risk of AML 
transformation.43 High-risk patients show increased mortality as a consequence of Acute 
Myeloid Leukaemia (AML) development whereas low-risk patients more likely die of 
complications associated with bone marrow failure.  
Acquired cytogenetic alterations are detected in 50 to 60% of newly diagnosed patients with 
MDS;34,35 however low sensitivity methods such as conventional G-banding analysis fail to 
detect karyotypic abnormalities in a substantial proportion of patients (~50%).102 Although 
the karyotype is termed ‘normal’, patient outcome is heterogeneous103 with some 
individuals rapidly deteriorating following diagnosis.104 In contrast, the overall prognosis of 
patients who present with a complex karyotype is poor. These have been noted to occur 
within 15 to 30% of patients at diagnosis105 with the majority of these patients undergoing 
leukaemic transformation into AML.43 
Previous reports have shown increased telomere attrition in MDS patients with multiple 
cytopenias and low haemoglobin concentrations.332 It has also been documented that 
telomere shortening is commonly associated with the presence of complex chromosomal 
rearrangements.333,334,342 These data suggest that short telomeres may correlate with an 
inferior prognostic outlook. Accordingly, the importance of telomere length with respect to 
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clinical parameters of MDS was investigated in this chapter. Furthermore, telomere length 
was also analysed to determine if it predicted overall survival of MDS patients. 
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Results 
4.3 Telomere Length and Age at Onset 
Healthy individuals show telomere length variation that is influenced by a variety of 
determinants including age, lifestyle and genetic factors in the zygote, e.g. hTERT 
expression. A genetic contribution has been implicated in Dyskeratosis Congenita (DC) such 
that telomere shortening and disease anticipation have been linked to a reduction in 
telomerase activity.329 However, despite the level of heritability between individuals, 
environmental influences such as lifestyle and disease status can contribute to the rate of 
telomere attrition.238  
Figure 4.1 demonstrates a significant correlation between age and telomere length within 
cells derived from the peripheral blood of healthy individuals (r2 = 0.6001; p < 0.0001). 
Telomere attrition appears to occur at roughly 53bp/year; a similar erosion rate has been 
previously documented in haematopoietic CD34+ cells, i.e. 33bp/year.326 However, 
considerable telomere length variation is apparent within individuals of a similar age.  
Figure 4.1: A strong negative correlation exists between telomere length 
and age (r
2
 = 0.6001; p < 0.0001). Progressive telomere shortening occurs 
with aging. Telomere length measurements of healthy individuals were 
provided by Duncan Baird. 
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Figure 4.2: Telomere length at XpYp shows a weak negative correlation with age in MDS (r
2
 = 0.06250; p = 
0.0253) and a weak positive correlation with age in AML (r
2
 = 0.03662; p = 0.0442).  
In the context of MDS and AML, a weak correlation between age at diagnosis and telomere 
length at the XpYp telomere in MDS (r2 = 0.06250; p = 0.0253) and AML cells (r2 = 0.03662; p 
= 0.0442) was detected (Figure 4.2).  
Similarly, a weak correlation was detected between age at diagnosis and an age-related 
decline in MDS (r2 = 0.01770; p = 0.2395) and AML at the 17p telomere (r2 = 0.04068; p = 
0.3337) (Figure 4.3). Telomere length and age within the MDS cohort continues to conform 
to the aging dogma. Although only weakly correlated, shorter telomeric length was 
associated with increasing age in the MDS patient cohort. In contrast, a positive correlation 
was apparent within the AML cohort, i.e. telomere length appeared to increase with age. 
 
Figure 4.3: Telomere length at 17p shares a weak negative correlation with age in MDS (r
2
 = 0.01770; p = 
0.2395 and a weak positive correlation with age in AML (r
2
 = 0.04068; p = 0.3337). 
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Extensive heterogeneity in telomere length was observed within the MDS and AML cohorts 
(Figures 4.2 and 4.3). Many patients showed similar age-related telomere length whereas 
others presented with much longer and shorter telomere profiles when compared to age-
matched healthy controls. Although this may be associated with the duration and/or 
severity of the disease it also may be consistent with the process behind disease 
development.  
A comparison of age-related decline in MDS and control individuals clearly illustrated that 
normal age-adjusted telomere erosion cannot explain the radical telomere shortening 
observed in some patients. For example, one MDS patient presented at the age of 37 years 
but had a telomere length equivalent to a normal individual >100 years of age (Figure 4.4; 
highlighted in blue).   
 
 
 
 
Figure 4.4: Comparing the correlation between telomere length with age in 
MDS patients and healthy individuals. Elevated telomere attrition is apparent 
in several MDS cases relative to the telomere length of healthy individuals of a 
comparative age. A 37 year old patient (highlighted in blue) presented with a 
telomere length profile equivalent to that expected in a healthy individual 
>100 years of age. 
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4.4 Blast Cell Percentage and Telomere Length  
Telomere length was significantly reduced in patients with MDS compared to healthy 
individuals (p < 0.0001). Furthermore, when patient cohorts (MDS and AML) were broken 
down into subgroups classified on blast cell percentage there was a trend towards reduced 
telomere length with increasing blast count (Figure 4.5). Accordingly, the telomere length at 
XpYp was recorded as 4.68kb (1.09kb) within a bone marrow composed of fewer than 5% 
blast cells, 4.49kb (1.59kb) in marrow composed of 5 to 20% blast cells and 3.53kb 
(1.34kb) within marrow that had a high percentage of blast cells, i.e. over 20%. A 
significant difference in telomere length was apparent between divisions of <5% and >20% 
(p = 0.0009) as well as 5 to 20% and >20% (p = 0.0011). The telomeric length also reduced at 
the 17p telomere with blast cell expansion. Consistently, telomere length reduced from 
4.90kb (1.01kb) within populations composed of <5% blasts to 3.67kb (0.88kb) after an 
accumulation of over 20% blast cells (p < 0.0001). Previous reports have demonstrated the 
existence of a significant negative correlation between blast cell accumulation and telomere 
length.336  
Figure 4.5: Telomere length decreases with blast cell accumulation at XpYp (a) and 17p (b). A significant (p < 
0.05) reduction in telomere length is apparent between that of 5% and 20% as well as between 5-20% and 
20% at the XpYp and 17p telomere. 
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Figure 4.6: Intra-clonal telomere length variation decreased with elevated blast count percentage at (a) the 
XpYp and (b) the 17p telomere. The difference in telomere length variation was highly significant (p < 
0.0001) between that of healthy marrow and a marrow composed of over 20% blast cells. This is consistent 
with the clonal expansion of a single cell.  
The intra-clonal variation in telomere length also reduced with increasing blast count (Figure 
4.6) with a decline in the standard deviation (SD) from 2.06kb to 1.54kb at the XpYp 
telomere (p = 0.0017). A significant difference was detected between the SD of the XpYp 
telomeres of healthy age-matched marrow and that of prognostic subgroups presenting 
with >20% blasts (p < 0.0001). This reduction in SD probably reflects the increasing clonality 
of MDS with increasing blast count. The same phenomenon was also apparent at the 17p 
telomere, which demonstrated a significant reduction in the SD from 2.04kb to 1.51kb with 
increasing blast count (p = 0.0019). 
It is interesting to note that some patients presenting with long telomere profiles within the 
5 to 20% and >20% blast count subgroups, showed similar telomere length to individuals 
with <5% blast cells (Figure 4.5). To ensure that intra-clonal heterogeneity within each 
telomere profile was not responsible for this apparent finding, the lower 25th percentile was 
analysed to reduce any skewing caused by the inclusion of healthy cells (normal marrow) in 
the profile. Despite plotting the lower 25th percentile, a number of patients within the 5 to 
20% and >20% prognostic groups showed long mean telomere length (Figure 4.7). Given the 
known heterogeneity in the size of the TVR (Telomere Variant Repeats) from one individual 
to another,244 it seemed possible that these ‘outlier’ patients may have longer TVRs thereby 
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Figure 4.7: Specific telomeric length profiles within blast percentage prognostic subgroups were influenced 
by expansive TVR regions of >1.5kb. Several patients with over 20% blast cells presented extensive 
shortening of pure TTAGGG repeats (under 1kb) within the lower 25
th
 percentile of the telomere 
population (highlighted in red). 
raising the overall telomere length. In patients where the TVR data was available, it was 
apparent that patients exhibiting long telomere profiles also had long TVR regions that 
would be influencing the overall telomere length. Those samples with large TVR regions 
(>1.5kb) are highlighted in red and blue with individuals that presented a pure TTAGGG tract 
of under 1kb within the lower 25th percentile of telomere distributions highlighted in red 
(Figure 4.7). Notably, several patients had a pure TTAGGG tract of under 1kb within the 
>20% blast cohort.   
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Figure 4.8: Overall survival censored at 5 years. MDS patients presenting with a telomere length within the 
normal age-adjusted range did not show a more favourable prognosis (p = 0.1278; HR = 1.606; 95%CI 0.8729-
2.953). 
4.5 Age-Adjusted Telomere Length in MDS Patients 
MDS patients presenting with a telomere length within the normal age-adjusted range did 
not have a better outcome (p = 0.1278; Hazard Ratio (HR) = 1.606; HR 95% Confidence 
Interval (CI) 0.8729-2.953) when compared to individuals bearing shorter telomeres than 
expected in a healthy age-matched individual (Figure 4.8). However, a biphasic distribution 
was detected within the superior curve which may indicate a possibility that a subset of 
MDS patients presenting with a telomere length within the normal age-adjusted range may 
be associated with a better outcome. The relationship between telomere length and overall 
survival was therefore examined within the currently available prognostic subgroups within 
the MDS cohort.  
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Figure 4.9: Kaplan Meier curves illustrating a significant reduction (p < 0.0001) of overall survival in 
patients presenting multiple cytopenias. 
4.6 Telomere Length and Peripheral Blood Cytopenia 
Patients were next stratified based on the number of cytopenias initially present at 
diagnosis (Figure 4.9). The Kaplan Meier curves demonstrate that the presence of multiple 
cytopenias, i.e. 2 or 3 is associated with a poorer prognosis and significantly reduced overall 
survival. Accordingly, the median survival declined significantly from 2110 days in patients 
with 1 cytopenia to only 595 days and 445 days with 2 and 3 cytopenias respectively (p < 
0.0001). Given this finding, it was of interest to determine whether a decrease in telomere 
length may associate with an increased number of cytopenia.  
 
It might be assumed that elevated haematopoietic pressure accelerates the rate of telomere 
attrition as a consequence of increased CD34+ cell proliferation. Telomere shortening would 
inadvertently be the result of attempted haematopoietic reconstitution. However, a 
dichotomy exists as accelerated telomere shortening has the propensity to exacerbate 
cytopenia severity by reducing the capacity of haematopoietic cell reserves through 
telomere induced cell cycle arrest or apoptosis.314  
In this study, the number of cytopenias did not appear to influence the mean telomere 
length at XpYp or 17p (Figure 4.10). Accordingly, the average telomere length at XpYp was 
4.35kb (1.01kb) within patients showing uni-lineage cytopenia and 4.22kb (1.76kb) within 
those that shared tri-lineage cytopenia (p = 0.7405). A similar picture emerged when 
examining the telomere length at 17p. Patients with uni-lineage cytopenia showed a mean 
telomere length of 4.36kb (0.90kb) versus 4.32kb (1.49kb) within those that shared tri-
lineage cytopenias (p = 0.8908).  
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Figure 4.10: Telomere length did not show increased attrition with increasing cytopenia. No significant 
difference was detected between either of the cytopenia subgroups.  
 
It was apparent that a subset of patients with longer telomeres, particularly within the bi- 
and tri-lineage prognostic subgroups, might have been responsible for skewing the mean 
values. Since the number of haematopoietic precursors that undergo increased proliferation 
is unknown, evaluation of the lower 25th percentile of the telomere profiles may enable a 
more accurate assessment into cytopenia severity and telomere length. Accordingly, the 
superimposition of quiescent cells (and potentially long telomeres) has the propensity to 
skew the average value of the telomere length profiles. It may be assumed that the lower 
25th percentile of the telomere distributions could be comprised of a cellular population 
with shortened telomeres induced by prolonged replication or stochastic telomere rapid 
deletion (TRD). Notably, short telomeres superimposed within an apparently larger average 
telomeric distribution could contribute to the cytopenia severity in MDS patients.  
However, telomere shortening was not significant between the cytopenia subgroups even 
when comparing the lower 25th percentiles at the XpYp and 17p telomere (Figure 4.11). The 
uni-lineage cytopenia group had a mean lower 25th percentile of 3.13kb (0.79kb) at XpYp 
and 3.18kb (0.66kb) at 17p, whereas the mean lower 25th percentile of the tri-lineage 
group was 2.88kb (1.24kb) at the XpYp telomere and 3.00kb (0.95kb) at the 17p 
telomere. These differences did not reach statistical significance with p = 0.3797 at XpYp 
and p = 0.4167 at the 17p telomere. 
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Figure 4.11: Telomere length within the lower 25
th
 percentile was not significantly different within 
prognostic cohorts with multi-lineage cytopenia not showing elevated telomere shortening.  
Figure 4.12: Specific telomeric length profiles within cytopenia subgroups were influenced by expansive TVR 
regions of >1.5kb (red/blue). It was apparent that several individuals continued to show long pure TTAGGG 
tracts despite presenting with multi-lineage cytopenias. 
 
Longer telomeres were present within each of the cohorts, which may have been influenced 
by the length of the TVR region. Patients showing TVR regions above 1.5kb were noted 
within each cohort (Figure 4.12).  
To determine whether the pure TTAGGG tract declined with cytopenia severity, TVR regions 
were substracted from the average telomere length and analysed within each of the 
cytopenia cohorts (Figure 4.13). Although not significant (p = 0.1014), there was a general 
propensity of telomere shortening with progressing cytopenia. Accordingly, the pure 
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Figure 4.13: Although not statistically significant there was a 
general tendency of pure TTAGGG shortening with increased 
cytopenia.  
telomeric length within the lower 25th percentile was 2.86kb (0.85kb) and 2.21kb (1.32kb) 
within the uni- and tri-lineage cytopenias respectively.  
 
 
 
 
 
 
 
 
 
 
The telomere length profiles were looked into further by taking into account the patient age 
and respective telomere length (Figure 4.14).  
 
 
 
 
 
 
 
Figure 4.14: Telomere length was analysed further by taking into account relative age. 
Individuals diagnosed with a single cytopenia are highlighted in green. Those showing 
shorter telomeres relative to chronological age are presented in red. 
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Figure 4.14:  Telomere length was analysed further by taking into account relative age. 
Individuals diagnosed with a single cytopenia are highlighted in green. Those showing 
shorter telomeres relative to chronological age are presented in red. 
Figure 4.15: Overall survival censored at 5 years. Telomere length relative to age was able to stratify 
patients with a single cytopenia into favourable and unfavourable prognostic subgroups (p = 0.0144; 
HR = 7.457; 95%CI 1.492-37.26). 
Patients presenting with a single cytopenia who showed a telomere length below that 
expected in a healthy age-matched individual had a much shorter survival time (Figure 
4.15). Consistently, some of these patients shared similar mean telomere lengths to those 
individuals presenting with two or three cytopenias. Differences in survival times were 
particularly apparent within the first subgroup (cytopenia 1; p = 0.0144) with a hazard ratio 
(HR) of 7.457 (HR 95% confidence interval (CI) 1.492-37.26).  
 
 
 
 
 
 
 
 
In contrast, the ability of telomere length to refine subgroups with altered overall survival 
was lost in prognostic groups showing multi-lineage cytopenias (Figure 4.16). Accordingly, 
there was no significant difference in survival curves when comparing the overall survival 
within the cytopenia subgroups two (p = 0.2107) and three (p = 0.7499).  
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Figure 4.16: Telomere length was unable to delineate patients presenting multiple cytopenias into 
favourble and unfavourable prognostic subgroups.  
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Figure 4.17: Kaplan Meier curves illustrating reduced survival within patients that present with poor-risk 
karyotype at diagnosis (p = 0.0558).  
4.7 Telomere Length and Cytogenetic Risk in MDS 
Overall survival was determined within cytogenetic risk groups using the log rank test and 
was depicted in the form of Kaplan Meier curves. It was observed that the median survival 
declined within patients presenting with a poor cytogenetic profile. Notably, the median 
survival time for patients within the good cytogenetic subgroup was 1779 days in contrast to 
only 421 days within the poor cytogenetic subgroup (Figure 4.17).  
It has been implicated that telomere dysfunction may provide a stepwise accumulation of 
cytogenetic changes during cancer development through the formation of dicentric 
chromosomes generated by successive breakage-fusion-bridge (BFB) cycles.319 Thus, it was 
speculated that increased telomere attrition may be more apparent within the poor 
cytogenetic subgroup provided that several of these patients present an abnormal 
karyotype composed of three or more chromosomal alterations.105  
However, this was not the case when analysing telomere length at XpYp and 17p (Figure 
4.18). There was no significant difference in telomere length between either of the 
cytogenetic cohorts and the telomere length within the poor prognostic group did not show 
increased telomere attrition. Accordingly, the telomere length at XpYp was 4.38kb (1.18kb) 
and 4.87kb (2.03kb) within groups presenting with good and poor risk cytogenetic profiles, 
respectively. Conversely, the telomere length at 17p was 4.43kb (0.99kb) and 4.95kb 
(1.93kb) in the good and poor risk cohorts, respectively.   
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Figure 4.18: Telomere length did not show increased attrition with cytogenetic severity. No significant 
difference was detected between either of the cytogenetic profiles. 
A substantial number of MDS patients (50%) show a normal karyotype when analysed 
using conventional cytogenetic analysis.102 However it has been noted that this group can be 
fairly heterogeneous with respect to progression.103 A comparison of telomere length 
relative to age (Figure 4.19) demonstrated a significant difference (p < 0.0001; HR = 27.26; 
95%CI 5.538-134.2) in mortality rate. Patients exhibiting telomere profiles shorter than 
expected for their chronological age had a reduction in overall survival when compared with 
patients that presented with longer telomeres.  
 
Figure 4.19: Telomere length relative to age was able to delineate patients with a favourable and 
unfavourable outcome within the good prognostic cohort. Overall survival was significantly reduced with 
elevated telomere shortening (p < 0.0001; HR = 27.26; 95%CI 5.528-134.2). 
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The impact of telomere length was lost in the remaining cytogenetic prognostic groups; p = 
0.8618 and p = 0.1911 within the intermediate and poor cohorts, respectively (Figure 4.20). 
 
The risk of AML transformation has been observed to be very high in patients that show a 
poor cytogenetic profile.43 This is often consistent with the accumulation of genetic 
alterations and positive selection of leukaemia-favouring mutations. The lower 25th 
percentile of the telomere distribution is most likely enriched with cells with an increased 
propensity to undergo telomere fusion.255 Accordingly, this population of telomeres were 
Figure 4.20: Telomere length was unable to stratify patients that showed an intermediate or poor 
karyotype into favourable or unfavourable subgroups.  
 129 
 
analysed at the XpYp and 17p telomere within each prognostic subgroup (Figure 4.21). 
Although no significant difference was detected between each group, patients that 
developed AML were identified to determine if telomere length played a role in AML 
transformation. Several individuals exhibiting short telomeres developed AML (Figure 4.21; 
highlighted in red), this was particularly apparent at the XpYp telomere within the good 
prognostic subgroup. Telomere shortening may not have been as pronounced at the 17p 
telomere within these individuals possibly due to a larger TVR. This is consistent with the 
regression analysis in chapter 3 (Figure 3.5) which showed that the telomere at 17p was 
longer by 1.63kb within the MDS cohort. Furthermore, the majority of these individuals 
(apart from one) exhibited multiple cytopenias. This may suggest that increased 
proliferative pressure accelerating telomere attrition predisposes individuals to AML 
transformation by means of telomere induced genetic instability. Telomere shortening has 
been linked to non-reciprocal translocations,322 thus patients presenting with long telomere 
profiles despite AML progression may have acquired genetic alterations independent of 
telomere dysfunction, i.e. reciprocal translocations, inversions and whole chromosome 
losses and gains.342 One such individual gained an additional chromosome 8 (Trisomy 8-
highlighted in blue in Figure 4.21) which is unlikely to have developed from telomere 
attrition.  
 
 Figure 4.21: Telomere length was not significantly different within either of the cytogenetic risk groups. 
Several individuals progressed to AML (red). Furthermore, patients that presented long telomeres at 
diagnosis might have developed a karyotypic abnormality not associated with telomere dysfunction, 
i.e. reciprocal translocations, inversions and whole chromosome losses and gains. One such example is 
highlighted in blue. This patient presented with Trisomy 8 at diagnosis.  
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Telomere shortening may have an important prognostic role independent of the cytogenetic 
profile provided that short telomeres have the propensity to enter into BFB (breakage-
fusion-bridge) cycles that could initiate the development of an abnormal clone and enable 
AML propagation. Patients exhibiting telomere shortening may be identified as those with a 
more inferior prognosis. This was apparent within the good prognostic subgroup with 
respect to survival and AML transformation.  
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Figure 4.22: An increase in the IPSS score was not associated with elevated telomere attrition. Statistical 
significance was not reached between any of the prognostic cohorts. 
4.8 Telomere Length and the IPSS Scoring System 
Patients were separated into prognostic cohorts based on their IPSS (International 
Prognostic Scoring System) risk score. The risk score stratifies individuals into low, 
intermediate-1 (Int-1), intermediate-2 (Int-2) or high by combining independent variables 
including blast percentage, cytopenia(s) and cytogenetics in order to predict patient 
outcome and facilitate in making therapeutic decisions.43  
Telomere length was analysed within different risk groups to determine if it correlated with 
the severity of prognostic features. The average telomere length at XpYp and 17p failed to 
show any correlation with IPSS prognostic risk groups (Figure 4.22). Accordingly, the 
telomere length at XpYp was 4.28kb (0.82kb) within the low-risk group and was 4.46kb 
(1.71kb) within patients that had a high IPSS score. Similarly, the telomere length at 17p 
was 4.38kb (0.76kb) and 4.51kb (1.45kb) within the low and high-risk prognostic groups 
respectively. However, there appeared to be an increase in the heterogeneity with 
increasing risk score. Accordingly, the standard deviation recorded at the XpYp telomere 
was 0.82kb and 1.71kb within the low and high-risk, respectively. Similarly, that at 17p 
was observed as 0.76kb in patients presenting low-risk and 1.45kb within those 
presenting high-risk IPSS scores. This may share some relation with how patients are 
stratified into prognostic subgroups. Notably, risk scores are defined by cytogenetics, 
cytopenia and blast count.43  
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The lower 25th percentile of the telomere profiles within each subgroup was determined to 
see if the shorter distributions within a population of telomere molecules had the potential 
to influence the prognostic scoring of each patient (Figure 4.23). It appeared there was a 
trend for telomere shortening in high-risk cohorts. Notably, the telomere length at XpYp was 
3.07kb (0.69kb) and 3.03kb (1.21kb) within the low and high-risk, respectively and that at 
17p was 3.22kb (0.61kb) within the low-risk group and 3.09kb (0.90kb) within the high-
risk cohort. However, statistical significance was not achieved between any of the 
prognostic groups. Patient groups were examined further by determining which individuals 
had undergone AML transformation (Figure 4.23; AML transformation highlighted in red). 
The majority of patients developed AML within the high-risk cohort but it was also apparent 
that inter-patient telomere length heterogeneity existed. Notably, several high-risk patients 
presented a population of telomeres within the 25th percentile that were longer than those 
detected in the low-risk cohort. However, it was also noted that a minority of individuals 
with short telomeres developed AML within the low and Int-1 prognostic cohorts (Figure 
4.23). 
 
Figure 4.23: An increase in the IPSS score was not associated with elevated telomere attrition within the 
lower 25
th
 percentile of STELA distributions. Statistical significance was not reached between any of the 
prognostic cohorts. Patients that progressed to AML have been highlighted in red with the majority of 
individuals developing overt leukaemia within the high prognostic subgroup.  
 133 
 
Figure 4.24: Statistical significance was not achieved between 
the pure TTAGGG tract within the low and high IPSS cohorts (p 
= 0.4460). However, the median pure TTAGGG length within 
the 25
th
 percentile was shorter in high-risk MDS.  
It was speculated that the TVR region might have influenced the telomere length within 
some of these patients. In order to examine this, low and Int-1 subgroups were combined 
together as ‘Low-risk MDS’ and the Int-2 and high-risk were considered ‘High-risk MDS’. The 
telomere length did not show any significant difference again between the low and high-risk 
groups (p = 0.4460). However, the high-risk MDS group had a lower median telomere length 
than the low-risk MDS group. The median telomere length within the 25th percentile of the 
low-risk group following TVR removal was 2.52kb and that within the high-risk group was 
2.17kb (Figure.4.24).  
 
 
Patients were further analysed to determine telomere length relative to age (Figure 4.25). 
Low-risk (Low/Int-1) patients with long telomeres did not progress to AML whereas a 
minority of individuals with short telomeres had undergone leukaemic transformation. This 
may be of particular importance when stratifying low-risk patients with regard to AML risk. 
In contrast, the telomere length was heterogeneous with respect to AML progression in 
patients presenting high-risk profiles (Int-2/High). 
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Figure 4.25: 12% of patients within the low-risk prognostic group developed AML. All of which had shorter 
telomere distributions when compared to age-matched controls. Conversely, the majority of individuals 
(71%) progressed to AML within the high-risk group but telomere length distributions were 
heterogeneous.   
Furthermore, there appeared to be a tendency for reduced survival (p = 0.0489; HR = 3.026; 
95%CI 1.006-9.109) within the low-risk prognostic group in patients with short telomeres for 
their respective age, however this was not apparent within the high-risk group (p = 0.0938) 
(Figure 4.26). Since the majority of patients (Figure 4.25) within the high-risk prognostic 
group developed AML (71% in contrast to only 12% low-risk individuals) it is possible that 
telomerase up-regulation is induced in some high-risk individuals prior to AML 
transformation. 
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Figure 4.26: There appeared to be a tendency for reduced survival (p = 0.0489; HR = 3.026; 95%CI 
1.006-9.109) within the low-risk prognostic group in patients with short telomeres for their respective 
age, however this was not apparent within the high-risk group (p = 0.0938; HR = 1.909; 95%CI 0.8962-
4.065). 
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Figure 4.27: Overall survival censored at 5 years. A significant reduction (p < 0.05) in overall survival was 
apparent with elevated telomere attrition at XpYp. 
 
4.9 Telomere Length and Survival in MDS  
Telomere length may provide an independent prognostic factor that could refine the ability 
to provide accurate prognostic information for individual patients. Accordingly, survival was 
analysed with respect to telomere length in a group of 77 MDS patients; the data was 
censored at 5 years follow-up as data beyond this point was not available for the majority of 
individuals. Recursive partitioning was used to divide patients into groups above and below 
different telomere length cut-off points. In doing so, the influence of telomere length on 
overall survival was established.  
It was apparent that overall survival was influenced by telomere length. In comparison to 
patients with longer telomeres, those with shorter telomere profiles had a significantly 
worse overall survival (Figure 4.27 and Figure 4.28).  
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It was noted that the hazard ratio (HR) increased significantly with progressive telomere 
shortening. The HR increased to 11.51 (95%CI 2.577-51.42; p = 0.0014) and 56.32 (95%CI 
6.190-512.4; p = 0.0003) at the XpYp and 17p telomere, respectively in patients that 
presented with a telomere length below 2.5kb at diagnosis (Figure 4.29). The variation of 
the hazard ratio may be related to longer TVR (Telomere Variant Repeat) regions at the 17p 
telomere. Extensive TVR regions would make the apparent telomere length longer raising 
the HR value as a consequence of a shorter functional TTAGGG tract. Furthermore, the 
greater mortality risk at 17p may also share some association with LOH at the p53 locus, 
which has been shown to be correlated with a poor prognosis in MDS.135,136 However, 
despite the apparent variation in HR between the XpYp and 17p telomere, it should be 
taken into consideration that only a small number of patients, i.e. n = 6 at XpYp and n = 4 at 
Figure 4.28: Overall survival censored at 5 years. A significant reduction (p < 0.05) in overall survival was 
apparent with elevated telomere attrition at 17p. 
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Figure 4.29: A reduction in telomere length increased the value of the hazard ratio (HR) so that the 
mortality rate increased by 11.51 (p = 0.0014) and 56.32 (p = 0.0003) times at the XpYp and 17p telomere, 
respectively within patients that had a telomere length below 2.5kb at diagnosis. 
Table 4.1: It appeared that a pure TTAGGG tract of 2kb at the XpYp telomere was the cut-off point that 
defined the worst clinical outcome of MDS patients (p = 0.0005; HR = 7.123; 95%CI 2.365-21.45). 
17p presented with a telomere distribution of below 2.5kb at diagnosis. Accordingly, the 
95% confidence intervals were very wide, i.e. HR 95%CI 2.577-51.42 at XpYp and HR 95%CI 
6.190-512.4 at 17p (Figures 4.27 and 4.28). A larger number of patients would be necessary 
to determine whether telomere shortening at 17p elevates the mortality risk.  
Survival analysis was taken further by analysing how the overall outlook is influenced by the 
actual length of the pure TTAGGG tract, i.e. excluding the TVR region from the telomere 
length (Table 4.1 and Figure 4.30). It was apparent that a pure TTAGGG tract of 2.0kb at the 
XpYp telomere was the cut-off point that defined the worst clinical outcome in the MDS 
cohort (HR = 7.123; 95%CI 2.365-21.45; p = 0.0005).  
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Unfortunately, TVR data could not be achieved at the 17p telomere and thus the value of 
the hazard ratio in patients with a short pure functional TTAGGG tract could not be 
determined and compared to the TTAGGG tract at the XpYp telomere.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.30: Hazard ratio values increased with 
pure TTAGGG shortening. The cut-off point 
recorded was a pure TTAGGG tract repeat of 
2.0kb (p = 0.0005; HR = 7.123).   
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4.10 Discussion  
Quantitative and qualitative abnormalities of haematopoietic cells arise under conditions of 
deregulated haematological homeostasis and it has been suggested that increased cellular 
proliferation ensues in an attempt to compensate for haematological deficits.11 However, 
leukaemia becomes more prevalent under such settings likely due to an accumulation of 
genetic insults.11 Telomere dysfunction has been implicated as a mechanism that can induce 
genetic alterations and cancer progression by means of entering into breakage-fusion-
bridge (BFB) cycles.319 This paradigm has been observed in many human solid tumours 
including renal cell carcinoma, pancreatic carcinoma and osteosarcomas.320,321 In order to 
maintain telomere stability and function selected cells up-regulate telomerase to facilitate 
the outgrowth of the malignant clone.180,318 
The Myelodysplastic syndromes (MDSs) are comprised of a heterogeneous group of clonal 
disorders associated with ineffective haematopoiesis.18 Although one third of patients 
develop Acute Myeloid Leukaemia (AML), mortality commonly arises through complications 
of bone marrow failure, i.e. anaemia, bleeding complications or the patient becoming 
immune-compromised.15,24,26     
Telomere length is negatively correlated with age within healthy individuals however, 
telomere length heterogeneity exists within the human population.236,240 The reported 
impact of heritability in humans has been noted to vary from 36 to 90% with biological and 
environmental factors influencing telomere maintenance and shortening.238 Such biological 
factors may include components involved in telomere homeostasis (e.g. telomerase activity) 
and Shelterin function (e.g.TRF1/TRF2/POT1).238 Variations in telomere length maintenance 
may result in the reduction of telomere length which has the potential to limit tissue 
renewal and increase the predisposition to organ failure, particularly those of high cellular 
turnover, i.e. the bone marrow.362 Consistently, late generation mTR-/- or mTR+/- mice 
develop clinical manifestations similar to those observed within Dyskeratosis Congenita (DC) 
patients. Short telomeres were associated with a reduction in stem cell reserves and 
correlated with a decrease in erythrocyte, platelet and white blood cell count.362,363  
Telomere length continued to conform to the aging dogma, albeit only weakly, in the MDS 
cohort examined in this study. This suggests that chronological age plays a minimal role in 
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influencing the telomere length of haematological cells within MDS patients. Accordingly, a 
37-year-old MDS patient demonstrated extensive telomere attrition at diagnosis that was 
comparable to the expected telomere length of a healthy 114-year-old. This also suggests 
that despite being telomerase competent,325 haematopoietic cells continue to lose 
telomeric repeats, particularly under conditions that exert haematological stress. Although 
the variability observed within the MDS cohort may reflect inheritable traits of telomere 
maintenance and environmental influences,238 the rate of telomere attrition can be affected 
by the replicative history and damage to the stem cell pool as well as by acquired mutations 
that alter telomere length regulation. Moreover, telomere shortening in healthy individuals 
could increase the predisposition for MDS development. 
Telomere length was significantly shorter in MDS when compared to a healthy marrow 
which is possibly associated with an increase in the proliferative pressure on haematopoietic 
cells in a pathological environment. There also appeared to be a decline in telomere length 
with elevated bone marrow blast count. This is consistent with previous observations336   
which have also identified an association between progressive telomere shortening and a 
decrease in apoptosis of MDS CD34+ cells.346 It is possible that functional DNA damage 
response (DDR) mechanisms have become abrogated with development enabling cells with 
short telomeres to bypass cell cycle arrest and prolong telomere attrition. There was also a 
tendency towards telomere length homogenisation with elevated blast count which reached 
significance in marrow composed of over 20% blasts. Differentiating cells in early stage MDS 
is probably accountable for the extensive telomere length heterogeneity, i.e. division 
heterogeneity of differentiated precursors in the bone marrow. The acquisition of molecular 
changes prevents the differentiation of haematological cells resulting in the accumulation of 
immature cells in the marrow. The progressive decline in telomere length within the 
remaining healthy cells reduces the observation of long telomeres and the telomere length 
distribution tends towards homogenisation with disease progression. It is also plausible to 
suggest that the up-regulation of telomerase in a subset of patients335,342,347 may provide 
maintenance of short telomeres and reduce the extent of telomere length variation. It 
should be taken into account, however that this analysis was based on percentage 
subgroups, i.e. <5% and 5 to 20% and thus in a subsequent study, microscopic analysis of 
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bone marrow samples and blast quantification should be ensued so as to make a direct 
correlation between such parameters.  
A minority of samples exhibited long telomeres within the lower 25th percentile of 
distributions even in the presence of high blast cell counts. Although this may be compatible 
with early telomerase up-regulation, extensive TVR (telomere variant repeat) regions may 
also be responsible for the appearance of longer telomeres. Notably, several patients 
showed large TVR regions of over 1.5kb and it was also apparent that numerous patients 
with over 20% blast cells in the bone marrow presented extensive shortening of pure 
TTAGGG repeats (under 1kb) within the lower 25th percentile of telomere distributions. 
More importantly, a telomere length distribution of less than 1kb has been previously 
described in fibroblasts undergoing crisis in vitro.255     
MDS patients who endured multi-lineage cytopenia, i.e. 2 or 3 demonstrated a significantly 
elevated mortality rate when compared with those who presented with a single lineage 
cytopenia. Previous reports have implicated that telomeres lose repeats following an 
allogeneic bone marrow transplant prior to haematopoietic reconstitution by which, the 
extent of telomere shortening is inversely correlated with the number of cells received by 
the recipient.327 With this information at hand it was originally speculated that increased 
CD34+ cellular proliferation (and increased telomere attrition) may coincide with elevated 
haematological pressure in an attempt to regain reconstitution. Additionally, telomere 
shortening has the propensity to exacerbate cytopenia severity, particularly when a DDR 
response prevails. Accordingly, telomere induced apoptosis or senescence314 has the 
potential to abolish differentiating cells and reduce peripheral blood cell numbers.314 
However, in contrast with previous reports,332 telomere length was not significantly 
different within patients that endured a single or multi-lineage cytopenia. This was also 
reiterated when measuring the lower 25th percentile of the telomere distributions. Despite 
there being a tendency of pure TTAGGG repeat shortening within the lower end of the 
distributions (25th percentile), statistical significance was not reached with increasing 
cytopenia severity. This analysis was based on the number and not the actual depth of 
cytopenia and therefore a direct correlation between telomere length and cytopenia 
severity was not made. In a subsequent study it will be more informative to establish 
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whether telomere length was associated with the intensity of haematopoietic insufficiency 
along a specific lineage.   
The association between telomere length and cytopenia severity was analysed further by 
stratifying MDS patients into groups that were dependable on the telomere length for age in 
healthy individuals. Kaplan Meier curves illustrated that overall survival was significantly 
increased in patients who presented with normal or longer telomeres for age at diagnosis 
than those with shorter telomeric lengths. However, telomeric separation only had a 
prognostic influence within patients that endured a single lineage cytopenia (p = 0.0144; HR 
= 7.457; 95%CI 1.492-37.26). Patients who presented with short telomeres might have had a 
more severe degree of haematopoietic insufficiency along a single lineage and it may be 
speculated that this subset of patients may be at risk of developing multi-lineage cytopenia. 
Accordingly, elevated telomere shortening can exacerbate the problem by promoting 
premature cell cycle arrest and induce a further decline in haematopoietic cell reserves. 
Consistent with previous studies, overall survival deteriorated within patients who 
presented with a poor cytogenetic profile at diagnosis.105 Telomere dysfunction is a 
mechanism that can generate genetic instability by entering into breakage-fusion-bridge 
(BFB) cycles.319 Complex karyotypes involving genetic alterations of three or more 
chromosomes are characteristic of a poor cytogenetic profile,105 thus it was proposed that 
telomere length may appear shorter within this cohort. Although telomere shortening has 
been previously associated with complex chromosomal rearrangements in many 
haematological diseases, including MDS and AML333,334,342 the current data failed to show 
increased telomere attrition in patients presenting with a poor cytogenetic profile.  
Conventional cytogenetic G-banding fails to detect karyotypic alterations in a substantial 
number of MDS patients (~50%) as a result of its low resolution.102 Consequently, this group 
of individuals are considered to present with a normal karyotype. Separating telomere 
length into groups with respect to age revealed that patients could be delineated into those 
with an unfavourable and favourable prognosis. Accordingly, telomere length greatly 
influenced the overall survival of patients who presented with a good karyotype (p < 0.0001; 
HR = 27.26; 95%CI 5.538-134.2). Cryptic chromosomal lesions have been detected using 
high-resolution single-nucleotide polymorphism analysis (SNP-A) in cytogenetically normal 
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MDS102,130,364 and AML.365,366 Such alterations include terminal uniparental disomy (UPD), 
deletions and amplifications of which patients with copy number changes, particularly 
deletions, have a significantly poorer prognosis.102,364 Telomere dysfunction may initiate 
early events for neoplastic development and predispose to the evolution of pathogenetic 
chromosome aberrations that are detected by conventional cytogenetics. Moreover, due to 
the heterogeneity of patient outcome within the good cytogenetic cohort,103 telomere 
length may provide a prognostic marker that has the potential to delineate subgroups with 
an unfavourable prognosis. This may be particularly important in classifying patients early 
that have the potential to rapidly succumb to their disease. In contrast, overall survival was 
not influenced by telomere length within patients that presented with intermediate or poor 
cytogenetic profiles. It is possible that telomerase may have been up-regulated in order to 
stabilise the novel genome, particularly in cells which present with poor cytogenetics. 
Patients were separated into prognostic cohorts based on their IPSS (International 
Prognostic Scoring System) risk score. The risk score stratifies individuals into low, 
intermediate-1 (Int-1), intermediate-2 (Int-2) or high by combining independent variables 
including blast percentage, cytopenia(s) and cytogenetics in order to predict patient 
outcome and facilitate in making treatment decisions.43 Telomere length was not 
significantly different within any of the prognostic cohorts, however because the risk of 
disease development is based on categorical features and not on the actual depth of 
cytopenia severity, presenting blast count or specific karyotypic abnormality it may be 
speculated that variations of these features result in fluctuations in telomere length and 
contribute to the absence of an association between telomere length and IPSS score. It is 
also possible that telomerase is up-regulated in numerous patients removing the prognostic 
signature of telomere length, particularly within higher risk groups. This may also explain, in 
part the heterogeneity of telomere length that was detected amongst the higher risk scores. 
In spite of this, the current data suggest that the telomere length at diagnosis may be able 
to stratify low-risk (Low/Int-1) patients into those with a favourable or unfavourable 
outcome. Patients presenting with short telomeres relative to age at diagnosis had a 
reduced overall survival rate (p = 0.0489; HR = 3.026; 95%CI 1.006-9.109). It was also 
apparent that a minority of these individuals progressed to AML. In contrast, the telomere 
length was fairly heterogeneous with respect to AML progression in patients presenting 
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with high-risk IPSS (Int-2/High). Additionally, telomere length did not appear to influence 
the mortality rate within this group. The majority of individuals within the high-risk 
prognostic group developed AML (71% high-risk to 12% low-risk) therefore it is possible that 
telomerase was up-regulated in some high-risk patients prior to AML transformation in 
order to provide telomere stability.  
This study revealed that telomere length at diagnosis significantly influenced the overall 
survival of MDS patients irrespective of conventional markers. Accordingly, patients who 
presented with shorter telomere length showed a reduction in overall survival. The 
telomere length at diagnosis may be identified as a prognostic variable that is able to 
classify patients who have the potential to rapidly deteriorate. Notably, low-risk MDS cases 
are heterogeneous103 with respect to outcome and a fraction of these patients show poor 
prognoses similar to high-risk individuals.104     
Although these observations suggest that telomere length at diagnosis may have potential 
in refining patient outlook and facilitate in making therapeutic decisions it is highlighted that 
individual therapy was unknown for the MDS patients in this study and therefore these data 
are inconclusive. Notably, overall survival can be greatly influenced depending on individual 
therapy. Further analysis on a more robust cohort of patients who are undergoing uniform 
treatment would substantially improve these data and potentially show an association 
between diagnostic telomere length and prognosis in MDS patients.  
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Chapter 5: 
Telomere Length and Prognosis in AML 
5.1 Abstract 
Acute Myeloid Leukaemia (AML) is an aggressive myeloid neoplasm characterised by the 
clonal proliferation of undifferentiated myeloid precursor cells and represents a group of 
heterogeneous conditions with a diversity of clinical and biological features. 
Regression analysis revealed a significant correlation between the telomere length at XpYp 
and 17p (r2 = 0.6036; p < 0.0001). Telomere length was significantly reduced in patients with 
AML compared to healthy aged-matched individuals (p < 0.0001). However, a weak positive 
correlation was detected between telomere length and age at diagnosis suggesting that 
telomere length in AML fails to conform to the aging dogma. Categorically, patients ≤60 
years of age showed significantly shorter telomere length when compared to patients older 
than 60 years of age (p = 0.037).  
With respect to other clinical parameters telomere length was not correlated with gender, 
presenting white blood cell (WBC) count, blast percentage at diagnosis and WHO 
performance status. In contrast, significantly shorter telomeres were identified in cases with 
de novo AML (p = 0.0356) when compared to secondary AML cases. There was no significant 
difference between telomere length and cytogenetic subgroups; however this data set was 
limited. There was a tendency for telomere shortening in patients that had the FLT3/ITD 
mutation (p = 0.0724) possibly associated with an increase in mitotic history, whilst 
significantly longer telomeres were observed in patients positive for the FLT3/TKD (p = 
0.0344). Patients with the TKD mutation were significantly older when compared to patients 
without the mutation (p = 0.0018). Finally, the log-rank test failed to show any prognostic 
impact of telomere length on the number of disease-free days and overall survival at both 
the XpYp and 17p telomere. 
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5.2 Introduction 
Acute Myeloid Leukaemia (AML) is an aggressive myeloid neoplasm characterised by the 
clonal proliferation of undifferentiated myeloid precursor cells and represents a group of 
heterogeneous conditions with a diversity of clinical and biological features.367 According to 
the World Health Organisation (WHO) AML is predicted when a count of 20% or more 
myeloblasts are present in the bone marrow or peripheral blood.20 AML can evolve de novo 
or secondary which is defined as having an anecdotal haematopoietic disorder or following 
prior chemotherapy or radiotherapy for a non-haematological disorder.53    
A patient’s risk score has been devised that takes into account specific prognostic 
parameters including age, presenting white blood cell (WBC) count, cytogenetics, AML type 
(de novo/ secondary) and response status after the first cycle of induction chemotherapy 
(Complete Remission [CR]/Partial Remission [PR]/Resistant Disease [RD]). The calculated 
score can be used to categorise patients into good, standard or high-risk subgroups and thus 
facilitate in making therapeutic decisions, e.g. consolidation chemotherapy for good-risk or 
bone marrow transplant (BMT) for high-risk.         
Clinical management and decision making in AML relies strongly on risk stratification based 
on conventional karyotyping.368 Cytogenetic risk has been divided into three subcategories 
which include favourable, intermediate and adverse. Favourable abnormalities are 
composed of balanced translocations such as AML1-ETO t(8; 21), PML-RAR t(15;17) and 
CBF-MYH11 inv(16)/t(16;16) whereas unbalanced translocations and complex karyotypes 
(3 or more clonal abnormalities) are adverse cytogenetic characteristics.369 Patients 
presenting with favourable cytogenetics generally have good outcomes with conventional 
chemotherapy; whereas patients with an unfavourable karyotype have a very poor 
prognosis with conventional chemotherapy and are therefore considered for an allogeneic 
transplant.370 10% to 20% of AML cases present with a complex aberrant karyotype which 
has been identified as the worst group prognostically.371  
Balanced translocations are more commonly detected in younger AML patients whereas 
unbalanced and complex abnormalities are more frequent in older patients.57 A 24.6 fold 
increase in the incidence of complex karyotypes was observed in patients of age 61 to 70 
years in contrast to patients of age 21 to 30 years while only a 1.7 fold increase in balanced 
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translocations was detected with age.371 The loss of 5q, 7q or a deletion of 17p is regularly 
observed in patients with unbalanced karyotypes. Moreover, while p53 alterations are rare 
in other AML subtypes; they have been identified in more than 90% of cases with a complex 
karyotype.371  
Secondary AML (sAML) can arise from a preceding chronic phase such as a Myelodysplastic 
Syndrome (MDS) or Myeloproliferative disease (MPD).53 Unlike de novo AML patients who 
often achieve CR after treatment, patients who transform to sAML have a very poor 
prognosis and die within a few months following AML diagnosis.372 44.2% of sAML cases 
present with complex aberrations in contrast to only 11.4% of de novo AML patients. 
However genetic features typical of sAML with complex karyotypes have also been 
identified in de novo AML with complex aberrations. Such abnormalities include del7q, 
del5q or loss of p53.372 Thus, it has been proposed that de novo AML presenting with a 
complex karyotype may in fact be sAML evolved from a previous undiagnosed 
MDS/MPD.372,373        
AML with intermediate risk cytogenetics encompass a heterogeneous population of patients 
of which most are cytogenetically normal.60 Molecular markers have been used to further 
refine patient prognosis within this cytogenetic subgroup. Such molecular abnormalities 
include mutations of the FMS-like receptor tyrosine kinase-3 (FLT3) receptor374 and 
Nucleophosmin (NPM1).70,71  
FLT3 is expressed by cells found in the haematopoietic stem cell compartment and early 
committed progenitors.59,60 The stimulation of FLT3 by its ligand has been proposed to play 
a role in cell proliferation.59,60 Approximately 30% of AML patients present with mutations in 
the FLT3 receptor leading to its autophosphorylation and constitutive activation. 25% of 
adult AML patients present with an internal tandem duplication (FLT3/ITD) of the 
juxtamembrane domain whereas 7% carry point mutations within the tyrosine kinase 
domain (FLT3/TKD).62,63 The prognosis of patients harbouring the FLT3/ITD is poor with 
individuals exhibiting high relapse rates and an inferior overall survival (OS).64,65 Disease-free 
survival (DFS) is significantly shorter in patients bearing the FLT3/TKD than FLT3 wild-type 
cases and tend to have a worse OS and high relapse rates.66,67 However, other studies have 
 149 
 
observed no influence of the TKD mutation on OS or DFS60,68 and thus its prognostic 
implication continues to be controversial.       
The NPM1 protein functions as a molecular chaperone that shuttles between the nucleus 
and cytoplasm.69 It is predominately nucleolar but 30% of AML cases bear the cytoplasmic 
NPMc+.70,71NPM1 is composed of an NES (nucleus export signal) and NuLS (nucleolar 
localisation signal) sequence motif that reside at its C-terminal. In AML, the NuLS is 
substituted into an extra NES generating increased nuclear export and cytoplasmic 
accumulation of the protein.71 Mutations in NPM1 are associated with a more favourable 
outcome when compared to patients presenting with wild-type NPM1, however patients 
with the NPM1 mutation also present with FLT3/ITD more frequently than patients with 
wild-type NPM1.72 Therefore the favourable outcome is no longer applicable to patients 
presenting with the dual NPM1 and FLT3/ITD mutation.73,74  
Extensive telomere shortening has been observed among AML patients when compared to 
aged matched healthy controls.347,350 Patients with multiple cytogenetic abnormalities have 
been associated with shorter telomeres when compared to those presenting with reciprocal 
translocations or a normal karyotype.342,347 Moreover, Q-FISH analysis revealed extensive 
telomere shortening on individual chromosome arms in AML patients who presented with 
gains and or/losses.342 This raises speculation that critically short telomeres in these cells 
may have a role in generating chromosomal instability. Additionally, the extent of 
chromosomal abnormalities was correlated with hTERT expression347 and patients who 
presented with gains/losses of chromosomes showed elevated telomerase activity when 
compared to patients with normal or balanced karyotypes.342    
FLT3/ITD has been associated with shorter telomeric length which is likely associated with 
an extended proliferative history of AML cells347,350 but telomere length has failed to show 
an influence on overall survival, disease-free survival, the incidence of relapse or response 
to treatment.347,350  
The importance of telomere length with respect to clinical parameters of AML has been 
investigated in this chapter. Furthermore, telomere length was analysed to determine 
whether it influenced a chemotherapeutic response, overall survival and disease-free 
survival of AML patients following a cycle of intensive chemotherapy.  
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Results 
5.3 Telomere Length and Age at Diagnosis 
STELA analysis at both the XpYp and 17p telomere was available for 57 AML patients. 
Regression analysis revealed that the telomere length at XpYp and 17p were strongly 
correlated (Figure 5.1) with r2 = 0.6036; p < 0.0001. However, it was clear from the 
intersection of the axis that the 17p telomere was 1.37kb longer than XpYp. 
 
 
 
 
 
 
 
 
Telomere length was significantly reduced in patients with AML compared to healthy aged-
matched individuals (p < 0.0001). The telomere length at the XpYp telomere was analysed in 
a cohort of 110 AML patients (95 primary and 15 secondary) with a median age of 60 years 
(range 17 to 82 years) however, because the clinical information was only available for a 
subset of these individuals at 17p, telomere length was examined in only 23 of these 
individuals with a median age of 50 years (range 29 to 67 years). It was apparent that the 
telomere length at the XpYp and 17p telomere failed to conform to the aging dogma 
detected in healthy individuals, i.e. increased telomere attrition with age.240  
Figure 5.2 illustrates the tendency towards a weak positive correlation with telomere length 
at XpYp and age at diagnosis (r2 = 0.03017; p = 0.0696). It appeared that this was also the 
case at the 17p telomere (r2 = 0.09874; p = 0.1442) however, the limited number of patients 
is likely associated with a reduction in significance. 
Figure 5.1: Telomere length at XpYp and 17p are strongly 
correlated r
2
 = 0.6036; p < 0.0001. 
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Figure 5.2: Telomere length at XpYp (r
2
 = 0.03017; p = 0.0696) and 17p (r
2
 = 0.09874; p = 0.1442) show a 
tendency towards a weak positive correlation with patient age at diagnosis. 
Figure 5.3: Telomere length appeared to be shorter in younger patients at the XpYp and 17p telomere. 
This reached statistical significance at the XpYp telomere (p = 0.0370). 
Patients were further categorised into subgroups divided by the median age within the XpYp 
(60 years) and 17p (50 years) cohorts (Figure 5.3). Younger patients showed significantly 
shorter telomere length at XpYp when compared to patients older than 60 years of age (p = 
0.037). The mean telomere length recorded in patients ≤60 years of age and those older 
than 60 years was 3.33kb (1.12kb) and 3.90kb (1.66kb), respectively. In contrast, the 
difference in telomere length did not reach statistical significance (p = 0.2075) at the 17p 
telomere; however there was again a trend for short telomeres within the younger cohort. 
Accordingly, the mean telomere length in patients ≤50 years of age was 3.34kb (1.04kb) 
and 3.84kb (0.77kb) in patients older than 50. It is conceivable that the lack of statistical 
significance between age and telomere length at the 17p chromosome was likely due to the 
limited number of patients analysed. 
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5.4 Telomere Length and Gender  
Of the 110 AML patients analysed 52% were male (median age 62 years; range 17 to 79 
years) and 48% were female (median age 57 years; range 18 to 82 years). The difference in 
age did not reach statistical significance (p = 0.3796). There was no significant difference 
between the two gender subgroups at the XpYp (p = 0.8513) or 17p telomere (0.4771). 
Accordingly, the telomere length at XpYp was 3.61kb (1.46kb) and 3.56kb (1.37kb) within 
the male and female cohort, respectively. Conversely, the telomere length at 17p was 
3.42kb (0.93kb) within the male cohort and 3.71kb (0.93kb) within the female cohort 
(Figure 5.4).    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: There was no significant difference in telomere length at XpYp and 17p between male and female 
patients.  
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5.5 Telomere Length and Marrow Blast Count 
Of the 110 AML patients, the bone marrow blast count was available for 80 of these 
individuals at XpYp whereas the blast count was available for 21 of the 23 patients at 17p. 
Figure 5.5 shows no correlation between telomere length and bone marrow blasts at XpYp 
(r2 = 0.01385; p = 0.2985) and 17p (r2 = 0.04071; p = 0.3804).  
 
 
Figure 5.5: Telomere length at XpYp (r
2
 = 0.01385; p = 0.2985) and 17p (r
2
 = 0.04071; p = 0.3804) show no 
correlation with bone marrow blasts (%). 
 
Patients were further categorised into quartiles based on the bone marrow blast percentage 
(Figure 5.6). The mean telomere length at XpYp was 4.00kb (1.91kb) within the 1st quartile 
(bone marrow blasts 50.25%) and 3.31kb (0.98kb) within the 4th quartile (bone marrow 
blasts >90.75%). However, this did not reach statistical significance (p = 0.1618). Due to the 
limited number of patients measured at the 17p telomere (n = 21) the median (85%) blast 
percentage was used as a cut-off point. Again, telomere length was not significantly (p = 
0.1427) shorter in patients that presented with a higher blast count. Notably, the mean 
telomere length at 17p was 3.94kb (0.95kb) and 3.35kb (0.80kb) in patients presenting 
with 85% blasts in the bone marrow and those with >85% blasts, respectively.  
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Figure 5.7: Telomere length at XpYp (r
2
 = 0.004645; p = 0.4793) and 17p (r
2
 = 0.02809; p = 0.4447) show no 
correlation with presenting WBC. 
 
 
 
5.6 Telomere Length and Presenting White Blood Cell (WBC) Count 
In the context of white blood cell (WBC) count, telomere length was not correlated with 
WBC count at presentation. Figure 5.7 shows no correlation between telomere length and 
presenting white blood cell count at XpYp (r2 = 0.004645; p = 0.4793) and 17p (r2 = 0.02809; 
p = 0.4447). 
Figure 5.6: A decline in telomere length was not detected with increasing blast count. Telomere length was 
not significantly different between subgroups.  
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Patients were further categorised into quartiles based on the white blood cell (WBC) count 
at presentation (Figure 5.8). Individuals categorised within the 1st quartile presenting with a 
WBC count of 11.45 x109/l had a telomere length of 3.75kb (1.57kb) whereas patients 
categorised within the 4th quartile had a telomere length of 3.39kb (1.16kb) presenting 
with a WBC count of >76.53 x109/l. However this did not reach significance (p = 0.3526). Due 
to the limited number of patients measured at the 17p telomere (n = 23) the median (39.1 
x109/l) WBC at presentation was used as a cut-off point. Similarly, the telomere length was 
not significantly different (p = 0.4040) between patients presenting with a WBC count of 
39.1 x109/l or less and over 39.1 x109/l at 17p. Accordingly, the telomere length was 3.76kb 
(0.98kb) and 3.43kb (0.86kb), respectively.  
  
 
 
 
 
 
 
 
Figure 5.8: A decline in telomere length was not detected with increasing WBC count at presentation. 
Telomere length was not significantly different between the subgroups. 
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Figure 5.9: Telomere length was significantly shorter in patients presenting with de novo AML (p = 0.0356). 
Further analysis revealed that the standard deviation was not significantly different (p = 0.5583) suggesting 
that intra-clonal variation has no role in this finding.  
5.7 Telomere Length and AML Type (De novo/Secondary) 
Patients with de novo AML were significantly (p = 0.0021) younger (median 56 years; range 
17 to 80 years) when compared to secondary AML cases (median 68 years; range 41 to 82 
years). The telomere length at XpYp was analysed within patients presenting with de novo 
AML or secondary AML (Figure 5.9). De novo AML cases had significantly shorter telomeres 
(p = 0.0356) when compared to secondary AML cases. The mean telomere length was 
3.48kb (1.17kb) and 4.30kb (2.37kb) within patients presenting with de novo or secondary 
AML, respectively. The standard deviation (SD) was analysed at the XpYp telomere to 
determine whether this was related to intra-clonal variation of the disease subsets. The 
mean SD of the de novo cohort was 1.59kb (0.60kb) and 1.70kb (0.89kb) within secondary 
cases, however this was not significantly different (p = 0.5583). Unfortunately, all patients 
analysed at 17p (n = 23) had been diagnosed with de novo AML and therefore a comparison 
between AML type could not be performed at this telomere.  
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5.8 Telomere Length and WHO Performance Status 
Most of the AML patients analysed in this cohort did not present with an inferior WHO 
performance status at diagnosis; 55.5% of individuals had a performance status (PS) of 0 
(fully active) and 30.1% with a PS of 1 (ambulatory). In this study, telomere length was not 
associated (p = 0.7159) with WHO performance status (Figure 5.10) such that the mean 
telomere length recorded at XpYp was 3.47kb (1.10kb) in patients with a PS of 0 and 
3.63kb (1.36kb) in patients with a PS of 3 (in bed >50% of the time), respectively. There 
appeared to be a non-significant decline in telomere length with increasing PS at the 17p 
telomere such that a PS of 0 had a telomere length of 3.83kb (1.02kb) and a PS of 1 and 2 
had a telomere length of 3.36kb (0.70kb) and 2.98kb (0.43kb), respectively. However, this 
is likely associated with the limited data set at this telomere.  
 
 
   
 
 
 
Figure 5.10: Telomere length was not associated with increasing WHO performance status (PS) at XpYp (p = 
0.7159). Although there appeared to be a trend of increasing telomere attrition at the 17p telomere, the 
limited number of patients is likely accountable for this finding. 
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5.9 Telomere Length and Cytogenetic Risk Group in AML 
The cytogenetic profile derived from 94 AML patients (84 de novo and 10 secondary AML) 
was available for comparing telomere length at XpYp within each prognostic subgroup 
(Figure 5.11). Although not significant, telomere length at XpYp was longer within the 
adverse subgroup at 4.65kb (2.25kb) when compared to intermediate with a mean of 
3.52kb (1.41kb); p = 0.1324 and favourable with a mean of 3.86kb (1.03kb); p = 0.4360. 
However, a conclusion cannot be made due to the limited number of patients presenting 
with an adverse (n = 4) and favourable (n = 7) karyotype.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: Telomere length at XpYp was not associated with 
cytogenetic risk group. No significant difference was detected 
between either subgroup. 
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5.10 Telomere Length and FLT3/ITD Mutation Status 
Telomere length was analysed at XpYp and 17p to determine whether the FLT3/ITD 
mutation was associated with telomere length (Figure 5.12). Patients presenting with the 
FLT3/ITD mutation were younger than individuals who did not present with the mutation, 
however this did not reach significance (p = 0.7989). The median age of patients was 55.5 
years (range 20 to 82 years) and 62 years (range 17 to 80 years) in patients presenting with 
the ITD mutation and those who did not, respectively. Telomere length appeared to be 
shorter in cases with the FLT3/ITD however, this did not reach statistical significance at both 
XpYp (p = 0.0724) and 17p (p = 0.2410). The mean value at XpYp was 3.27kb (1.31kb) in 
patients who presented with the ITD mutation whereas it was 3.77kb (1.42kb) within 
patients that did not. Similarly, the mean value at the 17p telomere was 3.14kb (0.83kb) 
and 3.68kb (0.94kb) within patients that were positive and negative for the FLT3/ITD, 
respectively.   
   
 
 
Figure 5.12: Although not significantly different, there appeared to be a tendency for telomere shortening 
within patients that presented with the FLT3/ITD mutation.  
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Figure 5.13: Patients who presented with the FLT3/ITD mutation had significantly longer telomeres (p < 
0.05) compared to those that did not. Exclusion of patients who also shared the FLT3/ITD mutation also 
revealed that telomere length was longer in those exhibiting the FLT3/TKD mutation (b).  
 
5.11 Telomere Length and FLT3/TKD Mutation Status 
Telomere length was also analysed within patients that presented with the FLT3/TKD 
mutation (Figure 5.13). The telomere length at XpYp was 4.20kb (1.80kb) within TKD 
positive patients and 3.39kb (1.34kb) within those who did not present with the mutation. 
The difference in telomere length reached statistical significance (p = 0.0344). Regression 
analysis revealed a weak positive correlation between age and telomere length within the 
AML cohort (Figure 5.2). Notably, individuals presenting with the TKD mutation were 
significantly older (p = 0.0018) by 11 years. The median age of the patients within each 
prognostic cohort was 67 years (range 39 to 80 years) and 56 years (range 17 to 82 years) 
within the FLT3/TKD+ and FLT3/TKD- subgroup, respectively. Seeing, that there was a 
tendency of telomere shortening within patients who presented with the FLT3/ITD+ 
mutation (Figure 5.12) further analysis was performed to reassure this observation was 
based solely on the presence of the TKD mutation (Figure 5.13b). In patients in which both 
FLT3/ITD and FLT3/TKD status were established, telomere length was longer (although with 
reduced significance) within patients presenting with the TKD mutation following the 
exclusion of those also bearing an ITD mutation (p = 0.0463).  
 
 
 161 
 
5.12 Telomere Length and NPM1 and FLT3/ITD Mutation Status 
Patients presenting with the NPM1+ mutation have a favourable prognosis however, this 
outcome is abrogated if AML cells also share the FLT3/ITD+.72 Data was categorised into 
subgroups associated with FLT3/ITD and NPM1 status so that telomere length within each 
cohort could be analysed (Figure 5.14). Telomere length at XpYp was 3.27kb (1.62kb) in the 
ITD+NPM1+ subgroup whereas the telomere length in cases presenting with either a sole 
ITD+ or NPM1+ mutation was 3.30kb (0.80kb) and 3.88kb (1.45kb), respectively. However, 
these differences in telomere length did not reach significance with p = 0.9418 and p = 
0.1576, respectively. The mean telomere length was similar among patients with the 
ITD+NPM1+ and ITD+NPM1- however, further analysis revealed that the ITD+NPM1+ subgroup 
presented with the shortest median telomere length at 2.91kb. The NPM1+ is associated 
with favourable prognosis72 and although not significant, patients presenting with this 
mutation had longer telomeres.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14: There was no association between telomere 
length with ITD and NPM1 status, however the median 
was shorter in patients presenting with ITD
+
NPM1
+
. 
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5.13 Telomere Length and Status after First Cycle of Intensive Chemotherapy 
97 of 110 patients received intensive chemotherapy at diagnosis. 10 of these cases died of 
treatment related causes, i.e. induction death whereas 84 patients achieved complete 
remission and 3 showed resistant disease. Diagnostic telomere length was analysed to 
determine whether it influenced the patient’s response after the first cycle of intensive 
chemotherapy. Short telomere length appeared to be associated with chemo-resistance 
(Figure 5.15) however this result is inconclusive because only 3 patients were unsuccessful 
at achieving remission. The telomere length at XpYp was 3.54kb  1.34kb in patients who 
entered complete remission (CR) and 2.67kb  0.88kb in patients who were showing 
resistant disease. This did not reach significance (p = 0.2674).  
 
 
 
 
 
Figure 5.15: Telomere length was shorter in patients 
presenting with resistant AML however this was not 
significant and the data set was limited. 
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5.14 Telomere Length and Disease-Free Survival  
Disease-free survival is defined as the time from entering complete remission up to the 
point of relapse or death in 1st remission. The diagnostic telomere length at XpYp (Figure 
5.16) and 17p (Figure 5.17) divided patients into subgroups that were defined by telomere 
length cut-off points. Kaplan Meier curves were subsequently generated to determine 
whether telomere length could influence disease-free survival. In this study 84 of 97 
patients who received intensive chemotherapy entered complete remission however, the 
telomere length at 17p was only available for 23 of these cases. The log-rank test failed to 
show any prognostic impact of telomere length on the number of disease-free days at both 
the XpYp (Figure 5.16) and 17p (Figure 5.17) telomere.  
Figure 5.16: Kaplan Meier curves failed to show any prognostic impact of telomere length on the number of 
disease-free days at the XpYp telomere. 
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Figure 5.17: Kaplan Meier curves failed to show any prognostic impact of telomere length on the number of 
disease-free days at the 17p telomere.   
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5.15 Telomere Length and Overall Survival 
Overall survival was defined as time from diagnosis up to the point of death. Recursive 
partitioning was used to divide patients into groups above and below defined telomere 
length cut-off points at XpYp (Figure 5.18) and 17p (Figure 5.19). Kaplan Meier curves were 
subsequently generated to determine whether the telomere length at diagnosis influenced 
patient’s overall survival. 97 cases were analysed at the XpYp telomere whereas only 23 of 
these individuals were analysed at 17p. The log-rank test failed to show any prognostic 
impact of telomere length on overall survival at both the XpYp (Figure 5.18) and 17p (Figure 
5.19) telomere. 
Figure 5.18: Kaplan Meier curves failed to show any prognostic impact of telomere length on overall survival 
at the XpYp telomere.   
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Although the rate of entry into 1st remission was unavailable for this study it may be 
tempting to speculate that telomere length does not influence this parameter since the 
results from both disease-free survival and overall survival were consistent. Although Figure 
5.15 might indicate that telomere length at diagnosis could have a role in determining the 
patient’s response after the 1st cycle of intensive chemotherapy with short telomeres 
associated with resistant AML, the data set was very limited and thus no conclusion can be 
made. 
 
 
Figure 5.19: Kaplan Meier curves failed to show any prognostic impact of telomere length on overall survival 
at the 17p telomere.   
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5.16 Discussion 
Acute Myeloid Leukaemia (AML) is an aggressive myeloid neoplasm characterised by the 
clonal proliferation of undifferentiated myeloid precursor cells and represents a group of 
heterogeneous conditions with a diversity of clinical and biological features.367 AML can 
evolve de novo or secondary to an anecdotal haematopoietic disorder or to prior 
chemotherapy or radiotherapy for a non-haematological disorder.53    
Telomere length was analysed within a cohort of AML patients (de novo and secondary) to 
determine whether it was associated with clinical parameters at presentation. Additionally, 
in an attempt to establish if diagnostic telomere length influences patient outlook; response 
status after the 1st cycle of intensive chemotherapy, disease-free survival and overall 
survival were investigated with respect to telomere length.  
Consistent with these data, extensive telomere shortening has been observed among AML 
patients when compared to aged-matched healthy controls.347,350 Moreover, it was evident 
that telomere length did not comply with the aging dogma. Notably, younger cases were 
showing elevated telomere attrition when compared to older AML patients. Telomere 
length was significantly longer in patients >60 years in contrast to their younger 
counterparts (60 years). It has been previously shown that a large proportion of older AML 
cases present with poorly differentiated subtypes of AML (FAB: M0/M1) with the probability 
of these AML subtypes increasing with age.375 Interestingly, telomerase activity is correlated 
with FAB subgroups with activity following M1>M2>M5>M4376 with a significant increase in 
M1.377 Accordingly, longer telomeres within the aging population might be associated with a 
bias towards M1 cases however, FAB subgroups were not available for this study and 
therefore this cannot be concluded.     
Telomere length was not correlated with white blood cell (WBC) count and blast count at 
presentation. This was expressed as both categorical and continuous variables. The process 
behind clonal expansion is likely accountable for this finding, i.e. telomere dynamics and the 
process behind disease development. Notably, this study (Chapter 3; Figure 3.15) as well as 
others has shown a significant up-regulation in telomerase activity342,347 in AML and thus it is 
possible that in the presence of up-regulated telomerase and hTERT expression;342,347,376,377 
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the access of telomerase to the telomere is deregulated resulting in fluctuations in telomere 
length control within individual cases.  
The prognosis of patients harbouring the FLT3/ITD is poor with individuals exhibiting high 
relapse rates and an inferior overall survival (OS).64,65 However, the prognostic impact of 
FLT3/TKD remains controversial.60,66-68 This study, as well as others has identified telomere 
shortening within patients who express the FLT3/ITD mutation.347,350 FLT3 is expressed by 
cells found in the haematopoietic stem cell compartment and early committed 
progenitors.59,60 The stimulation of FLT3 by its ligand has been proposed to play a role in cell 
proliferation.59,60 The ITD and TKD mutation both result in an increase in cellular 
proliferation however, several studies378,379 have shown a weaker proliferative effect 
induced by the FLT3/TKD when compared to patients with the FLT3/ITD. The clonogenic 
ability of TKD expressing cells in vitro has been observed to be significantly less when 
compared to ITD cells.380 Notably, the ITD but not TKD mutation (or wild-type FLT3) has 
been shown to induce robust activation of the STAT5 signalling pathway in vitro.380,381 STAT5 
(signal transducer and activator of transcription-5) is one of the principal pathways that 
regulates gene expression in response to FLT3.382 Downstream targets of STAT5 include Pim-
1 and CCND3 which both play a role in cell cycle progression and are increased in FLT3/ITD 
cells.383 Thus, up-regulation of the STAT5 pathway may be in part accountable for the 
tendency towards shorter telomeric length in patients presenting with the ITD mutation. 
However, because this did not reach statistical significance it is tempting to speculate that 
telomerase activity is preferentially up-regulated in ITD+ AML cells which may mask the 
increased proliferation associated with this genetic mutation. Patients presenting with the 
TKD mutation had significantly longer telomeres when compared to those who did not. It is 
possible that this difference is in part, associated with differential STAT5 signalling between 
ITD+ and TKD+ AML cells.  
Different age profiles for molecular markers have been described such that the ITD occurs at 
a constant frequency irrespective of age384 and the incidence of the TKD increases by 29.4 
fold from 21 to 70 years.56 Patients who expressed the FLT3/TKD mutation were significantly 
older when compared to those who were negative for FLT3/TKD. Moreover, this cohort of 
patients presenting with the FLT3/TKD mutation had longer telomeric length. Therefore, it is 
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possible that the prevalence of FLT3/TKD in the elderly population may be in part 
accountable for the finding of longer telomeres within older patients.  
Patients were sub-divided based on the NPM1 and FLT3/ITD mutation status. Although not 
significantly different, patients presenting with a sole NPM1 mutation showed the longest 
telomere length when compared to the other three subgroups. Mutations in NPM1 are 
associated with a more favourable outcome when compared to patients presenting with 
wild-type NPM1.72  MicroRNA expression profiling of NPM1+ and NPM1wild-type AML cells has 
identified different patterns of microRNA (miRNA) expression. Consistent with a favourable 
prognosis, the tumour suppressor family of microRNAs let-7 is up-regulated in NPM1+.72 The 
overexpression of let-7 has been observed to inhibit cell proliferation in human lung cancer 
cell lines.385 Notably, it has been documented to interact with MYC and CDC25A386 
regulating cell proliferation and cell cycle progression, respectively. It is possible that the 
tendency for longer telomeres within the ITD-NPM1+ subgroup may attribute to the tumour 
suppressor effect, i.e. let-7 on inhibiting cellular proliferation. The reason behind the 
apparent elevated telomere attrition of the median length is inconclusive in patients 
presenting with both mutations. Inconsistent with the literature, NPM1+ has been proposed 
to oppose the FLT3/ITD dependent activation of STAT5387 however; cells expressing ITD+ 
without the NPM1 mutation may have already undergone an extensive period of 
proliferation and have preferentially up-regulated telomerase in order to maintain telomere 
stability. Thus, telomerase activity may in part be accountable for longer median telomeric 
length within the ITD+ NPM1- subgroup.  
Secondary AML can arise from a preceding chronic phase such as a Myelodysplastic 
Syndrome (MDS) or Myeloproliferative disease (MPD).53 This study identified significantly 
longer telomeres in patients with secondary AML when compared to de novo cases. 
Moreover, the standard deviation of the telomere distribution was not significantly different 
between the two subsets suggesting that this difference was not related to intra-clonal 
variation. It is possible that secondary AML cells accumulated multiple genetic alterations 
during its antecedent pathological phase and telomerase up-regulation was an early event 
before AML evolution which may be greater in patients with secondary AML. 
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Clinical management and decision making in AML relies strongly on risk stratification based 
on conventional karyotyping.368 Cytogenetic risk has been divided into three subcategories 
which include favourable, intermediate and adverse.369 Favourable abnormalities are 
composed of balanced translocations such as AML1-ETO t(8; 21), PML-RAR t(15;17) and 
CBF-MYH11 inv(16)/t(16;16) whereas unbalanced translocations and complex karyotypes 
(3 or more clonal abnormalities) are adverse cytogenetic characteristics.369 In contrast to 
previous studies,342,347 telomere length was not significantly different between any of the 
cytogenetic subgroups. However, it is possible that telomere dysfunction arose at an early 
stage in disease development, initiating BFB (Breakage-Fusion-Bridge) cycles and generated 
the cytogenetic complexity found in these cells. Subsequent telomerase activity would 
stabilise the telomeres possibly resulting in the longer telomere length identified in patients 
with an adverse karyotype. Notably, chromosomal complexity has been shown to be 
correlated with hTERT expression347 and patients who present with gains/losses of 
chromosomes show elevated telomerase activity when compared to patients with a normal 
or balanced karyotype.342 However, the limited number of cases presenting with an adverse 
or favourable karyotype in this study renders this finding inconclusive.   
Although not significant it appeared that shorter diagnostic telomere length was associated 
with chemo-resistance after the first cycle of intensive chemotherapy. However, due to the 
limited number of individuals’ refractory to therapy, a conclusion of whether telomere 
length can be used as prognostic marker in this instance is uncertain. 
Consistent with the literature,347,350 the log-rank test in this study failed to show any 
prognostic impact of telomere length on the number of disease-free days and overall 
survival. Although the rate of entry into 1st remission was unavailable for this study it may 
be tempting to speculate that telomere length does not influence this parameter since the 
results from both disease-free survival and overall survival were consistent. It may be 
speculated that telomerase up-regulation in AML cells provides telomere length stability 
thereby removing the prognostic signature of telomere length. This is in contrast with what 
was detected within the MDS cohort in which shorter telomeric length appeared to be 
associated with a poorer outlook.  
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In conclusion, telomere length at diagnosis appears to have a minimal role in influencing the 
outlook of AML patients. However, due to the limited number of patients presenting with 
specific clinical parameters such as adverse cytogenetics and resistant disease, a conclusion 
based on these factors cannot be made.  
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Chapter 6: 
Telomere Dysfunction and its Potential Role in Promoting Genetic Instability 
in MDS and AML 
6.1 Abstract 
Telomere induced genetic instability may contribute to the development of AML by means 
of promoting an accumulation of non-reciprocal translocations (NRTs) through multiple 
breakage-fusion-bridge (BFB) cycles resulting in gross chromosomal rearrangements.  
To examine the extent of telomere dysfunction in MDS and AML, telomere fusion events 
were quantified at the XpYp and 17p telomere using a PCR based fusion assay. The mean 
frequency of fusion events detected within the MDS cohort was 2.33x10-6 (5.80x10-6) and 
6.67x10-6 (1.27x10-5) at the XpYp and 17p telomere, respectively. There appeared to be a 
reduction in the frequency of fusion within the AML cohort possibly reflecting the up-
regulation of telomerase activity in AML cells. The mean frequency of telomere adjacent 
fusions at the XpYp and 17p telomere in AML was 1.76x10-6 (4.64x10-6) and 1.86x10-6 
(6.61x10-6), respectively. In one individual the fusion assay revealed the presence of a 
clonal telomere fusion that was shared by a 40% minimum of AML cells.  
Direct sequencing revealed that telomere fusion partners aligned at short patches of 100% 
homology that ranged in length from 2 to 33nts following the sub-telomeric deletion at one 
or both telomeres. This profile was consistent with error-prone Ku-independent alternative 
end joining processes. Sequencing also revealed the existence of complex fusion events 
involving insertions of non-telomeric genomic loci, including the common fragile sites 
FRA17B and FRA19A mapped to 17q23 and 19q13, respectively.  
Array-CGH demonstrated that telomere dysfunction may contribute to chromosomal 
instability and disease progression. This was emphasised in an array profile that presented 
gross chromosomal loss that extended to the telomeres.  
These data are consistent with the view that telomere dysfunction may contribute to the 
progression of MDS and AML via telomere fusion. The resultant Breakage-Fusion-Bridge 
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(BFB) cycles have the propensity to generate gross chromosomal rearrangements which 
may be detected by means of CGH analysis.  
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6.2 Introduction 
Chromosome end protection is maintained by the telomere cap, i.e. Shelterin in which TRF2 
has been proposed in playing a vital role in suppressing aberrant telomere-telomere 
fusion.199 It has been proposed that critically short telomeres are unable to provide 
sufficient stability of telomere binding proteins255 which in turn reduces the proficiency of 
Shelterin to maintain the integrity of chromosome ends. Consequently, chromosome ends 
may no longer be protected by the telomere ‘cap’ and are recognised as double strand 
breaks (DSBs).202 In the presence of a functional DNA damage response (DDR), the ATM or 
ATR pathway202 either eliminates the cell by apoptosis or supresses cell cycle progression by 
means of p53 or p21 activation.314 In the absence of a functional DNA damage response cells 
may re-enter the S phase and continue into post–senescent replication.314,317 Continued 
telomere shortening in these cells may lead to telomeres that are denuded of all TTAGGG 
repeats and induce further erosion into the sub-telomeric region of the chromosome. Short 
dysfunctional telomeres generated either as a consequence of cellular replication or 
stochastic telomere rapid deletion (TRDs) can be subjected to fusion with other telomeres 
or non-telomeric double stranded DNA breaks.255,351 This is consistent with observations in 
mouse models where numerous end-to-end fusions and signal free ends have been 
observed in late generation mTR-/- p53-/- mutant mice.322 Therefore telomere dysfunction 
has the potential to drive genetic instability during oncogenesis by initiating breakage-
fusion-bridge (BFB) cycles upon the formation of dicentric chromosomes.319  
Dicentric chromosomes are pulled apart to opposite poles during anaphase causing 
chromosome breakage.319 This generates new recombinogenic free ends that have the 
propensity to enter into another cycle of BFB. This paradigm has been documented to 
induce genetic instability in many human solid tumours including pancreatic carcinoma321 
and osteosarcomas321 as well as in human leukaemias including Chronic Lymphocytic 
Leukaemia (CLL).304 Ultimately, cells acquire a novel genetic profile that stabilises following 
telomere maintenance which can be achieved by the expression or up-regulation of hTERT 
which has been detected in over 90% of human cancers.180 Thus, this process has the ability 
to create gross chromosomal rearrangements driving the path towards cancer development 
prior to telomerase activation or up-regulation.  
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Cell cycle control is commonly abrogated in advanced MDS; such examples include the 
downregulation of Cdk1122 and hypermethylation of p15ink4B.124,388 Furthermore, the loss of 
ATM344 and p53130 has been observed in AML and MDS, respectively with which has been 
noted to accompany abnormal cytogenetics.130,136 It has also been demonstrated that hTERT 
expression347 and telomerase activity342 are more pronounced in AML with complex 
rearrangements. This may result in the stabilisation of telomere length and structure and a 
reduction in the frequency of end-to-end fusion events.212  
Classical Non-Homologous End Joining (C-NHEJ) appears to be the most common pathway 
of DSB repair in mammalian cells.280 It is dependent on the heterodimeric protein Ku,282 
DNA-PKcs285 and Ligase IV288,289 and appears to play a dominant role in telomere fusion 
following the experimental abrogation of TRF2.202 Conversely, fusion events between short 
dysfunctional telomeres have been detected in human and mouse cells deficient in NHEJ 
components including Ku292 and DNA-PKcs,293,294 respectively suggesting that an alternative 
repair mechanism may operate at dysfunctional telomeres. Alternative Non-Homologous 
End Joining (A-NHEJ) is error prone, resulting in large deletion events and is dependent on 
sites of microhomology at the fusion junction. It has been proposed that base pairing at 
sites of microhomology, particularly within those comprised of G:C bases,308,311 may 
compensate for the loss of stability in the absence of NHEJ components.298 Small regions of 
microhomology have been previously detected within telomere fusion junction points in 
human cells undergoing crisis in culture255 and tumour cells.304 Subsequent sequencing 
revealed that these events involved the deletion of one or both of the participating 
telomeres with deletions extending into sub-telomeric DNA.  
Genome-wide telomere shortening has been associated with complex chromosomal 
rearrangements and a poorer prognosis in MDS and AML.333,334,342  However; cell viability 
and chromosomal stability are coupled to the shortest telomere within the distribution and 
it is the shortest telomere within a distribution that has the propensity to initiate telomere 
fusion.209 Thus, it is of interest to determine whether telomere fusion events arise in MDS 
and AML provided that telomere dysfunction may play a role in the development and 
pathogenesis of these diseases.  
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Given the potential role of telomere length in the pathogenesis of MDS/AML, the extent of 
telomere dysfunction was examined in this study using a PCR-based telomere fusion assay.  
This assay enables the detection and quantification of single telomere-telomere fusion 
molecules between specific chromosome ends.255 Oligonucleotide primers are utilised that 
target the telomere-adjacent sequence of specific telomeres (Figure 6.1). Long-range single 
molecule amplification prior to Southern Hybridisation with telomere adjacent probes 
enables the detection of specific products. In order to identify the participating telomeres 
and coexisting fusion junction, putative single fusion molecules are re-amplified with nested 
PCR primers. Direct sequence analysis can determine the nature of the telomere fusions 
which is achieved over multiple sequence reactions.  
 
 
 
 
 
 
 
 
Figure 6.1: PCR based telomere fusion assay. XpYpM specific for the XpYp telomere extends 1655bp into 
telomere-adjacent DNA. 17p6 specific to 17p targets sub-telomeric DNA 3058bp from the start of the 
telomere. Primers extend in the 5’ to 3’ direction towards the chromosome terminus in order to cross 
the fusion junction. 
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Results  
6.3 MDS/AML and Telomere Fusion 
A subset of MDS patients (n = 55) were examined for fusion events at the XpYp and 17p 
telomeres. Of those that showed telomere fusions, 10 patients (18%) presented fusions 
involving the XpYp telomere and 22 (40%) demonstrated fusions involving the 17p telomere 
(Figure 6.2; dictated by red and yellow points). Each fusion reaction consisted of 100ng/l of 
DNA and upon taking into account the weight of nuclear DNA within a diploid cell, i.e. 6pg 
the frequency of fusion events could be quantified within each patient. The mean frequency 
of fusion events was 2.33x10-6 (5.80x10-6) and 6.67x10-6 (1.27x10-5) at the XpYp and 17p 
telomere, respectively. Furthermore, it was apparent that the frequency of fusion events at 
the 17p telomere occurred at a significantly higher frequency than at the XpYp telomere (p = 
0.0232). 
Figure 6.2: MDS patients highlighted in red and yellow show 
fusions at either the XpYp or 17p telomere. There appeared to be 
a significant increase in the number of fusion events involving the 
17p telomere (p = 0.0232). The patients marked in yellow present 
with extensive TVR regions that ranged between 1.5kb to 3kb.  
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Telomere fusion was also analysed within a subset of AML patients (n = 58; secondary and 
de novo AML). Of those that showed telomere fusions, 10 patients (18%) presented fusions 
involving the XpYp telomere and 7 (12%) demonstrated fusions involving the 17p telomere 
(Figure 6.3; dictated by coloured points). The mean frequency of fusion events at the XpYp 
and 17p telomere had been recorded at 1.76x10-6 (4.64x10-6) and 1.86x10-6 (6.61x10-6), 
respectively. The difference in the frequency of telomere fusion events at the XpYp and 17p 
telomeres did not reach statistical significance (p = 0.9225).  
The frequency of telomere fusion events was reduced within the AML cohort compared to 
the MDS cohort, although this was not significant at XpYp (p = 0.5652), but was at 17p (p = 
0.0125).  
Figure 6.3: AML patients highlighted in colour show fusions at either 
the XpYp or 17p telomere. There was not a significant difference in 
the number of fusion events between XpYp and 17p (p = 0.9225). The 
patients marked in yellow presented an extensive TVR region 
between 1.5 and 2.5kb. A clonal fusion event was detected at the 17p 
telomere within the patient marked in green. 
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Patients exhibiting apparently long, normal telomere lengths demonstrated the presence of 
telomere fusion events. It is possible that extensive TVR regions within the telomere played 
a role in this observation. Further analysis revealed that the length of the pure TTAGGG 
tract did not appear to be associated with the presence of telomere fusion events within the 
MDS and AML cohort (Figure 6.4). Accordingly, telomere fusion events were apparent 
within patients exhibiting long pure TTAGGG tracts whilst telomere fusion was not detected 
in several patients showing short pure TTAGGG tracts. 
 
 
 
 
However, it may be possible that a subset of individuals might be predisposed to telomere 
fusion if TVR regions are extensive. Notably, one MDS patient exhibited a TVR of 3.03kb 
Figure 6.4: Telomere fusion did not appear to be related to the 
length of the pure TTAGGG tract within the MDS and AML cohort. 
Fusion events were detected in patients highlighted in red and 
yellow. Those marked in yellow presented with large TVR regions 
that ranged between 1.5kb to 3kb and simultaneously presented 
with telomere fusions. There was not a significant difference (p = 
0.5720) between the frequency of fusion events at XpYp detected 
between the MDS and AML cohort in which TVR data was 
available. 
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Figure 6.5: The STELA profile at XpYp presented long telomeres with a mean of 
5.14kb however; this patient exhibited numerous telomere fusion events. Notably, 
the TVR was 3.03kb which indicated that the pure TTAGGG tract was only 2.11kb.  
(Figure 6.5). This MDS patient presented numerous telomere fusion events at the XpYp and 
17p telomere occurring at a frequency of 2.7x10-5 and 3.3x10-5, respectively. 
 
 
 
A putative clonal telomere adjacent fusion event (5.5kb) was detected within an AML 
patient (Figure 6.3 [marked in green] and Figure 6.6). The fusion assay amplifies single DNA 
molecules thus if the same fusion is identified in separate reactions, it would have been 
derived from the same precursor. Further analysis revealed that this clonal telomere fusion 
specifically involved the 17p telomere combined with the 21q family of telomeres as 
indicated in Figure 6.6(ii); the fusion product could only be detected in the fusion reaction 
containing the 17p6 + 21q1 reactions. In order to quantify the number of cells comprised of 
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this telomeric fusion event, serial dilution was required to reduce the fusion event down to 
single molecule level (Figure 6.6(iii)). A 1:5120 dilution achieved this objective. Taking into 
account the DNA content of a single diploid cell at 6pg it was calculated that the percentage 
of cells comprised of this fusion event was 40%. Considering that these were not purified 
cells it is possible that a large fraction of the AML clone consisted of this telomeric fusion.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: (i) A clonal telomere fusion product was detected within an AML patient (~5.5kb). This 
was detected following the use of the 17p7 probe. (ii) The telomeres participating in the clonal 
fusion event included specifically 17p and a member of the 21q family. The 293 cell line was used as 
a positive control. (iii) The clonal fusion was diluted by 1:5120 to the single molecule level and it 
was calculated that a 40% minimum of cells presented this fusion product.  
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6.4 Putative Telomere Fusion Events and Sequencing 
Putative single fusion molecules were re-amplified by means of nested PCR and were 
subsequently subjected to direct sequencing in order to determine the internal structure of 
individual fusion products. Following extensive investigation (Figure 6.7) into retrieving 
telomeric fusions, a total of 11 fusion events were characterised by DNA sequencing. Re-
amplification failed to detect fusion products coexisting within individual fusion profiles, 
however occasional re-amplification products could be generated some of which yielded 
interpretable DNA sequence.  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 6.7: Extensive investigation into retrieving telomere fusion products. Nested PCR was 
performed in an attempt to re-amplify target fusions however, re-amplification failed to detect 
target fusion products. Conversely, bright bands not coexistent on the fusion blot had been 
exposed following re-amplification. Direct sequencing revealed that these products were either 
un-readable or presented successful putative telomere fusion events. Accordingly, 11 fusion 
products were sequenced.  
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Unsuccessful Sequence Products 
                                                                                                                                                                                                      
PCR amplification from genomic DNA using primers that can potentially hybridise with 
several regions throughout the genome runs the risk of producing recombination artefacts. 
Accordingly, several re-amplified products which appeared promising throughout the course 
of the study were either non-telomeric, uninterpretable or PCR artefacts (Figures 6.8 to 
6.10). Putative telomere fusion events which shared the same primer sequence on each 
participating telomere were identified such that products could be read successfully up to 
the point of divergence from which the DNA downstream was composed of merged 
sequences (Figure 6.8); these products are consistent with telomere fusion, however the 
fusion point cannot be identified. Interpreting such products was particularly difficult in the 
case of analysing fusion events involving the 21q telomere in which 13 chromosome ends 
could be amplified. PCR artefacts consisted of uninterpretable sequence composed of 
multiple products (Figure 6.9).  Non-telomeric interstitial DNA located megabases from the 
telomere were also observed (Figure 6.10); one example of which was mapped to 
chromosome 3 (29Mb from the telomere). Whilst these events may represent genuine 
telomere fusion events, the absence of a fusion point with the sub-telomeric sequences 
targeted in the fusion assay, meant that these events could not be verified as arising as a 
consequence of telomere fusion. Putative telomeric fusions similar to that shown in Figure 
6.10i/ii were regularly detected in the current study however, it was uncertain as to 
whether they were possible fusion events since only the primer sequence was identified in 
one of the participating telomeres, i.e. XpYpMb or 17p6b. Additional sequence beyond the 
primer DNA would have supported the characterisation of such a sequence. Reducing the 
number of cycles or increasing the annealing temperature in a subsequent study may 
facilitate the reduction of non-specific re-amplification products. 
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Figure 6.8: The same primer sequence on each participating telomere can successfully amplify a putative 
fusion product up to the point of divergence (at base 253). Downstream DNA from this site is no longer 
readable due to the presence of merged sequences 
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Figure 6.9: Uninterpretable sequences detected throughout the study  
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Figure 6.10: Although clear, several sequences were interstitial and not located at the 
telomere. This particular reading was derived from chromosome 3, mapped 29Mb from 
telomere. Several sequences were ‘undecided’ due to the identification of only the primer 
sequence in the participating telomere. 
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Successful Sequencing Data 
Direct sequencing of re-amplified fusion products revealed the existence of putative 
telomeric fusion events.   
Upon examining the internal structure of several DNA sequences (Figures 6.12-17 and 6.19-
20) it was apparent that the fusion products involved the deletion of one or both telomeres. 
On average, the mean sub-telomeric deletion at the XpYp and 17p telomere was recorded 
as 1241bp (810bp) and 826bp (1388bp), respectively. The mean length of sub-telomeric 
deletion at the 21q family of telomeres was 2493bp (1096bp) (Figure 6.11(i)). Moreover, 
several deletion events extended into the telomere adjacent DNA close to the limits of the 
assay, i.e. 1655bp at XpYp and 3058bp at 17p. Interestingly, there appeared to be a frequent 
breakpoint observed 3640 to 3645bp from the 21q telomere. 
100% homology was apparent at the fusion junction which ranged from 2 to 33nts in length. 
Analysis revealed that the mean length of 100% homology was 8.3nt (10.5nt) (Figure 
6.11(ii), however it was also observed that 2 fusion products displayed no homology at the 
junction point (Figure 6.11).  
 
Three fusion products (Figure 6.12 and Figure 6.13) revealed an absence of sub-telomeric 
erosion which was apparent by the presence of telomeric TTAGGG or TVR (TTGGGG, 
TGAGGG or TCAGGG) repeats adjacent to the fusion junction. This included the clonal 
product that was detected within an AML patient (Figure 6.12). 
Figure 6.11: (i) A summary of the size of the sub-telomeric deletions at the XpYp and 17p telomere. 
Deletions at the 21q family of telomeres are also illustrated. (ii) A summary of the size of 100% homology 
detected at the fusion junction. 
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Figure 6.12: A 40% minimum of AML cells in this one individual contained this fusion event 
involving the telomere of 17p and that of the 21q family. There was no erosion into the 
sub-telomeric DNA of 17p but a deletion was evident at 21q. TVR and TTAGGG repeats of 
the 17p telomere were evident within the fusion product. Underlined bases illustrate 
sequence homology flanking the fusion junction. 
Figure 6.13: Telomere fusion involving either a pair of homologous chromosomes or 
sister chromatids at (i) XpYp and (ii) 17p. Microhomology is depicted in purple 
lettering with underlined bases illustrating sequence homology flanking the fusion 
junction.  
  
 
 
 
 
Fusion events resulting from the joining of homologous chromosomes or possible sister 
chromatid fusion, i.e. XpYp:XpYp (Figure 6.13 (i)) and 17p:17p (Figure 6.13 (ii)) had also been 
observed however, insufficient material at the XpYp fusion meant it was not possible to 
formally establish which XpYp alleles were involved. Interestingly, the fusion junction 
highlighted in Figure 6.13 (ii) appears to have occurred by means of nucleotide insertion. It 
was apparent that the sequence across the junction (highlighted in yellow) was duplicated 
in the adjacent DNA of one of the participating telomeres (17p telomere highlighted in 
green). This may have resulted in an increase in the local homology at the fusion site 
strengthening the synpasis between the two DNA ends.  
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Figure 6.14: Telomere fusion possibly involving a pair of homologous chromosomes 
or sister chromatids of the 21q family. The 5q telomere could be identified in Figure 
(ii). Deletions of the 21q family are predicted from specifically utilising the 21q 
telomere as a reference. Microhomology is depicted in purple lettering with 
underlined bases illustrating sequence homology flanking the fusion junction. 
Fusion was also observed involving the 21q family of telomeres (Figure 6.14(i) and (ii) 
however, due to the extensive homology shared by the 21q family of telomeres,351 only one 
of the fusion partners in Figure 6.14(ii) could be identified as the 5q telomere.  
Sequencing also revealed the existence of complex fusion events involving insertions of non-
telomeric genomic loci. It was noted that the mean length of the inserted loci was recorded 
as 707bp (248bp). Insertions could be identified as 17q23, 21q11, 5q33 and 19q13 within 
the fusion products illustrated in Figures 6.15-17 and 19, respectively. Notably, 17q23 and 
19q13 correspond to common fragile sites FRA17B389 and FRA19A,389 respectively. Common 
fragile sites have been noted to coincide with chromosomal breakpoints in cancer cells 
resulting in the possible deletion of tumour suppressor genes and in the generation of 
Breakage-Fusion-Bridge cycles (BFB).  
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Figure 6.16: A complex fusion event that includes 388bp interstitial non-telomeric 
DNA mapped to 21q11. 100% microhomology is depicted in purple lettering with 
underlined bases illustrating sequence homology flanking the fusion junctions. 
Deletions of the 21q family are predicted from specifically utilising the 21q telomere 
as a reference. 
Figure 6.15: A complex fusion event that includes 958bp interstitial non-telomeric 
DNA mapped to 17q23. Notably, this has been documented as the common fragile site 
listed as FRA17B. 100% microhomology is depicted in purple lettering with underlined 
bases illustrating sequence homology flanking the fusion junctions. Deletions of the 
21q family are predicted from specifically utilising the 21q telomere as a reference.  
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Figure 6.17: A complex fusion event that includes 647bp interstitial non-telomeric 
DNA mapped to 5q33. 100% microhomology is depicted in purple lettering with 
underlined bases illustrating sequence homology flanking the fusion junctions. 
Deletions of the 21q family are predicted from specifically utilising the 21q telomere 
as a reference. 
 
 
 
 
 
 
 
 
 
 
 
 
Direct sequencing revealed a complex fusion product with interstitial loci mapped to 5q33 
(Figure 6.17). 5q33 has been implicated as one of the most frequent breakpoints in MDS and 
AML and is commonly associated with complex chromosomal rearrangements390,391 thus, it 
was speculated that it may be a clonal event. However, further insight revealed that despite 
the documented persistence of breakpoints located at the 5q33 locus390,391 the fusion event 
was not detected with a custom assay utilising specific primers across the fusion junctions. 
This suggests that it was a single sporadic event and not clonal within this patient. This was 
confirmed by means of gradient PCR (Figure 6.18) in which increasing temperature failed to 
show the existence of the fusion event within the patient sample.  
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Figure 6.18: Primers that target along the fusion junctions were utilised in order to 
amplify the inserted sequence (647bp). A gradient PCR was performed to determine 
whether the fusion involving the 5q33 locus was present in multiple cells. Patient (P) 
and the 293 cell line (Ct) did not show the fusion product along the temperature 
gradient. Conversely, the amplified 5q33 fusion product (+) continued to amplify even 
at higher temperatures. This suggests that the 5q33 fusion event was only sporadic and 
occurred in a single cell.  
One event showed evidence of additional processing at the fusion point (Figure 6.19). It was 
apparent that further homology (bold orange lines) was apparent downstream of the 
highlighted A, thus it is possible that the misaligned A was removed by endonucleolytic 
activity resulting in an increase in the DNA sequence homology at the fusion point and 
stabilisation of the synapse.   
 
 
 
 
 
 
 
 
 
 
Figure 6.19: A complex fusion event that includes 833bp interstitial non-telomeric DNA 
mapped to 19q13 documented as the common fragile site listed as FRA19A. 100% 
microhomology is depicted in purple lettering with underlined bases illustrating sequence 
homology flanking the fusion junctions. Deletions of the 21q family are predicted from 
specifically utilising the 21q telomere as a reference. Bold orange lines indicate the homology 
shared downstream from the highlighted A. 
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Despite the observation of 100% homology at the fusion junction within the majority of 
products obtained (n = 9), two events displayed no homology at the junction point (Figures 
6.20 (i) and (ii)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.20: No homology was detected at the fusion junction in (i) involving the 12q 
telomere and 17p telomere and (ii) involving the XpYp telomere and possibly the 1q 
telomere.                                                                                                                                              
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6.5 The Development of 6q STELA 
Interestingly, multiple sequences identified over the course of this study appeared to 
involve the 6q telomere but unfortunately the sequencing of these putative fusion events 
was unsuccessful. However, as they were regularly detected it was of interest to examine 
the telomere dynamics at the 6q telomere.  
 
Single base differences within sub-telomeric regions are utilised by STELA to enable the 
amplification of specific chromosome ends however, due to the extensive sub-telomeric 
homology that exists among different chromosomes the development of a STELA specific to 
the 6q telomere is impeded.  
The available telomere-adjacent sequence of 6q did not extend to the start of the telomere 
repeat array and thus the distance from the published terminus to the start of the pure 
TTAGGG tract was unknown. However, STELA has long-range capacity of up to 25kb171 and 
thus it was speculated that it may be able to detect a 6q specific profile provided that base 
polymorphisms could be detected within the sequence adjacent to the published terminus.  
The 5457 bases proximal to the end of 6q were clustered in order to determine whether any 
6q specific bases were present. Sequence alignment (Figure 6.21) indicated that only a 
single base was present 4070bp proximal to the 6q terminus. This illustrates the extensive 
homology that exists within sub-telomeric regions, i.e. the published end of 6q shared 
nearly 100% homology with multiple chromosome ends. A STELA assay was subsequently 
designed making use of this single polymorphism to determine whether it was able to 
detect 6q telomeres. Figure 6.21 illustrates a sub-section of the alignment that shows the 
single base difference (highlighted in yellow).  
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6q        ACAGAAATCGTCAAAAAAAAAAAAAAAGCAGAGATTTCCCATGTAGCCGCAACCTAGTTT 
1p        ACAGAAATCGTCAAAAAAAAAAA----GCAGAGATTTCCCATGTAGCCGCAACCTAGTTT 
2q        ACGGAAATTGTCAA--------AAAAAGCAGAGATTTCCCATGTAGCCGCAACCTAGTTT 
5q        ACAGAAATCGTCAAAAAAAAAAA-------GAGATTTCCCATGTAGCCGCAACCTAGTTT 
17q       ACAGAAATCGTCAAAAAAAAAAAAA--GCAGAGATTTCCCATGTAGCCGCAACCTAGTTT 
2q13      ACAGAAATTGTCAAAAAAAA-------GCAGAGATTTCCCATGTAGCCGCAACCTAGTTT 
19q       ACAGAAATTGTCAAAAAAAA-------GCAGAGATTTCCCATGTAGCCGCAACCTAGTTT 
22q       ACAGAAATTGTCAAAAAAAA-------GCAGAGATTTCCCATGTAGCCGCAACCTAGTTT 
10q       ACAGAAATTGTCAAAAAAAA-------GCAGAGATTTCCCATGTAGCCGCAACCTAGTTT 
21q       ACAGAAATTGTCAAAAAAAA-------GCAGAGATTTCCCATGTAGCCGCAACCTAGTTT 
4q        ACAGAAATTGTCAAAAAAAA-------GCAGAGATTTCCCATGTAGCCGCAACCTAGTTT 
1q        ACAGAAATTGTCAAAAAAAA-------GCAGAGATTTCCCATGTAGCCGCAACCTAGTTT 
5p        ACAGAAATTGTC-------AAAAAAAAGCAGATATTTCCCATGTAGCCGCAACCTAGTTT 
19p       ACAGAAATTGTC-------AAAAAAAAGCAGAGATTTCCCATGTAGCCGCAACCTAGTTT 
16q       ACAGAAATCGTCAAAAAAAAAAA----GCAGAGATTTCCCATGTAGCCGCAACCTAGTTT 
8p        ACAGAAATTGTCAAAAAAAAAAAAAA-----AGATTTCCCATGTAGCCGCAACCTAGTTT 
14q       ACAGAAATTGTC--------AAAAAAAGCAGAAATTTCCCATGTAGCCGCAACCTAGTTT 
          **.***** ***                   * *************************** 
 
6q        CCTCTCTTATTAACATATTCTATCAGTGTGTC---TCACATGGCTTATTAATATCTTACA 
1p        CCTCTCTTATTAACATCTTCTATCAGTGTGTC---TCACATGGCTTATTAATATCTTACA 
2q        CCTCTCTTATTAACATCTTCTATCAGTGTGTT---TCACATGGCTTATTAATATCTTACA 
5q        CCTCTCTTATTAACATCTTCTATCAGTGTGTC---TCACATGGCTTATTAATATCTTACA 
17q       CCTCTCTTATTAACATCTTCTATCAGTGTGTC---TCACATGGCTTATTAATATCTTACA 
2q13      CCTCTCTTATTAACATCTTCTATCAGTGTGTC---TCACATGGCTTATTAATATCTTACA 
19q       CCTCTCTTATTAACATCTTCTATCAGTGTGTC---TCACATGGCTTATTAATATCTTACA 
22q       CCTCTCTTATTAACATCTCCTATCAGTGTGTC---TCACATGGCTTATTAATATCTTACA 
10q       CCTCTCTTATTAACATCTTCTATCAGTGTGTC---TCACATGGCTTATTAATATCTTACA 
21q       CCTCTCTTATTAACATCTTCTATCAGTGTGTC---TCACATGGCTTATTAATATCTTACA 
4q        CCTCTCTTATTAACATCTTCTATCAGTGTGTC---TCACATGGCTTATTAATATCTTACA 
1q        CCTCTCTTATTAACATCTTCTATCAGTGTGTC---TCACATGGCTTATTAATATCTTACA 
5p        CCTCTCTTATTAACATCTTTTATCAGTGTGTTCCTTCACATGGCTTATTAATATCTTACA 
19p       CCTCTCTTATTAACATCTTCTATCAGTGTGTC---TCACATGGCTTATTAATATCTTACA 
16q       CCTCTCTTATTAACATCTTCTATCAGTGTGTC---TCACATGGCTTATTAATATCTTACA 
8p        CCTCTCTTATTAACATCTTCTATTAGTGTGTC---TCACATGGCTTATTAATATCTTACA 
14q       CCTCTC---TTAACATCTTCTATCAGTGTGTC---TCACATGGCTTATTAATATCTTACA 
          ******   *******.*  *** *******    ************************* 
 
6q        TAATTTGCCACAGTTAATGAACCAATACTGATAGACTGTTATTAACTAAAGTTCATATTT 
1p        TAATTTGCCGCAGTTAATGAACCAATACTGATAGACTGTTATTAACTGAAGTTCATATTT 
2q        TAATTTGCCGCAGTTAATGAACCAATACTGATAGACTGTTATTAACTAAAGTTCATATTT 
5q        TAATTTGCCGCAGTTAATGAACCAATACTGATAGACTGTTATTAACTAAAGTTCATATTT 
17q       TAATTTGCCGCAGTTAATGAACCAATACTGATAGACTGTTATTAACTAAAGTTCATATTT 
2q13      TAATTTGTCACAGTTAATGAACCAATACTGATAGACTATTATTAACTGAAGTTCATATTT 
19q       TAATTTGTCACAGTTAATGAACCAATACTGATAGACTATTATTAATTGAAGTTCATATTT 
22q       TAATTTGTCACAGTTAATGAACCAATACTGATAGACTATTATTAACTGAAGTTCATATTT 
10q       TAATTTGTCACAGTTAATGAACCAATACTGATAGACTATTATTAACCGAAGTTCATATTT 
21q       TAATTTGTCACAGTTAATGAACCAATACTGATAGACTATTATTAATTGAAGTTCATATTT 
4q        TAATTTGTCACAGTTAATGAACCAATACTGATAGACTATTATTAACCGAAGTTCATATTT 
1q        TAATTTGTCACAGTTAATGAACCAATACTGATAGACTATTATTAACTGAAGTTCATATTT 
5p        CAATTTGTCACAGTTAATGAACCAATACTGATAG----------ACTAAAGTTCATATTT 
19p       TAATTTGTCACAGTTAATGAACCAATACTG--AGACTATTATTAACTAAAGTTCATATTT 
16q       TAATTTGCCGCAGTTAATGAACCAATACTGATAGACTGTTATTAACTGAAGTTCATATTT 
8p        CAATTTGTCACAGTTAATGAACCAATACTGATAG----------ACTAAAGTTCATATTT 
14q       TAATTTGTCACAATTAATGAACCAATACTGATAGACTATTATTAACTAAAGTTCATATTT 
           ****** *.**.*****************  **          *  .************ 
 
 
Figure 6.21: 5457 bases proximal to the end of 6q were clustered in order to determine 
whether base polymorphisms were present. Sequence alignment indicated that only a single 
base polymorphism (highlighted in yellow) was present 4070bp proximal to the 6q terminus. 
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STELA failed to show a product following the use of the 6q specific oligonucleotide with 
alternate annealing temperatures (Figure 6.22). It was postulated that the pure TTAGGG 
tract is at a distance from the published end and therefore unable to be amplified by STELA. 
Thus, in an attempt to develop a 6q specific STELA direct sequencing of the region 
downstream to its published terminus was performed in order to identify single base 
polymorphisms that may be located nearer to its terminus. 
 
 
A related sub-telomeric region that had been sequenced to the adjacent telomeric TTAGGG 
tract was utilised to design oligonucleotides that may be shared by the unidentified 6q 
terminus. Notably, the sub-telomeric region within the 6q family was required in order to 
achieve this. To confirm the telomeric location (and not interstitial) of the proposed sub-
telomere region, STELA was performed with a TTAGGG adjacent primer that is shared by 
Figure 6.22: A primer specific to 6q failed to show telomeric 
molecules following a STELA reaction at increasing temperature. 17p 
presents the positive control for the PCR. 
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multiple chromosome ends within the 6q family. A homogeneous telomere profile was 
detected amongst 24 individual profiles that was consistent with the amplification of a 
specific telomere within the 6q family (Figure 6.23). However, the true identity of the 
telomere detected with this assay is unknown provided that STELA has the capacity to 
amplify single telomeric molecules of up to 25kb.171   
 
 
A 6q specific product was amplified upon using a telomere-adjacent reverse oligonucleotide 
shared by the family in conjunction with the 6q specific primer previously identified 
following alignment (Figure 6.21). The presence of a product (Figure 6.24; size 10kb) 
following the use of a 6q specific probe suggested that the sequence homology shared by 
multiple chromosome ends may extend downstream to the published 6q terminus.  
 
 
 
Figure 6.23: Homogeneous telomere profiles were detected upon utilising a 6q family target 
sequence. Polymorphisms were also identified amongst the population which are presented in 
patient #3 and #5. The STELA at 17p is a positive control for the PCR reaction. 
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In an attempt to identify 6q specific nucleotides, direct sequencing of the 6q specific 
product was performed by designing oligonucleotides already present within the telomere 
adjacent region shared by members of the 6q family. Unfortunately no 6q specific 
sequences could be identified and thus a 6q specific STELA could not be achieved (Sub-
section Figure 6.25; Appendix 1).  
 
 
 
 
 
 
 
 
Figure 6.24: The amplification of a 6q specific product (~10kb) by utilising the 6q specific primer 
previously identified in conjunction with a TTAGGG adjacent reverse primer shared by the family.  
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6qPredictedSubTel      GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCTACTGGCAATGAAAAGAGTTCTTGTT 
10qSubTel              GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCTACTGGCAATGAAAAGAGTTCTTGTT 
22qSubTel              GGGGTGGCATAGTTTGGCCTTATACACTGTGTTCCACTGGCAATGAAAAGAGTTCTTGTT 
1pSubTel               GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCTACTGGCAATGAAAAGAGTTCTTGTT 
5qSubTel               GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCTACTGGCAATGAAAAGAGTTCTTGTT 
17qSubTel              GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCCACTGGCAATGAAAAGAGTTCTTGTT 
4qSubTel               GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCTACTGGCAATGAAAAGAGTTCTTGTT 
19qSubTel              GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCTACTGGCAATGAAAAGAGTTCTTGTT 
21qSubTel              GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCCACTGGCAATGAAAAGAGTTCTTGTT 
1qSubTel               GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCCACTGGCAATGAAAAGAGTTCTTGTT 
2qSubTel               GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCTACTGGCAATGAAAAGAGTTCTTGTT 
19p'End'               GGGGTGGCATATTTTGGTCTTATACACTGTGTTCCACCGGCAATGAAAAGAGTTCTTGTT 
8p'End'                GGGGTGGCATATTTTGGTCTTATACACTGTGTTCCACCGGCAATGAAAAGAGTTCTTGTT 
13qSubTel              GGGGTGGCATATTTTGGTCTTATACACTGTGTTCCACCGGCAATGAAAAGAGTTCTTGTT 
20qSubTel              ----TGGCATATTCTGGTCTTATACACTGTCTTCCACCAGCAATGAAAAGAGTTATTGTC 
12qSubTel              GGGGTGGCATATTTTGGTCTTATACACTGTGTTCCACAGGCAACGAAAAGAGTTCTTGTT 
7qSubTel               GGGGTGGCATATTTTGGTCTTATACACTGTGTTCCACAGGCAACGAAAAGAGTTCTTGTT 
                           ******* * *** ************ *** ** .**** **********.****  
 
6qPredictedSubTel      TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
10qSubTel              TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
22qSubTel              TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
1pSubTel               TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
5qSubTel               TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
17qSubTel              TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
4qSubTel               TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGGAGTTCTAAGAGATATAGACCAG 
19qSubTel              TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
21qSubTel              TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
1qSubTel               TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
2qSubTel               TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
19p'End'               TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGTTTAGCAGTTCTAAGAGATATAGACCAG 
8p'End'                TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGTTTAGCAGTTCTAAGAGATATAGACCAG 
13qSubTel              TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGTTTAGCAGTTCTAAGAGATACAGACCAG 
20qSubTel              TTTCTTGCAGCAATTTGTGATTT-TTTTAGAGTTTAGCAGTTCTAATAGATATAGACCAG 
12qSubTel              TTTCCTGCAGCAATTTGTCATTTTTAAAAGAGCTTAGCAGTTCTAAGAGCTATAGAGTAG 
7qSubTel               TTTCCTGCAGCAATTTGTCATTTTTTAAAGAGCTTAGCAGTTCTAAGAGCTATAGAGTAG 
                       **** * *********** **** *:::**** **** ******** **.** ***  ** 
 
6qPredictedSubTel      CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAGGTGT 
10qSubTel              CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTAAGCATCTTTTTGTAGGTGT 
22qSubTel              CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAAGTGT 
1pSubTel               CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAGGTGT 
5qSubTel               CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAGGTGT 
17qSubTel              CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAAGTGT 
4qSubTel               CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAGGTGT 
19qSubTel              CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAAGTGT 
21qSubTel              CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAAGTGT 
1qSubTel               CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAAGTGT 
2qSubTel               CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAGGTGT 
19p'End'               CTGTGCTATCTTTTTGTGGTTTTTAGTTCTCTAGTATGTTGAGCATCTTTTTGTAAGTGT 
8p'End'                CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAAGTGT 
13qSubTel              CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAAGTGT 
20qSubTel              CTGTGCTATCTCC---TGGTTTTCAGTTCTGTAGTATGTTGAGCATCTTTTTGTATGTTT 
12qSubTel              CTGTGCTATCTCATTGTGGTTTTCAATTCTCTAGTATGTTGAGCATCTTTTTGCACGTTT 
7qSubTel               CTGTGCTATCTCATTGTGGTTTTCAATTCTCTAGTATGTTGAGCGTCTTTTTGCACGTTT 
                       ***********     ******* *.**** *********.***.******** * ** * 
 
 
 
 
Figure 6.25: Direct sequencing of the 6q specific product revealed that a 6q specific STELA could not be 
achieved provided that single base polymorphisms were not present within the 6kb region succeeding its 
published terminus (Full sequence cluster in Appendix 1). 
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6.6 Array-Comparative Genomic Hybridisation 
Whole genome tiling using NimbleGen 130k-array CGH (aCGH) was carried out on 12 MDS 
samples (Figure 6.27) to determine whether telomere dysfunction correlated with genomic 
instability. Telomere dysfunction was assumed by the presence of fusion events at the XpYp 
and 17p telomere.  
Genomic alterations in the form of chromosome aneuploidy (Trisomy 8; patient #1, #12 and 
Monosomy 7; patient #9) and gains and losses (patients #5 and #8) were detected using 
aCGH analysis. Patients #5 and #8 displayed a complex karyotype (Figure 6.27). Compared to 
those in which no large genomic lesions could be detected; the two individuals with a 
complex karyotype showed shorter telomeres (Figure 6.26). Accordingly, the mean telomere 
length recorded within the cohorts presenting with a normal and complex karyotype was 
4.71kb (1.63kb) and 2.54kb (0.70kb), respectively. However, this did not reach statistical 
significance (p = 0.1200). In addition, individuals presenting with chromosomal aneuploidy, 
i.e. Trisomy 8 or Monosomy 7 displayed longer telomeres than those with complex 
rearrangements. Notably, the telomeric mean recorded was 5.31kb (2.49kb) but again the 
difference was not significant (p = 0.2393).  
Figure 6.26: Although not significant, telomere length appeared 
shorter within patients presenting with a complex karyotype. 
Fusion events were evident in patients highlighted in red. 
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Telomere fusions were particularly apparent within individuals that presented with a normal 
karyotype. Telomere dysfunction may initiate early events for neoplastic development and 
predispose to the evolution of gross chromosomal rearrangements that were apparent 
within those showing complex karyotypes. Higher resolution may have revealed cryptic 
alterations that had failed detection upon utilising 130000 probes or events that were not 
fully clonal in the population and therefore not detectable with aCGH. It is plausible to 
suggest that telomere fusion events were not observed within those individuals presenting 
a complex karyotype provided that telomere dysfunction is an early event and thus the 
fusion assay may be unable to detect subsequent rearrangements.   
These data indicate the possibility that telomere length is associated with karyotypic 
complexity. Further analysis using a larger cohort may provide a more detailed account of 
whether telomere dysfunction accompanies gross chromosomal rearrangements in 
MDS/AML.  
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Figure 6.27: Array-CGH was carried out on 12 MDS patients. Gross chromosomal rearrangements 
were evident in patient #8 that also showed extensive loss that extended to the telomeres. 
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6.7 Discussion 
Short telomeres have been observed to induce genetic instability by means of entering into 
breakage-fusion-bridge (BFB) cycles. Dysfunctional telomeres are recognised as DNA double 
strand breaks (DSBs) which can be inadvertently repaired by means of chromosomal fusion 
with an alternate recombinogenic free end. Aberrant chromosomal fusion results in the 
production of dicentric chromosomes which are subsequently pulled apart to opposite poles 
during mitosis.319 This has the propensity to cause a break along the chromatin bridge and 
generate new recombinogenic ends. Further chromosomal fusion and breakage can result in 
a wide spectrum of non-reciprocal translocations (NRTs) that may have the ability to drive 
neoplastic transformation. This paradigm has been considered as a mechanism to induce 
genetic instability in many human solid tumours including pancreatic carcinoma and 
osteosarcomas321 as well as in human leukaemias such as Chronic Lymphocytic Leukaemia 
(CLL).304  
There was no obvious relationship between telomere length and the presence of telomere 
fusion events. However, long telomere STELA profiles may be superimposed by large scale 
telomere deletion events (TRDs) that can result in a truncated telomere which has the 
propensity to enter into fusion171,352 with other chromosome ends or non-telomeric loci. 
The low frequency of fusion events was consistent with sporadic fusion arising as a 
consequence of TRD events. TRDs were detected within the MDS and AML cohorts (Chapter 
3; Section 3.7) part and there appeared to be a significant reduction in the mean frequency 
at 17p within the AML cohort when compared to those in MDS. Consistently, there 
appeared to be a significant reduction in the frequency of fusion events involving the 17p 
telomere within the AML cohort. Moreover, the tendency for telomere fusion at 17p has the 
propensity to induce loss of heterozygosity (LOH) at the p53 locus which may enable the 
progression to overt leukaemia. Notably, the extensive telomere deletion at a single 
telomere has the propensity to initiate genetic instability and play a role in the neoplastic 
transformation of normal cells. 
The reduction in the frequency of fusion events may be related to the up-regulation of 
telomerase activity in AML cells. MDS may represent the early episodic phase of telomere 
induced genetic instability that contributes to the development of AML by means of 
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promoting the generation of non-reciprocal translocations (NRTs). Telomerase activity342 
and hTERT expression347 are more pronounced in AML with complex rearrangements; it may 
be speculated that the reduction in telomeric fusion in AML cells could be associated with 
the up-regulation of telomerase and stabilisation of telomere length to enable the transition 
to a more stable genome.  
A putative clonal telomere adjacent fusion product was detected within an AML patient 
involving a telomere belonging to the 21q family and that of 17p. The persistence of this 
fusion event suggests that it was maintained throughout the cell cycle and has been 
propagated to daughter cells. This could arise through the inactivation of a single 
centromere on the dicentric chromosome.  Alternatively this fusion event may have resulted 
in large-scale rearrangements that led to the loss of key tumour suppressors or 
amplification of oncogenes and clonal evolution. Provided that these were not purified cells 
it may be speculated that a large fraction of the AML clone consisted of this telomeric 
fusion. 
 
The amplification and characterisation of chromosomal fusions arising from telomere 
dysfunction had revealed that fusion junctions are processed in a manner reminiscent of Ku-
independent Alternative-Non-Homologous End Joining (A-NHEJ).  
A-NHEJ has been implicated to utilise Poly (ADP-ribose) Polymerase I [PARP-1] as well as the 
DNA ligase III/ XRCC1 complex392 and has been previously implicated in DNA double strand 
break repair in both yeast280 and hamster cell lines.298 Furthermore, A-NHEJ has also been 
implicated in the production of telomere fusion products in human cells undergoing crisis in 
vitro255 and within tumour cells.304 
Chromosomal loss has been observed to flank the fusion junction site which is composed of 
a small region of perfect overlapping homology. Consistent with this, the current data show 
that telomere fusion partners align at short patches of 100% microhomology ranging in 
length from 2 to 33nts following the sub-telomeric deletion at one or both telomeres. 
Extensive deletion was apparent in several cases suggesting the possibility that 
exonucleolytic resection could extend beyond the proximal limit of the assay for which is 
1655bp at XpYp and 3058bp at 17p. It has been proposed that the extent of 5’ to 3’ 
exonuclease activity may be dependent on the compatibility of DNA ends. If microhomology 
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is exposed during the process of strand resection further degradation is inhibited and base 
pairing ensues.393 Mre11 has been proposed to play a role in the detection of 
microhomology and it has been suggested that it may function in conjunction with a 5’ to 3’ 
exonuclease255 in order to reveal sites of microhomology which can be utilised for strand 
alignment.  
One fusion event revealed a small inserted DNA tract at the fusion junction which appeared 
to arise from a duplication of the adjacent DNA from one of the participating telomeres. 
This has been previously observed at the telomere fusion junction within ATLD (Ataxia 
Telangiectasia-Like Disorder) cells in which hypomorphic mutations of Mre11 have been 
proposed in preventing the efficient synapsis of the two DNA ends.305 Templated 
nucleotides have also been detected in Drosophila mutants deficient in Rad51 and DNA 
ligase IV.307 It has been proposed that these duplicated regions may play a role in increasing 
the local homology and stability for DNA end joining.307 Moreover, an identified fusion 
product appeared to have been misaligned prior to successful joining. These events may be 
indicative to additional processing at the fusion point, for example via the removal of 
specific nucleotides resulting in an increase in the localised DNA sequence homology and an 
increase in the stability of DNA synapse. 
Fusion products were identified that presented TTAGGG and Telomere Variant Repeats 
(TVR) adjacent to the fusion junction. This is consistent with previous implications that the 
TVR region is incapable of providing termini protection.255 Notably, it has been previously 
documented that only 13 TTAGGG repeats is sufficient to initiate telomere fusion255 possibly 
due to the insufficient binding of Shelterin to maintain the terminal cap. 
Sequencing also revealed the existence of complex fusion events involving insertions of non-
telomeric genomic loci. Insertions could be identified as 17q23, 21q11, 5q33 and 19q13. 
17q23 and 19q13 correspond to common fragile sites FRA17B389 and FRA19A,389 
respectively. Not only have common fragile sites been noted to coincide with cancer 
breakpoints, interstitial TTAGGG and TVR repeats within fusion products may also promote 
chromosomal fragility by means of generating G-quadruplex structures. These secondary 
structures have the propensity to induce stalling of the replication fork221 and potentially 
result in the production of a double strand break.  
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Although 100% homology was detected at the fusion junction in the majority of fusions 
identified, two products showed no homology at the fusion junction. This may be suggestive 
of DSB repair by means of the classical Ku dependent Non-Homologous End Joining (C-
NHEJ).  
 
Deletions involving the long arm of chromosome 6 (6q) have been detected in various solid 
tumours and haematological disorders including Acute Lymphocytic Leukaemia (ALL),394 
Non-Hodgkin’s Lymphoma395 and secondary Acute Myeloid Leukaemia (AML).129 Molecular 
analysis has detected two regions of minimal deletion (RMD) that occur between 6q21-q23 
and 6q25-q27396,397 suggesting the presence of candidate tumour suppressor genes within 
these regions. Notably, SEN6; a cellular senescence gene has been previously mapped to 
6q27.398 Furthermore, 6q has been noted to harbour multiple common fragile sites which 
include FRA6F and FRA6E localised to 6q21 and 6q26, respectively.389 Due to the prevalence 
of 6q deletions it was of interest to determine whether telomere dysfunction contributed to 
the loss of genetic material on 6q. However, direct sequencing revealed that a 6q specific 
STELA could not be achieved since single base polymorphisms were not available within the 
region analysed. Homologous repeat tracts (90 to >99.5%) of sub-telomeric DNA have been 
identified at multiple chromosome ends which have been observed to extend for up to 
200kb in humans.241,247 The extensive sub-telomeric homology hinders the development of 
a chromosome specific STELA as a specific target sequence encompassing a single base 
polymorphism is required.  
 
The data provided from array-CGH analysis demonstrated that telomere dysfunction may 
contribute to chromosomal instability that can enable disease progression and AML 
transformation. This was particularly emphasised in a single individual that presented gross 
chromosomal loss which extended to the telomeres. Telomere dysfunction can result in an 
accumulation of non-reciprocal translocations322 producing gross chromosomal 
rearrangements as detected upon this array profile. Interestingly, whilst not statistically 
significant, telomere length appeared to be related to karyotypic complexity. This is 
consistent with previous reports which show telomere shortening coupled with complex 
chromosomal rearrangements.333,334,342 MDS samples with stable genomes displayed longer 
telomeres than those with complex karyotypes, characterised by gains and losses that 
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included the telomeres. Moreover, telomere length was not related to the presence of 
trisomy or monosomy, indicating that mechanisms distinct from telomere dysfunction may 
be implicated in this process, i.e. sister chromatid non-disjunction.399,400 However, it was 
also observed that patients presenting with a normal karyotype in conjunction with long 
STELA distributions exhibited telomere fusion events. This may be consistent with stochastic 
truncation events contributing to the development of a complex karyotype. It is possible 
that the presence of telomere fusion events is an early event in the neoplastic process 
which may confer an inferior prognosis following the generation of a complex pathological 
genomic profile.  
 
The data shown in this chapter indicate that telomere dysfunction may contribute to the 
progression of MDS and AML via telomere fusion. The resultant breakage-fusion-bridge 
(BFB) cycles have the propensity to generate gross chromosomal rearrangements that may 
be detected by means of CGH analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 208 
 
Chapter 7:  
Discussion 
The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukaemia (AML) each represent 
a group of heterogeneous haematological diseases characterised by the clonal proliferation 
of undifferentiated myeloid cells.18,367 According to the WHO criteria, a dysplastic marrow 
presents with dysplasia in at least 10% of cells derived from a single myeloid lineage.32  
Myelodysplasia carries a 30% risk of developing Acute Myeloid Leukaemia,19 defined by the 
clonal expansion (20%) of myeloblasts in the bone marrow or peripheral blood.20 AML can 
also arise de novo or follow prior chemotherapy or radiotherapy for a non-haematological 
disorder.53 Bone marrow failure in MDS and AML induces peripheral blood cytopenia(s)15 
defined by an insufficient production of erythrocytes, granulocytes and/or platelets 
increasing an individual’s susceptibility to anaemia, infection or to internal haemorrhaging, 
respectively.26  
Telomeres enable cells to distinguish their natural chromosome ends from double strand 
breaks (DSBs) in order to maintain genomic integrity and prevent premature senescence.190 
Telomeres retain this function by means of providing a specialised nucleoprotein ‘cap’ that 
prevents the chromosome terminus from initiating DNA repair pathways.258,401 A strong 
correlation between telomere length and cellular proliferative capacity has been 
documented164 with progressive telomere shortening associated with a concomitant 
reduction in a cell’s proliferative potential. However, previous studies have implicated that 
the shortest telomere within a distribution is vital for cell viability and chromosome 
stability209 and thus single short telomeres  generated by sporadic telomere rapid deletion 
(TRD) may induce premature cell cycle arrest or initiate cycles of Breakage-Fusion-Bridge 
(BFB) creating gross chromosomal rearrangements.255,319,351 
Haematopoietic CD34+ cells are telomerase competent; however they lose up to 33bp of 
telomere repeats per year.325,326 Several studies have shown that telomere length is 
significantly shorter in various myeloid disorders including the Myelodysplastic Syndromes 
(MDS) and Acute Myeloid Leukaemia (AML),336,342,346,347,349,350 Aplastic (AA)337,338 and 
 209 
 
Fanconi (FA) Anaemia402 and Chronic Myeloid Leukaemia (CML).339,340 Moreover, the 
physiological consequences of telomere shortening have been analysed in mTR-/- murine 
models in which late generation animals exhibit defects in highly proliferative tissues 
including the haematopoietic system.330 Telomere shortening is also associated with disease 
anticipation in Dyskeratosis Congenita (DC) in which the proliferative potential of 
haematopoietic stem cells is compromised with each generation due to insufficient 
telomerase activity.329 Such patients with DC show a 196-fold increase in AML 
progression.331 It has been speculated that telomere dysfunction may be in part accountable 
for disease progression and neoplastic transformation. Supporting this theory is the 
observation of numerous end-to-end fusions and signal free ends in epithelial cancers 
derived from late generation mTR-/-p53-/- mutant mice.322 In the presence of up-regulated 
telomerase activity, the frequency of end-to-end fusions is reduced212 so as to facilitate the 
outgrowth of a sub-clonal population.  
Owing to the heterogeneous clinical features and outcome of MDS and AML, prognostic 
scoring systems including the IPSS/IPSS-R43,44 and Hill’s Risk Score generated from data 
derived from the Medical Research Council (MRC) AML 10 and 12 trials are used to help 
predict patient outlook and facilitate in making therapeutic decisions. These prognostic 
systems are particularly informative when referring to high-risk individuals who are more 
likely to benefit from a bone marrow transplant in contrast to low-risk patients for whom 
supportive care or conventional treatment would be more appropriate.50,58,370 The IPSS 
calculates a risk score from cytogenetics, blast percentage and number of cytopenia(s) to 
predict overall survival and risk of AML transformation.43 In contrast, the Hill’s Risk score 
takes into account variable clinical parameters including age, presenting white blood cell 
(WBC) count, cytogenetics, AML type (de novo/ secondary) as well as the patient’s response 
status after the first cycle of induction chemotherapy (Complete Remission [CR]/Partial 
Remission [PR]/Resistant Disease [RD]). AML patients are subsequently categorised into 
subgroups based on their response to treatment and/or risk of relapse after the first cycle of 
induction chemotherapy. However, further refinement of the current prognostic scores 
would improve decisions in therapeutic intervention, particularly due to the heterogeneous 
outcomes of individual patients.18,25,103,104,367  
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High resolution methodology was utilised to analyse telomere length in MDS and AML. 
Single Telomere Length Analysis (STELA) is a long-range single molecule PCR approach that 
has the ability to amplify the double-stranded region of telomere repeats from specific 
chromosome ends.171 STELA has the ability to detect the full spectrum of telomere lengths 
and is able to identify critically short telomeres which have the potential to induce 
replicative senescence or initiate cycles of telomere fusion and breakage.255,304,351  In this 
study, telomere length was analysed using STELA at XpYp and 17p to determine the nature 
of telomere dynamics in a cohort of 80 MDS and 144 AML patients. Telomeric features 
specific to a single chromosome were identified with STELA including bimodal distributions, 
Telomere Rapid Deletion (TRD) events and Telomeric-Loss of Heterozygosity (Telomeric-
LOH); features that would not be readily detected or occult to other available assays such as 
Terminal Restriction Fragment (TRF) analysis, Quantitative-Fluorescence in situ Hybridisation 
(Q-FISH), Flow-FISH or Quantitative telomere-specific Polymerase Chain Reaction (Q-PCR). 
7.1 Telomere Length and Intra-Clonal Variation in MDS/ AML  
This study showed a strong correlation between the telomere length at XpYp and 17p within 
the MDS and AML cohorts. As previously reported,332-334 the current data showed a 
significant reduction in telomere length among MDS and AML patients when compared to 
aged-matched healthy individuals. However, this study as well as others,335,336 showed 
significantly shorter telomeres in AML when compared to MDS. It was also apparent that 
telomere length distributions were significantly more homogeneous in AML profiles 
suggestive of clonal expansion. This has been described in Chronic Lymphocytic Leukaemia 
(CLL) such that telomere shortening and homogenisation are concurrent with disease 
progression and severity.304 Heterogeneity of individual telomere length distributions could 
be identified on several STELA profiles amongst the patients analysed. Such variation could 
be characterised by differential maternal and paternal contributions in the zygote of 
patients heterozygous at the XpYp sub-telomeric region. However, it was conceivable that 
recombination at a specific telomere may be accountable for the dynamics at the 17p 
telomere in an MDS patient. This STELA profile was characterised with a small population of 
long telomeric molecules and a greater population of short telomeres, consequently 
generating a sub-clonal population.   
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7.2 Telomere Length and Age in MDS/ AML  
In the MDS cohort, telomere length conformed only weakly to the aging dogma with several 
patients showing extensive telomere attrition relative to the telomere length of healthy 
individuals of a comparative age. One extreme case was that of a patient who at the age of 
37 years presented with a telomere length profile equivalent to a healthy individual of over 
100 years. Furthermore, assuming haematopoietic cells lose 33bp each year,325,326 the 
current study revealed a 10-fold increase in the rate of telomere erosion in an MDS patient. 
This may reflect the stressful conditions that are endured by the haematopoietic system in 
an attempt to regain haematopoietic reconstitution. Accordingly, the fraction of 
proliferating LT-HSCs (Long-Term mitotic capacity-HSCs) has been demonstrated to increase 
significantly with age in vivo11 under conditions where haematological stress may be 
prevalent. Moreover, a transient phase of rapid telomere shortening has been observed 
following an allogeneic bone marrow transplant prior to stabilisation and haematopoietic 
reconstitution.327  
In contrast, telomere length increased with age in AML with significantly longer telomeres in 
patients >60 years in contrast to their younger counterparts (60 years). It is possible that 
this may reflect a bias towards the incidence of FAB (French-American-British) M1 cases in 
the elderly population. A large proportion of older AML cases present with poorly 
differentiated subtypes (FAB: M0/M1) with the probability of these AML subtypes increasing 
with age.375 Telomerase activity is correlated with the FAB AML subgroups with activity 
following M1>M2>M5>M4376 with a significant increase in M1377 and significantly lower 
activity in M0 and M3 when compared to the other subgroups.403,404 Therefore, it might be 
speculated that the elevated incidence of longer telomeres with age might be associated 
with a bias towards M1 cases. Unfortunately the degree of differentiation was unavailable 
for this study and therefore this cannot be concluded. However, it might have been 
informative to compare telomere length and telomerase activity in AML cells showing 
differential levels of haematopoietic differentiation.      
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7.3 Clinical Parameters in MDS/ AML 
A diagnosis of a blood cytopenia can be made when the peripheral blood presents with a 
reduction in cell count derived from a specific lineage.24 The development of cytopenia in 
the early stages of MDS is the result of elevated apoptosis of differentiating cells in the 
marrow.22,139 This is in contrast to late-stage MDS and AML which show a reduction in 
apoptosis but a block in haematopoietic differentiation and myeloblast expansion.141 The 
International Prognostic Scoring System (IPSS) defines anaemia, neutropenia and 
thrombocytopenia by a haemoglobin level of under 10g/dl, an absolute neutrophil count 
(ANC) of less than 1800/l and a platelet count of less than 100,000/l.43 In this study, the 
prognosis of MDS patients presenting with multiple cytopenias was poor and showed 
significantly reduced overall survival when compared with individuals enduring uni-lineage 
cytopenia. 
It was speculated that telomere shortening in haematopoietic cells would arise under 
conditions of haematopoietic stress to account for the deficits in peripheral blood count, i.e. 
compensatory cell divisions of stem cell reserves. Moreover, telomere shortening in itself 
might contribute to the development of cytopenia by telomere-induced cell cycle arrest. In 
the current study, uni-variate analysis failed to show a relationship between telomere 
length and multiple cytopenia(s). This is in contrast to previous reports which have 
identified a significant reduction of telomere length in MDS patients with multiple 
cytopenias.332 It might have been informative to establish whether telomere length was 
associated with the intensity of haematopoietic insufficiency along a specific lineage, 
particularly since the IPSS score only weighs the number of cytopenia(s) present.43 
Interestingly, it has been observed in vitro that the telomere length of cord blood derived 
CD34+ cells is a determinant of erythroid proliferative potential. This is in contrast to other 
myeloid lineages of which no relationship between telomere length and the production of 
granulocytes, megakaryocytes or monocytes could be found.405 This raises speculation that 
telomere dynamics may differ in cells derived from patients presenting with different 
lineage cytopenia and therefore telomere loss may not be as extensive in such cases.  
Cytogenetics is an independent predictor of patient outcome for MDS and AML patients 
such that poor cytogenetic profiles are associated with an inferior outlook.106,368,370,371 
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Telomere shortening has been observed to accompany complex chromosomal 
rearrangements in a variety of haematological disorders, including acquired Aplastic 
Anaemia (AA),337,338 Chronic Myeloid Leukaemia (CML)340 and MDS/AML,333,334,342 however, 
in this study telomere length was not associated with cytogenetics in MDS. It is possible that 
telomere dysfunction and subsequent BFB cycles occurred early in a subset of patients 
presenting with an adverse karyotype. The preferential up-regulation of telomerase would 
stabilise telomere length and enable clonal expansion allowing for its subsequent detection 
using conventional G-banding. Supporting this theory was that loss up to the telomere was 
identified in an array-CGH profile derived from an MDS patient presenting with losses and 
gains. Telomere length was not associated with cytogenetic complexity in AML; however, 
the data set was limited for patients who presented with a favourable or adverse karyotype. 
Nonetheless, it may be speculated that telomere dysfunction also occurred early in AML 
cells which later present with an adverse karyotype at diagnosis.    
7.4 Telomere Rapid Deletion and Telomere Fusion 
Telomere length distributions in MDS and AML were superimposed by sporadic, atypical 
large-scale telomere rapid deletion events (TRDs).255,352 Such events may play a significant 
role in cytopenia development and karyotypic complexity found in a subset of MDS and AML 
patients since the shortest telomere in a cell has been implicated in inducing premature 
arrest and genetic instability.209 It is possible that TRDs are generated as a consequence of 
increased Reactive Oxygen Species (ROS) or replicative stress endured by the 
haematopoietic system under MDS/AML pathological conditions. In this study a greater 
frequency of TRD events were detected at the XpYp and 17p telomere in MDS when 
compared to AML with a significantly greater frequency at 17p in MDS. It should be taken 
into account that only the XpYp and 17p telomere were analysed over the course of this 
study and therefore the actual incidence of TRDs is unknown. The probability of this event 
happening within a single cell could be considerable since 92 telomeres are susceptible to 
this process and possibly contribute greatly to the development of these diseases.  
To examine the extent of telomere dysfunction in MDS and AML, telomere fusion events 
were quantified at the XpYp and 17p telomere using a PCR based fusion assay.255 The 
modest amount of telomere fusion detected within the MDS and AML cohort appeared 
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consistent with sporadic fusion arising as a consequence of telomere rapid deletion. MDS 
patients appeared to show a higher frequency of telomere fusion when compared to the 
AML cohort. Moreover, a significantly greater percentage of TRD events at 17p appeared to 
accompany a significantly greater number of fusion events involving the 17p telomere 
within MDS patients. It is possible this was associated with the targeted abrogation of p53 
and development of the pathological clone in MDS. The prevalence of p53 mutations has 
been extensively studied in MDS133-136 and patients presenting with the complete 
abrogation of p53 show a significantly shorter overall survival, increased propensity to 
leukaemic progression and inferior response to chemotherapy.135  
The incidence of TRD events might be a predisposing factor to AML transformation in MDS 
patients prior to telomerase up-regulation, particularly since telomerase activity is low in 
MDS cells332 and may be insufficient in preventing an accumulation of TRD events. This 
study as well as others328,332,342,347 has reported telomerase up-regulation in AML cells which 
could be accountable for the reduction in TRDs and fusion events found among the AML 
cohort. Notably, up-regulated telomerase activity would enable unlimited proliferation by 
maintaining telomere stability212,224 and reduce the frequency of DSBs by adding TTAGGG 
repeats de novo onto broken ends.186  
7.5 Pure TTAGGG and Telomere Dysfunction  
STELA profiles provide an overestimate of the pure telomeric length due to variable 
measurements of Telomere Variant Repeats (TVR). The TVR is a non-functional region192,255  
within the proximal end of the telomere composed of an interspersion pattern of TTAGGG 
and variant repeats including TCAGGG and TGAGGG,242-244 which in this study ranged from 0 
to 3kb. Individuals had been identified as having extreme telomere shortening following the 
correction for the TVR region. An AML patient presented with a mean STELA profile of 
2.20kb but an uninterrupted TTAGGG tract with a mean of only 0.16kb or 26.7 TTAGGG 
repeats. This is shorter than what has been previously identified in a late-stage CLL patient 
(0.36kb) and possibly the shortest known in the literature.304 Also, an MDS patient with a 
STELA profile of 2.92kb presented with the shortest pure TTAGGG tract of only 0.58kb 
amongst the MDS cohort. This patient presented with a poor cytogenetic risk score at 
diagnosis and progressed to AML. The pure telomeric length measured in these individuals 
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is shorter than what has been previously detected in fibroblast cells undergoing crisis in 
culture (<1kb).255 Therefore, correction for the TVR region might reflect the true extent of 
telomere loss in these cells and potentially identify patients at risk of disease progression.   
7.6 Mechanism of Telomere Fusion in MDS/ AML  
It appeared that the chromosomal fusion events arising from short dysfunctional telomeres 
were processed in a manner reminiscent of Ku-independent Alternative Non-homologous 
end joining (A-NHEJ). Chromosomal loss adjacent to the fusion junction characterised by 
perfect overlapping homology has been observed to accompany A-NHEJ. Yeast and hamster 
cell lines deficient in rad52280and Ku80/Xrcc4,298 respectively have been observed to utilise 
this approach in double strand break repair. Moreover, its involvement has been detected in 
the production of telomere fusion products in human cells undergoing crisis in vitro255 and 
also within human leukaemic cells.304 A-NHEJ has been proposed to utilise Poly (ADP-ribose) 
Polymerase I [PARP-1] along with the DNA ligase III/ XRCC1 complex.392 Whereas the DNA 
ligase III/XRCC1 complex has been previously implicated in Base Excision Repair/Single 
Strand Break Repair (BER/SSBR); PARP-1 has been suggested in promoting the synapsis and 
ligation of double stand breaks following its activation by single stranded DNA.308  
Increased A-NHEJ activity, accompanied by elevated levels of DNA ligase III has been 
observed in BCR-ABL+ Chronic Myeloid Leukaemia (CML) cells.406 Notably, DSBs were 
repaired using regions of microhomology and characterised with a high frequency of 
deletions adjacent to the junction sites. Aberrant NHEJ components have also been 
detected in MDS and AML cells. The expression levels of major Classical-NHEJ (C-NHEJ) 
factors including DNA-PKcs, Ligase IV and Xrcc4 have been noted to decrease in 
NUP98/HOXD13 transgenic mice (a mouse model displaying phenotypical features of 
MDS)407 and in de novo MDS patients in which Ligase IV expression was negatively 
correlated with karyotypic complexity.408 The FLT3/ITD mutation, detected in AML patients 
has been observed to accompany a reduction of Ku in conjunction with an increase in DNA 
ligase III both in vitro and in vivo.409 Furthermore, DSB repair utilised sites of microhomology 
which also accompanied deletions adjacent to the junction point, of which were both 
reduced in the presence of a FLT3 inhibitor.409   
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It may be speculated that aberrant expression of C-NHEJ factors may also favour the 
induction of A-NHEJ in the fusion between dysfunctional telomeres. Notably, the current 
data illustrated that telomere fusion partners aligned at short patches of 100% homology 
which varied in length between 2 to 33nts (mean 8.3nts). It was also apparent that adjacent 
telomeric or sub-telomeric deletions occurred at one or both of the participating telomeres. 
Sub-telomeric deletion near the limit of the fusion assay was apparent in several cases. 
Thus, it may be postulated that telomeric loss may extend beyond the proximal limit of the 
assay for which was 1655bp and 3058bp at the XpYp and 17p telomere, respectively. Sub-
telomeric regions have demonstrated marked sensitivity to DNA double-strand breakage 
under drug-induced replicative stress221 such that it has been proposed that they may 
represent fragile sites in which fork stalling would result in DSB formation.221 Additionally, 
the ratio of C-NHEJ to other processes of DNA repair has been observed to decrease 
progressively towards telomeric loci whereby the joining of I-SceI endonucleolytic induced 
DSBs involves extensive resection up to 9kb near telomeric regions in haploid yeast 
strains.410 Similarly, large deletions of sub-telomeric DNA up to 30kb have been identified in 
the joining of DSBs in mouse embryonic stem cells.411 In keeping with the current study, 50% 
of cytogenetically normal AML cases have been identified with cryptic sub-telomeric 
aberrations that include deletions and gains which can encompass up to 600kb.412 
7.7 Complex Telomeric Fusion Events 
Sequencing revealed the existence of complex fusion events involving insertions of non-
telomeric genomic loci. Insertions could be identified as 17q23, 21q11, 5q33 and 19q13 
whereby 17q23 and 19q13 correspond to the common fragile sites FRA17B and FRA19A, 
respectively. Chromosomal translocations involving 21q11 have been identified in de novo 
MDS and AML413,414 suggesting the localisation of candidate genes involved in disease 
pathogenesis. Recurrent breakpoints mapped to 19q13 and 21q11 have been observed in de 
novo erythroid leukaemia (AML-M6) that present with complex karyotypes.415 Common 
breakpoints at the chromosomal region 19q13 have been previously observed in various 
solid tumours including pancreatic and glioblastoma.416 Notably, this region has been 
described to harbour candidate tumour suppressor genes including MLL2417 and AKT2.418 
Translocations involving 17q23 has been defined as a prognostic marker whereby more 
aggressive forms of AML have been described in patients displaying this abnormality. The 
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MSi2 (Musashi-2) gene has been mapped to 17q23419 in which its expression level in human 
myeloid leukaemia is directly correlated with overall survival.420 Overexpression of MSi2 
increases haematopoietic cell cycle progression in mouse models, whilst its depletion leads 
to decreased proliferation and increased apoptosis.420 Finally, 5q deletions are commonly 
detected in MDS and AML in which critical minimally deleted regions (CDR) have been 
identified between 5q32 to 5q33421,422 and at 5q31,423,424 associated with the indolent 5q- 
syndrome and aggressive forms of MDS/AML, respectively. Despite the failure in detecting a 
clonality of the telomeric fusion involving the 5q33 insertion; it is possible that this event 
may contribute in the development of del(5q).   
7.8 Telomere Length and Clonal Expansion 
Consistent with previous observations,336 it appeared that telomere length was decreasing 
with elevated marrow blast count in MDS. The MDSs may be considered as a chronic phase 
in pathological development in which telomerase is insufficient332 in preventing prolonged 
telomere loss with ongoing disease.335 Progressive telomere shortening has been associated 
with a decrease in apoptosis of MDS CD34+ cells.346 Accordingly, the DNA Damage Response 
(DDR) that is commonly present at pre-invasive stages of major human cancers becomes 
abrogated with development343 enabling ongoing entry into the cell cycle and prolonging 
telomere attrition. Disease progression in MDS is associated with a reduction or inactivation 
of such components involved in the DDR, including the p15INK4Bcyclin dependent kinase 
inhibitor,124,125 Chk1,122 p53135,136,117,114 and ATM.344 However, it should be pointed out that 
such results were based on percentage subgroups, i.e. <5% and 5 to 20% and thus in a 
subsequent study, microscopic analysis of bone marrow samples and blast quantification 
should be ensued so as to make a direct correlation between such parameters.  
Marrow blast and presenting white blood cell (WBC) count failed to show an association 
with telomere length in AML cells. This study, as well as others332,335,342,347 has shown an 
increase in telomerase activity in AML and therefore it is conceivable that a heterogeneous 
level of telomerase activity is in part accountable for this observation. However, in the 
presence of up-regulated telomerase and hTERT expression;342,347,376,377 the regulation of 
telomerase access to the telomere may be deregulated in AML cells. This has been 
previously suggested in a study that identified elevated TRF1 with hTERT expression in acute 
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leukaemias in which the authors suspected that TRF1 may be deregulated in a subset of 
patients.425 If this is true, telomere length would not be controlled and extensive telomere 
elongation or shortening may ensue.207 Moreover, shelterin genes, i.e. PTOP, RAP1 and TRF2 
as well as non-shelterin genes, i.e. Ku70 and Pinx1 have also been shown to be deregulated 
in acute leukaemias (AML and ALL) when compared to normal BMMNCs.404 Therefore, the 
regulation of telomerase access to the telomere may be deregulated resulting in 
fluctuations in telomere length control within individual cases. 
7.9 The IPSS Scoring System for MDS prognosis and Telomere Length  
The International Prognostic Scoring System (IPSS) accommodates specific variables 
including blast cell percentage, presenting cytopenia(s) and cytogenetic abnormalities to 
stratify patients into low, Intermediate-1 (Int-1), Intermediate-2 (Int-2) or high in order to 
predict overall survival, risk of AML evolution and facilitate in therapeutic decisions.43 In 
contrast to previous cases,332,346 telomere length failed to show increased attrition with 
greater IPSS scores, however because the risk of disease development is based on 
categorical features and not on the actual depth of cytopenia severity, presenting blast 
count or specific karyotypic abnormality it may be speculated that variations of these 
features result in fluctuations in telomere length and contribute to the absence of an 
association between telomere length and IPSS score. It is also possible that telomerase is 
up-regulated in numerous patients removing the prognostic signature of telomere length, 
particularly within higher risk groups. This may also explain, in part the heterogeneity of 
telomere length that was detected amongst the higher risk scores.  
It is possible that telomere length may be associated with increased risk in the more recent 
revised-IPSS (IPSS-R)44 which incorporates novel chromosomal abnormalities, refines bone 
marrow blast percentage and analyses the depth of blood cell cytopenia by using relative 
cut-off points. In the IPSS-R, prognostic outlook is differentiated into 5 prognostic 
subgroups: Very Low, Low, Intermediate, High and Very High. However, as in the IPSS, 
higher risk groups may also present with up-regulated telomerase activity removing the 
prognostic signature of telomere length.   
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7.10 Telomere Length and Molecular Mutations in AML 
The identification of specific molecular mutations can influence patient outcome so as to 
further refine patient prognosis, particularly in patients who present with a normal 
cytogenetic profile. Molecular markers that are commonly presented in AML patients are 
mutations involving the FLT3 (FMS-like tyrosine kinase 3)374 receptor and NPM1 
(nucleophosmin).70,71  
FLT3 is expressed by cells found in the haematopoietic stem cell compartment and early 
committed progenitors59,60 and has been proposed to play a role in cell proliferation 
survival, and differentiation.59,60,62 Mutations either in the form of an internal tandem 
duplication (ITD) of the juxtamembrane domain or point mutations within the tyrosine 
kinase domain (TKD) result in the constitutive activation of the receptor.61 The prognosis of 
patients harbouring the FLT3/ITD is poor with individuals exhibiting high rates of relapse and 
inferior overall survival (OS)64,65 however, the prognostic impact of FLT3/TKD remains 
controversial.60,66-68 Telomere shortening has been identified in patients who present with 
the FLT3/ITD mutation347,350 and this study also showed a tendency for telomere shortening 
in FLT3/ITD+ patients. In contrast, patients presenting with the TKD mutation had 
significantly longer telomeres when compared to those who did not. Interestingly, several 
studies378,379 have shown a weaker proliferative effect induced by the FLT3/TKD when 
compared to patients with the FLT3/ITD. The clonogenic ability of TKD expressing cells in 
vitro has been observed to be significantly less when compared to ITD+ cells.380 Accordingly, 
the ITD but not TKD mutation (or wild-type FLT3) has been shown to induce robust 
activation of the STAT5 signalling pathway in vitro.380,381 STAT5 (signal transducer and 
activator of transcription-5) is one of the principal pathways that regulates gene expression 
in response to FLT3.382 Downstream targets of STAT5 include Pim-1 and CCND3 which both 
play a role in cell cycle progression and are increased in FLT3/ITD+ cells.383 Thus, up-
regulation of the STAT5 pathway may be in part accountable for the tendency towards 
shorter telomeric length in patients presenting with the ITD mutation and its activation may 
be associated with the observed differences of telomere length in patients with the 
FLT3/ITD and FLT3/TKD mutation. Surprisingly, the difference in telomere length between 
the ITD+ and ITD- cohorts did not reach statistical significance; therefore it is tempting to 
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speculate that telomerase activity is preferentially up-regulated in ITD+ AML cells masking 
the increased proliferation associated with this genetic mutation.  
The current data illustrated significantly longer telomeres in AML patients carrying the 
FLT3/TKD mutation irrespective of the FLT3/ITD status. Regression analysis revealed a weak 
positive correlation between age and telomere length within the AML cohort and patients 
presenting with the TKD mutation were significantly older when compared to those who 
were negative for FLT3/TKD. Interestingly, different age profiles for molecular markers have 
been described such that the FLT3/ITD occurs at a constant frequency irrespective of age384 
and the incidence of FLT3/TKD increases by 29.4 fold from 21 to 70 years.56 Therefore, it is 
possible that in the current study, the prevalence of FLT3/TKD in the older AML population 
is also accountable for the finding of longer telomeres in patients over 60 years of age. 
The NPM1 protein functions as a molecular chaperone that shuttles between the nucleus 
and cytoplasm.69 It is predominately nucleolar but 30% of AML cases bear the cytoplasmic 
NPM1 (termed: NPMc+).70,71 Mutations in NPM1 are associated with a more favourable 
outcome when compared to patients presenting with wild-type NPM1.72 MicroRNA 
expression profiling of NPM1+ and NPM1wild-type AML cells has identified differential 
expression patterns of microRNAs including the up-regulation of let-7 in NPM1+.72 The 
overexpression of let-7 has been observed to inhibit cell proliferation in human lung cancer 
cell lines.385 Notably, it has been documented to interact with MYC and CDC25A386 
regulating cell proliferation and cell cycle progression, respectively. Although not significant, 
AML cells presenting with the ITD-NPM1+ had longer telomeres when analysed among ITD 
and NPM1 subgroups. It is possible that the tendency for longer telomeres within this 
subgroup may attribute to the tumour suppressor effect, i.e. let-7 on inhibiting cellular 
proliferation. The reason behind the apparent elevated telomere attrition of the median 
length is inconclusive in patients presenting with both the ITD+ and NPM1+ mutations. This is 
inconsistent with the literature which has suggested a role of NPM1+ to oppose the FLT3/ITD 
dependent activation of STAT5387 however; it may be speculated that cells negative for the 
NPM1 mutation and positive for the FLT3/ITD have already undergone an extensive period 
of proliferation and have preferentially up-regulated telomerase in order to maintain 
telomere stability. Thus, telomerase activity may, in part be accountable for longer 
telomeres within this subgroup.  
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7.11 Telomere length and Survival Parameters   
When telomere length was adjusted for age, MDS patients within the normal range failed to 
present with a better outcome, however a biphasic distribution was identified within the 
superior curve suggesting that a subset of individuals presenting with a telomere length 
within the normal age-adjusted range may have a more favourable prognosis. Further 
analysis revealed that the mortality rate within favourable prognostic subgroups including 
good-risk cytogenetics, uni-lineage cytopenia and low-risk IPSS scores was influenced by 
telomere length. Notably, patients who presented with shorter age-adjusted telomere 
length also showed a reduction in overall survival. Its prognostic potential was lost within 
more unfavourable prognostic categories. Moreover, when analysed by means of recursive 
partitioning, telomere length at diagnosis significantly influenced the overall survival of MDS 
patients irrespective of conventional markers.  
These observations may have potential in refining patient outlook and facilitate in making 
therapeutic decisions, however these data are inconclusive because individual therapy was 
unknown for patients in the MDS cohort. Notably, overall survival can be greatly influenced 
depending on individual therapy. Further analysis on a cohort of patients who are 
undergoing uniform treatment would substantially improve these data and potentially show 
an association between diagnostic telomere length and prognosis in MDS patients.  
Consistent with the literature,347,350 telomere length did not influence the number of 
disease-free days or overall survival of AML patients who had received intensive 
chemotherapy. Although the rate of entry into 1st remission was unavailable for this study it 
is also possible that telomere length does not influence this parameter since the results 
from both disease-free survival and overall survival were consistent. It may be speculated 
that telomerase up-regulation in AML cells provides telomere length stability and removes 
the prognostic signature of telomere length.  
Telomere length at diagnosis appeared to be shorter in AML patients who failed to achieve 
complete remission after the 1st cycle of intensive chemotherapy. However, this difference 
was not significant and the data set was limited. Accordingly, only a very small number of 
cases were resistant to therapy rendering this analysis inconclusive. 
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7.12 In Conclusion 
The current data showed a significant reduction in telomere length among MDS and AML 
patients when compared to aged-matched healthy individuals with significantly shorter and 
homogeneous telomere distributions detected amongst the AML cohort. In this study, 
telomere length conformed only weakly to the aging dogma in the MDS cohort with several 
individuals showing extensive telomere loss. One such patient presented with a 10-fold 
increase in the rate of telomere shortening at follow-up. In contrast, telomere length 
appeared to increase with age in patients with AML.  
Telomere length appeared to decline with increasing bone marrow blasts in the MDS cohort 
however, the marrow blast percentage and presenting white blood cell (WBC) count failed 
to show an association with telomere length in AML cells. With respect to other clinical 
parameters, telomere length was not associated with the number of cytopenia in MDS or 
cytogenetic complexity in MDS/AML. Throughout the study, large-scale telomere rapid 
deletion events (TRDs) were detected among STELA profiles. Such telomeres may play a role 
in the development of cytopenia severity and in the karyotypic complexity that is later 
detected in MDS and AML cells using low resolution conventional G-banding. Of note, 
telomere-telomere fusion events which were processed in a manner reminiscent of Ku-
independent Alternative Non-Homologous end joining (A-NHEJ) were detected within the 
MDS cohort and to a lesser degree in the AML cohort. A reduction in telomere fusion events 
in AML possibly reflects the up-regulation of telomerase activity that was detected in AML 
cells.  
Elevated telomere shortening in patients with MDS may be a prognostic indicator with 
shorter telomeres associated with an inferior outcome, however because individual therapy 
was unknown this finding is inconclusive. In contrast, telomere length did not influence the 
number of disease-free days or overall survival of AML patients who received intensive 
chemotherapy.  
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7.13 Future Work and Implications 
This study was limited in particular areas and therefore in order to improve these data 
specific questions should be answered.  
One such weakness included blast quantification in the MDS cohort. In a subsequent study 
the correlation between telomere length and presenting blast count should be determined, 
particularly since this analysis could only be carried out as categorical data composed of 
wide intervals, i.e. 5 to 20%. The morphological features of a myeloblast have been 
described by the International Working Group on Morphology of MDS426 and as such are 
used to detect and quantify the percentage of myeloblasts in the marrow. Blast count as a 
percentage of all marrow nucleated cells can be determined from a 500-cell differential 
performed on marrow aspirate smears analysed by light microscope. STELA will be used to 
determine marrow telomere length of individual patients and a correlation between the 
presenting marrow blast percentages will be performed so as to establish an association 
between such parameters.  
In the current study, telomere length appeared to increase with age in the AML cohort. 
Although the reason for this is unknown it was speculated that it might share some 
association with the subtype of AML. AML-M1 is frequently identified in older patients 
which has also been associated with significantly higher telomerase activity when compared 
to the remaining maturation subgroups.375-377 In a subsequent study, AML blasts will be 
subtyped by immunohistochemical investigation using a panel of antibodies directed against 
specific cellular antigens, e.g. MPO, CD61 or Glycophorin A. Of the maturation subgroups 
available for analysis, TRAP will be utilised to quantify telomerase activity and telomere 
length will be measured by means of STELA so as to determine the relationship between 
marrow telomere length and telomerase activity within such subgroups. This analysis might 
add to the apparent finding of longer telomeres in older patients with AML if telomere 
length also increases with age in a subsequent study. 
Telomere length was not associated with the number of cytopenia(s) in the current study; 
however the depth of cytopenia was unavailable for patients within the MDS cohort and 
therefore this analysis is inconclusive. In a follow-up study, marrow telomere length should 
be correlated with the intensity of haematopoietic insufficiency along a specific lineage in 
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order to determine whether an association exists between such parameters. Telomere 
length can be measured using STELA and peripheral blood cell counts can be analysed by 
means of automated cell counting.   
Telomere length was significantly longer in patients with secondary AML when compared to 
their de novo counterparts. In order to determine whether this finding was associated with 
greater telomerase activity in secondary AML cells, TRAP will be carried out in a subsequent 
study to elucidate this theory. Additionally, telomerase activity should be measured in 
FLT3/ITD+ cases and compared with patients who do not present with the FLT3/ITD 
mutation, particularly since the difference in telomere length between such subgroups was 
not statistically significant in this study. The FLT3/ITD mutation can be characterised by gene 
mutational screening as previously described379 and then TRAP and STELA can be utilised to 
quantify telomerase activity and telomere length, respectively between patients presenting 
with the ITD and patients who do not.  
In this retrospective study, short telomeres were associated with significantly shorter overall 
survival of MDS patients. In particular, age-adjusted telomere length could refine patients 
with favourable prognostic markers and distinguish low-risk individuals with a poorer 
outlook. In a prospective study telomere length should be analysed on patients receiving 
uniform treatment in a more robust cohort in order to validate the prognostic significance 
of telomere length. Accordingly, telomere length (including patient work-up, i.e. marrow 
and peripheral blast counts, complete blood count (CBC) and cytogenetics) should be 
analysed initially at diagnosis and at regular intervals throughout the course of the disease 
in a homogeneous cohort of low-risk patients in order to establish whether telomere 
dynamics correlate with disease progression. 
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Appendix: 1  
 
Cluster analysis of the 6kb region succeeding the published terminus of 6q:  
 
6qPredictedSubTel      ATCTAAACTGAGTCCAGCTGGCTAACTCTAAATATATGTGTATTTTTTCAGCATAAAAAA 
10qSubTel              ATCTAAACTGAGTCCAGCTGGCTAACTCTAAATATATGTGTATTTTTTCAGCATAAAAAA 
22qSubTel              --CTAAACTGAGTCCAGCTGGCTAACTCTAAATATATGTGTATCTTTTCAGCATAAAAAA 
1pSubTel               ------------------------------------------------------------ 
5qSubTel               ------------------------------------------------------------ 
17qSubTel              ------------------------------------------------------------ 
4qSubTel               ------------------------------------------------------------ 
19qSubTel              ------------------------------------------------------------ 
21qSubTel              ------------------------------------------------------------ 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      ATAATGTTTTTCATAAGAATGACAACTTAATTAGAATCAAATCTATAAGCTTTAAGATTT 
10qSubTel              ATAATGTTTTTCATAAGAATGACAACTTAATTAGAATCAAATCTATAAGCTTTAAGATTT 
22qSubTel              ATAATGTTTTTCATAAGAATGACAACTTAATTAGAATCAAATCTATAAGCTTTAAGATTT 
1pSubTel               ------------------------------------------------------------ 
5qSubTel               ------------------------------------------------------------ 
17qSubTel              ------------------------------------------------------------ 
4qSubTel               ------------------------------------------------------------ 
19qSubTel              ------------------------------------------------------------ 
21qSubTel              ------------------------------------------------------------ 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      TACATTTCTAGTAAGTATAATATTAGCTTATTTGACTAGAACTCAAGCAGAATAGGAATT 
10qSubTel              TACATTTCTAGTAAGTATAATATTAGCTTATTTGACTAGAACTCAAGCAGAATAGGAATT 
22qSubTel              TACGTTTCTAGTAAGTATAATATTAGCTTATTTGACTAGAACTCAAGCAGAATAGGAATT 
1pSubTel               ------------------------------------------------------------ 
5qSubTel               ------------------------------------------------------------ 
17qSubTel              ------------------------------------------------------------ 
4qSubTel               ------------------------------------------------------------ 
19qSubTel              ------------------------------------------------------------ 
21qSubTel              ------------------------------------------------------------ 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      TATGCTTGTTTTATATTCAATAATGATAATTTTGAAGATATAGTTGTTTTATTACACCAA 
10qSubTel              TATGCTTGTTTTATATTCAATAATGATAATTTTGAAGATATAGTTGTTTTATTACACCAA 
22qSubTel              TATGCTTGTTTTATATTCAATAATGATAATTTTGAAGATATAGTTGTTTTATTACACCAA 
1pSubTel               ------------------------------------------------------------ 
5qSubTel               ------------------------------------------------------------ 
17qSubTel              ------------------------------------------------------------ 
4qSubTel               ------------------------------------------------------------ 
19qSubTel              ------------------------------------------------------------ 
21qSubTel              ------------------------------------------------------------ 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      AAATACTATATTAATCTTATTTAACTAAGTTTTATCCAAATCATGTTAACTTAAGAAACA 
10qSubTel              AAATACTATATTAATCTTATTTAACTAAGTTTTATCCAAATCATGTTAACTTAAGAAACA 
22qSubTel              AAATACTATATTAATCTTATTTAACTAAGTTTTATCCAAATCATGTTAACTTAAGAAACA 
1pSubTel               ------------------------------------------------------------ 
5qSubTel               ------------------------------------------------------------ 
17qSubTel              ------------------------------------------------------------ 
4qSubTel               ------------------------------------------------------------ 
19qSubTel              ------------------------------------------------------------ 
21qSubTel              ------------------------------------------------------------ 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      TTTGATCAGTTCCTATATTTCTAGGAGTTTGGTGAATATTTATTTATAAATGCTTATTTT 
10qSubTel              TTTGATCAGTTCCTATATTTCTAGGAGTTTGGTGAATATTTATTTATAAATGCTTATTTT 
22qSubTel              TTTGATCAGTTCCTATATTTCTAGGAGTTTGGTGAATATTTATTTATAAATGCTTATTTT 
1pSubTel               ------------------------------------------------------------ 
5qSubTel               ------------------------------------------------------------ 
17qSubTel              ------------------------------------------------------------ 
4qSubTel               ------------------------------------------------------------ 
19qSubTel              ------------------------------------------------------------ 
21qSubTel              ------------------------------------------------------------ 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      TTTCCAAGCCAAGTTAGAATAGAGCACTTTTAGAGGATTTCATAAATGAATTTTGCAATG 
10qSubTel              TTTCCAAGCCAAGTTAGAATAGAGCACTTTTAGAGGATTTCATAAATGAATTTTGCAATG 
22qSubTel              TTTCCAAGCCAAGTTAGAATAGAGCACTTTTAGAGGATTTCATAAATGAATTTTGCAATG 
1pSubTel               ------------------------------------------------------------ 
5qSubTel               ------------------------------------------------------------ 
17qSubTel              ------------------------------------------------------------ 
4qSubTel               ------------------------------------------------------------ 
19qSubTel              ------------------------------------------------------------ 
21qSubTel              ------------------------------------------------------------ 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      CTCTCTGGAGTTAAGAAAATATCACATATACATAACATACATTAATAGATATACAAACAC 
10qSubTel              CTCTCTGGAGTTAAGAAAATATCACATATACATAACATACATTAATAGATATACAAACAC 
22qSubTel              CTCTCTGGAGTTAAGAAAATATCACATATACATAACATACATTAATAGATACACAAACAC 
1pSubTel               ------------------------------------------------------------ 
5qSubTel               ------------------------------------------------------------ 
17qSubTel              ------------------------------------------------------------ 
4qSubTel               ------------------------------------------------------------ 
19qSubTel              ------------------------------------------------------------ 
21qSubTel              ------------------------------------------------------------ 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      AAATAGAGATTTCATAGCTTTCATCCTGAAATTTCAGCCTTGAATCAGGCATAAATATTC 
10qSubTel              AAATAGAGATTTCATAGCTTTCATCCTGAAATTTCAGCCATGAATCAGGCATAAATATTC 
22qSubTel              AAATAGAGATTTCATAGCTTTCATCCTGAAATTTCAGCCATGAATCAGGCATAAATATTC 
1pSubTel               ------------------------------ATTTCAGCCATGAATCAGGCATAAATATTC 
5qSubTel               ------------------------------ATTTCAGCCTTGAATCAGGCATAAATATTC 
17qSubTel              ------------------------------ATTTCAGCCATGAATCAGGCATAAATATTC 
4qSubTel               ------------------------------------------------------------ 
19qSubTel              ------------------------------------------------------------ 
21qSubTel              ------------------------------------------------------------ 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      TGATGGTTAATTTCAGACATCTACTTGATCCGACTGAGAGACACACATAGCTGGTCAAAC 
10qSubTel              TGATGGTTAATTTCAGACATCTACTTGATCCGATTGAGAGACACACATAGCTGGTCAAAC 
22qSubTel              TGATGGTTAATTTCAGACATCTACTTGATCGGATTGAGAGACACGCATAGCTGGTCAAAC 
1pSubTel               TGACGGTTAATTGTAGACATCTACTTGACTGGATTAAGAGACACACATAGCTGGTCAAAC 
5qSubTel               TGATGGTTAATTTCAGACATCTACTTGATCCGACTGAGAGACACACATAGCTGGTCAAAC 
17qSubTel              TGT-GGTTAATTTTAGACATCTACTTGAGTGGATTGAGAGACACACATAGCTGGTCAAAC 
4qSubTel               ------------------------------------------------------------ 
19qSubTel              ------------------------------------------------------------ 
21qSubTel              ------------------------------------------------------------ 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      ACGATTTCAGCCATGAATCAGGCATAAATATTCTGACGGTTAATTGTAGACATCTACTTG 
10qSubTel              ACGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTGTAGACATCTACTTG 
22qSubTel              ACGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTAGACATCTACTTG 
1pSubTel               AAGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTGTAGACATCTACTTG 
5qSubTel               ACGATTTCAGCCATGAATCAGGCATAAATATTCTGACGGTTAATTGTAGACATCTACTTG 
17qSubTel              --AATTTCAGCCATGAATCAGGCATAAATATTCTGACGGTTAATTTTAGACATCTACTTG 
4qSubTel               ---ATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTTCAGATATCTACTTG 
19qSubTel              ------------------------------------------------------------ 
21qSubTel              ------------------------------------------------------------ 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      ACTGGATTAAGAGACACACATAGCTGGTCAAACAAGATTTCAGCCATGAATCAGGCATAA 
10qSubTel              ACTGGATTAAGAGACACACATAGCTGGTCAAACAAGATTTCAGCCATGAATCAGGCATAA 
22qSubTel              ACTGGATTAAGAGACACACATAGCTGGTCAAACATGATTTCTGACATGAATCAGGCATAA 
1pSubTel               ACTGGATTAAGAGACACACATAGCTGGTCTAACACGATTTCAGCCATGAATCAGGCATAA 
5qSubTel               ACTGGATTAAGAGACACACATAGCTGGTCAAACAAGATTTCAGCCATGAATCAGGCATAA 
17qSubTel              AGTGGATTGAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAA 
4qSubTel               ATCCGATTGAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAA 
19qSubTel              ------------------------------------------------------------ 
21qSubTel              ------------------------------------------------------------ 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      ATATTCTGATGGTTAATTGTAGACATCTACTTGACTGGATTAAGAGACACACATAGCTGG 
10qSubTel              ATATTCTGATGGTTAATTGTAGACATCTACTTGACTGGATTAAGAGACACACATAGCTGG 
22qSubTel              ATATTCTGACGGTTAATTTTAGACATCTACTTGACTGGATTAAGAGACACACATAGCTGG 
1pSubTel               ATATTCTGATGGTTAACTTTAGGCATCTACTTGATTGGATTGAGAGACACACATAGCTGG 
5qSubTel               ATATTCTGATGGTTAATTGTAGACATCTACTTGACTGGATTAAGAGACACACATAGCTGG 
17qSubTel              ATATTCTGACGGTTAATTTTAGACATCAACTTGACTGGATTAAGGGACACACATAGCTGG 
4qSubTel               ATATTCTGATGGTTAATTGTAGACATCTACTTGACTGGATTAAGAGACACACATAGCTGG 
19qSubTel              ------------------------------------------------------------ 
21qSubTel              ------------------------------------------------------------ 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      TCTAACACGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAACTTTAGACATC 
10qSubTel              TCTAACACGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAACTTTAGGCATC 
22qSubTel              TCAAACATGATTTCAGCCATGAATCAGCCATAAATATTCTGACGGTTAATTTTAGACATC 
1pSubTel               TCAAACACGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTGTAGACATC 
5qSubTel               TCTAACACGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAACTTTAGACATC 
17qSubTel              TCAAACACGATTTCAGCCATGAATCAGGCATAAATATTCTGACGGTTAATTGTAGACATC 
4qSubTel               TCAAACAAGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTGTAGACATC 
19qSubTel              ---------ATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTTCAGACATC 
21qSubTel              ---------ATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTTCAGACATC 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      TACTTGATTGGATTGAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAG 
10qSubTel              TACTTGATTGGATTGAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAG 
22qSubTel              TACTTGATCGGATTGAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAG 
1pSubTel               TACTTGACTGGATTGAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAG 
5qSubTel               TACTTGATTGGATTGAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAG 
17qSubTel              TACTTGACTGGATTGAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAG 
4qSubTel               TACTTGACTGGATTAAGAGACACACATAGCTGGTCTAACACGATTTCAGCCATGAATCAG 
19qSubTel              TACTTGATCGGATTGAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAG 
21qSubTel              TACTTGATCGGATTGAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAG 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      GCATAAATATTCTGATGGTTAATTGTAGACATCTACTTGACTGGATTGAGAGACACACAT 
10qSubTel              -CATAAATATTCTGATGGTTAATTGTAGACATCTACTTGACTGGATTGAGAGACACACAT 
22qSubTel              GCATAAATATTCTGATGGTTAATTTTAGACATCTACTTGAGTGGATTGAGAGACACACAT 
1pSubTel               GCATAAATATTCTGATGGTTAATTTTAGACATCTACTTGACTGGATTAAGGGACACACAC 
5qSubTel               GCATAAATATTCTGATGGTTAATTGTAGACATCTACTTGACTGGATTGAGAGACACACAT 
17qSubTel              GCATAAATATTCTGATGGTTAATTGTAGACATCTACTTGACTGGATTGAGAGACACACAT 
4qSubTel               GCATAAATATTCTGATGGTTAACTTTAGGCATCTACTTGATTGGATTGAGAGACACACAT 
19qSubTel              GCATAAATATTCTGATGGTTAATTTTAGACATCTACTTGAGTGGATTAAGAGACACACAT 
21qSubTel              GCATAAATATTCTGATGGTTAATTTTAGACATCTACTTGACTGGATTAAGAGACACACAT 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      AGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTA 
10qSubTel              AGCTGGCCAAACACGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTA 
22qSubTel              AGCTGGTCAAACACAATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTA 
1pSubTel               AGCTGGTCAAACACAATTTCAGCCATGAATCAGGCATAAATATTCTGACAGTTAATTTTA 
5qSubTel               AGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTA 
17qSubTel              AGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATATTCTGACGGTTAATTTTA 
4qSubTel               AGCTGGTCAAACACGATTTCAGCCATGAAGCAGGCATAAATATTCTGATGGTTAATTGTA 
19qSubTel              AGCTGGTCAAACATGATTTCAGCCATGAATCAGCCATAAATATTCTGATGGTTAATTTTA 
21qSubTel              AGCTGGTCAAACATGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTA 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      GACATCTACTTGACTGGATTAAGGGACACACACAGCTGGTCAAACACAATTTCAGCCATG 
10qSubTel              GACATCTACTTGACTGGATTAAGGGACACACACAGCTGGTCAAACACAATTTCAGCCATG 
22qSubTel              GACATCTACTTGAGTGGATTGAGAGACACACATAGCTGGTCAAACA--ATTTCAGCCATG 
1pSubTel               GACATCTACTTGACTGGATTAAGAGACACACATAGCTGGTCAAACACGATTTCAGCCGTG 
5qSubTel               GACATCTACTTGACTGGATTAAGGGACACACACAGCTGGTCAAACACAATTTCAGCCATG 
17qSubTel              GACATCAACTTGACTGGATTAAGGGACACACATAGCTGGTCAAACACGATTTCAGCCATG 
4qSubTel               GACATCTACTTGACTGGATTAAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATG 
19qSubTel              GACATCTACTTGAGTGGATTAAGAGACACACATAGCTGGTCAAACACAATTTCAGCCATG 
21qSubTel              GATATCTACTTGAGTGGATTAAGAGACACACATAGCTGGTCAAACACAATTTCAGCCATG 
1qSubTel               ------------------TTAAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATG 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      AATCAGGCATAAATATTCTGACAGTTAATTTTAGACATCTACTTGACTGGATTAAGAGAC 
10qSubTel              AATCAGGCATAAATATTCTGACAGTTAATTTTAGACATCTACTTGACTGGATTAAGAGAC 
22qSubTel              AATCAGGCATAAATATTCTGACGGTTAATTTTAGACATCTACTTGAGTGGATTGAGAGAC 
1pSubTel               AAGCAGGCATAAATATTCTGATGGTTAATTGTAGACATCTACTTGACTGGATTGAGAGAC 
5qSubTel               AATCAGGCATAAATATTCTGACAGTTAATTTTAGACATCTACTTGACTGGATTAAGAGAC 
17qSubTel              AATCAGGCATAA-TATTCTGATGGTTAATTTTAGACATCTACTTGAGTGGATTGAGAGAC 
4qSubTel               AAGCAGGCATAAATATTCTGATGGTTAATTGTAGACATCTACTTGACTGGATTAAGAGAC 
19qSubTel              AATCAGGCATAAATATTCTGACGGTTAATTTTAGACATCTACTTGATCGGATTGAGAGAC 
21qSubTel              AATCAGGCATAAATATTCTGACGGTTAATTTTAGACATCTACTTGATCGGATTGAGAGAC 
1qSubTel               AATCAGGCATAAATATTCTGATGGTTAATTTTAGACATCTACTTGACTGGATTAAGAGAC 
2qSubTel               ------------------------------------------------------------ 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      ACACATAGCTGGTCAAACACGATTTCAGCCGTGAAGCAGGCATAAATATTCTGATGGTTA 
10qSubTel              ACACATAGCTGGTCAAACATGATTTCAGCCGTGAAGCAGGCATAAATATTCTGATGGTTA 
22qSubTel              ACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATATTCTGACGGTTA 
1pSubTel               ACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCGTAAATATTCTGATGGTTA 
5qSubTel               ACACATAGCTGGTCAAACACGATTTCAGCCGTGAAGCAGGCATAAATATTCTGATGGTTA 
17qSubTel              ACACATAGCTGGTCAAACATGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTA 
4qSubTel               ACACATAGCTGGTCAAACACAATTTCAGCCATGAATCAGGCGTAAATATTCTGATGGTTA 
19qSubTel              ACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATATTCTGACGGTTA 
21qSubTel              ACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTA 
1qSubTel               ACACATAGCTGGTCAAACATGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTA 
2qSubTel               --------------------AATTTCAGCCTTGAATCAGGCATAAATATTCTGATGGTTA 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      ATTGTAGACATCTACTTGACTGGATTGAGAGACACACATAGCTGGTCAAACACGATTTCA 
10qSubTel              ATTGTAGACATCTACTTGACTGGATTGAGAGACACACATAGCTGGTCAAACACAATTTCA 
22qSubTel              ATTTTAGACATCAACTTGACTGGATTAAGGGACACACATAGCTGGTCAAACACGATTTCA 
1pSubTel               ATTGTAGACATCTACTTGAGTGGATTGAGAGACACACATAGCTGGTCAAACACAATTTCA 
5qSubTel               ATTGTAGACATCTACTTGACTGGATTGAGAGACACACATAGCTGGTCAAACACGATTTCA 
17qSubTel              ATTTTAGGCATCTACTTGAGTGGATTGAGAGACACACATAGCTGGTCAAAC--AATTTCA 
4qSubTel               ATTGTAGACATCTACTTGAGTGGATTGAGAGACACACATAGCTGGTCAAACACGATTTCA 
19qSubTel              ATTTTAGACATCTACTTGAGTGGATTGAGAGACACACATAGCTGGTCAAACACAATTTCA 
21qSubTel              ATTTTAGACATCTACTTGAGTGGATTGAGAGACACACATAGCTGGTCAAACACAATTTCA 
1qSubTel               ATTTTAGACATCTACTTGAGTGGATTAAGAGACACACATAGCTGGTCAAACACGATTTCA 
2qSubTel               ATTTCAGACATCTACTTGATCCGATTGAGAGACACACATAGCTGGTCAAACACGATTTCA 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      GCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTAGACATCTACTTGAGTGGATTG 
10qSubTel              GCCATGAATCAGGCGTAAATATTCTGATGGTTAATTGTAGACATCTACTTGAGTGGATTG 
22qSubTel              GCCATGAATCAGGCATAAATATTCTGACGGTTAATCGTAGACGTCTACTTGACTGGATTG 
1pSubTel               GCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTAGACATGTACTTGACTGGATTA 
5qSubTel               GCCATGAATCAGGCGTAAATATTCTGATGGTTAATTGTAGACATCTACTTGAGTGGATTG 
17qSubTel              GCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTAGACATCTACTTGAGTGGATTG 
4qSubTel               GCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTAGACATGTACTTGACTGGATTA 
19qSubTel              GCCATGAATCAGGCATAAATATTCTGACGGTTAATTTTAGACATCTACTTGAGTGGATTG 
21qSubTel              GCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTAGACATCTACTTGAGTGGATTG 
1qSubTel               GCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTAGACATCTACTTGAGTGGATTA 
2qSubTel               GCCATGAATCAGGCATAAATATTCTGACGGTTAATTGTAGACATCTACTTGACTGGATTA 
19p'End'               ------------------------------------------------------------ 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      AGAGACACACATAGCTGGTCAAACACAATTTCAGCCATGAATCAGGCATAAATATTCTGA 
10qSubTel              AGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATATTCTGA 
22qSubTel              AGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATATTCTGA 
1pSubTel               AGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAAGCAGGCATAAATATTCTGA 
5qSubTel               AGAGACACACATAGCTGGTCAAACACAATTTCAGCCATGAATCAGGCATAAATATTCTGA 
17qSubTel              AGAGACACACATAGCTGGTCAAAC--AATTTCAGCCATGAATCAGGCATAAATATTCTGA 
4qSubTel               AGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAAGCAGGCATAAATATTCTGA 
19qSubTel              AGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATATTCTGA 
21qSubTel              AGAGACACACATAGCTGGTCAAAC--AATTTCAGCCATGAATCAGGCATAAATATTCTGA 
1qSubTel               AGAGACATACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATATTCTGA 
2qSubTel               AGAGACACACATAGCTGGTCAAACAAGATTTCAGCCATGAATCAGGCATAAATATTCTGA 
19p'End'               --------------------------AATTTCAGCCATGAATCAGGCATAAATATTCTGA 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      TGGTTAATTTTAGACATCTACTTGACTGGATTAAGAGACACACATAGCTGGTCAAACACG 
10qSubTel              TGGTTAATTTTAGACATGTACTTGACTGGATTAAGAGACACACATAGCTGGTCAAACACG 
22qSubTel              TGGTTAATCGTAGACATCTACTTAACTGGATTGAGAGACACACATAGCTGGTCAAACACG 
1pSubTel               TGGTTAATTGTAGACATCTACTTGACTGGATTAAGAGACACACATAGCTGGTCAAACACG 
5qSubTel               TGGTTAATTTTAGACATCTACTTGACTGGATTAAGAGACACACATAGCTGGTCAAACACG 
17qSubTel              CGGTTAATTTTAGACATCTACTTGAGTGGATTGAGAGACACACATAGCTGGTCAAACACG 
4qSubTel               TGGTTAATTGTAGACATCTACTTGACTGGATTAAGAGACACACATAGCTGGTCAAACACG 
19qSubTel              CGGTTAATTTTAGACATCTACTTGACTGGATTAAGAGACACACATAGCTGGTGAAACACG 
21qSubTel              CGGTTAATTTTAGACATCAACTTGACTGGATTAAGGGACACACATAGCTGGTCAAACACG 
1qSubTel               TGGTTAATTGTAGACATCTACTTGAGTGGATTAAGAGACACGCATAGCTGGTCAAACACG 
2qSubTel               TGGTTAATTGTAGACATCTACTTGACTGGATTAAGAGACACACATAGCTGGTCAAACACG 
19p'End'               TGGTTAATTTTAGACATCCACTTGATCGGATTAAGAGACACACATAGCTGGTCAAACACG 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      ATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTAGACATCTACTTGACT 
10qSubTel              ATTTCAGCCATGAAGCAGGCATAAATATTCTGATGGTTAATTGTAGACATCTACTTGACT 
22qSubTel              ATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATCGTAGACATCTACTTGACT 
1pSubTel               ATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAACTTTAGGCATCTACTTGATT 
5qSubTel               ATTTCAGCCATGAAGCAGGCATAAATATTCTGATGGTTAATTGTAGACATCTACTTGACT 
17qSubTel              ATTTCAGCCATGAATCAGGCATAAATATTCTGACGGTTAATTTTAGACATCAACTTGACT 
4qSubTel               ATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAACTTTAGGCATCTACTTGATT 
19qSubTel              ATTTCAGCCATGAATCAGGCATAAATATTCTGACGGTTAACTTTAGACATCTACTTGACT 
21qSubTel              ATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTGTAGACATCTACTTGACT 
1qSubTel               ATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTAGACATCTACTTGAGT 
2qSubTel               ATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAACTTTAGGCATCTACTTGATT 
19p'End'               ATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTAGACATCTACTTGACT 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      GGATTGAGAGACACACATAGCTGGTCAAACACAATTTCAGCCATGAATCAGGCATAAATA 
10qSubTel              GGATTAAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATA 
22qSubTel              GGATTGAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATA 
1pSubTel               GGATTGAGAGACACACATAGCTGATCAAACACAATTTCAGCCATGAATCAGGCATAAATA 
5qSubTel               GGATTAAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATA 
17qSubTel              GGATTAAGGGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATACATA 
4qSubTel               GGATTGAGAGACACACATAGCTGATCAAACACAATTTCAGCCATGAATCAGGCATAAATA 
19qSubTel              GGATTAAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATA 
21qSubTel              GGATTGAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATA 
1qSubTel               GGATTAAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATA 
2qSubTel               GGATTGAGAGACACACATAGCTGATCAAACACAATTTCAGCCATGAATCAGGCATAAATA 
19p'End'               GGATTGAGAGACACACACAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCATAAATA 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      TTCTGATGGTTAATTGTAGACATCTACTTGACTGGATTGAGAGACACACATAGCTGATCA 
10qSubTel              TTCTGATGGTTAACTTTAGGCATCTACTTGATTGGATTGAGAGACACACATAGCTGATCA 
22qSubTel              TTCTGATGGTTAATCGTAGACATCTACTTGACTGGATTGAGAGACACACATAGCTGGTCA 
1pSubTel               TTCTGACAGTTAATTTTAGACATCTACTTGAGTGGATTAAGAGACACACACAGCTGGTCA 
5qSubTel               TTCTGATGGTTAACTTTAGGCATCTACTTGATTGGATTGAGAGACACACATAGCTGATCA 
17qSubTel              TTCTGATGGTTAATTGTAGACATCTACTTGACTGGATTGAGAGACACACATAGCTGGTCA 
4qSubTel               TTCTGACGGTTAATTTTAGA---------------------------------------- 
19qSubTel              TTCTGACGGTTAACTTTAGACATCTACTTGATTGGATTGAGAGACACACATAGCTGGTCA 
21qSubTel              TTCTGATGGTTAATCGTAGACGTCTACTTGACTGGATTGAGAGACACACATAGCTGGTCA 
1qSubTel               TTCTGATGGTTAATTGTAGACATCTACTTGAGTGGATTAAGAGACACGCATAGCTGGTCA 
2qSubTel               TTCTGACAGT-------------------------------------------------- 
19p'End'               TTCTGATGGTTAATTTTAGACATCTACTTGATCGGATTA-AGGACACACACAGCTGGTCA 
8p'End'                ------------------------------------------------------------ 
13qSubTel              ------------------------------------------------------------ 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      AACACGATTTCAGCCATGAATCAGGCATAAATATTCTGACGGTTAATTTTAGACATCTAC 
10qSubTel              AACACAATTTCAGCCATGAATCAGGCATAAATATTCTGACGGTTAATTTTAGACATCTAC 
22qSubTel              AACACGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATCGTAGACATCTAC 
1pSubTel               AACA--ATTTCAGCCATGAATCAGGCATAAATATTCTGACAGTTAATTTTAGACATCTAC 
5qSubTel               AACACAATTTCAGCCATGAATCAGGCATAAATATTCT----------------------- 
17qSubTel              AACAGGATTTCAGCCATGAATCAGACATAAATATTCTGATGGTTAATTGTAGACGTCTAC 
4qSubTel               -----------------------------------------------------CATCTAC 
19qSubTel              AACACAATTTCAGCCATGAATCAGGCATAAATATTCTGACGGTTAATTTTAGACATCTAC 
21qSubTel              AACACGATTTCAGCCATGAATCAGGCATAAATATTCT----------------------- 
1qSubTel               AACACGATTTCAGCCATGAATCAGGCATAAATATTCTG---------------------- 
2qSubTel               ------------------------------------------------------------ 
19p'End'               AACACGATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTAGACATCTAC 
8p'End'                ------ATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTAGACATCTAC 
13qSubTel              ------ATTTCAGCCATGAATCAGGCATAAATATTCTGATGGTTAATTTTAGACATCTAC 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      TTGACTGGATTAAGGGACACACACAGCTGGTCAAAC--AATTTCAGCCATGAATCAGGCA 
10qSubTel              TTGACTGGATTAAGGGACACACACAGCTGGTCAAAC--AATTTCAGCCATGAATCAGGCA 
22qSubTel              TTGACTGGATTGAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCA 
1pSubTel               TTGAGTGGATTAAGAGACACACACAGCTGGTCAAAC--AATTTCAGCCATGAATCAGGCA 
5qSubTel               ------------------------------------------------------------ 
17qSubTel              TTGACTGGATTGAGAGACACACATAGCTGGTCAAACACGATTTCAGCCATGAATCAGGCA 
4qSubTel               TTGACTGGATTAAGGGACACACACAGCTGGTCAAAC--AATTTCAGCCATGAATCAGGCA 
19qSubTel              TTGACTGGATTAAGGGACACACACAGCTGGTCAAAC--AATTTCAGCCATGAATCAGGCA 
21qSubTel              ------------------------------------------------------------ 
1qSubTel               ------------------------------------------------------------ 
2qSubTel               ------------------------------------------------------------ 
19p'End'               TTGACTGGATTAAGAGACACACATAGCTGGTCAAACACAATTTCAGCCATGAATCTAGCA 
8p'End'                TTGATTGGATTAAGAAACATACATAGCTGGTCAAAC--AATTTCAGCCATGAAACAGGCA 
13qSubTel              TTGACTGGACTAAGAGACACACATAGCTGGTCAAACACAATTTCAGCCATGAATCAGGCA 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      TAAATATTCTGACAGTTAATTTTAGACATCTACTTGAGTGGATTAAGAGACACACATAGC 
10qSubTel              TAAATATTCTGACAGTTAATTTTAGACATCTACTTGAGTGGATTAAGAGACACACATAGC 
22qSubTel              TAAATATTCTGATGGTTAATCGTAGACGTCTACTTGACTGGATTGAGAGACACACACAGC 
1pSubTel               TAAATATTCTGACAGTTAATTTTAGACATCTACTTGAGTGGATTAAGAGACACACATAGC 
5qSubTel               ----------GACAGTTAATTTTAGACATCTACTTGAGTGGATTAAGAGACACACATAGC 
17qSubTel              TAAATATTCTGATGGTTAATCGTAGACGTCTACTTGACTGGATTGAGAGACACACACAGC 
4qSubTel               TAAATATTCTGACAGTTAATTTTAGACATCTATTTGAGTGGATTAAGAGACACACATAGC 
19qSubTel              TAAATATTCTGACAGTTAATTTTAGACATCTACTTGAGTGGATTAAGAGACACACATAGC 
21qSubTel              ----------GATGGTTAATCGTAGACGTCTACTTGACTGGATTGAGAGACACACACAGC 
1qSubTel               -----------ATGGTTAATCGTAGACGTCTACTTGACTGGATTGAGAGACACACACAGC 
2qSubTel               ----------------TAATTTTAGACATCTACTTGAGTGGATTAAGAGACACACATAGC 
19p'End'               TAAATATTCTGATGGTTAATTGTAGACATCTACTTGGCTGGATTGAGAGACACACACAGC 
8p'End'                TAAATATTCTGATGGTTAATTTTAGACATCTACTTGACTGGATTGAGAGACACACATAGC 
13qSubTel              TAAATATTCTGATGGTTAAGTTTAGACATCTACTTGATTGGATTAAGAGACACACATAGC 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      TGGTCAAACACGATTTCTGGGCATATCTATGAGGGTGTTTCTGGAAGACACTGAGATAAC 
10qSubTel              TGGTCAAACACGATTTCTGGGCATATCTATGAGGGTGTTTCTGGAAGACACTGAGATAAC 
22qSubTel              TGGTCAAACACGATTTCTGGGCATATCTATGAGGGTGTTTCTGGAAGACACTGAGATAAC 
1pSubTel               TGGTCAAACACGATTTCTGGGCATATCTATGAGGGTGTTTCTGGAAGACACTGAGATAAC 
5qSubTel               TGGTCAAACACGATTTCTGGGCATATCTATGAGGGTGTTTCTGGAAGACACTGAGATAAC 
17qSubTel              TGGTCAAACACGATTTCTGGGCATATCTATGAGGGTGTTTCTGGAAGACACTGAGATAAC 
4qSubTel               TGGTCAAACACGATTTCTGGGCATATCTATGAGGGTGTTTCTGGAAGACACTGAGATAAC 
19qSubTel              TGGTCAAACACGATTTCTGGGCATATCTATGAGGGTGTTTCTGGAAGACACTGAGATAAC 
21qSubTel              TGGTCAAACACGATTTCTGGGCATATCTATGAGGGTGTTTCTGGAAGACACTGAGATAAC 
1qSubTel               TGGTCAAACACGATTTCTGGGCATATCTATGAGGGTGTTTCTGGAAGACACTGAGATAAC 
2qSubTel               TGGTCAAACACGATTTCTGGGCATATCTATGAGGGTGTTTCTGGAAGACACTGAGATAAC 
19p'End'               TGGTCAAACACAATTGCTGGGCATATCTGTGAGGGTGTTTCTGGAAGACACTGAGATAAG 
8p'End'                TGGTGAAACACAATTTCTGGGCATATCTGTGAAGGTGTTTCTGGAAGACACTGAGATAAC 
13qSubTel              TGGTCAAACACAATTTCTGGGCATATCTGTGAGGGTGTTTCTGGAAGACACTGAGATAAC 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      CATGACC-CAATGTGGATGGGCACTGAT---ATGGTTTGGCTGTGTCCCCACCCAGATCT 
10qSubTel              CAGTCAAACACGATTTCTGGGCATATCTATGAGGGTGTTTCTGGAA-GACA--CTGA-GA 
22qSubTel              CATGACC-CAATGTGGATGGGCACTGA---TATGGTTTGGCTGTGTCCCCACCCAGATCT 
1pSubTel               CATGACC-CAATGTGGATGGGCACTGA---TATGGTTTGGCTGTGTCCCCACCCAGATCT 
5qSubTel               CATGACC-CAATGTGGATGGGCACTGAT---ATGGTTTGGCTGTGTCCCCACCCAGATCT 
17qSubTel              CATGACC-CAATGTGGATGGGCACTGAT---ATGGTTTGGCTGTGTCCCCACCCAGATCT 
4qSubTel               CATGACC-CAATGTGGATGGGCACTGA---TATGGTTTGGCTGTGTCCCCACCCAGATCT 
19qSubTel              CATGACC-CAATGTGGATGGGCACTGA---TATGGTTTGGCTGTGTCCCCACCCAGATCT 
21qSubTel              CATGACC-CAATGTGGATGGGCACTGAT---ATGGTTTGGCTGTGTCCCCACCCAGATCT 
1qSubTel               CATGACC-CAATGTGGATGGGCACTGA---TATGGTTTGGCTGTGTCCCCACCCAGATCT 
2qSubTel               CATGACC-CAATGTGGATGGGCACTGA---TATGGTTTGGCTGTGTCCCCACCCAGATCT 
19p'End'               CATGATC-CAGTGTGGATGGGCACTGA---TAGGGTTTGGCTGTGTCCCCACCCAGATCT 
8p'End'                CCTGACC-CAGTGTGGATGGGCACTGA---TATGGTTTGCCTGTGTCCCCACCCAGATCT 
13qSubTel              CATGACC-CAGTGTAGATGGGAACTGAT---ATGGTTTGCCTGTTTCCCCACCCAGATCT 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      CATCTTGAATTGTAGTTCCTGTAATACCTACATGTCGTGGGAGGGACCCAGTGGGAGGTG 
10qSubTel              TAACCAGAATTGTAGTTCCTGTAATACCTACATGTCGTGGGAGGGACCCAGTGGGAGGTG 
22qSubTel              CATCTTGAATTGTAGTTCCTGTAATACCTACATGTCGTGGGAGGGACCCAATGGGAGGTG 
1pSubTel               CATCTTGAATTGTAGTTCCTGTAATACCTACATGTCGTGGGAGGGACCCAGTGGGAGGTG 
5qSubTel               CATCTTGAATTGTAGTTCCTGTAATACCTACATGTCGTGGGAGGGACCCAGTGGGAGGTG 
17qSubTel              CATCTTGAATTGTAGTTCCTGTAATACCTACATGTCGTGGGAGGGACCCAATGGGAGGTG 
4qSubTel               CATCTTGAATTGTAGTTCCTGTAATACCTACATGTCGTGGGAGGGACCCAGTGGGAGGTG 
19qSubTel              CATCTTGAATTGTAGTTCCTGTAATACCTACATGTCGTGGGAGGGACCCAGTGGGAGGTG 
21qSubTel              CATCTTGAATTGTAGTTCCTGTAATACCTACATGTCGTGGGAGGGACCCAATGGGAGGTG 
1qSubTel               CATCTTGAATTGTAGTTCCTGTAATACCTACATGTCGTGGGAGGGACCCAATGGGAGGTG 
2qSubTel               CATCTTGAATTGTAGTTCCTGTAATACCTACATGTCGTGGGAGGGACCCAATGGGAGGTG 
19p'End'               CATCTTGAATTGTAGTTCCTATAATCCCTACATGTCGTGGGAGGGACCCAGTGGGAGGTG 
8p'End'                CATCTTGAATTGTAGTTCCTATAATCCGTACATGTCGTGGGAGGGACCCAGTGGGAGGTG 
13qSubTel              CATCTTGAATTGTAGTTCCTATAATCCCTAAATGTCGTGGGAGGGACCCGGTGGGAGGTG 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      ACTGAATCATGGTGGTGGTTACCGCCATGCTGTTCTCATGACAGTGAGTGAGTTCTCATG 
10qSubTel              ACTGAATCATGGTGGTGGTTACCGCCATGCTGTTCTCATGACAGTGAGTGAGTTCTCATG 
22qSubTel              ACTGAATCATGGTGGTGGTTACCGCCATGCTGTTCTCATGACAGTGAGTGAGTTCTCATG 
1pSubTel               ACTGAATCATGGTGGTGGTTACCGCCATGCTGTTCTCATGACAGTGAGTGAGTTCTCATG 
5qSubTel               ACTGAATCATGGTGGTGGTTACCGCCATGCTGTTCTCATGACAGTGAGTGAGTTCTCATG 
17qSubTel              ACTGAATCATGGTGGTGGTTACCGCCATGCTGTTCTCATGACAGTGAGTGAGTTCTCATG 
4qSubTel               ACTGAATCATGGTGGTGGTTACCGCCATGCTGTTCTCATGACAGTGAGTGAGTTCTCATG 
19qSubTel              ACTGAATCATGGTGGTGGTTACCGCCATGCTGTTCTCATGACAGTGAGTGAGTTCTCATG 
21qSubTel              ACTGAATCATGGTGGTGGTTACTGCCATGCTGTTCTCATGACAGTGAGTGAGTTCTCATG 
1qSubTel               ACTGAATCATGGTGGTGGTTACTGCCATGCTGTTCTCATGACAGTGAGTGAGTTCTCATG 
2qSubTel               ACTGAATCATGGTGGTGGTTACCGCCATGCTGTTCTCATGACAGTGAGTGAGTTCTCATG 
19p'End'               ACTGAATCATGGTGGTGGTTACTGCCATGCTGTTCCCATGACAGTGAGTGAGTTCTCACG 
8p'End'                ATTGAATCATGGTGGTTGTTACTGCCATTCTGTTTTCATGGCAGTGAGTGAGTTCTCATG 
13qSubTel              ATTGAATCATGGTGGTGGTTACTGCCATGCTGTTCTCATGACAGTGAGTGAGTTCTCACG 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      ATCTGATGGTTTTATAAGGGGCTTTTCCCCTTTGGCTCAGCACTT---CTTGTTGCTGCC 
10qSubTel              ATCTGATGGTTTTATAAGGGGCTTTTCCCCTTTGGCTCAGCACTT---CTTGTTGCTACC 
22qSubTel              ATCTGATGGTTTTATAAGGGGCTTTTCCCCTTTGGGTCAGCACTT---CTTGTTGCTGCC 
1pSubTel               ATCTGATGGTTTTATAAGGGGCTTTTCCCCTTTGGCTCAGCACTT---CTTGTTGCTGCC 
5qSubTel               ATCTGATGGTTTTATAAGGGGCTTTTCCCCTTTGGCTCAGCACTT---CTTGTTGCTGCC 
17qSubTel              ATCTGATGGTTTTATAAGGGGCTTTTCCCCTTTGGCTCAGCACTT---CTTGTTGCTGCC 
4qSubTel               ATCTGATGGTTTTATAAGGGGCTTTTCCCCTTTGGCTCAGCACTT---CTTGTTGCTGCC 
19qSubTel              ATCTGATGGTTTTATAAGGGGCTTTTCCCCTTTGGGTCAGCACTT---CTTGTTGCTGCC 
21qSubTel              ATCTGATGGTTTTATAAGGGGCTTTTCCCCTTTGGCTCAGCACTT---CTTGTTGCTGCC 
1qSubTel               ATCTGATGGTTTTATAAGGGGCTTTTCCCCTTTGGCTCAGCACTT---CTTGTTGCTGCC 
2qSubTel               ATCTGATGGTTTTATAAGGGGCTTTTCCCCTTTGGCTCAGCACTT---CTTGTTGCTGCC 
19p'End'               ATCTCATGGTTTTATAAGGGGCTTTTCCCCTTTGGCTCAGCACTTCTCCTTGTTGCTGCC 
8p'End'                ATCCAATGGTTTCATAAGGGGCTGTTCCCCTTTGGCTCAGCACTTCTTCTTGTTGCTGCC 
13qSubTel              ATCTCATGGTTTTATAAGGGGCTTTTCCCCTTTGGCTCAGCACTTCTCCTTGTTGCTGCC 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      ATGTGAAGAGGGATAGCTTTGCTTCCCCTTCTGCCATGATTGTGAGGCCCCTGCAGCCAT 
10qSubTel              ATGTGAAGAGGGATAGCTTTGCTTCCCCTTCTGCCATGATTGTGAGGCCCCTGCAGCCAT 
22qSubTel              ATGTGAAGAGGGACAGCTTTGCTTCCCCTTCTGCCATGATTTTGAGGCCCCTGCAGCCAT 
1pSubTel               ATGTGAAGAGGGACAGCTTTGCTTCCCCTTCTGCCATGATTGTGAGGCCCCTGCAGCCAC 
5qSubTel               ATGTGAAGAGGGATAGCTTTGCTTCCCCTTCTGCCATGATTGTGAGGCCCCTGCAGCCAT 
17qSubTel              ATGTGAAGAGGGATAGCTTTGCTTCCCCTTCTGCCATGATTGTGAGGCCCCTGCAGCCAT 
4qSubTel               ATGTGAAGAGGGATAGCTTTGCTTCCCCTTCTGCCATGATTGTGAGGCCCCTGCAGCCAT 
19qSubTel              ATGTGAAGAGGGATAGCTTTGCTTCCCCTTCTGCCATGATTGTGAGGCCCCTGCAGCCAT 
21qSubTel              ATGTGAAGAGGGATAGCTTTGCTTCCCCTTCTGCCATGATTGTGAGGCCCCTGCAGCCAT 
1qSubTel               ATGTGAAGAGGGATAGCTTTGCTTCCCCTTCTGCCATGATTGTGAGGCCCCCGCAGCCAT 
2qSubTel               ATGTGAAGAGGGATAGCTTTGCTTCCCCTTCTGCCATGATTGTGAGGCCCCTGCAGCCAT 
19p'End'               TTGTGAAGAAGGACAGCTTTGCTTCCCCTTCTGCCATGATTGTGAGGGCCCTGCAGCCAT 
8p'End'                ATGTGAAGAAGGACGTCTTTGTTTCCCCTTCTGCCATGATTGTGAGGCCTCTGCAGCCAC 
13qSubTel              TTGTGAAGAGGGATAGATTTGCTTCCCCTTCTGCCATGATTGTGAGGCCCCTGCAGCCAT 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      GTGGAACTGTCAGCCCATTAAACCCCTTTGTTCTTTATAAATTGCTCAGACTCAGGTATT 
10qSubTel              GTGGAACTGTCAGCCCATTAAACCCCTTTGTTCTTTATAAATTGCTCAGACTCAGGTATT 
22qSubTel              GTGGAACTGTCAGCCCATTAAACCCCTTTGTTCTTTATAAATTGCTCAGACTCAGGTATT 
1pSubTel               GTGGAACTGTCAGCCCATTAAACCCCTTTGTTCTTTATAAATTGCTCAGACTCAGGAATT 
5qSubTel               GTGGAACTGTCAGCCCATTAAACCCCTTTGTTCTTTATAAATTGCTCAGACTCAGGTATT 
17qSubTel              GTGGAACTGTCAGCCCATTAAACCCCTTTGTTCTTTATAAATTGCTCAGACTCAGATATT 
4qSubTel               GTGGAACTGTCAGCCCATTAAACCCCTTTGTTCTTTATAAATTGCTCAGACTCAGGTATT 
19qSubTel              GTGGAACTGTCAGCCCATTAAACCCCTTTGTTCTTTATAAATTGCTCAGACTCAGGTATT 
21qSubTel              GTGGAACTGTCAGCCCATTAAACCCCTTTGTTCTTTATAAATTGCTCAGACTCAGGTATT 
1qSubTel               GTGGAACTGTCAGCCCATTAAACCCCTTTGTTCTTTATAAATTGCTCAGACTCAGGTATT 
2qSubTel               GTGGAACTGTCAGCCCATTAAACCCCTTTGTTCTTTATAAATTGCTCAGACTCAGGTATT 
19p'End'               GTGGAACTGTCAGCCCATTCAACCTCTTTGTTCTTTATAAATTGCTCAGACTCAGGTATT 
8p'End'                GTGGAACTGTCAGCCCATTTAACCTCTTTGTTCTTTATAAATTGCTCAGACTCAGGTATT 
13qSubTel              GTGGAACTGTCAGCCCATTAAACCTCTTTGTTCTTTATAAATTGCTCAGACTCAGGTATT 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      TCTTCATAGCTGTATAAAAATGGATGAATACAGGCACCATCCAATTGGTTGAGAGCCCAG 
10qSubTel              TCTTCATAGCTGTATAAAAATGGATGAATACAGGCACCATCCAATTGGTTGAGAGCCCAG 
22qSubTel              TCTTCATAGCTGTATAAAAATGGATGAATACAGGCAGCATCCAATTGGTTGAGAGCCCAG 
1pSubTel               TCTTCATAGCTGTATAAAAATGGATGAATACAGGCAGCATCCAATTGGTTGAGAGCCCAG 
5qSubTel               TCTTCATAGCTGTATAAAAATGGATGAATACAGGCACCATCCAATTGGTTGAGAGCCCAG 
17qSubTel              TCTTCATAGCTGTATAAAAATGGATGAATACAGGCAGCATCCAATTGGTTGAGAGCCCAG 
4qSubTel               TCTTCATAGCTGTATAAAAATGGATGAATACAGGCACCATCCAATTGGTTGAGAGCCCAG 
19qSubTel              TCTTCATAGCTGTATAAAAATGGATGAATACAGGCACCATCCAATTGGTTGAGAGCCCAG 
21qSubTel              TCTTCATAGCTGTATAAAAATGGATGAATACAGGCAGCATCCAATTGGTTGAGAGCCCAG 
1qSubTel               TCTTCATAGCTGTATAAAAATGGATGAATACAGGCAGCATCCAATTGGTTGAGAGCCCAG 
2qSubTel               TCTTCATAGCTGTATAAAAATGGATGAATACAGGCACCATCCAATTGGTTGAGAGCCCAG 
19p'End'               TCTTCATAGCTGTATAAAAATGGATGAATACAGGCACCATCCAATTGGTTGAGAGCCCAG 
8p'End'                TCTTCACAGCTGTATAAAAATGGATGAATACAGGCACCATCCAATTGGTTGAGAGCCCAG 
13qSubTel              TCTTCATAGCTGTATAAAAATGGATGAATACAGGCACCATCCAATTGGTTGAGAGCCCAG 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      ATAGAATAACAAGGAAGAGGAAAGGTGAATTATCTCCTTCTGAAATGGAAACATCCTTCT 
10qSubTel              ATAGAATAACAAGGAAGAGGAAAGGTGAATTATCTCCTTCTGAAATGGAAACATCCTTCT 
22qSubTel              ATAGAATAACAAGGAAGAGGAAAGGTGAATTATCTCCTTCTGAAATGGAAACATCCTTCT 
1pSubTel               ATAGAATAACAAGGAAGAGGAAAGGTGAATTATCTCCTTCTGAAGTGGAAACATCCTTCT 
5qSubTel               ATAGAATAACAAGGAAGAGGAAAGGTGAATTATCTCCTTCTGAAATGGAAACATCCTTCT 
17qSubTel              ATAGAATAACAAGGAAGAGGAAAGGTGAATTATCTCCTTCTGAAATGGAAACATCCTTCT 
4qSubTel               ATAGAATAACAAGGAAGAGGAAAGGTGAATTATCTCCTTCTGAAATGGAAACATCCTTCT 
19qSubTel              ATAGAATAACAAGGAAGAGGAAAGGTGAATTATCTCCTTCTGAAATGGAAACATCCTTCT 
21qSubTel              ATAGAATAACAAGGAAGAGGAAAGGTGAATTATCTCCTTCTGAAATGGAAACATCCTTCT 
1qSubTel               ATAGAATAACAAGGAAGAGGAAAGGTGAATTATCTCCTTCTGAAATGGAAACATCCTTCT 
2qSubTel               ATAGAATAACAAGGAAGAGGAAAGGTGAATTATCTCCTTCTGAAGTGGAAACATCCTTCT 
19p'End'               ATAAAACAACAAGGAAGAGGAAAGGTGAATTATCTCCTTCTGAAATGGAAACATCCTTCT 
8p'End'                ATAGAATAACAAGGAAGAGGAAAGGTGAATTATCTCC---TGAAATTGAAACATCCTTCT 
13qSubTel              ATAGAACAAAAAGGAAGAGGAAAGGTGAATTATCTCCTTCTGAAACGGAAACATCCTTCT 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      TCTCCTGCCCTTGACATCAGAACTTCAGGGTCTCAGACCTTTGGCCTCACAATCAGAGTT 
10qSubTel              TCTCCTGCCCTTGACATCAGAACTTCAGGGTCTCAGACCTTTGGCCTCACAATCAGAGTT 
22qSubTel              TCTCCTGCCCTTGACATCAGAACTTCAGGGTCTCAGACCTTTGGCCTCACAATCAGAGTT 
1pSubTel               TCTCCTGCCCTTGACATCAGAACTTCAGGGTCTCAGACCTTTGGCCTCACAATCAGAGTT 
5qSubTel               TCTCCTGCCCTTGACATCAGAACTTCAGGGTCTCAGACCTTTGGCCTCACAATCAGAGTT 
17qSubTel              TCTCCTGCCCTTGACATCAGAACTTCAGGGTCTCAGACCTTTGGCCTCACAATCAGAGTT 
4qSubTel               TCTCCTGCCCTTGACATCAGAACTTCAGGGTCTCAGACCTTTGGCCTCACAATCAGAGTT 
19qSubTel              TCTCCTGCCCTTGACATCAGAACTTCAGGGTCTCAGACCTTTGGCCTCACAATCAGAGTT 
21qSubTel              TCTCCTGCCCTTGACATCAGAACTTCAGGGTCTCAGACCTTTGGCCTCACAATCAGAGTT 
1qSubTel               TCTCCTGCCCTTGACATCAGAACTTCAGGGTCTCAGACCTTTGGCCTCACAATCAGAGTT 
2qSubTel               TCTCCTGCCCTTGACATCAGAACTTCAGGGTCTCAGACCTTTGGCCTCACAATCAGAGTT 
19p'End'               TCTCCTGCCCTTGACATCAGAACTTCAGGGTCTCAGACCTTTGGCCTCAGAATCAGAGTT 
8p'End'                TCTCCTGCCCTTGACATCAGAA--TCAGTGTCTCAGAGCTTTGGCCTCAGAATCAGAGTT 
13qSubTel              TCTCCTGCCCTTGACATCAGAACTTCGGGGTCTCAGACCTTTGGCCTCACAATCAGAGTT 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      ACACCATTGGCTTCCCTGATTCTGAGTCCTTTGTATCTGGAGTGAGCCATGCTACCAGCT 
10qSubTel              ACACCATTGGCTTCCCTGATTCTGAGTCCTTTGTATCTGGAGTGAGCCATGCTACCAGCT 
22qSubTel              ACACCATTGGCTTCCCCGATTCTGAGTCCTTTGTATCTGGAGTGAGCCATGCTACCAGCT 
1pSubTel               ACACCATTGGCTTCCCTGATTCTGAGTCCTTTGTATCTGGAGTGAGCCATGCTACCAGCT 
5qSubTel               ACACCATTGGCTTCCCTGATTCTGAGTCCTTTGTATCTGGAGTGAGCCATGCTACCAGCT 
17qSubTel              ACACCATTGGCTTCCCCGATTCTGAGTCCTTTGTATCTGGAGTGAGCCATGCTACCAGCT 
4qSubTel               ACACCATTGGCTTCCCTGATTCTGAGTCCTTTGTATCTGGAGTGAGCCATGCTACCAGCT 
19qSubTel              ACACCATTGGCTTCCCCGATTCTGAGTCCTTTGTATCTGGAGTGAGCCATGCTACCAGCT 
21qSubTel              ACACCATTGGCTTCCCCGATTCTGAGTCCTTTGTATCTGGAGTGAGCCATGCTACCAGCT 
1qSubTel               ACACCATTGGCTTCCCCGATTCTGAGTCCTTTGTATCTGGAGTGAGCCATGCTACCAGCT 
2qSubTel               ACACCATTGGCTTCCCTGATTCTGAGTCCTTTGTATCTGGAGTGAGCCATGCTACCAGCT 
19p'End'               ACACTATTGGCTTCCCTGATTCTGAGTCCTTTGTATCTGGAGTGAGCCACGCTACCAGCT 
8p'End'                ACACCATTGGCTTCCCTGATTCTGAGTCCTTTATATCTGGAGTGAGTCATGCTGCCAGCT 
13qSubTel              ACACCATTGGCTTCCCTGATTCTGAGTCCTTTATATCTGGAGTGAGCCATGCTGCCAGCT 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      TTCCTGGTTCTCCAACTTGGAGACAGGCTATTGTGGAACTTCTCAGCCTCCATAATTATG 
10qSubTel              TTCCTGGTTCTCCAACTTGGAGACAGGCTATTGTGGAAATTCTCAGCCTCCATAATTATG 
22qSubTel              TTCCTGGTTCTCCAACTTGGAGACAGGCTATTGTGGAACTTCTCAGCCTCCATAATTATG 
1pSubTel               TTCCTGGTTCTCCAACTTGGAGACAGGCTATTGTGGAACTTCTCAGCCTCCATAATTATG 
5qSubTel               TTCCTGGTTCTCCAACTTGGAGACAGGCTATTGTGGAACTTCTCAGCCTCCATAATTATG 
17qSubTel              TTCCTGGTTCTCCAACTTGGAGACAGGCTATTGTGGAACTTCTCAGCCTCCATAATTATG 
4qSubTel               TTCCTGGTTCTCCAACTTGGAGACAGGCTATTGTGGAACTTCTCAGCCTCCATAATTATG 
19qSubTel              TTCCTGGTTCTCCAACTTGGAGACAGGCTATTGTGGAACTTCTCAGCCTCCATAATTATG 
21qSubTel              TTCCTGGTTCTCCAACTTGGAGACAGGCTATTGTGGAACTTCTCAGCCTCCATAATTATG 
1qSubTel               TTCCTGGTTCTCCAACTTGGAGACAGGCTATTGTGGAACTTCTCAGCCTCCATAGTTATG 
2qSubTel               TTCCTGGTTCTCCAACTTGGAGACAGGCTATTGTGGAACTTCTCAGCCTCCATAATTATG 
19p'End'               TTCCTGGTTCTCCAACTTGGAGACAGGCTATTGTGGAACTTCTCAGCCTCCATAATTATG 
8p'End'                TTCCTGGTTCTCCAACTTGGAGACAGGCTATTGTGTAACTTCTCAGCCTCCATAATTATG 
13qSubTel              TTCCTGGTTCTCGAACTTGGAGACAGGCTATTGTGTAACTTCTCAGCCTCCATAATTATG 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      TGAACCAGTTCCCCTAATGAATCTTCTCTCATCTA----TCTACATATATCCTATTGATT 
10qSubTel              TGAACCAGTTCCCCTAATGAATCTTCTCTCATCTA----TCTACATATATCCTATTGATT 
22qSubTel              TGAACCAGTTCCCCTAATGAATCTTCTGTCATCTG----TCTACATATATCCTATTGATT 
1pSubTel               TGAACCAGTTCCCCTAATGAATCTTCTCTCATCTA----TCTACATATATCCTATTGATT 
5qSubTel               TGAACCAGTTCCCCTAATGAATCTTCTCTCATCTA----TCTACATATATCCTATTGATT 
17qSubTel              TGAACCAGTTCCCCTAATGAATCTTCTCTCATCTG----TCTACATATATCCTATTGATT 
4qSubTel               TGAACCAGTTCCCCTAATGAATCTTCTCTCATCTA----TCTACATATATCCTATTGATT 
19qSubTel              TGAACCAGTTCCCCTAATGAATCTTCTCTCATCTA----TCTACATATATCCTATTGATT 
21qSubTel              TGAACCAGTTCCCCTAATGAATCTTCTCTCATCTG----TCTACATATATCCTATTGATT 
1qSubTel               TGAACCAGTTCCCCTAATGAATCTTCTCTCATCTG----TCTACATATATCCTATTGATT 
2qSubTel               TGAACCAGTTCCCCTAATGAATCTTCTCTCATCTA----TCTACATATATCCTATTGATT 
19p'End'               TGAACCAATTCCCCTAATGAATCTTCTCTCATCTA----TCTACATATATCCTATTGATT 
8p'End'                TGAACCAATTCCCCTAATGAGTCTTCTCTCATCTA----TCTACATATATCCTATTGATT 
13qSubTel              TGAACCAATTCCCCTAATGAGTCTTCTCTCATCTATCTATCTACATATATCCTATTGATT 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      CTGCCTTTCTGGAGACCCCTGCCTAATGTGATTACAATAACTACAAAATTCACTACTTTA 
10qSubTel              CTGCCTTTATGGAGACCCCTGCCTAATGTGATTACAATAACTACAAAATTCACTACTTTA 
22qSubTel              CTGCCTTTCTGGAGACCCCTGACTAATGTGATTACAATAACTACACAATTCACTAGTTTA 
1pSubTel               CTGCCTTTCTGGAGACCCCTGCCTAATGTGATTACAATAACTACAAAATTCACTACTTTA 
5qSubTel               CTGCCTTTCTGGAGACCCCTGCCTAATGTGATTACAATAACTACAAAATTCACTACTTTA 
17qSubTel              CTGCCTTTCTGGAGACCCCTGACTAATGTGATTACAATAACTACACAATTCACTAGTTTA 
4qSubTel               CTGCCTTTATGGAGACCCCTGCCTAATGTGATTACAATAACTACAAAATTCACCACTTTA 
19qSubTel              CTGCCTTTATGGAGACCCCTGCCTAATGTGATTACAATAACTACAAAATTCACTAGTTTA 
21qSubTel              CTGCCTTTCTGGAGACCCCTGACTAATGTGATTACAATAACTACACAATTCACTAGTTTA 
1qSubTel               CTGCCTTTCTGGAGACCCCTGACTAATGTGATTACAATAACTACACAATTCACTAGTTTA 
2qSubTel               CTGCCTTTCTGGAGACCCCTGCCTAATGTGATTACAATAACTACAAAATTCACTACTTTA 
19p'End'               CTGCCT-TCTGGAGAACCCTGACTAATGTGATTGCAAT-ACTACAAAATTCACTAGTTTA 
8p'End'                CTGCCTTTCTGGAGAACCCTGACTAATGTTATTACAATA-ATACAAAATTCACTAGTTTA 
13qSubTel              CTGCCTTTCTGGAGAACCCTGACTAATGTTATTACAATA-ATACTAAATTCACTAGTTTA 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      TATAGAAGACTTGGTTTTTGTCTTTGCCCCATTTTATATTTGTATTATAACTATGTATCT 
10qSubTel              TATAGAAGACTTGGTTTTTGTCTTTGCCCCATTTTATATTTGTATTATAACTATGTATCT 
22qSubTel              TATAGAAGACTTGGTTTTTGTCTTTGCCCCATTTTATATTTGTATTATAACTATGTATCT 
1pSubTel               TATAGAAGACTTGGTTTTTGTCTTTGCCCCATTTTATATTTGTATTATAACTATGTATCT 
5qSubTel               TATAGAAGACTTGGTTTTTGTCTTTGCCCCATTTTATATTTGTATTATAACTATGTATCT 
17qSubTel              TATAGAAGACTTGGTTTTTGTCTTTGCCCCATTTTATATTTGTATTATAACTATGTATCT 
4qSubTel               TATAGAAGACTTGGTTTTTGTCTTTGCCCCATTTTATATTTGTATTATAACTATGTGTCT 
19qSubTel              TATAGAAGACTTGGTTTTTGTCTTTGCCCCATTTTATATTTGTATTATAACTATGTATCT 
21qSubTel              TATAGAAGACTTGGTTTTTGTCTTTGCCCCATTTTATATTTGTATTATAACTATGTATCT 
1qSubTel               TATAGAAGACTTGGTTTTTGTCTTTGCCCCATTTTATATTTGTATTATAACTATGTATCT 
2qSubTel               TATAGAAGACTTGGTTTTTGTCTTTGCCCCATTTTATATTTGTATTATAACTATGTATCT 
19p'End'               TATAGAAGACTTGGTTTTTGTCTTTGCCTCATTTTATATTTGTATTATAACTGTGTAACT 
8p'End'                TATAGAAGACTTGGTTTTTGTCTTTGCCCCATTTTGTATTTGTATTATAACTGTGTATCT 
13qSubTel              TGTAGAAGACTTGGTTTTTGTCTTTGCCCAATTTTATATTTGTATTATAACTGTGTATCT 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      GGAAAATGGAACAAGTTT-TTTCTTCTTCATATGAGGGCTAAGGCTTTTTTCTCACCAAT 
10qSubTel              GGAAAATGGAACAAGTTT-TTTCTTCTTCATATGAGGGCTAAGGCTTTTTTCTCACCAAT 
22qSubTel              GGAAAATGGAACAAGTTT-TTTCTTCTTCATATGAGGGCTAAGGCTTTTTTCTCACCAAT 
1pSubTel               GGAAAGTGGAACAAGTTT-TTTCTTCTTCATATGAGGGCTAAGGCTTTTTTCTCACCAAT 
5qSubTel               GGAAAATGGAACAAGTTT-TTTCTTCTTCATATGAGGGCTAAGGCTTTTTTCTCACCAAT 
17qSubTel              GGAAAATGGAACAAGTTT-TTTCTTCTTCATATGAGGGCTAAGGCTTTTTTCTCACCAAT 
4qSubTel               GGAAAATGGAACAAGTTT-TTTCTTCTTCATATGAGGGCTAAGGCTTTTTTCTCACCAAT 
19qSubTel              GGAAAATGGAACAAGTTT-TTTCTTCTTTATATGAGGGCTAAGGCTTTTTTCTCACCAAT 
21qSubTel              GGAAAATGGAACAAGTTT-TTTCTTCTTCATATGAGGGCTAAGGCTTTTTTCTCACCAAT 
1qSubTel               GGAAAATGGAACAAGTTT-TTTCTTCTTCATATGAGGGCTAAGGCTTTTTTCTCACCAAT 
2qSubTel               GGAAAATGGAACAAGTTT-TTTCTTCTTCATATGAGGGCTAAGGCTTTTTTCTCACCAAT 
19p'End'               GGAAAATGGAACAAGTTT-TTTCTTCTTCATATGAGGGCTAAGGCTTTTTTCTCACCAAT 
8p'End'                GGAAAATGGAACAAGTTTTTATCTTCTTCATATGAGGGCCAAAGCTTTTTTCTCACCAAT 
13qSubTel              GGAAAATGGAACAAGTTTTTATCTTCTTCATATGAGCGCCAAAGCTTTTGTCTCACCAAT 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      ATTTTTGGAGATTTTAAAGATTTTCTTTTT-TTTTTGACATAGAATCTTATGGAGGCTGA 
10qSubTel              ATTTTTGGAGATTTTAAAGATTTTCTTTTT-TTTTTGACATAGAATCTTATGGAGGCTGA 
22qSubTel              ATTTTTGGAGATTTTAAAGATTTTCTTTT-TTTTT-GACATAGAATCTTATGGAGGCTGA 
1pSubTel               ATTTTTGGAGATTTTAAAGATTTTC-TTT-TTTTTTGACATAGAATCTTATGGAGGCTGA 
5qSubTel               ATTTTTGGAGATTTTAAAGATTTTCTTTTT-TTTT-GACATAGAATCTTATGGAGGCTGA 
17qSubTel              ATTTTTGGAGATTTTAAAGATTTTCTTTT--TTTTTGACATAGAATCTTATGGAGGCTGA 
4qSubTel               ATTTTTGGAGATTTTAAAGATTTTCTTTT-TTTTTTGACATAGAATCTTATGGAGGCTGA 
19qSubTel              ATTTTTGGAGATTTTAAAGATTTTCTTTTTTTTTTTGACATAGAATCTTATGGAGGCTGA 
21qSubTel              ATTTTTGGAGATTTTAAAGATTTTCTTTT--TTTTTGACATAGAATCTTATGGAGGCTGA 
1qSubTel               ATTTTTGGAGATTTTAAAGATTTTCTTT--TTTTTTGACATAGAATCTTATGGAGGCTGA 
2qSubTel               ATTTTTGGAGATTTTAAAGATTTTCTTTT--TTTTTGACATAGAATCTTATGGAGACTGA 
19p'End'               ATTTTTGGAGATTTTTAAGGTTTTCTTTT--GTTTTCACATACAATCTTATGGAGGATGA 
8p'End'                ATTTTTGGAGATTTTTAAGATTTTCTTTT--GTTTGGACATACAATCTTATGGAGGCTGA 
13qSubTel              ATTTTTGGAGATTTTTAAGATTTTCTTTT--GTTTGGACATACAATCTTATGGAGGATGA 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      GAAATAATT-TTTTTTCTATTTTATTCTTCAGCCCCAGGTGTTTGCTTTTGCAGATTCTT 
10qSubTel              GAAATAATT-TTTTTTCTATTTTATTCTTCAGCCCCAGGTGTTTGCTTTTGCAGATTCTT 
22qSubTel              GAAATAATT-TTTTTTCTATTTTATTCTTCAGCCCCAGGTGTTTGCTTTTGCAGATTCTT 
1pSubTel               GAAATAATT-TTTTTTCTATTTTATTCTTCAGCCCCAGGTGTTTGCTTTTGCAGATTCTT 
5qSubTel               GAAATAATT-TTTTTTCTATTTTATTCTTCAGCCCCAGGTGTTTGCTTTTGCAGATTCTT 
17qSubTel              GAAATAATT-TTTTTTCTATTTTATTCTTCAGCCCCAGGTGTTTGCTTTTGCAGATTCTT 
4qSubTel               GAAATAATT-TTTTTTCTATTTTATTCTTCAGCCCCAGGTGTTTGCTTTTGCAGATTCTT 
19qSubTel              GAAATAATT-TTTTTTCTATTTTATTCTTCAGCCCCAGGTGTTTGCTTTTGCAGATTCTT 
21qSubTel              GAAATAATT-TTTTTTCTATTTTATTCTTCAGCCCCAGGTGTTTGCTTTTGCAGATTCTT 
1qSubTel               GAAATAATT-TTTTTTCTATTTTATTCTTCAGCCCCAGGTGTTTGCTTTTGCAGATTCTT 
2qSubTel               GAAATAATT-TTTTTTCTATTTTATTCTTCAGCCCCAGGTGTTTGCTTTTGCAGATTCTT 
19p'End'               GAAATATTTTTTTTTTCTATTTTATTTTTCAGCCCCAGGTGTTTGCTTTTGCAGATTCTT 
8p'End'                GAAATAAAA-TTTTTTCTATTTTATTTTTCAGCCCCAGATGTTTGCTTTTGCAGATTCTT 
13qSubTel              GAAATATTT-TTTTTTCTATTTTATTTTTCAGCCCCAGGTGTTTGCTTTTGCAGATTCTT 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      GAGCACATTGAGAGC----------TTCCAAGGCATGGAGTGGGGTGCCTGAAGTTTCAG 
10qSubTel              GAGCACATTGAGAGC----------CTCCAAGGCATGGAGTGGGGTGCCTGAAGTTTCAG 
22qSubTel              GAGCACATTGAGAGC----------CTCCAAGGCATGGAGTGGGGTGCCTGAAGTTTCAG 
1pSubTel               GAGCACATTGAGAGC----------TTCCAAGGCATGGAGTGGGGTGCCTGAAGTTTCAG 
5qSubTel               GAGCACATTGAGAGC----------TTCCAAGGCATGGAGTGGGGTGCCTGAAGTTTCAG 
17qSubTel              GAGCACATTGAGAGC----------CTCCAAGGCATGGAGTGGGGTGCCTGAAGTTTCAG 
4qSubTel               GAGCACATTGAGAGC----------CTCCAAGGCATGGAGTGGGGTGCCTGAAGTTTCAG 
19qSubTel              GAGCACATTGAGAGC----------CTCCAAGGCATGGAGTGGGGTGCCTGAAGTTTCAG 
21qSubTel              GAGCACACTGAGAGC----------CTCCAAGGCATGGAGTGGGGTGCCTGAAGTTTCAG 
1qSubTel               GAGCACACTGAGAGC----------CTCCAAGGCATGGAGTGGGGTGCCTGAAGTTTCAG 
2qSubTel               GAGCACATTGAGAGC----------TTCCAAGGCATGGAGTGGGGTGCCTGAAGTTTCAG 
19p'End'               GAGCACATTGAGAGC----------CTCCAAGGCATGGAGTGGGGTGCCTAAAGTTTCAG 
8p'End'                GAGCACATTGAGAGCATGGAGAGCACTCCAAGGCATGGAGTGGGGTGCCTAAAGTTTCAG 
13qSubTel              GAGCACATTGAGAGCATGGAGAGCACTCCAAGGCATGGAGTGGGGTGCCTAAAGTTTCAG 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      TGATTATAGGGAGTTGAGAGACTCAACTGGGAAAGGAAAGGTCTAAAAGGAGGCAATTTG 
10qSubTel              TGATTATAGGGAGTTGAGAGACTCAACTGGGAAAGGAAAGGTCTAAAAGGAGGCAATTTG 
22qSubTel              TGATTATAGGGAGTTGAGAGACTCAACTGGGAAAGGAAAGGTCTAAAAGGAGGCAATTTG 
1pSubTel               TGATTATAGGGAGTTGAGAGACTCAACTGGGAAAGGAAAGGTCTAAAAGGAGGCAATTTG 
5qSubTel               TGATTATAGGGAGTTGAGAGACTCAACTGGGAAAGGAAAGGTCTAAAAGGAGGCAATTTG 
17qSubTel              TGATTATAGGGAGTTGAGAGACTCAACTGGGAAAGGAAAGGTCTAAAAGGAGGCAATTTG 
4qSubTel               TGATTATAGGGAGTTGAGAGACTCAACTGGGAAAGGAAAGGTCTAAAAGGAGGCAATTTG 
19qSubTel              TGATTATAGGGAGTTGAGAGACTCAACTGGGAAAGGAAAGGTCTAAAAGGAGGCAATTTG 
21qSubTel              TGATTATAGGGAGTTGAGAGACTCAACTGGGAAAGGAAAGGTCTAAAAGGAGGCAATTTG 
1qSubTel               TGATTATAGGGAGTTGAGAGACTCAACTGGGAAAGGAAAGGTCTAAAAGGAGGCAATTTG 
2qSubTel               TGATTATAGGGAGTTGAGAGACTCAACTGGGAAAGGAAAGGTCTAAAAGGAGGCAATTTG 
19p'End'               TGATTACAGGGAGTTGAGAGACTCAACTGGGAAAGGAAAAGTCTAAAAGGAGGCAATTTG 
8p'End'                TGATTACAGGGAGTTGAGAGACTCAACTGGGAAAGGAAAAGTCTAAAAGGAGGCAATTTG 
13qSubTel              TGATTACAGGGAGTTGAGATACTCAACTGGGAAAGGAAAAGTCTAAAAGGAGGCAATTTG 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      GAAAATAAAAATTTTCTCAAAGGAGCCATTAAAGTTGTAAATAATTCTTAGTAAAGTCAT 
10qSubTel              GAAAATAAAAATTTTCTCAAAGGAGCCATTAAAGTTGTAAATAATTCTTAGTAAAGTCAT 
22qSubTel              GAAGATAAAAATTTTCTCAAAGGAGCCATTAAAGTTGTAAATAATTCTTAGTAAAGTCAT 
1pSubTel               GAAAATAAAAATTTTCTCAAAGGAGCCATTAAAGTTGTAAATAATTCTTAGTAAAGTCAT 
5qSubTel               GAAAATAAAAATTTTCTCAAAGGAGCCATTAAAGTTGTAAATAATTCTTAGTAAAGTCAT 
17qSubTel              GAAGATAAAAATTTTCTCAAAGGAGCCATTAAAGTTGTAAATAATTCTTAGTAAAGTCAT 
4qSubTel               GAAAATAAAAATTTTCTCAAAGGAGCCATTAAAGTTGTAAATAATTCTTAGTAAAGTCAT 
19qSubTel              GAAAATAAAAATTTTCTCAAAGGAGCCATTAAAGTTGTAAATAATTCTTAGTAAAGTCAT 
21qSubTel              GAAGATAAAAATTTTCTCAAAGGAGCCATTAAAGTTGTAAATAATTCTTAGTAAAGTCAT 
1qSubTel               GAAGATAAAAATTTTCTCAAAGGAGCCATTAAAGTTGTAAATAATTCTTAGTAAAGTCAT 
2qSubTel               GAAAATAAAAATTTTCTCAAAGGAGCCATTAAAGTTGTAAATAATTCTTAGTAAAGTCAT 
19p'End'               GAAGATAAAAATTTTCTCAAAGGAGCAATTAAATTTCTAAATAATTCTTAGTAAAATCAT 
8p'End'                GAAGATAAAAATTTTCTCAAAGGAGCGATTAAATTTCTAAATAATTCTTAGTAAAATCAT 
13qSubTel              GAAGATAAAAATTTTCTCAAAAGAGCGATTAAATTTCTAAATAATTCTTAGTAAAATCAT 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      GCAAACAGGAAAAGAAGTAGAATTAGTTCCATATTGGTGGAACACATAGTCAGCAGAGGT 
10qSubTel              GCAAACAGGAAAAGAAGTAGAATTAGTTCCATATTGGTGGAACACATAGTCAGCAGAGGT 
22qSubTel              GCAAACAGGAAAAGAAGTAGAATTAGTTCCATATTGGTGGAACACATAGTCAGCAGAGGT 
1pSubTel               GCAAACAGGAAAAGAAGTAGAATTAGTTCCATATTGGTGGAACACATAGTCAGCAGAGGT 
5qSubTel               GCAAACAGGAAAAGAAGTAGAATTAGTTCCATATTGGTGGAACACATAGTCAGCAGAGGT 
17qSubTel              GCAAACAGGAAAAGAAGTAGAATTAGTTCCATATTGGTGGAACACATAGTCAGCAGAGGT 
4qSubTel               GCAAACAGGAAAAGAAGTAGAATTAGTTCCATATTGGTGGAACACATAGTCAGCAGAGGT 
19qSubTel              GCAAACAGGAAAAGAAGTAGAATTAGTTCCATATTGGTGGAACACATAGTCAGCAGAGGT 
21qSubTel              GCAAACAGGAAAAGAAGTAGAATTAGTTCCATATTGGTGGAACACATAGTCAGCAGAGGT 
1qSubTel               GCAAACAGGAAAAGAAGTAGAATTAGTTCCATATTGGTGGAACACATAGTCAGCAGAGGT 
2qSubTel               GCAAACAGGAAAAGAAGTAGAATTAGTTCCATATTGGTGGAACACATAGTCAGCAGAGGT 
19p'End'               GTAAACAGGAAAGGAAGTAGAATTAGTTCCATATTGGTGGAACACATA----GCAGAGGT 
8p'End'                GTAAACAGGAAAGGAAATAGAATTAGTTCCATATTGGTGGAACACATA----GCAGAGGT 
13qSubTel              GCAAACAGGAAAGGAAGTAGAATTAGTTCCATATTGTTGGAACACATAGTCAGCAGAGGT 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      TGGAGAAGGGAGAA-TTTAGTGAACTGAGAAGTTCCCATGAAAGCAGCAAGATCAAGATC 
10qSubTel              TGGAGAAGGGAG-AATTTAGTGAACTGAGAAGTTCCCATGAAAGCAGCAAGATCAAGATC 
22qSubTel              TTGAGAAGGGAGAA-TTTAGTGAAGTGAGAAGTTCCCATGAAAGCAGCAAGATCAAGATC 
1pSubTel               TGGAGAAGGGAG-AATTTAGTGAACTGAGAAGTTCCCATGAAAGCAGCAAGATCAAGATC 
5qSubTel               TGGAGAAGGGAG-AATTTAGTGAACTGAGAAGTTCCCATGAAAGCAGCAAGATCAAGATC 
17qSubTel              TTGAGAAGGGAGAA-TTTAGTGAAGTGAGAAGTTCCCATGAAAGCAGCAAGATCAAGATC 
4qSubTel               TGGAGAAGGGAGAA-TTTAGTGAACTGAGAAGTTCCCATGAAAGCAGCAAGATCAAGATC 
19qSubTel              TGGAGAAGGGAGAA-TTTAGTGAACTGAGAAGTTCCCATGAAAGCAGCAAGATCAAGATC 
21qSubTel              TTGAGAAGGGAGAA-TTTAGTGAAGTGAGAAGTTCCCATGAAAGCAGCAAGATCAAGATC 
1qSubTel               TTGAGAAGGGAGAA-TTTAGTGAAGTGAGAAGTTCCCATGAAAGCAGCAAGATCAAGATC 
2qSubTel               TGGAGAAGGGAGAA-TTTAGTGAACTGAGAAGTTCCCATGAAAGCAGCAAGATCAAGATC 
19p'End'               TTGAGAAGGGAGAA-TTTAGTCAACTGAGAAGTTCTCATGAAAGGAGCAAGTTCAAGATC 
8p'End'                TTGAGAAGGGAGAA-TTTAGTCAACTGAGAAGTTCTCATGAAAGGAGCAAGTTCAAGATC 
13qSubTel              TTGAGAAGGGAGAA-TTTAGTCAACTGAGAAGTTCCCATGAAAGGAGCAAGTTCAAGATC 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      ACAGAGACACCTTGAAACAAAAAGCCAGGAATAACTTCCAACCCAAGAGGAGAACAGAGA 
10qSubTel              ACAGAGACACCTTGAAACAAAAAGCCAGGAATAACTTCCAACCCAAGAGGAGAACAGAGA 
22qSubTel              ACAGA--CACCTTGAAACAAAAAGCCAGGAATAACTTCCAACCCAAGAGGAGAACAGAGA 
1pSubTel               ACAGAGACACCTTGAAACAAAAAGCCAGGAATAACTTCCAACCCAAGAGGAGAACAGAGA 
5qSubTel               ACAGAGACACCTTGAAACAAAAAGCCAGGAATAACTTCCAACCCAAGAGGAGAACAGAGA 
17qSubTel              ACA--GACACCTTGAAACAAAAAGCCAGGAATAACTTCCAACCCAAGAGGAGAACAGAGA 
4qSubTel               ACAGAGACACCTTGAAACAAAAAGCCAGGAATAACTTCCAACCCAAGAGGAGAACAGAGA 
19qSubTel              ACAGAGACACCTTGAAACAAAAAGCCAGGAATAACTTCCAACCCAAGAGGAGAACAGAGA 
21qSubTel              ACA--GACACCTTGAAACAAAAAGCCAGGAATAACTTCCAACCCAAGAGGAGAACAGAGA 
1qSubTel               ACA--GACACCTTGAAACAAAAAGCCAGGAATAACTTCCAACCCAAGAGGAGAACAGAGA 
2qSubTel               ACAGAGACACCTTGAAACAAAAAGCCAGGAATAACTTCCAACCCAAGAGGAGAACAGAGA 
19p'End'               ACAGAGACACCTTGAAACAAAAAGCCAGGAATAACTTCCAACCCAAGAGGAGAACAGAGA 
8p'End'                ACAGAGACACCTTGAAACAAAAAGCCAGGAATAACTTCCAACCCAAGAGGAGAACAGAGA 
13qSubTel              ACAGAGACACCTTGAAACAAAAAGCCAGGAATAACTTCCGACCCAAGAAGAGAACAGAGA 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      GGCCTCAAAACCAAAGCTAGGATAAGAAACTTGTAGCCCAAGAGTTATCTTCCAGACAAA 
10qSubTel              GGCCTCAAAACCAAAGCTAGGATAAGAAACTTGTAGCCCAAGAGTTATCTTCCAGACAAA 
22qSubTel              GGCCTCAAAACCAAAGGTAGGATAAGAAACTTGTAGCCCAAGAGTTATCTTCCAGACAAA 
1pSubTel               GGCCTCAAAACCAAAGCTAGGATAAGAAACTTGTAGCCCAAGAGTTATCTTCCAGACAAA 
5qSubTel               GGCCTCAAAACCAAAGCTAGGATAAGAAACTTGTAGCCCAAGAGTTATCTTCCAGACAAA 
17qSubTel              GGCCTCAAAACCAAAGCTAGGATAAGAAACTTGTAGCCCAAGAGTTATCTTCCAGACAAA 
4qSubTel               GGCCTCAAAACCAAAGCTAGGATAAGAAACTTGTAGCCCAAGAGTTATCTTCCAGACAAA 
19qSubTel              GGCCTCAAAACCAAAGCTAGGATAAGAAACTTGTAGCCCAAGAGTTATCTTCCAGACAAA 
21qSubTel              GGCCTCAAAACCAAAGGTAGGATAAGAAACTTGTAGCCCAAGAGTTATCTTCCAGACAAA 
1qSubTel               GGCCTCAAAACCAAAGCTAGGATAAGAAACTTGTAGCCCAAGAGTTATCTTCCAGACAAA 
2qSubTel               GGCCTCAAAACCAAAGCTAGGATAAGAAACTTGTAGCCCAAGAGTTATCTTCCAGACAAA 
19p'End'               GGCCTCAAAACCAAAGCTAGGATAAGAAACTTGTAGCCCAAGAGTTATCTTCCAGACAAA 
8p'End'                GGCCTCAAAACCAAAGCTAGGATAAGAAACTTGTAGCCCAAGAGTTATCTTCCAGACAAA 
13qSubTel              GGCCTCAAAACCAAAGCTAGGATAAGAAACTTGTAGCCCAAGAGTTATCTTCCAGACAAA 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      GAAGCCTGAGATTCCAACGCAGCTTCAGAGAGTACTCACTCAAAATGTTACTGAAACTGT 
10qSubTel              GAAGCCTGAGATTCCAACGCAGCTTCAGAGAGTACTCACTCAAAATGTTACTGAAACTGT 
22qSubTel              GAAGCCTGAGATTCCAACGCAGCTTCAGAGAGTGCTCACTCAAAATGTTACTGAAACTGT 
1pSubTel               GAAGCCTGAGATTCCAACGCAGCTTCAGAGAGTACTCACTCAAAATGTTACTGAAACTGT 
5qSubTel               GAAGCCTGAGATTCCAACGCAGCTTCAGAGAGTACTCACTCAAAATGTTACTGAAACTGT 
17qSubTel              GAAGCCTGAGATTCCAACGCAGCTTCAGAGAGTGCTCACTCAAAATGTTACTAAAACTGT 
4qSubTel               GAAGCCTGAGATTCCAACGCAGCTTCAGAGAGTACTCACTCAAAATGTTACTGAAACTGT 
19qSubTel              GAAGCCTGAGATTCCAACGCAGCTTCAGAGAGTGCTCACTCAAAATGTTACTGAAACTGT 
21qSubTel              GAAGCCTGAGATTCCAACGCAGCTTCAGAGAGTGCTCACTCAAAATGTTACTGAAACTGT 
1qSubTel               GAAGCCTGAGATTCCAACGCAGCTTCAGAGAGTGCTCACTCAAAATGTTACTGAAACTGT 
2qSubTel               GAAGCCTGAGATTCCAACGCAGCTTCAGAGAGTACTCACTCAAAATGTTACTGAAACTGT 
19p'End'               GAAGCCTGAGATTCCAACGCAGCTTCAGAGAGTACTCACTCAAAATGTTACTGAAACTGT 
8p'End'                GAAGCCTGAGATTCCAACGCAGCTTCAGAGAGTACTCACTCAAAATGTTACTGAAACTGA 
13qSubTel              GAAGCCTGAGATTCCAACGCAGCTTCAGAGAGTGCTCACTCAAAATGTTACTGAAACTGT 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      AGGCTTTTTAATGACTTAGCCATGCCTGCAAAAGGCATTCCCTAAGGTGGCACAGAAGAC 
10qSubTel              AGGCTTTTTAATGACTTAGCCATGCCTGCAAAAGGCATTCCCTAAGGTGGCACAGAAGAC 
22qSubTel              AGGCTTTTTAATGAGTTAGCCATGCCTGCAAAAGGCATTCCCTAAGGTGGCACAGAAGAC 
1pSubTel               AGGCTTTTTAATGACTTAGCCATGCCTGCAAAAGGCATTCCCTAAGGTGGCACAGAAGAC 
5qSubTel               AGGCTTTTTAATGACTTAGCCATGCCTGCAAAAGGCATTCCCTAAGGTGGCACAGAAGAC 
17qSubTel              AGGCTTTTTAATGACTTAGCCATGCCTGCAAAAGGCATTCCCTAAGGTGGCACAGAAGAC 
4qSubTel               AGGCTTTTTAATGACTTAGCCATGCCTGCAAAAGGCATTCCCTAAGGTGGCACAGAAGAC 
19qSubTel              AGGCTTTTTAATGACTTAGCCATGCCTGCAAAAGGCATTCCCTAAGGTGGCACAGAAGAT 
21qSubTel              AGGCTTTTTAATGACTTAGCCATGCCTGCAAAAGGCATTCCCTAAGGTGGCACAGAAGAC 
1qSubTel               AGGCTTTTTAATGACTTAGCCATGCCTGCAAAAGGCATTCCCTAAGGTGGCACAGAAGAC 
2qSubTel               AGGCTTTTTAATGACTTAGCCATGCCTGCAAAAGGCATTCCCTAAGGTGGCACAGAAGAC 
19p'End'               AGGCTTTTTAATGACTTAGCCATGCATGCAAAAGGCATTCCCTAAGGTGGCACAGAAGAC 
8p'End'                AGGCTTTTTAATGACTTAGCCATGCCTGCAAAAGGCATTCCCTAAGGTGGCACAGAAGAC 
13qSubTel              AGGCTTTTTAATGACTTAGCCATGCCTGCAAAAGGCATTCCCTAAGGTGGCACAGAAGAC 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      GGAGCCCCCATATCCAAAGATAGCCAAGGAGAAAGAAAGACCCCTGTTGCCAGAGCCAGT 
10qSubTel              GGAGCCCCCATATCCAAAGATAGCCAAGGAGAAAGAAAGACCCCTGTTGCCAGAGCCAGT 
22qSubTel              GGAGCCCCCATATCCAAAGATAGCCAAGGAGAAAGAAAGACCCCTGTTGCCAGAGCCAGT 
1pSubTel               GGAGCCCCCATATCCAAAGATAGCCAAGGAGAAAGAAAGACCCCTGTTGCCAGAGCCAGT 
5qSubTel               GGAGCCCCCATATCCAAAGATAGCCAAGGAGAAAGAAAGACCCCTGTTGCCAGAGCCAGT 
17qSubTel              GGAGCCCCCATATCCAAAGATAGCCAAGGAGAAAGAAAGACCCCTGTTGCCAGAGCCAGT 
4qSubTel               GGAGCCCCCATATCCAAAGATAGCCAAGGAGAAAGAAAGACCCCTGTTGCCAGAGCCAGT 
19qSubTel              GGAGCCCCCATATCCAAAGATAGCCAAGGAGAAAGAAAGACCCCTGTTGCCAGAGCCAGT 
21qSubTel              GGAGCCCCCATATCCAAAGATAGCCAAGGAGAAAGAAAGACCCCTGTTGCCAGAGCCAGT 
1qSubTel               GGAGCCCCCATATCCAAAGATAGCCAAGGAGAAAGAAAGACCCCTGTTGCCAGAGCCAGT 
2qSubTel               GGAGCCCCCATATCCAAAGATAGCCAAGGAGAAAGAAAGACCCCTGTTGCCAGAGCCAGT 
19p'End'               GGAGCCCCCATATCCAAAGATAGCCAAGGAGAAAGAAAGACCCCTGTTGCCAGAGCCAGT 
8p'End'                GGAGCCCCCATATCCAAAGATAGCCAAGGAGAAAGAAAGACCCCTGTTGCCAGAGCCAGT 
13qSubTel              GGAGCCCCCATATCCAAAGATAGCCAAGGAGAAAGAAAGACCCCTGTTGCCAGAGCCAGT 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      GGGCAAAGGCAACAGAAAAGGAGACAAGGGTCCTAATGGGGTGAGATCCTTTCGGATTTA 
10qSubTel              GGGAAAAGGTAACAGAAAAGGAGACAAGGGTCCTAATGGGATGAGATCCTTTCGGATTTA 
22qSubTel              GGGCAAAGGCAACAGAAAAGGAGACAAGGGTCCTAATGGGATGAGATCCTTTCGGATTTA 
1pSubTel               GGGAAAAGGTAACAGAAAAGGAGACAAGGGTCCTAATGGGATGAGATCCTTTCGGATTTA 
5qSubTel               GGGCAAAGGCAACAGAAAAGGAGACAAGGGTCCTAATGGGGTGAGATCCTTTCGGATTTA 
17qSubTel              GGGCAAAGGCAACAGAAAAGGAGACAAGGGTCCTAATGGGATGAGATCCTTTCGGATTTA 
4qSubTel               GGGAAAAGGTAACAGAAAAGGAGACAAGGGTCCTAATGGGATGAGATCCTTTCGGATTTA 
19qSubTel              GGGCAAAGGCAACAGAAAAGGAGACAAGGGTCCTAATGGGATGAGATCCTTTCGGATTTA 
21qSubTel              GGGCAAAGGCAACAGAAAAGGAGACAAGGGTCCTAATGGGATGAGATCCTTTCGGATTTA 
1qSubTel               GGGCAAAGGCAACAGAAAAGGAGACAAGGGTCCTAATGGGATGAGATCCTTTCGGATTTA 
2qSubTel               GGGAAAAGGTAACAGAAAAGGAGACAAGGGTCCTAATGGGATGAGATCCTTTCGGATTTA 
19p'End'               GGGCAAAGGCAACAGAAAAGGAGACAAGGGTCCTAATGGGATGAGATCCTTTCGGATTTA 
8p'End'                GGGCAAAGGCAACAGAAAAGGAGACAAGGGTCCTAATGGGATGAGATCCTTTCGGATTTA 
13qSubTel              GGGCAAAGGCAACAGAAAAGGAGACAAGGGTCCTAATGGGATGAGATCCTTTCGGATTTA 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      GGCTTT--TACAAACTCCTGAGAACTGGCAGGTTGACAGCCATAAATGGGGTACCAAACT 
10qSubTel              GGCTTA--TACAAACTCCTGAGAACTGGCAGGTTGACAGCCATAATTGGGGTACCAAACT 
22qSubTel              GGCTTTTATACAAACTCCTGAGAACTGGCAGGTTGACAGCCATAAATGGGGTACCAAACT 
1pSubTel               GGCTTT--TACAAACTCCTGAGAACTGGCAGGTTGACAGCCATAAATGGGGTACCAAACT 
5qSubTel               GGCTTT--TACAAACTCCTGAGAACTGGCAGGTTGACAGCCATAAATGGGGTACCAAACT 
17qSubTel              GGCTTTTATACAAACTCCTGAGAACTGGCAGGTTGACAGCCATAAATGGGGTACCAAACT 
4qSubTel               GGCTTTTATACAAACTCCTGAGAACTGGCAGGTTGACAGCCATAATTGGGGTACCAAACT 
19qSubTel              GGCTTTTATACAAACTCCTGAGAACTGGCAGGTTGACAGCCATAAATGGGGTACCAAACT 
21qSubTel              GGCTTTTATACAAACTCCTGAGAACTGGCAGGTTGACAGCCATAAATGGGGTACCAAACT 
1qSubTel               GGCTTTTATACAAACTCCTGAGAACTGGCAGGTTGACAGCCATAAATGGGGTACCAAACT 
2qSubTel               GGCTTT--TACAAACTCCTGAGAACTGGCAGGTTGACAGCCATAAATGGGGTACCAAACT 
19p'End'               GGCTTT--TACAAACTCCTGAGAACTGGCAGGTTGACAGCCATAAATGGGGTACCAAACT 
8p'End'                GGCTTTTATACAAACTCCTGAGAACTGGCAGGTTGACAGCCATAAATGGGGTACCAAACT 
13qSubTel              GGCTTTTATACAAACTCCTGAGAACTGGCAGGTTGACAGCCATAAATGGGGTACCAAACT 
20qSubTel              ------------------------------------------------------------ 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
 
 
 
 
 
 
 
 
 
 
 
 245 
 
6qPredictedSubTel      TTCTACTCATTGGATTACAAGTTCTCAGGCATCCAGAATGATTAACAAAATGACAATTTC 
10qSubTel              TTCTACTCATTGGATTACAAGTTCTCAGGCATCCAGAATGATTAACAAAATGATAATTTC 
22qSubTel              TTCTACTCATTGGATTACAAGTTCTCAGGCATCCAGAATGATGAACAAAATGACAATTTC 
1pSubTel               TTCTACTCATTGGATTACAAGTTCCCAGGCATCCAGAATGATGAACAAAATGACAATTTC 
5qSubTel               TTCTACTCATTGGATTACAAGTTCTCAGGCATCCAGAATGATTAACAAAATGACAATTTC 
17qSubTel              TTCTACTCATTGGATTACAAGTTCTCAGGCATCCAGAATGATGAACAAAATGACAATTTC 
4qSubTel               TTCTACTCATTGGATTACAAGTTCTCAGGCATCCAGAATGATTAACAAAATGATAATTTC 
19qSubTel              TTCTACTCATTGGATTACAAGTTCTCAGGCATCCAGAATGATTAACAAAATGACAATTTC 
21qSubTel              TTCTACTCATTGGATTACAAGTTCTCAGGCATCCAGAATGATTAACAAAATGACAATTTC 
1qSubTel               TTCTACTCATTGGATTACAAGTTCTCAGGCATCCAGAATGATTAACAAAATGACAATTTC 
2qSubTel               TTCTACTCATTGGATTACAAGTTCTCAGGCATCCAGAATGATTAACAAAATGACAATTTC 
19p'End'               TTCTACTCATTGGATTACAAGTTCTCAGGCATCCAGAATGATGAACAAAATGACAATTTC 
8p'End'                TTCTACTCATTGGATTACAAGTTCTCAGGCATCCAGAATGATGAACAAAATGACAATTTC 
13qSubTel              TTCTACTCATTGGATTACAAGTTCTCAGGCATCCAGAATGATGAACAAAATGACAATTTC 
20qSubTel              -------------------AGTTCTCAAGCATCCAAAATGATTAACAAAATGACAATTTC 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      TAGGGCTTCTGTGGGAGAGTATGGAAAGGTCTTTTTGAACCTTTTAATGCTGTCAACGGA 
10qSubTel              TAGGGCTTCTGTGGGAGAGTATGGAAAGGTCTTTTTGAACCTTTTAATGCTGTCAACGGA 
22qSubTel              TAGGGCTTCTGTGGGAGAGTATGGAAAGGTCTTTTTGAACCTTTTAATGCTGTGAACGGA 
1pSubTel               TAGGGCTTCTGTGGGAGAGTATGGAAAGGTCTTTTTGAACCTTTTAATGCTGTCAACGGA 
5qSubTel               TAGGGCTTCTGTGGGAGAGTATGGAAAGGTCTTTTTGAACCTTTTAATGCTGTCAACGGA 
17qSubTel              TAGGGCTTCTGTGGGAGAGTATGGAAAGGTCTTTTTGAACCTTTTAATGCTGTGAACGGA 
4qSubTel               TAGGGCTTCTGTGGGAGAGTATGGAAAGGTCTTTTTGAACCTTTTAATGCTGTCAACGGA 
19qSubTel              TAGGGCTTCTGTGGGAGAGTATGGAAAGGTCTTTTTGAACCTTTTAATGCTGTCAATGGA 
21qSubTel              TAGGGCTTCTGTGGGAGAGTATGGAAAGGTCTTTTTGAACCTTTTAATGCTGTGAACGGA 
1qSubTel               TAGGGCTTCTGTGGGAGAGTATGGAAAGGTCTTTTTGAACCTTTTAATGCTGTGAACGGA 
2qSubTel               TAGGGCTTCTGTGGGAGAGTATGGAAAGGTCTTTTTGAACCTTTTAATGCTGTCAATGGA 
19p'End'               TAGGGCTTCTGTGGGAGAGTATGGAAAGGTCTTTTTGAACCTTTTAATGCTGTCAACGGA 
8p'End'                TAGGGCTTCTGTGGGAGAGTATGGAAAGGTCTTTTTGAACCTTTTAATGCTGTCAACGGA 
13qSubTel              TAGGGCTTCTGTGGGAGAGTATGGAAAGATCTTTTTGAACCTTTTAATGCTATCAGTGGA 
20qSubTel              TAGGGCTTCTGTGGGAGAGTATGGA-AGGTCTTTTTGAACTTTTTAATGCTGTCAACTAA 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      AGAATGATGAGGTTCATAAATTTGGAAAGGAGACATTTCTTCATTTTTATGCTTATTTTT 
10qSubTel              AGAATGATGAGGTTCATAAATTTGGAAAGGAGACATTTCTTCATTTTTATGCTTATTTTT 
22qSubTel              AGAATGATGAGGTTCATAAATTTGGAAAGGAGACATTTCTTCATTTTTATGCTTATTTTT 
1pSubTel               AGAATGATGAGGTTCATAAATTTGGAAAGGAGACATTTCTTCATTTTTATGCTTATTTTT 
5qSubTel               AGAATGATGAGGTTCATAAATTTGGAAAGGAGACATTTCTTCATTTTTATGCTTATTTTT 
17qSubTel              AGAATGATGAGGTTCATAAATTTGGAAAGGAGACATTTCTTCATTTTTATGCTTATTTTT 
4qSubTel               AGAATGATGAGGTTCATAAATTTGGAAAGGAGACATTTCTTCATTTTTATGCTTATTTTT 
19qSubTel              AGAATGATGAGGTTCATAAATTTGGAAAGGAGACATTTCTTCATTTTTATGCTTATTTTT 
21qSubTel              AGAATGATGAGGTTCATAAATTTGGAAAGGAGACATTTCTTCACTTTTATGCTTATTTTT 
1qSubTel               AGAATGATGAGGTTCATAAATTTGGAAAGGAGACATTTCTTCATTTTTATGCTTATTTTT 
2qSubTel               AGAATGATGAGGTTCATAAATTTGGAAAGGAGACATTTCTTCATTTTTATGCTTATTTTT 
19p'End'               AGAATGATGAGGTTCATAAATTTGGAAAGGAGACATTTCTTCATTTTTATGTTTATTTTT 
8p'End'                AGAATGATGAGGTTCATAAATTTGGAAAGGAGACATTTCTTCATTTTTATGTTTATTTTT 
13qSubTel              AGAACGATGAGGTTCATAAATTTGGAAAGGAGACATTTCTTCATTTTTATGTTTATTTTT 
20qSubTel              AGAATGATGAGGTTCATAAATATGGAAAGGAGAGATTTCTATATTTTTGT--TTA----- 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      AT---TTTTTTTTGAGACAGAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGTATG 
10qSubTel              AT---TCTTTTTTGAGACAGAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGTATG 
22qSubTel              AT---TTTTTTT-GAGACAGAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGCGTG 
1pSubTel               ATT--TTTTTTTTGAGACAGAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGTATG 
5qSubTel               AT---TTTTTTTTGAGACAGAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGTATG 
17qSubTel              AT----TTTTTTTGAGACAGAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGCATG 
4qSubTel               ATT--TTTTTTTTGAGACAGAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGTATG 
19qSubTel              ATT---TTTTTTTGAGACAGAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGTAGG 
21qSubTel              AT---TTTTTTTTGAGACAGAGTTTCACTCTTGTTGCCCAGGCTGCAGTGCAATGGCATG 
1qSubTel               ATT---TTTTTTTGAGACAGAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGCATG 
2qSubTel               ATT---TTTTTTTGAGACAGAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGTATG 
19p'End'               A----TTTTTTTTGAGACAGAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGCGTG 
8p'End'                A----TTTTTTGTGAGACAGAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGCGTG 
13qSubTel              ATTTTTATTTTTTGAGACAGAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGTGTG 
20qSubTel              TTTTTATTTTTTTGAGACGGAGTTTCACTCTTCTTGCCCAGGCTGGAGTGCAATGGCGTA 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      ATCTTGGTTCACTGCAACCTCCACCTCCTGGGTTGAAGCGATTCTCCTGCCTCAGCCTCC 
10qSubTel              ATCTTGGTTCACTGCAACCTCCACCTCCTGGGTTGAAGCGATTCTCCTGCCTCAGCCTCC 
22qSubTel              ATCTTGGTTCACTGCAACCTCCACCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCC 
1pSubTel               ATCTTGGTTCACTGCAACCTCCACCTCCTGGGTTGAAGCGATTCTCCTGCCTCAGCCTCC 
5qSubTel               ATCTTGGTTCACTGCAACCTCCACCTCCTGGGTTGAAGCGATTCTCCTGCCTCAGCCTCC 
17qSubTel              ATCTTGGTTCACTGCAACCTCCACCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCC 
4qSubTel               ATCTTGGTTCACTGCAACCTCCACCTCCTGGGTTGAAGCGATTCTCCTGCCTCAGCCTCC 
19qSubTel              ATCTTGGTTCACTGCAACCTCCACCTCCTGGGTTGAAGCGATTCTCCTGCCTCAGCCTCC 
21qSubTel              ATCTTGGTTCACTGCAACCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCC 
1qSubTel               ATCTTGGTTCACTGCAACCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCC 
2qSubTel               ATCTTGGTTCACTGCAACCTCCACCTCCTGGGTTGAAGCGATTCTCCTGCCTCAGCCTCC 
19p'End'               ATCTTGGCTCACTGCAACCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCC 
8p'End'                ATCTTGGCTCACTGCAACCTCCACCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCC 
13qSubTel              ATCTTGGTTCACTGCAACCTCCACCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCC 
20qSubTel              ATCTTGGCTCACTGCAACCTCCACCTCCCAGGTTCAAGTGATTCTCCTGCATCAGCCTCT 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      TGATTAGCTGGGATTACAGATGCCCACCACCACACCTGGCTAATTTTT---TGCAGTTTT 
10qSubTel              TGATTAGCTGGGATTACAGATGCCCACCACCACACCTGGCTAATTTTT---TGCAGTTTT 
22qSubTel              TGATTAGCTGGGATTACAGATGCCCACCACCACACCTGGCTAATTTTT---TGCAGTTTT 
1pSubTel               TGATTAGCTGGGATTACAGATGCCCACCACCACACCTGGCTAATTTTT---TGCAGTTTT 
5qSubTel               TGATTAGCTGGGATTACAGATGCCCACCACCACACCTGGCTAATTTTT---TGCAGTTTT 
17qSubTel              TGATTAGCTGGGATTACAGATGCCCACCACCACACCTGGCTAATTTTT---TGCAGTTTT 
4qSubTel               TGATTAGCTGGGATTACAGATGCCCACCACCACACCTGGCTAATTTTT---TGCAGTTTT 
19qSubTel              TGATTAGCTGGGATTACAGATGCCCACCACCACACCTGGCTAATTTTT---TGCAGTTTT 
21qSubTel              TGATTAGCTGGGATTACAGATGCCCACCACCACACCTGGCTAATTTTT---TGCAGTTTT 
1qSubTel               TGATTAGCTGGGATTACAGATGCCCACCACCACACCTGGCTAATTTTT---TGCAGTTTT 
2qSubTel               TGATTAGCTGGGATTACAGATGCCCACCACCACACCTGGCTAATTTTT---TGCAGTTTT 
19p'End'               TGATTAGCTGGGATTACAGATGCCCACCACCACACCTGGCTAATTTTT---TGCAGTTTT 
8p'End'                TGATTAGCTGGGATTACAGATGCCCACCACCACACCTGGCTAATTTTT---TGCAGTTTT 
13qSubTel              TGATTAGCTGGGATTACAGATACCCACCACCACACCTGGATAATTTTTTTTTGTATTTTT 
20qSubTel              CGATTAGCTGGGATTACAGACCCTCACCACTATGCCTGGCTAATTTT----TGTTTTTTT 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      GGTAGAGACAGGGTTTCATCATGTTGGCCAGGCTGGTCTGAAACTCCTGACCTCAGGTGA 
10qSubTel              GGTAGAGACAGGGTTTCATCATGTTGGCCAGGCTGGTCTGAAACTCCTCACCTCAGGTGA 
22qSubTel              GGTAGAGACAGGATTTCATCATGTTGGCCAGGCTGGTCTGAAACTCCTGACCTCAGGTGA 
1pSubTel               GGTAGAGACAGGGTTTCATCATGTTGGCCAGGCTGGTCTGAAACTCCTGACCTCAGGTGA 
5qSubTel               GGTAGAGACAGGGTTTCATCATGTTGGCCAGGCTGGTCTGAAACTCCTGACCTCAGGTGA 
17qSubTel              GGTAGAGACAGGATTTCATCATGTTGGCCAGGCTGGTCTGAAACTCCTGACCTCAGGTGA 
4qSubTel               GGTAGAGACAGGGTTTCATCATGTTGGCCAGGCTGGTCTGAAACTCCTGACCTCAGGTGA 
19qSubTel              GGTAGAGACAGGGTTTCATCATGTTGGCCAGGCTGGTCTGAAACTCCTGACCTCAGGTGA 
21qSubTel              GGTAGAGACAGGGTTTCATCATGTTGGCCAGGCTGGTCTGAAACTCCTGACCTCAGGTGA 
1qSubTel               GGTAGAGACAGGGTTTCATCATGTTGGCCAGGCTGGTCTGAAACTCCTGACCTCAGGTGA 
2qSubTel               GGTAGAGACAGGGTTTCATCATGTTGGCCAGGCTGGTCTGAAACTCCTGACCTCAGGTGA 
19p'End'               AGTAGAGACAGGGTTTCATCATGTTGGCCAGGCTGGTCTGAAACTCGTGACCTCAGGTGA 
8p'End'                AGTAGAGACAGGGTTTCATCATGTTGGCCAGGCTGGTCTGAAACTCGTGAGCTCAGGTGA 
13qSubTel              AGTAGAGACAGGGTGTCATCATGTTGGCCAGGCTGGTCTGAAACTCCTGACCTCAGGTGA 
20qSubTel              AGTAGAGATGAGGTTTCACCATGTTGGCCAGTCTGGTCTTGAACGCCTGACCTCAGGTGA 
12qSubTel              ---AGAGGAAGGGTTTCATCATGTTGGCCAGGCTGGTCTGAAACTCCTGACCTCAGGTGA 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      TCCACCCACCTCGGCCTCCCAAAGTGCTGGGATTACAAGCATGAGCCA-CCCACCCAGTG 
10qSubTel              TCCACCCACCTCGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCA-CCCACCCAGTG 
22qSubTel              TCCACCCACCTCGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCA-CCCACCCAGTG 
1pSubTel               TCCACCCACCTCGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCA-CCCACCCAGTG 
5qSubTel               TCCACCCACCTCGGCCTCCCAAAGTGCTGGGATTACAAGCATGAGCCA-CCCACCCAGTG 
17qSubTel              TCCACCCACCTCGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCA-CCCACCCAGTG 
4qSubTel               TCCACCCACCTCGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCA-CCCACCCAGTG 
19qSubTel              TCCACCCACCTCGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCA-CCCACCCAGTG 
21qSubTel              TCCACCCACCTCGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCA-CCCACCCAGTG 
1qSubTel               TCCACCCACCTCGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCA-CCCACCCAGTG 
2qSubTel               TCCACCCACCTCGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCA-CCCACCCAGTG 
19p'End'               TCCACTCGCCTTAGCCTCCCAAAGTGCTGGGATTGCAGGCATGAGCCA-CCCAACCAGTG 
8p'End'                TCCACTTGCCTTAGCCTCCCAAAGTGCTGGGATTGCAGGCATGAGCCA-CCCAACCAGTG 
13qSubTel              TCCACCTGCCTTGGCCTCCCAAAGTGCTGGGTTTACAGGCATGAGCCACCACACCCAATG 
20qSubTel              TCCACCTGCCTCGGCCTCCCAAAGTGCTGGGATTATAGGC-------ACTGCACCCAGTG 
12qSubTel              TCCACCTGCCTCAGCATCCCAAAGTGCTGGGATTACAGGCATGAGCCATCACAACCAGTG 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      AGAGATTTATTTTCTATAAAGGGTTGTAGCCTGCAGGGTTGTCCTTCTGACAGGCTGGGA 
10qSubTel              AGAGATTTATTTTCTATAAAGGGTTGTAGCCTGCAGGGTTGTCCTTCTGACAGGCTGGGA 
22qSubTel              AGAGATTTATTTTCTATAAAGGGTTGTAGCCTGCAGGGTTGTCCTTCTGACAGGCTGGGA 
1pSubTel               AGAGATTTATTTTCTATAAAGGGTTGTAGCCTGCAGGGTTGTCCTTCTGACAGGCTGGGA 
5qSubTel               AGAGATTTATTTTCTATAAAGGGTTGTAGCCTGCAGGGTTGTCCTTCTGACAGGCTGGGA 
17qSubTel              AGAGATTTATTTTCTATAAAGGGTTGTAGCCTGCAGGGTTGTCCTTCTGACAGGCTGGGA 
4qSubTel               AGAGATTTATTTTCTATAAAGGGTTGTAGCCTGCAGGGTTGTCCTTCTGACAGGCTGGGA 
19qSubTel              AGAGATTTATTTTCTATAAAGGGTTGTAGCCTGCAGGGTTGTCCTTCTGACAGGCTGGGA 
21qSubTel              AGAGATTTATTTTCTATAAAGGGTTGTAGCCTGCAGGGTTGTCCTTCTGACAGGCTGGGA 
1qSubTel               AGAGATTTATTTTCTATAAAGGGTTGTAGCCTGCAGGGTTGTCCTTCTGACAGGCTGGGA 
2qSubTel               AGAGATTTATTTTCTATAAAGGGTTGTAGCCTGCAGGGTTGTCCTTCTGACAGGCTGGGA 
19p'End'               AGAGATTTATTTCCTATAAAGGGTTGTAGCCTGCAGGGTTGTCCTTCTGACAGGCTGGGA 
8p'End'                AGAGATTTATTTCCTATAAAGGGTTGTAGCCTGCAGGGTTGTCCTTCTGACAGGCTGGGA 
13qSubTel              AGAGATTTATTTCTTATAAAGGGTTGCAGCCTGAAGGGTTGTCCTTCTGACAGGCTGGGA 
20qSubTel              AGGTATTTATTTCCTGTAAAGGGTTGCAGCCTGCAGGGTAGTCCTTCTGATAGGCTGGGA 
12qSubTel              AGAGATTTGTTTCCTATAAAGGGTTGCAGCCTTCAGGGTTGTCCTTCTGACAGACTGGGA 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      AGCATAGCCTCCAGCCAGAAGCCAGAAACA-GATGTTTCAAGGAGGAGGTAAAGGAAATA 
10qSubTel              AGCATAGCCTCCAGCCAGAAGCCAGAAACA-GATGCTTCAAGGAGGAGGTAAAGGAAATA 
22qSubTel              AGCATAACCTCCAGCCAGAAGCCAGAAACA-GATGCTTCAAGGAGGAGGTAAAGGAAATA 
1pSubTel               AGCATAGCCTCCAGCCAGAAGCCAGAAACA-GATGCTTCAAGGAGGAGGTAAAGGAAATA 
5qSubTel               AGCATAGCCTCCAGCCAGAAGCCAGAAACA-GATGTTTCAAGGAGGAGGTAAAGGAAATA 
17qSubTel              AGCATAGCCTCCAGCCAGAAGCCAGAAACA-GATGCTTCAAGGAGGAGGTAAAGGAAATA 
4qSubTel               AGCATAGCCTCCAGCCAGAAGCCAGAAACA-GATGCTTCAAGGAGGAGGTAAAGGAAATA 
19qSubTel              AGCATAGCCTCCAGCCAGAAGCCAGAAACA-GATGCTTCAAGGAGGAGGTAAAGGAAATA 
21qSubTel              AGCATAGCCTCCAGCCAGAAGCCAGAAACA-GATGCTTCAAGGAGGAGGTAAAGGAAATA 
1qSubTel               AGCATAGCCTCCAGCCAGAAGCCAGAAACA-GATGCTTCAAGGAGGAGGTAAAGGAAATA 
2qSubTel               AGCATAGCCTCCAGCCAGAAGCCAGAAACA-GATGCTTCAAGGAGGAGGTAAAGGAAATA 
19p'End'               AGCATAGCCTCCAGCCAGAAGCCAGAAACA-GACTCTTCAAGGAGGAGGTAAAGGAAATA 
8p'End'                AGCATAGCCTCCAGCCAGAAGCCAGAAACA-GACTCTTCAAGGAGGAGGTAAAGGAAATA 
13qSubTel              AGCACAGCCTCCAGCCAGAAGCCAGAAACA-GATGCTTCAAGGAGGAGGTAAAGGAAATA 
20qSubTel              AGCATAGCCTCCAGCCAGAAACTAGAAACAAGACACTTCAAGGAAGAGGTGAAGGAAACA 
12qSubTel              AGCATAGCTTCCAGGCAGAAGCCAGAAACG-GATGCTTCAAGGAGGATGCAAAGGAAATA 
7qSubTel               --------------------------------------------------------AATA 
                                                                               ** * 
 
6qPredictedSubTel      GCAATTTATGCTGAGTGGAATGGCCAAATAGATTTATTTAATAAGCTCTAGGAGGAGTCA 
10qSubTel              GCAATTTATGCTGAGTGGAATGGCCAAATAGATTTATTTAATAAGCTCTAGGAGGAGTCA 
22qSubTel              GCAACTTATGCTGAGTGGAATGGCCAAATAGATTTATTTAATAAGCTCTAGGAGGAGTCA 
1pSubTel               GCAATTTATGCTGAGTGGAATGGCCAAATAGATTTATTTAATAAGCTCTAGGAGGAGTCA 
5qSubTel               GCAATTTATGCTGAGTGGAATGGCCAAATAGATTTATTTAATAAGCTCTAGGAGGAGTCA 
17qSubTel              GCAACTTATGCTGAGTGGAATGGCCAAATAGATTTATTTAATAAGCTCTAGGAGGAGTCA 
4qSubTel               GCAATTTATGCTGAGTGGAATGGCCAAATAGATTTATTTAATAAGCTCTAGGAGGAGTCA 
19qSubTel              GCAACTTATGCTGAGTGGAATGGCCAAATAGATTTATTTAATAAGCTCTAGGAGGAGTCA 
21qSubTel              GCAACTTATGCTGAGTGGAATGGCCAATTAGATTTATTTAATAAGCTCTAGGAGGAGTCA 
1qSubTel               GCAACTTATGCTGAGTGGAATGGCCAAATAGATTTATTTAATAAGCTCTAGGAGGAGTCA 
2qSubTel               GCAATTTATGCTGAGTGGAATGGCCAAATAGATTTATTTAATAAGCTCTAGGAGGAGTCA 
19p'End'               GCAATTTATGCTGACTGGAATGGCCAAATACATTTATTTAATAAGCTCCAGGAGGAGTCA 
8p'End'                GCAATTTATGCTGACTGGAATGGCCAAATACATTTATTTAATAAGCTCCAGGAGGAGTCA 
13qSubTel              GTAATTTATGCTGATTGGAATGGCCAAATGCATTTATTTAATAAGCTCTAGGAGGAGTCA 
20qSubTel              GTAATTTATGCTGAGTGGCATGGCCAAATACACATCTTTAATAAGCTCTAGGCGGAGTCA 
12qSubTel              GTAATTTATGCTGAGTGGAATGGCCAAATACATTTATTTAATATGCTCTAGGAGGAGTCA 
7qSubTel               GTAATTTATGCTGAGTGGAATGGCCAAATACATTTATTTAATATGCTCTAGGAGGAGTCA 
                       * ** ********* ***.********:*. * :*.*******:**** ***.******* 
 
6qPredictedSubTel      TGAATATTTATGGAAGGAGAAATGCATGCACGCACA-ATTGAGTTTCTTGCTTCTTCATG 
10qSubTel              TGAATATTTATGGAAGGAGAAATGCATGCACGCACA-ATTGAGTTTCTTGCTTCTTCATG 
22qSubTel              TGAATATTTATGGAAGGAGAAATGCATGCACGCACA-ATTGAGTTTCTTGCTTCTTCATG 
1pSubTel               TGAATATTTATGGAAGGAGAAATGCATGCACGCACA-ATTGAGTTTCTTGCTTCTTCATG 
5qSubTel               TGAATATTTATGGAAGGAGAAATGCATGCACGCACA-ATTGAGTTTCTTGCTTCTTCATG 
17qSubTel              TGAATATTTATGGAAGGAGAAATGCATGCACGCACA-ATTGAGTTTCTTGCTTCTTCATG 
4qSubTel               TGAATATTTATGGAAGGAGAAATGCATGCACACACA-ATTGAGTTTCTTGCTTCTTCATG 
19qSubTel              TGAATATTTATGGAAGGAGAAATGCATGCACGCACA-ATTGAGTTTCTTGCTTCTTCATG 
21qSubTel              TGAATATTTATGGAAGGAGAAATGCATGCACGCACA-ATTGAGTTTCTTGCTTCTTCATG 
1qSubTel               TGAATATTTATGGAAGGAGAAATGCATGCACGCACA-ATTGAGTTTCTTGCTTCTTCATG 
2qSubTel               TGAATATTTATGGAAGGAGAAATGCATGCACGCACA-ATTGAGTTTCTTGCTTCTTCATG 
19p'End'               TGAATATTTATGGAAGGAGAAATGCATGCATGCACA-ATTGAGTTTCTGGCTTCTTCATG 
8p'End'                TGAATATTTATGGAAGGAGAAATGCATGCATGCACA-ATTGAGTTTCTGGCTTCTTCATG 
13qSubTel              TGAATATTTATGGAAGGAGAAATGCATGCATGTGCA-ATTGAGTTTCTTGCTTCTTCATG 
20qSubTel              TGAATATTTATGAAAGGGGAAATGCGTGCATGCACA-ACTGAGTTCCTTGGTTCTTCATG 
12qSubTel              TGAATATTTATGGAAGGAGAAATGCATGCATGCTTTAATTGAGTTTCTTGCTTCTTCATG 
7qSubTel               TGAATATTTATGGAAGGAGAAATGCATGCATGCGCA-ATTGAGTTTCTTGCTTCTTCATG 
                       ************.****.*******.**** .   : * ****** ** * ********* 
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6qPredictedSubTel      GGTCCCATGTACAAAAAATGGCAGTGTTAGCATGATCCCAGGGTGGAGTTTTCAGCCCTC 
10qSubTel              GGTCCCATGTACAAAAAATGGCAGTGTTAGCATGATCCCAGGGTGGAGTTTTCAGCCCTC 
22qSubTel              GGTCCCATGTACAAAAAATGGCAGTGTTAGCATGATCCCAGGGTGGAGTTTTCAGCCCTC 
1pSubTel               GGTCCCATGTACAAAAAATGGCAGTGTTAGCATGATCCCAGGGTGGAGTTTTCAGCCCTC 
5qSubTel               GGTCCCATGTACAAAAAATGGCAGTGTTAGCATGATCCCAGGGTGGAGTTTTCAGCCCTC 
17qSubTel              GGTCCCATGTACAAAAAATGGCAGTGTTAGCATGATCCCAGGGTGGAGTTTTCAGCCCTC 
4qSubTel               GGTCCCATGTACAAAAAATGGCAGTGTTAGCATGATCCCAGGGTGGAGTTTTCAGCCCTC 
19qSubTel              GGTCCCATGTACAAAAAATGGCAGTGTTAGCATGATCCCAGGGTGGAGTTTTCAGCCCTC 
21qSubTel              GGTCCCATGTACAAAAAATGGCAGTGTTAGCATGATCCCAGGGTGGAGTTTTCAGCCCTC 
1qSubTel               GGTCCCATGTACAAAAAATGGCAGTGTTAGCATGATCCCAGGGTGGAGTTTTCAGCCCTC 
2qSubTel               GGTCCCATGTACAAAAAATGGCAGTGTTAGCATGATCCCAGGGTGGAGTTTTCAGCCCTC 
19p'End'               GGTCCCATGTACAAAAAATGGCAGTGTTAGCATGATCCCAGGGTGGAGTTTTCAGCCCTC 
8p'End'                GGTCCCATGTACAAAAAATGGCAGTGTTAGCATGATCCCAGGGTTGAGTTTTCAGCCCTC 
13qSubTel              GGTCCCATGTACAAAAAATGGCAGTGTTATCATGATCCCAGGGTGGAGTTTTCAGCTATC 
20qSubTel              GGTCCCATGTACAAAAAATAGCAGTGTTAGCATCATCCCAGGGTGGAGTTTTCAGCCCTC 
12qSubTel              GGTCCCATGTACAAAAAATGGCAGTGTTAGCATGATCCCATGGTGGAGTTTTCAGCCCTC 
7qSubTel               GGTCCCATGTACAAAAAATGGCGGTGTTAGCATGATCCCATGGTGGAGTTTTCAGCCCTC 
                       *******************.**.****** *** ****** *** *********** .** 
 
6qPredictedSubTel      TGACATTAAAAGGTGAAGCAGAGGAAATGAAAACTCGCTCTGTGCATCCTCTGTACGCTG 
10qSubTel              TGACATTAAAAGGTGAAGCAGAGGAAATGAAAACTCGCTCTGTGCATCCTCTGTACGCTG 
22qSubTel              TGACATTAAAAGGTGAAGCAGAGGACATGAAAACTCGCTCTGTGCATCCTCTGTACGCTG 
1pSubTel               TGACGTTAAAAGGTGAAGCAGAGGAAATGAAAACTCGCTCTGTGCATCCTCTGTACGCTG 
5qSubTel               TGACATTAAAAGGTGAAGCAGAGGAAATGAAAACTCGCTCTGTGCATCCTCTGTACGCTG 
17qSubTel              TGACATTAAAAGGTGAAGTAGAGGACATGAAAACTTGCTCTGTGCATCCTCTGTACGCTG 
4qSubTel               TGACATTAAAAGGTGAAGCAGAGGAAATGAAAACTCGCTCTGTGCATCCTCTGTACGCTG 
19qSubTel              TGACATTAAAAGGTGAAGCAGAGGACATGAAAACTTGCTCTGTGCATCCTCTGTACGCTG 
21qSubTel              TGACATTAAAAGGTGAAGCAGAGGACATGAAAACTTGCTCTGTGCATCCTCTGTACACTG 
1qSubTel               TGACATTAAAAGGTGAAGCAGAGGACATGAAAACTTGCTCTGTGCATCCTCTGTACGCTG 
2qSubTel               TGACATTAAAAGGTGAAGCAGAGGAAATGAAAACTCGCTCTGTGCATCCTCTGTACGCTG 
19p'End'               TGACATTAAAAGGTGAAGCAGAGGACATGAAAACTCGCTCTGTGCATCCTCTGTACGCTG 
8p'End'                TGACATTAAAAGGTGAAGCAGAGGACATGAAAACTCGCTCTGTGCATCCTCTGTACGCTG 
13qSubTel              TGACATTAAAAGGTGAAGCAGAGGACATGAAAACTCGCTCTGTGCATCCTCTGTACACTG 
20qSubTel              TGACATTAAAAGGTGAAGCAGAGGACATGAAAACTCGCTCTGTGCATCCTCTGTGTGCTG 
12qSubTel              TGACATTAAAAGGTGAAGCAGAGTACATGAAAACTCGCTCTGTGCATCCTCTGTATGCTG 
7qSubTel               TGACATTAAAAGGTGAAGCAGAGTACATGAAAACTCGCTCGGTGCATCCTCTGTATGCTG 
                       ****.************* **** *.********* **** *************. .*** 
 
6qPredictedSubTel      GCCAGAACCTCTCCATCGTGGGTGGTCTCTTATCAGGCAAGAAAGGAGAGGTTGATATCA 
10qSubTel              GCCAGAACCTCTCCATCGTGGGTGGTCTCTTATCAGGCAAGAAAGGAGAGGTTGATATCA 
22qSubTel              GCCAGAACCTCTCCATCGTGGGTGGTCTCTTATCAGGCAAGAAAGGAGAGGTTGATATCA 
1pSubTel               GCCAGAACCTCTCCATCGTGGGTGGTCTCTTATCAGGCAAGAAAGGAGAGGTTGATATCA 
5qSubTel               GCCAGAACCTCTCCATCGTGGGTGGTCTCTTATCAGGCAAGAAAGGAGAGGTTGATATCA 
17qSubTel              GCCAGAACCTCTCCATCGTGGGTGGTCTCTTATCAGGGAAGAAAGGAGAGGTTGATATCA 
4qSubTel               GCCAGAACCTCTCCATCGTGGGTGGTCTCTTATCAGGCAAGAAAGGAGAGGTTGATATCA 
19qSubTel              GCCAGAACCTCTCCATCGTGGGTGGTCTCTTATCAGGCAAGAAAGGAGAGGTTGATATCA 
21qSubTel              GCCAGAACCTCTCCATCGTGGGTGGTCTCTTATCAGGCAAGAAAGGAGAGGTTGATATCA 
1qSubTel               GCCAGAACCTCTCCATCGTGGGTGGTCTCTTATCAGGCAAGAAAGGAGAGGTTGATATCA 
2qSubTel               GCCAGAACCTCTCCATCGTGGGTGGTCTCTTATCAGGCAAGAAAGGAGAGGTTGATATCA 
19p'End'               GCCAGAACCTCTCTGTTGTGGGTGGTCTCTTATCAGGCAAGAAAGGAGAGGTTGATATCA 
8p'End'                GCCAGAACCTCTCTGTTGTGGGTGGTCTCTTATCAGGCAAGAAAGGAGAGGTTGATATCG 
13qSubTel              GCCAGAACCTCTCCATTGTGGGTGGTCTCTTATCAGGCAAGAAAGGAGAGGTTGATATCA 
20qSubTel              TCCAGAACCTCTCCGTCATGGGTGGTCTCTTATCAGGCAAGAAAGGAGAGGTTGATATCA 
12qSubTel              GCCAGAACCTCTCCATCATGGGTGGTCTCTTATCAGGCAAGAAAGGAGAGGTTGATATCA 
7qSubTel               GCCAGAACCTCTCCATCATGGGTGGTCTCTTATCAGGCAAGAAAGGAGAGGTTGATATCA 
                        ************ .* .******************* *********************. 
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6qPredictedSubTel      GTGGTGGAGGCTTTGAAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
10qSubTel              GTGGTGGAGGCTTTGAAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
22qSubTel              GTGGTGGAGGCTTTGAAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
1pSubTel               GTGGTGGAGGCTTTGAAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
5qSubTel               GTGGTGGAGGCTTTGAAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
17qSubTel              GTGGTGGAGGCTTTGAAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
4qSubTel               GTGGTGGAGGCTTTGAAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
19qSubTel              GTAGTGGAGGCTTTGAAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
21qSubTel              GTGGTGGAGGCTTTGAAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
1qSubTel               GTGGTGGAGGCTTTGAAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
2qSubTel               GTGGTGGAGGCTTTGAAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
19p'End'               GTAGTGGAGGCTTTGAAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
8p'End'                GTAGTGGAGGCTTTGAAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
13qSubTel              GTGGTAGAGCCTTTGAAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
20qSubTel              GTGGT---GATTTTGAAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
12qSubTel              GTGGTGTAGCCTTTGGAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
7qSubTel               GTGGTGTAGCCTTTGGAAGGGCTGGTTTCTGTTAAATCCTTAGGGAAGAAAGCCTCATCA 
                       **.**   *  ****.******************************************** 
 
6qPredictedSubTel      TGGTTAGCAAAGGAGGGGGTATAACGATGTGTATCTTAACCCCATCATCCCATCCTAGCA 
10qSubTel              TGGTTAGCAAAGGAGGGGGTATAACGATGTGTATCTTAACCCCATCATCGCATCCTAGCA 
22qSubTel              TGGTTAGCAAAGGAGGGGGTATAACGATGTGTATCTTAACCCCATCATCCCATCCTAGCA 
1pSubTel               TGGTTAGCAAAGGAGGGGGTATAACGATGTGTATCTTAACCCCATCATCGCATCCTAGCA 
5qSubTel               TGGTTAGCAAAGGAGGGGGTATAACGATGTGTATCTTAACCCCATCATCCCATCCTAGCA 
17qSubTel              TGGTTAGCAAAGGAGGGGGTATAACGATGTGTATCTTAACCCCATCATCCCATCCTAGCA 
4qSubTel               TGGTTAGCAAAGGAGGGGGTATAACGATGTGTATCTTAACCCCATCATCGCATCCTAGCA 
19qSubTel              TGGTTAGCAAAGGAGGGGGTATAACGATGTGTATCTTAACCCCATCATCCCATCCTAGCA 
21qSubTel              TGGTTAGCAAAGGAGGGGGTATAACGATGTGTATCTTAACCCCATCATCCCATCCTAGCA 
1qSubTel               TGGTTAGCAAAGGAGGGGGTATAACGATGTGTATCTTAACCCCATCATCCCATCCTAGCA 
2qSubTel               TGGTTAGCAAAGGAGGGGGTATAACGATGTGTATCTTAACCCCATCATCGCATCCTAGCA 
19p'End'               TGGTTAGCAAAGGAGTGGGTTTAACGATGTGTATGTTAACCCCATCATCCCATCCTAGCA 
8p'End'                TGGTTAGCAAAGGAGTGGGTTTAACGATGTGTATGTTAACCCCATCATCCCATCCTAGCA 
13qSubTel              AGGTTAGCAAAGGAAGGGGTATAACGATGTGTATCTGACCTCCATCATCCCATCCTAGCA 
20qSubTel              TGGTTTGCAAAGCAGGGGGTATAATGGGGTGTACCTGACTCCCATCATCCCATTCTGGCC 
12qSubTel              TGGTTAGCAAAGGAGGGGGTATAACGATGTGTATCTGACCCCCATCATCCCATCCTAGCA 
7qSubTel               TGGTTAGCAAAGGAGGGGGTATAACGATGTGTATCTGACCCCCATCATCCCATCCTAGCA 
                       :****:****** *. ****:*** *. *****  * *.  ******** *** **.**. 
 
6qPredictedSubTel      AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGGGGTCCCCTCAGCCAAGAGTGGGTCTGT 
10qSubTel              AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGGGGTCCCCTCAGCCAAGAGTGGGTCTGT 
22qSubTel              AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGGGGTCCCCTCAGCCAAGAGTGGGTCTGT 
1pSubTel               AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGGGGTCCCCTCAGCCAAGAGTGGGTCTGT 
5qSubTel               AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGGGGTCCCCTCAGCCAAGAGTGGGTCTGT 
17qSubTel              AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGGGGTCCCCTCAGCCAAGAGTGGGTCTGT 
4qSubTel               AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGGGGTCCCCTCAGCCAAGAGTGGGTCTGT 
19qSubTel              AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGGGGTCCCCTCAGCCAAGAGTGGGTCTGT 
21qSubTel              AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGGGGTCCCCTCAGCCAAGAGTGGGTCTGT 
1qSubTel               AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGGGGTCCCCTCAGCCAAGAGTGGGTCTGT 
2qSubTel               AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGGGGTCCCCTCAGCCAAGAGTGGGTCTGT 
19p'End'               AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGTGGTCCCCTCAGCCAAGAGTGGTTCTGT 
8p'End'                AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGTGGTCCCCTCAGCCAAGAGTGGTTCTGT 
13qSubTel              AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGGGGTCCCCTCAGCCAAGAGTGGGTCTGT 
20qSubTel              AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGGGGTCCCCTCAGCCAAGAGTGGGTCTGT 
12qSubTel              AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGGGGTCCCCTCAGCCAAGAGTGGGTCTGT 
7qSubTel               AAGCTGAGAACTCAGTTTTGAAAGTTACTCTGGGGTCCCCTCAGCCAAGAGTGGGTCTGT 
                       ******************************** ********************* ***** 
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6qPredictedSubTel      TCAGTCAGTTGGGAGCTTAGAATTTAATTTTCATTTATCAATGCTAATGCGAAAGAGTAC 
10qSubTel              TCAGTCAGTTGGGAGCTTAGAATTTAATTTTCATTTATCAATGCTAATGCGAAAGAGTAC 
22qSubTel              TCAGTCAGTTGGGAGCTTAGAATTTAATTTTCATTTATCAATGCTAATGGGAAAGAGTAC 
1pSubTel               TCAGTCAGTTGGGAGCTTAGAATTTAATTTTCATTTATCAATGCTAATGCGAAAGAGTAC 
5qSubTel               TCAGTCAGTTGGGAGCTTAGAATTTAATTTTCATTTATCAATGCTAATGCGAAAGAGTAC 
17qSubTel              TCAGTCAGTTGGGAGCTTAGAATTTAATTTTCATTTATCAATGCTAATGGGAAAGAGTAC 
4qSubTel               TCAGTCAGTTGGGAGCTTAGAATTTAATTTTCATTTATCAATGCTAATGCGAAAGAGTAC 
19qSubTel              TCAGTCAGTTGGGAGCTTAGAATTTAATTTTCATTTATCAATGCTAATGGGAAAGAGTAC 
21qSubTel              TCAGTCAGTTGGGAGCTTAGAATTTAATTTTCATTTATCAATGCTAATGGGAAAGAGTAC 
1qSubTel               TCAGTCAGTTGGGAGCTTAGAATTTAATTTTCATTTATCAATGCTAATGGGAAAGAGTAC 
2qSubTel               TCAGTCAGTTGGGAGCTTAGAATTTAATTTTCATTTATCAATGCTAATGCGAAAGAGTAC 
19p'End'               TCAGTCAGTTGGGAGCTTATAATTTAATTTTTGTTTATCAATGCTAATGCGAAAGAGTAC 
8p'End'                TCAGTCAGTTGGGAGCTTATAATTTAATTTTTGTTTATCAATGCTAATGCGAAAGAGTAC 
13qSubTel              TCAGTCAGTTGGGAGCTTAGGATTTTATTTTCATTTATCAATGCTAATGGGAAAGAGTAC 
20qSubTel              TCAGTCAGCTGGGAGCTTAGGATTTCATTTTCATTTATCAATGCTAATGGGAATGAGCAG 
12qSubTel              TCAGTCAGTTGGGAGCTTAGGATTTCATTTTCATTTATCAATGCTAATGGGAAAGAGTAC 
7qSubTel               TCAGTCAGTTGGGAGCTTAGGATTTCATTTTCATTTATCAATGCTAATGGGAAAGAGTAC 
                       ******** ********** .**** ***** .**************** ***:*** *  
 
6qPredictedSubTel      GCTGTCTTCATGGCAGCTGAATTTGCAAGAAAC--------------------------- 
10qSubTel              GCTGTCTTCATGGCAGCTGAATTTGCAAGAAAC--------------------------- 
22qSubTel              GCTGTCTTCATGGCAGCTGAATTTGCAAGAAAC--------------------------- 
1pSubTel               GCTGTCTTCATGGCAGCTGAATTTGCAAGAAAC--------------------------- 
5qSubTel               GCTGTCTTCATGGCAGCTGAATTTGCAAGAAAC--------------------------- 
17qSubTel              GCTGTCTTCATGGCAGCTGAATTTGCAAGAAAC--------------------------- 
4qSubTel               GCTGTCTTCATGGCAGCTGAATTTGCAAGAAAC--------------------------- 
19qSubTel              GCTGTCTTCATGGCAGCTGAATTTGCAAGAAAC--------------------------- 
21qSubTel              GCTGTCTTCATGGCAGCTGAATTTGCAAGAAAC--------------------------- 
1qSubTel               GCTGTCTTCATGGCAGCTGAATTTGCAAGAAAC--------------------------- 
2qSubTel               GCTGTCTTCATGGCAGCTGAATTTGCAAGAAAC--------------------------- 
19p'End'               GCTGTCTTCATGGCAGCTGAATTTGCAAGAAAC--------------------------- 
8p'End'                GCTGTCTTCATGGCAGCTGAATTTGCAAGAAAC--------------------------- 
13qSubTel              GCTGTGTCTATGGCAGCTGAATTTGCAAGAAAC--------------------------- 
20qSubTel              TCTATCTTCATGGCAGCTGAATTTGCAAGAAACTTCGTGGATGGGGTTAACGGCAGCTGT 
12qSubTel              ACTGTCTTCATGGCAGCTGAATTTGCAAGAAAC--------------------------- 
7qSubTel               ACTGTCTTCATGGCAGCTGAATTTGCAAGAAAC--------------------------- 
                        **.* *  ************************                            
 
6qPredictedSubTel      -----------------------------------------------------TCCTTGG 
10qSubTel              -----------------------------------------------------TCCTTGG 
22qSubTel              -----------------------------------------------------TCCTTGG 
1pSubTel               -----------------------------------------------------TCCTTGG 
5qSubTel               -----------------------------------------------------TCCTTGG 
17qSubTel              -----------------------------------------------------TCCTTGG 
4qSubTel               -----------------------------------------------------TCCTTGG 
19qSubTel              -----------------------------------------------------TCCTTGG 
21qSubTel              -----------------------------------------------------TCCTTGG 
1qSubTel               -----------------------------------------------------TCCTTGG 
2qSubTel               -----------------------------------------------------TCCTTGG 
19p'End'               -----------------------------------------------------TCCTTGG 
8p'End'                -----------------------------------------------------TCCTTGG 
13qSubTel              -----------------------------------------------------TCCTTGG 
20qSubTel              ATTTTCTGGGCGCTCCATGGATGGGGTTAACGGCAGCTGAATTTGCAAGGAACTCCGTGG 
12qSubTel              -----------------------------------------------------TCCTTGG 
7qSubTel               -----------------------------------------------------TCCTTGG 
                                                                            *** *** 
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6qPredictedSubTel      ATGGGGTTAATGGCAGCTGTATTTTACTGGGAGCTCTGCTTTAATTGGATAAAGTAAGTT 
10qSubTel              ATGGGGTTAATGGCAGCTGTATTTTACTGGGAGCTCTGCTTTAATTGGATAAAGTAAGTT 
22qSubTel              ATGGGGTTAATGGCAGCTGTATTTTTCTGGGAGCTGTGCTTTAATTGGATAAAGTAAGTT 
1pSubTel               ATGGGGTTAATGGCAGCTGTATTTTACTGGGAGCTCTGCTTTAATTGGATAAAGTAAGTT 
5qSubTel               ATGGGGTTAATGGCAGCTGTATTTTACTGGGAGCTCTGCTTTAATTGGATAAAGTAAGTT 
17qSubTel              ATGGGGTTAATGGCAGCTGTATTTTTCTGGGAGCTGTGCTTTAATTGGATAAAGTAAGTT 
4qSubTel               ATGGGGTTAATGGCAGCTGTATTTTACTGGGAGCTCTGCTTTAATTGGATAAAGTAAGTT 
19qSubTel              ATGGGGTTAATGGCAGCTGTATTTTTCTGGGAGCTGTGCTTTAATTGGATAAAGTAAGTT 
21qSubTel              ATGGGGTTAATGGCAGCTGTATTTTTCTGGGAGCTGTGCTTTAATTGGATAAAGTAAGTT 
1qSubTel               ATGGGGTTAATGGCAGCTGTATTTTTCTGGGAGCTGTGCTTTAATTGGATAAAGTAAGTT 
2qSubTel               ATGGGGTTAATGCCAGCTGTATTTTACTGGGAGCTCTGCTTTAATTGGATAAAGTAAGTT 
19p'End'               ATGGGGTTAATGGCAGCTGTATTTTTCTGGGAGCTCTGCTTTAATTGGACAAAGTAAGTT 
8p'End'                ATGGGGTTAATGGCAGCTGTATTTTTCTGGGAGCTCTGCTTTAATTGGACAAAGTAAGTT 
13qSubTel              ATGGGGTTAATGGCAGTTGTATTTTTCTGGGAGTTCTGCTTTAATTGGATAAAGTAAGTT 
20qSubTel              ATGGGGTTAATGGCAGCTGTAT-TTTCTGGGAGCTGTGCTTTAATTGGATAAAGTAAGTT 
12qSubTel              ATGGGGTTAA-TGCAGCTGTATTTTTCTGGGAGCTCTGCTTTAATTGGATAAAGTAAGTT 
7qSubTel               ATGGGGTTAA-TGCAGCTGTATTTTTCTGGGAGCTCTGCTTTAATTGGATAAAGTAAGTT 
                       **********   *** ***** **:******* * ************* ********** 
 
6qPredictedSubTel      CTGGTAAGATTTCTTC----TTCTTCAGTATCTCAAATGTTTTCATTTAAATAATCTTTA 
10qSubTel              CTGGTAAGATTTCTTC----ATCTTCAGTATCTCAAATGTTTTCATTTAAATAATCTTTA 
22qSubTel              CTGGTAAGATTTCTTC----ATCTTCAGTATCTCAAATGTTTTCATTTAAATAATCTTTA 
1pSubTel               CTGGTAAGATTTCTTC----ATCTTCAGTATCTCAAATGTTTTCATTTAAATAATCTTTA 
5qSubTel               CTGGTAAGATTTCTTC----TTCTTCAGTATCTCAAATGTTTTCATTTAAATAATCTTTA 
17qSubTel              CTGGTAAGATTTCTTC----ATCTTCAGTATCTCAAATGTTTTCATTTAAATAATCTTTA 
4qSubTel               CTGGTAAGATTTCTTC----ATCTTCAGTATCTCAAATGTTTTCATTTAAATAATCTTTA 
19qSubTel              CTGGTAAGATTTCTTC----ATCTTCAGTATCTCAAATGTTTTCATTTAAATAATCTTTA 
21qSubTel              CTGGTAAGATTTCTTC----ATCTTCAGTATCTCAAATGTTTTCATTTAAATAATCTTTA 
1qSubTel               CTGGTAAGATTTCTTC----ATCTTCAGTATCTCAAATGTTTTCATTTAAATAATCTTTA 
2qSubTel               CTGGTAAGATTTCTTC----ATCTTCAGTATCTCAAATGTTTTCATTTAAATAATCTTTA 
19p'End'               GTGGTAAGATTTCTTCTTTTATCTTCAGTATCTCAAATGTTTTCATTTAAATAATCTTTA 
8p'End'                GTGGTAAGATTTCTTCTTTTATCTTCAGTATCTCAAATGTTTTCATTTAAATAATCTTTA 
13qSubTel              CTGGTAAGATTTCTTCCTTTATCTTCAGTATCTCAAGTGTTTTCACTTAAATAATCTTTA 
20qSubTel              CTGGTAAGATTTCTTCCTTCATCTTCGGTATCTCAAATGTTTTCATTTAAATAATCTTTA 
12qSubTel              CTGGTAAGATTTCTTCCTTTATCTTCAGTATCTCAAATGTTTTCATTTAAATAATCTGTG 
7qSubTel               CTGGTATGATTTCTTCCTTTATCTTCAGTATCTCAAATGTTTTCATTTAAATAATCTGTG 
                        *****:*********    :*****.*********.******** *********** *. 
 
6qPredictedSubTel      TAACAACTTTTGATGTCTGAGTGGAGTCCCACACAGTCATCTATTGT-AAGACTTTCTGA 
10qSubTel              TAACAACTTTTGATGTCTGAGTGGAGTCCCACACAGTCATCTATTGT-AAGACTTTCTGA 
22qSubTel              TAACAACTTTTGATGTCTGAGTGGATTCCCACACAGTCATCTATTGT-AAGACTTTCTGA 
1pSubTel               TAACAACTTTTGATGTCTGAGTGGAGTCCCACACAGTCATCTATTGT-AAGACTTTCTGA 
5qSubTel               TAACAACTTTTGATGTCTGAGTGGAGTCCCACACAGTCATCTATTGT-AAGACTTTCTGA 
17qSubTel              TAACAACTTTTGATGTCTGAGTGGATTCCCACACAGTCATCTATTGT-AAGACTTTCTGA 
4qSubTel               TAACAACTTTTGATGTCTGAGTGGAGTCCCACACAGTCATCTATTGT-AAGACTTTCTGA 
19qSubTel              TAACAACTTTTGATGTCTGAGTGGATTCCCACACAGTCATCTATTGT-AAGACTTTCTGA 
21qSubTel              TAACAACTTTTGATGTCTGAGTGGATTCCCACACAGTCATCTATTGT-AAGACTTTCTGA 
1qSubTel               TAACAACTTTTGATGTCTGAGTGGATTCCCACACAGTCATCTATTGT-AAGACTTTCTGA 
2qSubTel               TAACAACTTTTGATGTCTGAGTGGATTCCCACACAGTCATCTATTGT-AAGGCTTTCTGA 
19p'End'               TAACAACTTTTGATGTCTGAGTGGATTCCCACACAGTCATCTATTGT-AAGACTTTCTGA 
8p'End'                TAACAACTTTTGATGTCTGAGTGGATTCCCATACAGTCATCTATTGT-AAGACTTTCTGA 
13qSubTel              TAACAACTTTTGATGTCTGAGTGGAGTCCCACACAGTCGTCTATTGT-AAGACTTTCTGA 
20qSubTel              TAATAACTCTTGATGTCTGAGGGGGTTCCCACACAGTCATCTATTGT-AAGACTTTCTGA 
12qSubTel              TAAAAATTTTTGATGTCAGAGTGGATTCCCACACAGTCATCTATTGT-AAGACTTTCTGA 
7qSubTel               TAACAATTTTTGATGTCAGAGTAGATTCCCACACAGTCATCTATTGTTAAGACTTTCTGA 
                       *** ** * ********:*** .*. ***** ******.******** ***.******** 
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6qPredictedSubTel      TTCCTTTTTTTTCCTTTGGTCATTATGAATAGGGCTTCTGTAAATAACTGCATGGTAGCT 
10qSubTel              TTCCTTTTTTTTCCTTTGGTCATTATGAATAGGGCTTCTGTAAATAACTGCATGGTAGCT 
22qSubTel              TTCCTTTTTTTTCCTTTGGTCATTATGAATAGGGCTTCTGTAAATAACTGCATGGTAGCT 
1pSubTel               TTCCTTTTTTTTCCTTTGGTCATTATGAATAGGGCTTCTGTAAATAACTGCATGGTAGCT 
5qSubTel               TTCCTTTTTTTTCCTTTGGTCATTATGAATAGGGCTTCTGTAAATAACTGCATGGTAGCT 
17qSubTel              TTCCTTTTTTTTCCTTTGGTCATTATGAATAGGGCTTCTGTAAATAACTGCATGGTAGCT 
4qSubTel               TTCCTTTTTTTTCCTTTGGTCATTATGAATAGGGCTTCTGTAAATAACTGCATGGTAGCT 
19qSubTel              TTCCTTTTTTTTCCTTTGGTCATTATGAATAGGGCTTCTGTAAATAACTGCATGGTAGCT 
21qSubTel              TTCCTTTTTTTTCCTTTGGTCATTATGAATAGGGCTTCTGTAAATAACTGCATGGTAGCT 
1qSubTel               TTCATTTTTTTTCCTTTGGTCATTATGAATAGGGCTTCTGTAAATAACTGCATGGTAGCT 
2qSubTel               TTCCTTTTTTTTCCTTTGGTCATTATGAATAGGGCTTCTGTAAATAACTGCATGGTAGCT 
19p'End'               TTCCGTTTTTTTCCTTTGGTCATTATGAATAGGGCTTATGTAAATAATTGCATGGTAGCT 
8p'End'                TTCCGTTTTTTTCCTTTGGTCATTATGAATAGGGCTTATGTAAATAATTGCATGGTAGCT 
13qSubTel              TTCCTTTTTTTTCCTTTAGTCATTCTGAATAGGGCTTCTGTAAATAATTGCATGGTAGCT 
20qSubTel              TTCCTTT-TTTTCCTTTGGTCATTATGAATAGGGCTTCTGTACATAATTGCATGGTAGCT 
12qSubTel              TTCCTTTTTTTTCCTCTGGTCATTATGAATAGGGCTTCTGTAAATAATGGCATGGTAGCT 
7qSubTel               TTCCCTTTTTTTCCTCTGGTCATTATGAATAGGGCTTATGTAAATAATGGCATGGTAGCT 
                       ***. ** ******* *.******.************.****.****  *********** 
 
6qPredictedSubTel      TTTGATGGGAAATAACATCAAAGTAGTTGTCAAAATACTTAGGAATGTTATTTTTGGATT 
10qSubTel              TTTGATGGGAAATAACATCAAAGTAGTTGTCAAAATACTTAGGAATGTTATTTTTGGATT 
22qSubTel              TTTGATGGGAAATAACATCAAAGTAGTTGTCAAAATACCTAGGAATGTTATTTTTGGATT 
1pSubTel               TTTGATGGGAAATAACATCAAAGTAGTTGTCAAAATACTTAGGAATGTTATTTTTGGATT 
5qSubTel               TTTGATGGGAAATAACATCAAAGTAGTTGTCAAAATACTTAGGAATGTTATTTTTGGATT 
17qSubTel              TTTGATGGGAAATAACATCAAAGTAGTTGTCAAAATACCTAGGAATGTTATTTTTGGATT 
4qSubTel               TTTGATGGGAAATAACATCAAAGTAGTTGTCAAAATCCTTAGGAATGTTATTTTTGGATT 
19qSubTel              TTTGATGGGAAATAACATCAAAGTAGTTGTCAAAATACCTAGGAATGTTATTTTTGGATT 
21qSubTel              TTTGATGGGAAATAACATCAAAGTAGTTGTCAAAATACCTAGGAATGTTATTTTTGGATT 
1qSubTel               TTTGATGGGAAATAACATCAAAGTAGTTGTCAAAATACCTAGGAATGTTATTTTTGGATT 
2qSubTel               TTTGATGGGAAATAACATCAAAGTAGTTGTCAAAATACTTAGGAATGTTATTTTTGGATT 
19p'End'               TTTGATTGGAAATAACATCAAAGTAGTTGTCAAAATACTTAGGAATGTTATTTTTGGATT 
8p'End'                TTTGATTGGAAATAACATCAAAGTAGTTGTCAAAATACTTAGGAATGTTATTTTTGGATT 
13qSubTel              TTTGTTTGGAAATAACATCAAAGTAGTTGTCAAAATACTTAGGAATGTGATTTTTGGATT 
20qSubTel              TTTGTTTGGAAATCACATCAAAGTGGTTGTCAAAATACTTAGGAATGTCGTTTTTGGATT 
12qSubTel              TTTGATCGGAAATAACATCAAAGTAGTTGTCAAAATACTTAGGAATGTGATTTTTGGATT 
7qSubTel               TTTGATTGGAAATAACATCAAAGTAGTTGTCAAAATACTTAGGAATGTGATTTTTGGATT 
                       ****:* ******.**********.***********.* ********* .********** 
 
6qPredictedSubTel      GTAAGGTGAGACTTGTTTAGCTTTGGAA-AAAAATGCCCAACTTGTAATAGGGGAGGAAA 
10qSubTel              GTAAGGTGAGACTTGTTTAGCTTTGGAA-AAAAATGCCCAACTTGTAATAGGGGAGGAAA 
22qSubTel              GTAAGGTGAGACTTGTTTAGCTTTGGAA-AAAAATGACCAACTTGTAATAGGGGAGGAAA 
1pSubTel               GTAAGGTGAGACTTGTTTAGCTTTGGAA-AAAAATGCCCAACTTGTAATAGGGGAGGAAA 
5qSubTel               GTAAGGTGAGACTTGTTTAGCTTTGGAA-AAAAATGCCCAACTTGTAATAGGGGAGGAAA 
17qSubTel              GTAAGGTGAGACTTGTTTAGCTTTGGAA-AAAAATGCCCAACTTGTAATAGGGGAGGAAA 
4qSubTel               GTAAGGTGAGACTTGTTTAGCTTTGGAA-AAAAATGCCCAACTTGTAATAGGGGAGGAAA 
19qSubTel              GTAAGGTGAGACTTGTTTAGCTTTGGAA-AAAAATGCCCAACTTGTAATAGGGGAGGAAA 
21qSubTel              GTAAGGTGAGACTTGTTTAGCTTTGGAA-AAAAATGCCCAACTTGTAATAGGGGAGGAAA 
1qSubTel               GTAAGGTGAGACTTGTTTAGCTTTGGAA-AAAAATGCCCAACTTGTAATAGGGGAGGAAA 
2qSubTel               GTAAGGTGAGACTTGTTTAGCTTTGGAA-AAAAATGCCCAACTTGTAATAGGGGAGGAAA 
19p'End'               GTAAGGTGAGACTTGTTTAGCTTTGGAA-AAAAATGCCCAACTTGTAATAGGGGAGGAAA 
8p'End'                GTAAGGTGAGACTTGTTTAGCTTTGGAA-AAAAATGCCCAACTTGTAATAGGGGAGGAAA 
13qSubTel              GTAAGGTGAGACTTGTTTAGCTTTAGAAAAA-ACTGCCGAAATTT-TAATGGGGAGGAA- 
20qSubTel              GTAAGGTGAGACTTATTTAGCTTTGGAA-AAAACTGCCCAACTTGTAATAGGTGAGGAAA 
12qSubTel              GTAAGGTGAGACTTGTTTAGCTTTGGGGAAAAAATGCCCAAGTTGTAATAGGGGAGGAAA 
7qSubTel               GTAAGGTGAGACTTGTTTAGCTTTGGGGAAAAAATGCCCAACTTGTAATAGGGGAGGAAA 
                       **************.*********.*.. ** *.**.* ** **  :*::** ******  
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6qPredictedSubTel      AATAATTTTC------TGTTTTTGGAATTCTTAGATGGAACGCTCTGTAAAAAGTGACAG 
10qSubTel              AATAATTTTC------TGTTTTTGGAATTCTTAGATGGAACGCTCTGTAAAAACTGACAG 
22qSubTel              AATAATTTTC------TGTTTTTGGAATTCTTAGATGGAACGCTCTGTAAAAACTGACAG 
1pSubTel               AATAATTTTC------TGTTTTTGGAATTCTTAGATGGAACGCTCTGTAAAAAGTGACAG 
5qSubTel               AATAATTTTC------TGTTTTTGGAATTCTTAGATGGAACGCTCTGTAAAAAGTGACAG 
17qSubTel              AATAATTTTC------TGTTTTTGGAATTCTTAGATGGAACGCTCTGTAAAAACTGACAG 
4qSubTel               AATAATTTTC------TGTTTTTGGAATTCTTAGATGGAACGCTCTGTAAAAACTGACAG 
19qSubTel              AATAATTTTC------TGTTTTTGGAATTCTTAGATGGAACGCTCTGTAAAAACTGACAG 
21qSubTel              AATAATTTTC------TGTTTTTGGAATTCTTAGATGGAACGCTCTGTAAAAACTGACAG 
1qSubTel               AATAATTTTC------TGTTTTTGGAATTCTTAGATGGAACGCTCTGTAAAAACTGACAG 
2qSubTel               AATAATTTTC------TGTTTTTGGAATTCTTAGATGGAACGCTCTGTAAAAAGTGACAG 
19p'End'               AATAATTTTC------TGTTTTCAGAATTCTTAGATGGGATGCTCTGTAAAAACTGACAG 
8p'End'                AATAATTTTC------TGTTTTCGGAATTCTTAGATGGGATGCTCTGTAAAAACTGACAG 
13qSubTel              AAAAATTTTC----TATGTTTTTGGAATTCTTAGATGGGACCCGCTGTAAAAACTGACAG 
20qSubTel              AATAATTTTCTCTCTATCTTTTCAGAATTCTTAGATTGGACCCTCTGTAACAAATGACAG 
12qSubTel              AATAATTTTC----TATGTTTTCAGAATTCTTAGATGGGACCCTCTGTAAAAACTGACGG 
7qSubTel               AATAATTTTC----TATGTTTTCAGAATTCTTAGATGGGACCTTCTGTAAAAACTGACGG 
                       **:*******      * **** .************ *.*    ******.** ****.* 
 
6qPredictedSubTel      ATTAAAATGAGAAAA--ACAGAAAAGTTTAAAAACATGTATATCTTATGGTTACATGGGA 
10qSubTel              ATTAAAATGAGAAAA--ACAGAAAAGTTTAAAAACATGTATATCTTATGGTTACATGGGA 
22qSubTel              ATTAAAATGAGAAAA--AGAGAAAAGTTTAAAAACATGTATATCTTATGGTTACATGGGA 
1pSubTel               ATTAAAATGAGAAAA--ACAGAAAAGTTTAAAAACATGTATATCTTATGGTTACATGGGA 
5qSubTel               ATTAAAATGAGAAAA--ACAGAAAAGTTTAAAAACATGTATATCTTATGGTTACATGGGA 
17qSubTel              ATTAAAATGAGAAAA--AGAGAAAAGTTTAAAAACATGTATATCTTATGGTTACATGGGA 
4qSubTel               ATTAAAATGAGAAAA--ACAGAAAAGTTTAAAAACATGTATATCTTATGGTTACATGGGA 
19qSubTel              ATTAAAATGAGAAAA--AGAGAAAAGTTTAAAAACATGTATATCTTATGGTTACATGGGA 
21qSubTel              ATTAAAATGAGAAAA--AGAGAAAAGTTTAAAAACATGTATATCTTATGGTTACATGGGA 
1qSubTel               ATTAAAATGAGAAAA--AGAGAAAAGTTTAAAAACATGTATATCTTATGGTTACATGGGA 
2qSubTel               ATTAAAATGAGAAAA--ACAGAAAAGTTTAAAAACATGTATATCTTATGGTTACATGGGA 
19p'End'               ATTAAAATGAGAAAA--ACAGAAAAGTAGAAAAACACGTATACCTTATGGTTACATGGGA 
8p'End'                ATTAAAATGAGAAAA--ACAGAAAAGTTGAAAAACACGTATACCTTATGGTTACATGGGA 
13qSubTel              ATTAAAATGAGAAAA--ACAGAAAAGTTTAAAAACATGTATACCTTATGGATACATGGGA 
20qSubTel              ATTAAAATGAGAAAAATGTAGAAAAGTTTAAAAACATGTATACCTTATGGATACATGGGC 
12qSubTel              ATTAAAATTAGAAAA--ATAGAAAAGTTTAAAAACATGTATACCTTATGGATACATGGGA 
7qSubTel               ATTAAAATTAGAAAA--ATAGAAAAGTTTAGAAACATGTATACCTTATGGATACATGGGA 
                       ******** ******  . ********: *.***** ***** *******:********. 
 
6qPredictedSubTel      TATACTCAGGGAAAAATGAGTAAATCTCCAACAGGTGGCTTTCAATTCAAGCATAAATAC 
10qSubTel              TATACTCAGGGAAAAATGAGTAAATCTCCAACAGGTGGCTTTCAATTCAAGCATAAATAC 
22qSubTel              GATACTCAGGGAAAAATGAGTAAATCTCCAACAGGTGGCTTTCAATTCAAGCATAAATAC 
1pSubTel               TATACTCAGGGAAAAATGAGTAAATCTCCAACAGGTGGCTTTCAATTCAAGCATAAATAC 
5qSubTel               TATACTCAGGGAAAAATGAGTAAATCTCCAACAGGTGGCTTTCAATTCAAGCATAAATAC 
17qSubTel              GATACTCAGGGAAAAATGAGTAAATCTCCAACAGGTGGCTTTCAATTCAAGCATAAATAC 
4qSubTel               TATACTCAGGGAAAAATGAGTAAATCTCCAACAGGTGGCTTTCAATTCAAGCATAAATAC 
19qSubTel              TATACTCAGGGAAAAATGAGTAAATCTCCAACAGGTGGCTTTCAATTCAAGCATAAATAC 
21qSubTel              GATACTCAGGGAAAAATGAGTAAATCTCCAACAGGTGGCTTTCAATTCAAGCATAAATAC 
1qSubTel               GATACTCAGGGAAAAATGAGTAAATCTCCAACAGGTGGCTTTCAATTCAAGCATAAATAC 
2qSubTel               TATACTCAGGGAAAAATGAGTAAATCTCCAACAGGTGGCTTTCAATTCAAGCATAAATAC 
19p'End'               GATACTCAGGGAAAAATGAGTAAATCTCCAACAGGTGGCTTTCAATTCAAGCATAAGTAC 
8p'End'                GATATTCAGGGAAAAATGAGTAAATCTCCAACAGGTGGCTTTCAATTCAAGCATAAATAC 
13qSubTel              GATACTCAAGGAAAAATGAGTAAATCTCCAACAGGTGGCTTTCAATTAAAGCATAAATAC 
20qSubTel              GATACTCAGGGAAAAATGAGTAAATCTCCAGCAGGTGGTTTTCAATTCAAGTGTAAATAC 
12qSubTel              GATACTCAGGAAAAAACGAGTAAATCTCCAACAGGTGGCTTTCAATTCAAGCATAAATAC 
7qSubTel               GATACTCAGGAAAAAACGAGTAAATCTGCAACAGGTGGCTTTCAATTCAAGCATAAATAC 
                        *** ***.*.***** ********** **.******* ********.*** .***.*** 
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6qPredictedSubTel      TATCTTCAACTTAAAGAAAGAAGATTTGAGGTGCAGTAG----TGGGAAGTTAACCAGCA 
10qSubTel              TATCTTCAACTTAAAGAAAGAAGATTTGAGGTGCAGTAG----TGGGAAGTTAACCAGCA 
22qSubTel              TATCTTCAACTTAAAGAAAGAAGATTTGAGGTGCAGTAG----TGGGGAGTTAACCAGCA 
1pSubTel               TATCTTCAACTTAAAGAAAGAAGATTTGAGGTGCAGTAG----TGGGAAGTTAACCAGCA 
5qSubTel               TATCTTCAACTTAAAGAAAGAAGATTTGAGGTGCAGTAG----TGGGAAGTTAACCAGCA 
17qSubTel              TATCTTCAACTTAAAGAAAGAAGATTTGAGGTGCAGTAG----TGGGGAGTTAACCAGCA 
4qSubTel               TATCTTCAACTTAAAGAAAGAAGATTTGAGGTGCAGTAG----TGGGAAGTTAACCAGCA 
19qSubTel              TATCTTCAACTTAAAGAAAGAAGATTTGAGGTGCAGTAG----TGGGAAGTTAACCAGCA 
21qSubTel              TATCTTCAACTTAAAGAAAGAAGATTTGAGGTGCAGTAG----TGGGGAGTTAACCAGCA 
1qSubTel               TATCTTCAACTTAAAGAAAGAAGATTTGAGGTGCAGTAG----TGGGGAGTTAACCAGCA 
2qSubTel               TATCTTCAACTTAAAGAAAGAAGATTTGAGGTGCAGTAG----TGGGAAGTTAACCAGCA 
19p'End'               TGTCTTCAACTTAAAGAAAGAAGATTTGAGGTGCAGTAT----TGGGGAGTTAACCAGCA 
8p'End'                TGTCTTCAACTTAAAGAAAGAAGATTTGAGGTGCAGTAT----TGGGGAGTTAACCAGCA 
13qSubTel              TATCTTCAACTTAAAGAAAGAAGATTTGAGGTGCAGTGGTGAGTGGGGAGTTAGCCAGCA 
20qSubTel              TATCTTCAACTTGAA-------GATTTGAGGCACAGTAG----TGGGGAGTTAACCAGCA 
12qSubTel              TATCTTCAACTTAAAGAAAGAAGATTTGAGGTGCAGTAG----TGGGGATCTAACCAGCA 
7qSubTel               TATCTTCAACTTAAAGAAAGAAGATTTGAGGTGCAGTAG----TGGGGATCTAACTAGCA 
                       *.**********.**       ********* .****.     ****.*  **.* **** 
 
6qPredictedSubTel      AAAGCACATTAGACAGGGGTAAGGTTCATTATACAGAGTTAAGTCCATGCATTCTCCATT 
10qSubTel              AAAGCACATTAGACAGGGGTAAGGTTCGTTATACAGAGTTAAGTCCATGCATTCTCCATT 
22qSubTel              AAAGCACATTAGACAAGGGTAAGGTTCGTTATACAGACTTAAGTCCATGCATTCTCCATT 
1pSubTel               AAAGCACATTAGACAGGGGTAAGGTTCATTATACAGAGTTAAGTCCATGCATTCTTCATT 
5qSubTel               AAAGCACATTAGACAGAGGTAAGGTTCATTATACAGAGTTAAGTCCATGCATTCTCCATT 
17qSubTel              AAAGCACATTAGACAAGGGTAAGGTTCGTTATACAGACTTAAGTCCATGCATTCTCCATT 
4qSubTel               AAAGCACATTAGACAGGGGTAAGGTTCGTTATACAGAGTTAAGTCCATGCATTCTCCATT 
19qSubTel              AAAGCACATTAGACAGGGGTAAGGTTTGTTATACAGAGTTAAGTCCATGCAGTCTCCATT 
21qSubTel              AAAGCACATTAGACAAGAGTAAGGTACGTTATACAGACTTAAGTCCATGCATTCTCCATT 
1qSubTel               AAAGCACATTAGACAAGGGTAAGGTTCGTTATACAGACTTAAGTCCATGCATTCTCCATT 
2qSubTel               AAAGCACATTAGACAGGGGTAAGGTTCATTATACAGAGTTAAGTCCATGCATTCTTCATT 
19p'End'               AAAGCACATTAGACAAGGGTAAGGTTCGTTATACAGACTTAAGTCCATGCATTCTCCATT 
8p'End'                AAAGCACATTAGACAAGGGTAAGGTTCATTATACAGACTTAAGTCCATGCATTCTCCATT 
13qSubTel              AAAGCACATTAGACAAGGGTAAGGTTCGTTATACAGACTTAAGTCCATGCATTCTCCATT 
20qSubTel              AAACCACATTAGACAAGAGTAACGTTTGTTATGCAGACTGAAGTCCATGCATCCTCCATT 
12qSubTel              AAAGCACAGTAGACAAGGGTAAGGTTTGTTATACAGACTGAAGTCTATGCATTCTCCATT 
7qSubTel               AAAGCACAGTAGACAAGGGTAAGGTTTGTTATACAGACTGAAGTCTATGCATTCTCCATT 
                       *** **** ******...**** **: .****.**** * ***** *****  ** **** 
 
6qPredictedSubTel      GATAAGACTCTTCAGTGATTTAGTTATCCTTCTCTTCTTGGTGTCGAGA--GAGGTAGCT 
10qSubTel              GATAAGACTCTTCAGTGATTTAGTTATCCTTCTCTTCTTGGTGTCGAGA--GAGGTAGCT 
22qSubTel              GATAAGACTCTTCAGTGATTTAGTTATCCTTCTCTTCTTGGTGTCGAGA--GAGGTAGCT 
1pSubTel               GATAAGACTCTTCAGTGATTTAGTTATCCTTCTCTTCTTGGTGTCGAGA--GAGGTAGCT 
5qSubTel               GATAAGACTCTTCAGTGATTTAGTTATCCTTCTCTTCTTGGTGTCGAGA--GAGGTAGCT 
17qSubTel              GATAAGACTCTTCAGTGATTTAGTTATCCTTCTCTTCTTGGTGTTGAGA--GAGGTAGCT 
4qSubTel               GATAAGACTCTTCAGTGATTTAGTTATCCTTCTCTTCTTGGTGTCGAGA--GAGGTAGCT 
19qSubTel              GATAAGACTCTTCAGTGATTTAGTTATCCTTCTCTTCTTGGTGTCGAGA--GAGGTAGCT 
21qSubTel              GATAAGACTCTTCAGTGATTTAGTTATCCTTCTCTTCTTGGTGTCGAGA--GAGGTAGCT 
1qSubTel               GATAAGACTCTTCAGTGATTTAGTTATCCTTCTCTTCTTGGTGTCGAGA--GAGGTAGCT 
2qSubTel               GATAAGACTCTTCAGTGATTTAGTTATCCTTCTCTTCTTGGTGTCGAGA--GAGGTAGCT 
19p'End'               GATAAGACTCTTTAGTGATTTAGTTATCCTTCTCTTCTTGGTGTCGAGA--GAGGTAGCT 
8p'End'                GATAAGACTCTTTAGTGATTTAGTTATCCTTCTCTTCTTGGTGTCGAGA--GAGGTAGCT 
13qSubTel              GATAAGAGTCTTTAGTGATTTAGTTATCCT-----TCTTGGTGTCGAGA--GAGGTAGCT 
20qSubTel              GATAAGACTCT--AGTGATTTAGTTATCCTTCTCTTCTTGGTGCCGAGAGAGAGGTAGCT 
12qSubTel              GATAAGACTCT--AGTGATTTACTTATCCTTCTCTTCTTGATGTCGACA--GAGGTAGCT 
7qSubTel               GATAAGACTCT--AGTGATTTACTTATCCTTCTCTTCTTGATGTTGACA--GAGGTAGCT 
                       ******* ***  ********* *******     *****.**  ** *  ********* 
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6qPredictedSubTel      TTTAAATGGTGATTTCCTTTATAGGTGTAAATTTTCCTTACACAAGT--AACTTTTACTC 
10qSubTel              TTTAAATGGTGATTTCCTTTATAGGTGTAAATTTTCCTTACACAAGT--AACTTTTACTC 
22qSubTel              TTTAAATGGTGATTTCCTTTATAGATGTAAATTTTCCTTACACAAGT--AACTTCTACTC 
1pSubTel               TTTAAATGGTGATTTCCTTTATAGGTGTAAATTTTCCTTACACAAGT--AACTTTTA--C 
5qSubTel               TTTAAATGGTGATTTCCTTTATAGGTGTAAATTTTCCTTACACAAGT--AACTTTTACTC 
17qSubTel              TTTAAATGGTGATTTCCTTTATAGATGTAAATTTTCCTTACACAAGT--AACTTCTACTT 
4qSubTel               TTTAAATGGTGATTTCCTTTATAGGTGTAAATTTTCCTTACACAAGT--AACTTTTACTC 
19qSubTel              TTTAAATGGTGATTTCCTTTATAGATGTAAATTTTCCTTACACAAGT--AACTTCTACTC 
21qSubTel              TTTAAATGGTGATTTCCTTTATAGATGTAAATTTTCCTTACACAAGT--AACTTCTACTC 
1qSubTel               TTTAAATGGTGATTTCCTTTATAGATGTAAATTTTCCTTACACAAGT--AACTTCTACTC 
2qSubTel               TTTAAATGGTGATTTCCTTTATAGGTGTAAATTTTCCTTACACAAGT--AACTTTTACTC 
19p'End'               TTTAAATGGTGATTTCCTTTATAGATGTAAATTTTCCTTACACAAGTGTAACTTCTACTC 
8p'End'                TTTAAATGGTGATTTCCTTTATAGATGTAAATTTTCCTTACACAAGT--GT-AACTTCTC 
13qSubTel              TTTAAATGGTGATTTCCTTTATAGATGTAAATTTTCCTTACACAAGTGTAACTTCTACTC 
20qSubTel              TTTAAATGGGGATTTCCTTTATAGATGTAAATTTTCCTTACAGAAGGGTAACTTCTACTC 
12qSubTel              TTTAAATGGGGATTTCCTTTATAGATGTAAATTTTCCTTACACAAGGGTAACTTCTACTC 
7qSubTel               TTTAAATGGGGATTTCCTTTATAGATGTAAATTTTCCTTACACAAGGGTAACTTCTACTC 
                       ********* **************.***************** ***   .: :: *:    
 
6qPredictedSubTel      TGTTTTCACAACTTCCTTTGTTAGCATTTTTTTTTT-CAAAATAATTAGCTTGGAATAAT 
10qSubTel              TGTTTTCACAACTTCCTTTGTTAGCATTTTTT-TTTTCAAAATAATTAGCTTGGAATAAT 
22qSubTel              TATTTTCACAACTTCCTTTGTTAGCATTTTTT-TTTTCAAAATAATTAGCTTGGAATAAT 
1pSubTel               TGTTTTCACAACTTCCTTTGTTAGCATTTTTT-TTTTCAAAATAATTAGCTTGGAATAAT 
5qSubTel               TGTTTTCACAACTTCCTTTGTTAGCATTTTTT-TTTTCAAAATAATTAGCTTGGAATAAT 
17qSubTel              TATTTTCACAACTTCCTTTGTTAGCATTTTTTTTTTCCAAAATAATTAGCTTGGAATAAT 
4qSubTel               TGTTTTCACAACTTCCTTTGTTAGCATTTTTT-TTTTCAAAATAATTAGCTTGGAATAAT 
19qSubTel              TGTTTTCACAACTTCCTTTGTTAGCATTTTT--TTTTCAAAATAATTAGCTTGGAATAAT 
21qSubTel              TATTTTCACAACTTCCTTTGTTAGCATTTTTTTTTTTCAAAATAATTAGCTTGGAATAAT 
1qSubTel               TATTTTCACAACTTCCTTTGTTAGCATTTTTT-TTTTCAAAATAATTAGCTTGGAATAAT 
2qSubTel               TGTTTTCACAACTTCCTTTGTTAGCATTTTTT-TTTTCAAAATAATTAGCTTGGAATAAT 
19p'End'               TGTTTTCACAACTTCCTTTGTTAGCGTTTTTTTTTTTCAAAATAATTAGCTTGGAATAAT 
8p'End'                TGTTTTCACAACTTCCTTTGTTAGCATTTTTTTTTTTCAAAATAATTAGCTTGGAATAAT 
13qSubTel              TGTTTTCACAACTTCCTTTGTTAGCATTTTTT-TTTTCAAAATAATTAGCTTGGAATAAT 
20qSubTel              TGGTTTTGGAACTTCCTTTGTTAGCATTTTT---TTTCAAAATAATCATCTTGGAATAAT 
12qSubTel              TGTTTTCAGAACT----TTGTTAGCATTTTTTT--------TAAAATAGCTTGGAATAAT 
7qSubTel               TGTTTTCAGAACG----TTGTTAGCATTTTTTT--------TAAAATAGCTTGGAATAAT 
                       *. *** . ***     ********.*****          ::**: * *********** 
 
6qPredictedSubTel      TTTTAAGCCAAAGGGACATATTTTGGGGTTGCATATTCTGGTTTCCTACCATTATATTTT 
10qSubTel              TTTTAAGCCAAAGGGACATATTTTGGGGTTGCATATTCTGGTTTCCTACCATTATATTTT 
22qSubTel              TCTTAAGCCAAAGGGACATATTTTGGGGTTGCATATTCTGGTTTCCTACCATTATATTTT 
1pSubTel               TTTTAAGCCAAAGGGACATATTTTGGGGTTGCATATTCCGGTTTCCTACCATTATATTTT 
5qSubTel               TTTTAAGCCAAAGGGACATATTTTGGGGTTGCATATTCTGGTTTCCTACCATTATATTTT 
17qSubTel              TCTTAAGCCAAAGGGACATATTTTGGGGTTGCATATTCTGGTTTCCTACCATTATATTTT 
4qSubTel               TTTTAAGCCAAAGGGACATATTTTGGGGTTGCATATTCTGGTTTCCTACCATTATATTTT 
19qSubTel              TTTTAAGCCAAAGGGACATATTTTGGGGTTGCATATTCTGGTTTCCTACCATTATATTTT 
21qSubTel              TCTTAAGCCAAAGGGACATATTTTGGGGTTGCATATTCTGGTTTCCTACCATTATATTTT 
1qSubTel               TCTTAAGCCAAAGGGACATATTTTGGGGTTGCATATTCTGGTTTCCTACCATTATATTTT 
2qSubTel               TTTTAAGCCAAAGGGACATATTTTGGGGTTGCATATTCTGGTTTCCTACCATTATATTTT 
19p'End'               TCTTAAGCCAAAGGGACATATTTTGGGGTTGCATATTCTGGTTTCCTACCATTATATTTT 
8p'End'                TCTTAAGCCAAAGGGACATATTTTGGGGTTGCATATTCTGGTTTCCTACCATTATATTTT 
13qSubTel              TGTTAAGCCAAAGGGACATATTTTGGGGTTTCATATTCTGGTTTCCTACCATTATATTTT 
20qSubTel              TCTTATGCCAAAGGGACATATTTTGGGG-------------------------------- 
12qSubTel              TCTTAAGCCAAAGGGACATATTTTGGGACAGCATATTCTGGTTACCTACCATTATATTTT 
7qSubTel               TCTTAAGCCAAAGGGACATATTTTGGGACAGCATATTCTGGTTTCCTACCATTATATTTT 
                       * ***:*********************.                                 
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6qPredictedSubTel      GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCTACTGGCAATGAAAAGAGTTCTTGTT 
10qSubTel              GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCTACTGGCAATGAAAAGAGTTCTTGTT 
22qSubTel              GGGGTGGCATAGTTTGGCCTTATACACTGTGTTCCACTGGCAATGAAAAGAGTTCTTGTT 
1pSubTel               GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCTACTGGCAATGAAAAGAGTTCTTGTT 
5qSubTel               GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCTACTGGCAATGAAAAGAGTTCTTGTT 
17qSubTel              GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCCACTGGCAATGAAAAGAGTTCTTGTT 
4qSubTel               GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCTACTGGCAATGAAAAGAGTTCTTGTT 
19qSubTel              GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCTACTGGCAATGAAAAGAGTTCTTGTT 
21qSubTel              GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCCACTGGCAATGAAAAGAGTTCTTGTT 
1qSubTel               GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCCACTGGCAATGAAAAGAGTTCTTGTT 
2qSubTel               GGGGTGGCATAGTTTGGTCTTATACACTGTGTTCTACTGGCAATGAAAAGAGTTCTTGTT 
19p'End'               GGGGTGGCATATTTTGGTCTTATACACTGTGTTCCACCGGCAATGAAAAGAGTTCTTGTT 
8p'End'                GGGGTGGCATATTTTGGTCTTATACACTGTGTTCCACCGGCAATGAAAAGAGTTCTTGTT 
13qSubTel              GGGGTGGCATATTTTGGTCTTATACACTGTGTTCCACCGGCAATGAAAAGAGTTCTTGTT 
20qSubTel              ----TGGCATATTCTGGTCTTATACACTGTCTTCCACCAGCAATGAAAAGAGTTATTGTC 
12qSubTel              GGGGTGGCATATTTTGGTCTTATACACTGTGTTCCACAGGCAACGAAAAGAGTTCTTGTT 
7qSubTel               GGGGTGGCATATTTTGGTCTTATACACTGTGTTCCACAGGCAACGAAAAGAGTTCTTGTT 
                           ******* * *** ************ *** ** .**** **********.****  
 
6qPredictedSubTel      TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
10qSubTel              TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
22qSubTel              TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
1pSubTel               TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
5qSubTel               TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
17qSubTel              TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
4qSubTel               TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGGAGTTCTAAGAGATATAGACCAG 
19qSubTel              TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
21qSubTel              TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
1qSubTel               TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
2qSubTel               TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGCTTAGCAGTTCTAAGAGATATAGACCAG 
19p'End'               TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGTTTAGCAGTTCTAAGAGATATAGACCAG 
8p'End'                TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGTTTAGCAGTTCTAAGAGATATAGACCAG 
13qSubTel              TTTCCTCCAGCAATTTGTCATTTGTTAAAGAGTTTAGCAGTTCTAAGAGATACAGACCAG 
20qSubTel              TTTCTTGCAGCAATTTGTGATTT-TTTTAGAGTTTAGCAGTTCTAATAGATATAGACCAG 
12qSubTel              TTTCCTGCAGCAATTTGTCATTTTTAAAAGAGCTTAGCAGTTCTAAGAGCTATAGAGTAG 
7qSubTel               TTTCCTGCAGCAATTTGTCATTTTTTAAAGAGCTTAGCAGTTCTAAGAGCTATAGAGTAG 
                       **** * *********** **** *:::**** **** ******** **.** ***  ** 
 
6qPredictedSubTel      CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAGGTGT 
10qSubTel              CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTAAGCATCTTTTTGTAGGTGT 
22qSubTel              CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAAGTGT 
1pSubTel               CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAGGTGT 
5qSubTel               CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAGGTGT 
17qSubTel              CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAAGTGT 
4qSubTel               CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAGGTGT 
19qSubTel              CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAAGTGT 
21qSubTel              CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAAGTGT 
1qSubTel               CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAAGTGT 
2qSubTel               CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAGGTGT 
19p'End'               CTGTGCTATCTTTTTGTGGTTTTTAGTTCTCTAGTATGTTGAGCATCTTTTTGTAAGTGT 
8p'End'                CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAAGTGT 
13qSubTel              CTGTGCTATCTTTTTGTGGTTTTCAGTTCTCTAGTATGTTGAGCATCTTTTTGTAAGTGT 
20qSubTel              CTGTGCTATCTCC---TGGTTTTCAGTTCTGTAGTATGTTGAGCATCTTTTTGTATGTTT 
12qSubTel              CTGTGCTATCTCATTGTGGTTTTCAATTCTCTAGTATGTTGAGCATCTTTTTGCACGTTT 
7qSubTel               CTGTGCTATCTCATTGTGGTTTTCAATTCTCTAGTATGTTGAGCGTCTTTTTGCACGTTT 
                       ***********     ******* *.**** *********.***.******** * ** * 
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6qPredictedSubTel      ACTTGCCATCTGTAGATCTTCTTTGATGAGGCGTCTGTTCAGATCTGTGTGCATTTTTAA 
10qSubTel              ACTTGCCATCTGTAGATCTTCTTTGATGAGGCATCTGTTCAGATCTGTGTGCATTTTTAA 
22qSubTel              ACTTGCCATCTGTAGATCTTCTTTGGTGAAGTGTCTGTTCAGATCTGTGTGCATTTTTAA 
1pSubTel               ACTTGCCATCTGTAGATCTTCTTTGATGAGGCATCTGTTCAGATCTGTGTGCATTTTTAA 
5qSubTel               ACTTGCCATCTGTAGATCTTCTTTGATGAGGCGTCTGTTCAGATCTGTGTGCATTTTTAA 
17qSubTel              ACTTGCCATCTGTAGATCTTCTTTGGTGAAGTGTCTGTTCAGATCTGTGTGCATTTTTAA 
4qSubTel               ACTTGCCATCTGTAGATCTTCTTTGATGAGGCGTCTGTTCAGATCTGTGTGCATTTTTAA 
19qSubTel              ACTTGCCATCTGTAGATCTTCTTTGGTGAGGTGTCTGTTCAGATCTGTGTGCATTTTTAA 
21qSubTel              ACTTGCCATCTGTAGATCTTCTTTGGTGAAGTGTCTGTTCAGATCTGTGTGCATTTTTAA 
1qSubTel               ACTTGCCATCTGTAGATCTTCTTTGGTGAAGTGTCTGTTCAGATCTGTGTGCATTTTTAA 
2qSubTel               ACTTGCCATCTGTAGATCTTCTTTGATGAGGCGTCTGTTCAGATCTGTGTGCATTTTTAA 
19p'End'               ACTTGCCATCTGTAGATCTTCTTTGGTGAGGCGTCTGTTCAGATCTGTGTGCATTTTTAA 
8p'End'                ACTTGCCATCTGTAGATCTTCTTTGGTGAGGCGTCTGTTCAGATCTGTGTGCATTTTTAA 
13qSubTel              ACTTGCCATCTGTAGATCTTCTTTGGTGAGGTGTCTGTTTAGATCTGTGTGT--TTTTAA 
20qSubTel              ACTTGCCATCTGTAGATCTTCTTTGGTGAGGTGTCTGTTCAGATCTGTGTGCATTTTTAA 
12qSubTel              ACTTGCCATA----GATCTTCTCTGC---------------------------------- 
7qSubTel               ACTTGCCATA----GATCTTTTT------------------------------------- 
                       *********.    ****** *                                       
 
6qPredictedSubTel      TTGGGCTGTTTAACTTATTGTTTAGTTTTAACAATTTTTTATATATTTTGAATACAAA-- 
10qSubTel              TTGGGCTGTTTAACTTATTGTTTAGTTTTAACAATTTTTTATATATTTTGAATACAAA-- 
22qSubTel              TTGGGTTGTTTAACTTA---TTTAGTTTTAACAATTTTTTATATATTTTGAATACAAA-- 
1pSubTel               TTGGGCTGTTTAACTTATTGTTTAGTTTTAACAATTTTTTATATATTTTGAATACAAA-- 
5qSubTel               TTGGGCTGTTTAACTTATTGTTTAGTTTTAACAATTTTTTATATATTTTGAATACAAA-- 
17qSubTel              TTGGGTTGTTTAACTTATTGTTTAGTTTTAACAATTTTTTATATATTTTGAATACAAA-- 
4qSubTel               TTGGGCTGTTTAACTTATTGTTTAGTTTTAACAATTTTTTATATATTTTGAATACAAA-- 
19qSubTel              TTGGGCTGTTTAACTTATTGTTTAGTTTTAACAATTTTTTATATATTTTGAATACAAA-- 
21qSubTel              TTGGGTTGTTTAACTTATTGTTTAGTTTTAACAATTTTTTATATATTTTGAATACAAA-- 
1qSubTel               TTGGGTTGTTTAACTTATTGTTTAGTTTTAACAATTTTTTATATATTTTGAATACAAA-- 
2qSubTel               TTGGGCTGTTTAACTTATTGTTTAGTTTTAACAATTTTTTATATATTTTGAATACAAA-- 
19p'End'               TTGGGCTGTTTAACTTATTGTTTAGTTTTAACAATTTTTTATGTATTTTGAATACAAA-- 
8p'End'                TTGGGCTGTTTAACTTATTGTTTAGTTTTAACAATTTTTTATGTATTTTGAATACAAA-- 
13qSubTel              TTGGGCTGTTTAACTTATTGTTTAGTTTTAACACTTTTTTATATATTTTGAATACAAA-- 
20qSubTel              TTGTGCTGTTTAACTTGT---TTAGTTTTAAGAATTTTTTATATATTTTGAATACAAATT 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      --TTCTCAGATCTGTATTTTGCAAATATTTTCTTCAATATGTGGCTTGTCTTTTTGTTCT 
10qSubTel              --TTCTCAGATCTGTATTTTGCAAATATTTTCTTCAATATGTGGCTTGTCTTTTTGTTCT 
22qSubTel              --TTCTCAGATCTGTATTTTGCAAATATTTTCTTCAATATGTGGCTTGTCTTTTTGTTCT 
1pSubTel               --TTCTCAGATCTGTATTTTGCAAATATTTTCTTCAATATGTGGCTTGTCTTTTTGTTCT 
5qSubTel               --TTCTCAGATCTGTATTTTGCAAATATTTTCTTCAATATGTGGCTTGTCTTTTTGTTCT 
17qSubTel              --TTCTCAGATCTGTATTTTGCAAATATTTTCTTCAATATGTGGCTTGTGTTTTTGTTCT 
4qSubTel               --TTCTCAGATCTGTATTTTGCAAATATTTTCTTCAATATGTGGCTTGTCTTTTTGTTCT 
19qSubTel              --TTCTCAGATCTGTATTTTGCAAATATTTTCTTCAATATGTGGCTTGTCTTTTTGTTCT 
21qSubTel              --TTCTCAGATCTGTATTTTGCAAATATTTTCTTCAATATGTGGCTTGTCTTTTTGTTCT 
1qSubTel               --TTCTCAGATCTGTATTTTGCAAATATTTTCTTCAATATGTGGCTTGTCTTTTTGTTCT 
2qSubTel               --TTCTCAGATCTGTATTTTGCAAATATTTTCTTCAATATGTGGCTTGTCTTTTTGTTCT 
19p'End'               --TTCTCAGATCTGTATTTTGCAAATATTTTCTTCAATATGTGGCTTGTCTTTTGGTTCT 
8p'End'                --TTCTCAGATCTGTATTTTGCAAATATTTTCTTCAATATGTGGCTTGTCTTTTGGTTCT 
13qSubTel              --TTCTCAGATCTGTATTTTGCAAATATTTTCTTCAATATGTGGCTTGTCTTTTTGTTCT 
20qSubTel              CTTTCTCAGATCTGTATTTTGCAAATATTTTCTTCAATATGTGGCTTGTCTTTTTGTTCT 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
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6qPredictedSubTel      CTTAACAAGGTCTCTTCCAGAGTATAAACTGTAAATATTAAGAAATCCACATTGTCATTT 
10qSubTel              CTTAACAAGGTCTCTTCCAGAGTATAAACTGTAAATATTAAGAAATCCACATTGTCATTT 
22qSubTel              CTTGACAAGGTCTCTTCCAGAGTATAAACTGTAAATATTAAGAAATCCACATTGTCATTT 
1pSubTel               CTTAACAAGGTCTCTTCCAGAGTATAAACTGTAAATATTAAGAAATCCACATTGTCATTT 
5qSubTel               CTTAACAAGGTCTCTTCCAGAGTATAAACTGTAAATATTAAGAAATCCACATTGTCATTT 
17qSubTel              CTTGACAAGGTCTCTTCCAGAGTATAAACTGTAAATATTAAGAAATCCACATTGTCATTT 
4qSubTel               CTTAACAAGGTCTCTTCCAGAGTATAAACTGTAAATATTAAGAAATCCACATTGTCATTT 
19qSubTel              CTTAACAAGGTCTCTTCCAGAGTATAAACTGTAAATATTAAGAAATCCACATTGTCATTT 
21qSubTel              CTTGACAAGGTCTCTTCCAGAGTATAAACTGTAAATATTAAGAAATCCACATTGTCATTT 
1qSubTel               CTTGACAAGGTCTCTTCCAGAGTATAAACTGTAAATATTAAGAAATCCACATTGTCATTT 
2qSubTel               CTTAACAAGGTCTCTTCCAGAGTATAAACTGTAAATATTAAGAAATCCACATTGTCATTT 
19p'End'               CTTAACAAGGTCTCTTCCAGAGTATAAACTGTAAATATTAAGAAATCCACATTGTCATTT 
8p'End'                CTTAACAAGGTCTCTTCCAGAGTATAAACTGTAAATATTAAGAAATCCACATTGTCATTT 
13qSubTel              CTTAACAAGGTCTCTTCCAGAGTATAAACTGTAAATATTAAGAAATCCACATTGTCATTT 
20qSubTel              CTTAAGAAGGTCTCTTCCAGAGTATAAACTTTAAAGATTAAGAAATCCACATTGTCATTT 
12qSubTel              ------------------------------------------------------------ 
7qSubTel               ------------------------------------------------------------ 
                                                                                    
 
6qPredictedSubTel      CTTCTGTGTA------------------------ 
10qSubTel              CTTCTGTGTA------------------------ 
22qSubTel              CTTCTGTGTA------------------------ 
1pSubTel               CTTCTGTGTA------------------------ 
5qSubTel               CTTCTGTGTA------------------------ 
17qSubTel              CTTCTGTGTA------------------------ 
4qSubTel               CTTCTGTGTA------------------------ 
19qSubTel              CTTCTGTGTA------------------------ 
21qSubTel              CTTCTGTGTA------------------------ 
1qSubTel               CTTCTGTGTA------------------------ 
2qSubTel               CTTCTGTGTA------------------------ 
19p'End'               CTTCTGTGTA------------------------ 
8p'End'                CTTCTGTGTATATCAACCTTCTGTGTCATTTGTT 
13qSubTel              CTTCTGTGTATATC-------------------- 
20qSubTel              CTTCTGTGTA------------------------ 
12qSubTel              ---------------------------------- 
7qSubTel               ---------------------------------- 
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